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abbreviations anD acronyms
ACS  Acute coronary syndrome
AS  Area stenosis
Bif  Bifurcation
BMS  Bare metal stent
BRS  Bioresorbable scaffold
BVS  Bioresorbable vascular scaffold
CABG  Coronary artery bypass graft
Calc  Calcified
CAD  Coronary artery disease
CAG  Coronary angiogram
CTA  Computed tomography angiography
CTO  Chronic total occlusion
CVD  Cardiovascular disease
DAPT  Dual antiplatelet therapy
DES  Drug-eluting stent
DM  Diabetes mellitus
DS  Diameter stenosis
Dmax  Maximum diameter
Dmin  Minimum diameter
DOCE  Device oriented composite endpoint
ECG  Electrocardiogram
IVUS  Intravascular ultrasound
LAD  Left anterior descending coronary artery
LCX  Left circumflex coronary artery
LM  Left main
M  Month
MACE  Major adverse cardiac events
MI  Myocardial infarction
MLA  Minimal lumen area
MLD  Minimal lumen diameter
MSCT  Multislice computed tomography
NOAC  New oral anticoagulans
Non-TVR Non-target vessel revascularization
NSTEMI  Nom ST-elevation myocardial infarction
OAC  Oral anticoagulans
OCT  Optimal Coherence Tomography
POCE  Patient oriented composite endpoint
PCI  Percutaneous coronary intervention
PLLA  Poly L- lactide
PT  Per treatment
QCA  Quantitative coronary analysis
RCA  Right coronary artery
RCT  Randomized controlled trail
RVA  Reference vessel area
RVD  Reference vessel diameter
SAP  Stable angina pectoris
ScT  Scaffold thrombosis
ST  Stent thrombosis
STEMI  ST-elevation myocardial infarction
TLF  Target lesion failure
TLR  Target lesion revascularization
TVR  Target vessel revascularization
UA  Unstable angina
VLScT  Very late scaffold thrombosis
VLST  Very late stent thrombosis
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Cardiovascular diseases (CVD), with coronary artery disease (CAD) being the most 
common type, are the leading cause of death globally. After numerous experiments 
on animals1, coronary bypass grafting (CABG) was developed as treatment option for 
stenosed or completely occluded coronary. A German surgeon named Robert Goetz 
performed a CABG (IMA to LAD) on a human in a New York hospital in 1960, using a non-
suture technique. The first suture technique based CABG procedure took place in 1964 
by the Russian Vasilli Kolesov. Unfortunately, rate of mortality was high in these days, 
yet technology accelerated and improvements were made, which reduced the one-year 
mortality rate to approximately 3%. 2
Andreas Gruentzig performed his first successful coronary angioplasty in 1977.3 How-
ever, still in these early days many patients died or needed surgery the same day. Since 
then, numerous important developments have taken place within the field of interven-
tional cardiology with a subsequent decrease in event rates. From the mid-eighties, the 
use of bare metal stents (BMS) reduced the high rate of acute recoil seen with classical 
angioplasty 4 but they went along with the frequent (up to 25%) occurrence of in-stent 
restenosis (ISR) within the first year after implant due to neointimal hyperplasia. 5 This 
phenomenon was contested by the introduction of metallic drug-eluting coronary 
stent (DES) in 1999 which subsequently, reduced the 1- and 2-year rates of restenosis 
and repeated revascularizations below 10% and soon, they became the gold standard 
for the treatment of CAD. However, DES were not devoid of limitations such as chronic 
inflammation, neoatherosclerosis, stent fracture, incomplete endothelization, loss of 
normal vessel geometry and vasomotion. Re-intervention rate using DES beyond 1 year 
post-implant, is on average 1 - 2% per year. 6, 7 
The mean age of patients treated with PCI is approximately 65 years. While treatment 
of ischemic heart disease improves and patients become older, the PCI population has 
quite some years to live after their first stent implant and the long-term risk of adverse 
events can be up to 20%. Therefore, new technologies have to be developed with the 
aim of improving outcomes beyond one year and envision 10 to 20 year durability of 
PCI. As mechanical support is most important to prevent acute recoil and preserving the 
lumen during the subsequent vascular healing process in the next three months, a tem-
porary supportive device should be sufficient. This would eliminate the late response to 
the permanent metallic devices mentioned above.
Up to this moment, five bioresorbable scaffolds (BRS) received “Conformité Européene” 
(CE) mark: 1) the DESolve novolimus-eluting bioresorbable coronary scaffold system 
(Elixir Medical Corporation, Sunnyvale, California, USA), made of  poly-L-lactic acid; 8 ; 2) 
ART Pure (Terumo Corporation, Tokio, Japan and Arterial Remodeling Technologies S.A. 
[ART], Noisy le Roi, France), a scaffold made of poly-D, L-lactic acid without any drug-
elution; 3) the Magmaris scaffold (previously known as DREAMS, Biotronik AG, Bülach, 
Switzerland),  a sirolimus-eluting and magnesium based scaffold. 9; 4) Fantom (REVA 
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Medical, San Diego, California, USA), a sirolimus-eluting poly-tyrosine–derived poly-
carbonate scaffold. 10 5) the everolimus-eluting Absorb bioresorbable vascular scaffold 
(BVS, Abbott Vascular, Santa Clara, California, USA), made of poly-L-lactide. Hypothesized 
advantages of the BVS over DES are late lumen enlargement, restored vasomotion, no 
interference with non-invasive imaging and complete resorption in approximately three 
years, leaving nothing behind. 11, 12
The first iteration of the BVS (1.0) was tested in the ABSORB Cohort A in 2006. This study 
included only low-risk patients with simple lesions, with late lumen loss (LLL) as primary 
endpoint. 13 A second iteration of the device was developed with improvement in me-
chanical integrity and was tested in the ABSORB cohort B trial, revealing good results, 
with LLL of 0.19±0.18 mm at six months. Multiple randomized controlled trials (RCTs), 
mainly designed for regulatory approval in different countries which compare BVS with 
the best-in-class everolimus DES (Xience, Abbott Vascular, Santa Clara, California, USA), 
reported comparable results on the short-term (one year). 14-17  However, complex pa-
tients (acute myocardial infarction) and lesions (bifurcation, heavy calcification, chronic 
total inclusion [CTO]) were excluded. Because of the limited in- and exclusion criteria 
used in RCTs, patients included in registries are more representative of usual practise. 
Therefore, registry-based results are important and have a higher generalizability. 
At the Absorb BVS’s clinical introduction in September 2012, the Erasmus Medical 
Centre started two prospective, single-arm, investigator-initiated registries as a struc-
tured program, aiming at hospital quality control and an increase in knowledge to share 
with the interventional cardiology community through scientific publications. Up to this 
day, there is still a lack of data concerning the implementation of this new technology in 
‘real-world’ patients, consisting of more complex subsets such as ACS patients, calcified 
and bifurcation lesions and with a longer duration of follow-up. 
Scope of this thesis
The aim of this thesis is to investigate the early and mid-term performance of the 
Absorb BVS in more complex lesions and higher-risk patients, when treated in a diverse 
clinical practice. 
Also, the purpose is to identify potential factors that could influence these outcomes 
to optimize patient and lesion selection, procedural strategies and post-procedural 
pharmaceutical treatment. Lastly, more information is necessary regarding the mecha-
nisms of scaffold failure (both scaffold thrombosis and restenosis) and to develop this 
treatment further and treatment options are provided. 
The early outcomes of this new device in will be investigated in Part I, using different 
quantitative techniques in different clinical scenarios. We will use early proven surrogate 
endpoints and look at short-term outcomes.
Part II will examine the mid-term outcomes in relation to complex lesion and patient 
subtypes and clinical presentations to identify predictors of potential unfavourable 
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results. This was done in a more general population and in specific higher-risk groups 
such ACS patients, calcified and bifurcation lesions.
Part III will report on late events, occurring during the resorption phase. It will focus on 
scaffold thrombosis and restenosis and concerns results from cases with poor outcome. 
Also, we will provide some suggestions for how to handle these. 
In the final section (Discussion), observations from this research will be discussed 
while integrating these with the current international literature to an updated state-
ment on the use of this first-generation bioresorbable vascular scaffold and directions 
for improvement in outcome. 
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 Chapter 1
Current status of clinically available bioresorbable 
scaffolds in percutaneous coronary interventions
CM Felix, BRC Everaert, R Diletti, NM van Mieghem, J Daemen, M Valgimigli, 
PP de Jaegere, F Zijlstra, ES Regar, C Simsek, Y Onuma, RJM van Geuns
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abstract
Drug eluting stents are widely used as first choice devices in percutaneous coronary 
interventions. However, certain concerns are associated with the use of drug-eluting 
stents (DES), i.e. delayed arterial healing with a subsequent risk of neo-atherosclerosis, 
late stent thrombosis and hypersensitivity reactions to the DES polymer. Bioresorbable 
vascular scaffolds (BVS) are the next step in percutaneous coronary interventions intro-
ducing the concept of supporting the natural healing process following initial interven-
tion without leaving any foreign body materials resulting in late adverse events. The 
first generation devices have shown encouraging results in multiple studies of selected 
patients up to the point of full bioresorption supporting the introduction in regular pa-
tient care. During its introduction in daily clinical practice outside the previous selected 
patient groups, a careful approach should be followed in which outcome is continuously 
monitored. 
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introDuction
Drug-eluting stents (DES) are widely used as devices of first choice in percutaneous 
coronary interventions (PCI). However, certain concerns are associated with the use of 
DES, i.e. delayed arterial healing with a subsequent risk of neo-atherosclerosis, late stent 
thrombosis and hypersensitivity reactions to the DES polymer 1. 
Furthermore, from a more general physiological point of view, a vessel that is indefi-
nitely caged in a metal scaffold is not desirable both on short and long term, because of 
the risk of impaired endothelial function, the reduced potential for vessel remodelling, 
interference with the normal arterial healing process and the risk of occlusion of covered 
side-branches by neointima hyperplasia. Also, interference with non-invasive imaging 
(cardiac computed tomography or magnetic resonance imaging) during patient follow-
up and possible impairment of future treatment options (re-percutaneous coronary 
interventions or coronary artery bypass surgery) are drawbacks of metallic stents 2. 
Therefore, a stent type made of a bioresorbable material could provide the desirable 
transient vessel support without compromising the restoration of normal vessel biol-
ogy, vessel imaging or treatment options in the long run. Furthermore, the need for 
long-term dual anti-platelet therapy (DAPT) could potentially be reduced.
The Igaki-Tamai stent was the first-in-man fully biodegradable coronary stent made of 
poly-L-lactic acid (PLLA). However, this stent did not possess any active anti-proliferative 
drug coating and this resulted in an unacceptably high early target vessel revascularisa-
tion rate. On the other hand, late invasive follow-up confirmed the fully bioresorption 
process and coverage of complex atherosclerotic lesions with a stable layer of neo-
media . From September 1998 until April 2000, 50 patients were treated. Data of 10 year 
follow-up showed highly first year target vessel failure (TVF) with acceptable rates of 
major adverse cardiac events (MACE) during the late follow 3. 
The Absorb Bioresorbable Vascular Scaffold (BVS, Abbott Vascular, Santa Clara, CA) 
consists of a poly L-lactide (PLLA) bioresorbable scaffold with poly D, L-lactide biore-
sorbable (PDLLA) coating that releases the anti-proliferative drug everolimus. The long 
chains of PLLA and PDLLA are degraded via hydrolysis of the ester bonds and the result-
ing lactate and its oligomers are metabolized by the pyruvate and Krebs energy cycles. 
Two adjacent radio-opaque platinum markers are located at both Absorb edges to allow 
long term visualisation. The strut thickness is approximately 150 µm. 
There is suggested that patients treated with a BVS need more aggressive anti-platelet 
therapy because of these thicker struts. Prasugrel, a third-generation thienopyridine 
prodrug, induces platelet inhibition more consistently and to a greater extent than 
clopidogrel which resulted in less stent thrombosis, urgent target vessel revascularisa-
tion and myocardial infarct a the costs of a small increase in major bleedings in the ran-
domized controlled PLATO study 4. The Rijnmond Collective Cardiology Research (CCR) 
14 Chapter 1
registry is a prospective, observational study that will assess the adaption of Prasugrel 
into routine clinical practice and in the nearby future will deliver real-world numbers 
about reducing ischemic events on one hand and the increased risk of bleeding on the 
other hand 5. If safety is confirmed in this routine clinical practice prasugrel might be the 
preferred treatment for patients treated with BVS.
The Absorb Bioresorbable Vascular Scaffold was the first fully bioresorbable scaffold 
that received a CE-mark. A comparable PLLA based scaffold coated with myolimus has 
completed its first-in-man study with encouraging results and also obtained CE-mark 6. 
With its current limited scientific evidence of efficacy this review will concentrate on the 
only widely available BVS, the Absorb scaffold.
the beginning of bvs: absorb cohort a and b
ABSORB Cohort A was the first-in-man trial to investigate the safety and feasibility of 
the everolimus-eluting bioresorbable vascular scaffold (BVS). In this prospective, multi-
center, single arm, open-label trial thirty patients with stable, unstable or silent ischemia 
were enrolled from March until July 2006. Coronary lesions had to be single and de novo 
in a native coronary artery with a stenosis of > 50% and with a TIMI flow grade > 1.
Major exclusion criteria were ST-elevation myocardial infarction (STEMI) patients, 
patients presenting with unstable arrhythmias or those with a ventricular ejection frac-
tion < 30%. Significant stenosis in the left main coronary artery, lesions involving a side 
branch > 2 mm in diameter and lesions with the presence of thrombus or more than one 
clinically significant stenosis in the target vessel were excluded.
The clinical endpoints were assessed at 30 days, 6 and 9 months and 1, 2, 3, 4 and 5 
years and were excellent. Except from one non-Q wave myocardial infarction no other 
major adverse cardiac events were noted up to 2 years (defined as cardiac death, myo-
cardial infarction (MI) and ischemia-driven target lesion revascularization (TLR)). 
After 2 years, invasive coronary imaging studies showed that the BVS were largely 
absorbed and had been incorporated into the vessel wall. The remaining strut parts 
were apposed and late lumen enlargement could be demonstrated. Vasomotion and 
endothelial function were evaluated after intracoronary injection of methergin (a 
vasoconstrictor) and acetylcholine (an endothelium-dependent vasodilatator). This 
confirmed restoration of normal endothelium-dependent vessel wall function after 
degradation of the vascular scaffold 7. (Figure 1)
A 5-year clinical follow up was obtained in twenty-seven patients (one patient with-
drew consent and two patients died of a non-cardiac cause). Major adverse cardiac 
event rate at 5-year follow-up was low (3.4%). No scaffold thrombosis was reported 8. In 
ABSORB Cohort A the first generation device was used. Tanimoto et al. described that 
acute stent recoil was slightly but insignificantly larger when compared to that of the 
everolimus-eluting stent (EES) (6.9% vs 4.3%) 9. This first generation BVS showed a late 
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lumen loss of 0.44 mm, probably due to device shrinkage. To overcome the potential 
issue of acute scaffold recoil, a second generation BVS with a modified scaffold design 
was tested in the ABSORB Cohort B trial. This revised scaffold was developed to provide a 
greater vessel wall support, a more consistent drug delivery and device storage at room 
temperature. 
The ABSORB Cohort B trial had a prospective, multicenter, single arm, open-label de-
sign. Hundred and one patients were included and subdivided into two groups accord-
ing to the invasive imaging protocol. The first group (B1, n = 56) underwent angiography 
at 6 and 24 months and the second  group (B2, n = 45) received follow-up angiography at 
12 and 36 months. Also, during angiography, the implanted scaffolds were additionally 
investigated with intravascular ultrasound (IVUS) and optical coherence tomography 
(OCT). In ABSORB Cohort B, patients with a maximum of 2 de novo coronary artery lesions 
were included (maximum lesion diameter and length of 3.0 mm and 14 mm respectively, 
for a scaffold size of 3.0 x 18 mm). The other in- and exclusion criteria did not differ from 
the ABSORB Cohort A trial. At 3 year follow up there had been no cases of cardiac death 
or scaffold thrombosis, three cases of myocardial infarction (all non-Q-wave), and seven 
ischemia-driven target lesion revascularization with a major cardiac adverse event rate 
of 10%. No scaffold thrombosis was evident during follow-up 10.
figure 1 Optical coherence tomography images of coronary arteries from matched sites at 6 months (A-C) 
and 5 years (D-F) after BVS implantation
(Adapted from A. Karanasos et al. (33))
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Imaging with intravascular ultrasound demonstrated late lumen enlargement of 
the scaffolded lesions in the ABSORB cohort A and B patients. This observation could 
represent a paradigm shift from late lumen loss to late lumen gain when applying BVS 
Also, results on restoration of vasomotor function were reported for the ABSORB A 
and B Cohorts. These data suggest a progressive recovery of normal vascular function in 
the scaffolded segments during the resorption process 11. 
Recently Karanasos et al reported about the long-term vascular healing response of 8 
patients from the ABSORB Cohort A. 5 years after BVS implantation patients underwent 
invasive follow-up with optical coherence tomography , revealing late luminal enlarge-
ment, complete strut bioresorption and development of a ‘sealing layer’ covering under-
lying thrombogenic plaque components 12.
In brief, the ABSORB Cohort A and Cohort B trial included only non-complex lesions 
with low-risk patients. Placement of BVS proved to be feasible and safe, with major 
cardiac adverse events and stent thrombosis rate similar to Xience V. Based on the clini-
cal safety demonstrated in the first studies (ABSORB Cohort A and B), the everolimus-
eluting BVS acquired a CE-mark in Europe and has since become commercially available. 
However, to further expand the indication for BVS use in more complex coronary lesions 
and acute coronary syndrome patients, the BVS Expand, ABSORB Extend and ABSORB II 
and BVS STEMI first study, respectively, were initiated.
extend clinical evaluation of bvs
To explore the performance of BVS in a larger group of patients with different operators, 
the ABSORB Extend study was initiated in more than 100 non-US sites worldwide. This 
continued access, non-randomized, prospective, single arm clinical trial was started in 
January 2011 and intended to include more than 800 patients with up to 2 de novo lesions 
in different epicardial vessels. The range of scaffold diameters and sizes was extended 
(2.5, 3.0 and 3,5 mm in diameter and 12, 18 and 28 mm in scaffold length, respectively) 
to allow the treatment of a broader range of coronary lesions (≤ 28 mm in length and 
reference vessel diameter of 2.0-3.8 mm (as assessed by on-line QCA or intravascular 
ultrasound)). One stent overlap was allowed for lesions of more than 22 and less than 28 
mm. Target lesions located in the left main coronary artery, arterial or saphenous vein 
grafts, in-stent restenosis, lesions previously treated with brachytherapy, chronic total 
occlusions (CTO, TIMI 0 prior to wire crossing), bifurcation lesions with side branches ≥ 2 
mm in diameter, ostial lesion of > 40% stenosis or a side branch requiring pre-dilatation 
were excluded from the study. Also lesions with excessive calcification, high tortuosity 
or visible thrombus were excluded.
Recently, an interim analysis on the twelve-month clinical outcome of the 512 first 
BVS implanted patients demonstrated a favourable clinical outcome and safety profile 
(Table 1). Cardiovascular death, ischemia-driven major adverse cardiac events and 
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target vessel failure occurred in 0.4, 4.3 and 4.9% of patients respectively. The incidence 
of scaffold thrombosis was low (0.8%) 13. Propensity matched clinical outcomes at one 
year showed identical cardiovascular death, hierarchical major adverse cardiac event 
and stent thrombosis rates for BVS compared to second generation DES (Xience V) (0.3 
vs. 0.6%, 5.2 vs. 5.5% and 0.5 vs 0.5%, respectively) 14 . Interestingly, in a propensity score 
analysis comparison between Absorb Cohort B/ Extend patients and Xience V patients 
from Spirit Cohorts, target vessel failure rates were significantly lower in BVS compared 
to DES (5.5 vs. 8.6%, respectively, p = 0.04). A 2-year follow-up propensity matched 
analysis confirmed the non-inferiority of BVS compared to Xience V 15.
Interestingly, the result from a propensity matched analysis of 250 patients,  compar-
ing patients implanted with BVS to patients implanted with Xience V in the SPIRIT IV 
trial, showed a decrease in angina pectoris reported by the sites through adverse event 
reporting at one year (16.0 vs 28.1%, respectively) 16. This difference was highly sig-
nificant and probably accounts for the lower target vessel failure rate in the BVS group. 
Also, the percentage of angina diagnosed through adverse event reporting was notably 
lower with BVS than that reported in previous large interventional trials (FREEDOM 
(sirolimus-eluting stent/paclitaxel-eluting stent): 21%; SYNTAX (paclitaxel-eluting stent): 
28%; COURAGE (bare metal stent: 34%) (16). Further follow-up is needed to confirm this 
observation on the potential reduction of post-percutaneous coronary intervention an-
gina. If confirmed, repeat angiography with or without additional coronary intervention 
would be significantly reduced. This could greatly impact on patient quality of life and 
additionally reduce health care costs.
The ABSORB II study started in November 2011 as the first randomized (2:1), prospec-
tive, single-blinded, multicenter trial, in which patients were assigned to the ABSORB BVS 
or a second generation everolimus-eluting coronary stent (Xience Prime). A total of 501 
patients were randomized across forty European sites and in New Zealand. Patients with 
stable or unstable angina, silent ischemia and with up to 2 de novo lesions in different 
epicardial vessels with a maximal lesion length of 48 mm were enrolled. Major exclusion 
criteria were STEMI, left ventricular ejection fraction < 30%, unstable arrhythmias, left 
main disease, chronic total occlusions and severely calcified or tortuous lesions. Patients 
will be followed for five years, with an invasive evaluation by angiography, intravascular 
ultrasound, optical coherence tomography, and vasomotion testing at final follow-up for 
superiority 17. First one year interim analysis showed non-inferiority between BVS and DES 
on major adverse cardiac events which is essential to achieve the superiority endpoint 18.
bvs in more complex coronary lesions in every day patients.
In September 2012, at the Erasmus MC, the Expand registry was initiated to evaluate 
the long term safety and performance of the BVS in routine clinical practice. In this 
monocenter, prospective, observational registry, patients presenting with non ST-
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elevation myocardial infarction (NSTEMI), stable or unstable angina or silent ischemia in 
combination with a de novo stenotic lesion in a native, previously untreated, coronary 
artery were included. A reference vessel diameter up to 4 mm and a longer lesion length 
(> 32 mm) was allowed, as was a higher degree of calcification and bifurcation lesions. 
Major exclusion criteria were previous coronary artery bypass graft or metallic stent in 
the target vessel, cardiogenic shock, STEMI, bifurcation lesions requiring kissing balloon 
post-dilatation, allergy or contra-indications to dual antiplatelet therapy. In the first 200 
patients, on average 1.9 scaffolds were implanted per patient, with stent overlap in 32% 
of patients. Mean lesion length was 25.4±13.5 mm. 41.1% of lesions were scored as B2 
or C lesions, 5.8% were chronic total occlusions and in 29.1% a bifurcation was included. 
38.5% of patients had multi-vessel disease. The procedural success rate of BVS implan-
tation was 98.2%, with a radial approach in 76.6% and lesion preparation in 91.9% of 
lesions (275 in total). The six months results were excellent with a mortality of 2%, a 
definite scaffold thrombosis of 2.2% and no other target lesion revascularization within 
this period. Final rate of major adverse cardiac events at 6 months was 3.3% (Table 1) 19. 
Recently, the 6 month outcome data of the Italian all-comer patient GHOST-EU 
registry, including 1189 patients with moderate to high complex lesion and/or patient 
characteristics, were reported, showing acceptable rates of cardiovascular death (1.0%), 
target vessel myocardial infarction (2.0%) and of target lesion failure (4.4%) 20. Definite 
scaffold thrombosis rates were 1.7% at 6 months. Also, the Academic Medical Centre 
(AMC) single arm first experience, including a high number of complex patients, showed 
a somewhat higher major adverse cardiac events rate at this time point, especially re-
figure 2 Evolution of the IVUS-measured mean lumen area in coronary arteries treated with BVS in ABSORB 
Cohort B1 and B2 
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lated to scaffold thrombosis. The investigators claim that this was due to a learning curve 
where major changes were made with regard to lesion preparation and post-dilatation 
to achieve full scaffold expansion and avoiding underexpansion as observed in the first 
scaffold thrombosis cases 21. Conversely, a propensity matched analysis from the single 
center San Raffaele Scientific Institute BVS registry (Milan, Italy), comparing BVS (n = 92) 
with Xience V (n = 92) in complex lesions (83.9% B2 or C lesions, 45.2% bifurcations), 
did reveal similar early outcomes of BVS to second generation DES and no evidence for 
increased scaffold thrombosis rates 22. 
Other registries mainly including less complex lesions have provided good data on 
BVS safety and performance in true clinical experience. The German multi-center AS-
SURE registry showed low rates of cardiovascular death, myocardial infarction and target 
lesion revascularization (0.5, 1.6 and 2.8%, respectively) at twelve months after implan-
tation (n = 183). No cases of scaffold thrombosis were observed 23. Lastly, the ongoing 
multi-center ABSORB FIRST study was designed to enrol a high number of moderately 
complex ‘real world’ patients. An interim analysis of the results from the first 800 patients 
at 30 days of follow-up demonstrated excellent device success rates (98.9%), no cases of 
cardiovascular death and a low risk of definite or probable scaffold thrombosis (0.3%) 24. 
bvs in acs and stemi patients: what do we know?
Immediately after clinical availability several institutions started treatment of more 
complex lesions with strict follow-up in several registries. We excluded STEMI patients 
as large amount of thrombus is usually present which might result in malapposition if 
resolved in time. In the first registries a high number of  NSTEMI patients where included 
of which a significant number early angiography demonstrated full vessel occlusion, an 
observation made by others 25. After thrombus aspiration BVS implantation was per-
formed in a similar fashion as non-ACS patients and OCT controlled showed excellent 
apposition. This opened the door for BVS in STEMI patients.
In 2013, Wiebe and co-workers presented a first report on the short-term outcome of 
STEMI patients treated with an everolimus-eluting bioresorbable scaffold. Twenty-five 
patients with thirty-one lesions were included with a procedural success rate of 97% and 
major adverse cardiac event rate of 8.3% during a mean follow-up period of 137 days 26.
Recently, our group reported the 30-day clinical outcome of the BVS STEMI First 
Study. In this prospective, single-arm, monocenter safety and feasibility study 49 STEMI 
patients were treated with a BVS (direct stenting in 32.7% and pre-dilatation in 67.3%). 
The procedural success rate of BVS implantation was 97.9%. TIMI-flow III was obtained 
in 91.7% of patients after BVS implantation. At 30 days, the major adverse cardiac event 
rate was 2.6% (one patient with a non Q-wave myocardial infarction in a non-target ves-
sel). Target lesion failure (composite of cardiac death, target-vessel myocardial infarction 
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1or ischemia driven target lesion revascularization) did not occur and there were no cases of scaffold thrombosis 27.
Additionally, in the prospective Prague 19 trial, BVS were implanted in consecutive 
STEMI patients from December 2012 until August 2013. The authors recently reported 
on forty-one patients who received a BVS compared to a control group who were im-
planted with a drug eluting or bare metal stent (n = 57) 28. BVS device success rate was 
98%. There were two events in the BVS group: one early (day 13) scaffold thrombosis 
after stopping aspirin and ticagrelor for which the patient underwent re-PCI and one 
non-target vessel myocardial infarction after a staged procedure with a DES. Four events 
(one cardiac death, two patients with unstable angina due to stent thrombosis and one 
myocardial infarction in a non-target vessel) were witnessed in the control group (95% 
for BVS and 93% for the control group, p = 0.674). 
Recently, an update of the Prague-19 study, comprising seventy-six STEMI patients 
implanted with BVS was presented during EuroPCR 2014, showing a target lesion re-
vascularization of 1.3%, and a stent thrombosis and major adverse cardiac event rate of 
1.3% and 2.6%, respectively, with an average follow-up of about 6 months 29
Concerning acute coronary syndromes, Gori et al reported the short-term results in 
hundred and fifty consecutive patients (unstable angina 16%, NSTEMI 40%, STEMI 44%), 
treated with in total 194 BVS between May 2012 and July 2013. These patients were 
compared with 103 consecutive control patients who received a DES (XIENCE Prime). 
Major adverse cardiac event rates at thirty days and six months were similar between 
both groups. Scaffold thrombosis occurred in three BVS patients and two DES patients 
within the first month 30. 
Also the POLAR ACS study (100 patients; unstable angina 46%, NSTEMI 38%, STEMI 
16%), reported excellent device success rate (100%) with limited (3.0%) in-hospital 
major adverse cardiac event rate (due to two peri-procedural myocardial infarctions and 
one non-target vessel revascularization) 31.
Overall, the first trials although still on a small number of patients, suggest that im-
plantation of BVS in STEMI patients is feasible and safe, with early outcomes comparable 
to drug-eluting metal stents. However, these preliminary data need to be confirmed in 
future larger randomized controlled trials. 
General conclusion
Bioresorbable coronary artery scaffolds are the next step in percutaneous coronary 
intervention introducing the concept of the natural healing following percutaneous 
coronary intervention without leaving foreign body material in situ. The first generation 
devices have shown encouraging results in selected patient studies up to the point of 
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fully bioresorption supporting the introduction in regular patient care. During their 
introduction in daily clinical practice outside the previously selected patient groups a 
careful approach should be followed where outcome is continuously monitored. 
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introDuction 
Percutaneous coronary interventions (PCI) have become a reliable revascularization 
option to treat ischemic coronary artery disease (CAD) [1].  Drug eluting stents (DES) are 
widely used as first choice devices in many procedures due to their established good 
medium to long term outcomes [2]. These permanent implants however, do not have 
any residual function after vascular healing following the PCI. Beyond this initial heal-
ing period, metallic stents may induce new problems, resulting in an average rate of 
2% reinterventions per year [3]. To eliminate this potential late limitation of permanent 
metallic DES, bioresorbable coronary stents or ‘Vascular Scaffolds’ (BVS) have been 
developed. In a parallel publication in this journal an overview of the current clinical 
performance of these scaffolds is presented. As these scaffolds are currently CE-marked 
and commercially available in many countries and as clinical evidence is still limited, 
recommendations for their general usage are needed to allow for a successful clinical 
introduction. 
introduction of new technologies
Continuous technological innovation has contributed to the impressive improvement of 
medical care over the past decades. On the other hand, many new technologies failed 
to deliver on their promises and disappeared soon after introduction, such as coronary 
laser angioplasty and brachytherapy. Moreover, recently, several examples exist of 
new technologies that were introduced without appropriate recommendations and 
assessment. A recent example is the introduction of a metal-on-metal hip prosthesis, 
considered beneficial for younger patients, in which an unexpectedly high rate of device 
failure was present. Based on similar examples, the Dutch Society of Cardiology (NVVC) 
adopted policy documents for the introduction of new technologies [4]. Later, the Dutch 
Order of Medical Specialists in collaboration with ‘Zorginstituut Nederland’ composed a 
similar document for all medical specialists in the Netherlands [5]. Both documents pro-
vide important information on the introduction process for new devices. In these docu-
ments a preparation phase is described including a risk analysis and a multi-disciplinary 
co-operation before advising on device introduction. Furthermore, post-introduction 
outcome registration and reporting are essential to assess for any unexpected adverse 
events. Also, due to the substantial increase in health care costs when CAD patients have 
to undergo PCI and taking into account that the number of PCI has more than a doubled 
over the past 10 years in the Netherlands [6-7], the cost-effectiveness of any new PCI 
technology remains an important issue. Regarding the need of adjunctive imaging and 
supporting techniques for optimal BVS placement, the cost-effectiveness of treating 
CAD with BVS has yet to be determined in an all-comer patient population.
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lesion selection
Numerous reviews on the current status of bioresorbable vascular scaffolds (BVS) for 
PCI have been published. In this journal, we have updated these reviews with the lat-
est data presented during the EuroPCR meeting from May 20th to 23rd 2014 in Paris. In 
short, the safety of BVS has once again been confirmed in a large group of patients for 
non-complex lesions up to 2 years after scaffold implantation after initial good results 
for 5 years in smaller groups [8-9]. Based on these results we think that the use of the 
Absorb BVS can be considered as ‘appropriate’ for lesions that were included in the initial 
ABSORB Cohort A and B trial and the ABSORB Extend registry. The details of these ‘Ab-
sorb Extend-like lesions’ are summarized in Table 1. The first randomized study (ABSORB 
II trial) on whether the Absorb BVS offers an advantage over DES is currently ongoing. 
The results of the physiologic study will be available in 2016. An interim analysis at one 
year of follow-up showed similar rates in a composite clinical endpoint based on death, 
myocardial infarction and coronary revascularization [10].
For patients with more complex lesions, who were excluded from the initial BVS 
studies, some short term data have been reported during the last EuroPCR meeting. 
In addition, several medium sized trials (100-300 patients) with outcome data up to 12 
months were also presented. Based on these data and the experience of the authors, the 
previous exclusion criteria for the Absorb BVS use currently seem outdated. However, as 
the follow-up period for these more complex lesions as well as patient numbers are still 
limited, the level of recommendation made cannot exceed ‘probably appropriate’. With 
this limited evidence in mind, it is important for every operator and PCI center to keep a 
table 1 BVS Extend-like lesions. 
Absorb Extend-like lesions Exclusion
‘de novo’ lesions Left main
Diameter 2.3 - 3.8 mm Arterial or venous grafts
Length max 28 mm In-stent restenosis
One BVS scaffold overlap Chronic total occlusion (CTO)
Maximum 2 lesions Ostial lesions
Stable, unstable or silent ischemia Bifurcation lesions with side branches ≥2 mm diameter 
Excessive calcification
High tortuosity 
Visible thrombus
(N)STEMI 
LVEF <30%
NSTEMI non-ST-elevation myocardial infarction, STEMI ST-elevation myocardial infarction
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registry of patients treated with BVS including data on patient outcomes as described in 
the NVVC guideline on the introduction of new technologies. 
Within these real world registries the number of patients with true complex lesions, 
such as two scaffold bifurcations, heavily calcified lesions with rotablator lesion prepara-
tion and CTO is limited. For these complex lesions no recommendation can be given as 
the patient number is too small and the outcomes are still uncertain.  Probably, the AIDA 
(Amsterdam Investigator-initiateD Absorb strategy All-comers) trial, a Dutch multicenter 
trial with over 2700 patients included will provide more insights into the use of BVS in 
these more complex lesions.
Furthermore, two special subsets of lesions should be mentioned: arterial or venous 
grafts and in-stent restenosis (ISR). For both, the current Absorb BVS label (de novo le-
sions in native vessels) does not apply and at this moment for these types of lesions the 
recommendation has to be off-label which should only be deviated from with a clear 
motivation. 
A final - technical - limitation is the overexpansion capabilities of the Absorb BVS 
that is currently restricted to 0.5 mm. As the largest commercially available Absorb BVS 
is 3.5 mm at nominal pressure, vessels with a diameter above 4.0 mm (quantitatively 
measured by QCA, IVUS or OCT) should not be targeted because of the greater risk of 
extensive malapposition.
Patient selection
Every introduction of a new technology targets a specific subgroup of patients. With 
the introduction of DES with higher health-care costs, initially, only patients with a 
high risk of early restenosis (DM patients, long lesions and small vessels) were selected. 
table 2 Lesion selection.
Appropriate Absorb A/B and Extend-like lesions: ‘de novo’ lesions, max. length 28mm, one stent overlap, 
max. 2 lesions
Probably 
appropriate, 
early evidence
ACS patients, long lesions (>28 mm), calcified lesions with proper lesion preparation 
(diameter stenosis <40% after preparation), provisional bifurcation treatment (including 
fenestration into side branch) 
Uncertain Bifurcations requiring a two scaffold approach
Chronic total occlusion with subintimal crossing
Extensively calcified lesions where aggressive lesion preparation is necessary
Off-label In-stent restenosis
Arterial and venous grafts
Vessels > 4.0 mm in diameter
ACS acute coronary syndrome
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Solid clinical data and a price cut paved the way for DES use in the majority of patients 
undergoing PCI in the Netherlands. As bioresorbable therapy aims to improve patient 
outcomes after the first year of implantation, patient selection has to take into account 
other arguments. Although many classical predictors of early restenosis also apply for 
treatment failure beyond one year (j-Cypher Registry) i.e. diabetes mellitus (DM), renal 
failure, dialysis and long lesions, some factors are less important for long term TLR such 
as bifurcation lesions with side branch stenting [11]. It is important to make a differentia-
tion between factors mainly affecting late TLR and those also impacting on patient long 
term (>5 year) survival. 
It is therefore essential to appropriately select patients in which BVS may yield the 
highest beneficial effect on long time clinical outcome. The American NCDR registry 
recently provided valuable information for patient selection [12]. Although a relatively 
complex model was used, some major points have been identified. Patients above >80 
years, patients with severe renal failure or on dialysis or patients who are in cardiogenic 
shock at the time of the procedure, have a limited live expectancy and therefore the 
overall potential long term benefit of BVS therapy is very limited. Other patient-related 
conditions, such as DM, body mass index (BMI) >40, left ventricular ejection fraction 
(LVEF) <40%, CVA, peripheral artery disease (PAD) and chronic obstructive pulmonary 
disease (COPD), have a negative impact on patient’s life expectancy and should lower 
the upper age limit for patient selection. In table 3 we provide a simplistic model that 
can be used for patient selection.
technical considerations for bvs implantation
Lesion preparation is especially important, as the current Absorb BVS strut thickness 
is higher (150 µ) than that of conventionally used DES. Also, before inflation, the initial 
scaffold diameter is quite large (1.4 mm) which is related to the specific scaffold-related 
folding characteristics of the Absorb BVS. Therefore, highly calcified or tortuous lesions 
or lesions with a high degree of angulation can be quite challenging for BVS implanta-
tion. However, with extensive lesion pre-dilatation using increasing balloon sizes, even 
highly calcified lesions can be successfully treated with BVS, although special care has to 
be paid to a good implantation technique. In summary, the 5 golden ‘P’s for BVS implan-
table 3 Patient specific criteria.
Optimal Young patients or
with good life expectancy (i.e. 
>5 years)
Age <70 years or age 70-80 with max 1 of PAD, COPD, 
CVA, renal failure, DM, 
BMI >40 or LVEF <40%
No potential benefit 
to be expected
Limited life expectancy  
(i.e. <1 or 2 years)
Cardiogenic shock, severe heart failure (EF <30%), 
dialysis
BMI body mass index, COPD chronic obstructive pulmonary disease, CVA cerebrovascular accident, DM dia-
betes mellitus, LVEF left ventricular ejection fraction, PAD peripheral artery disease
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tation: Prepare the lesion, Properly size the vessel, Pay attention to the expansion limits 
of the BVS, Post-dilate the scaffold with a properly sized non-compliant balloon and pay 
attention to the DAPT compliance of the patient.
To avoid BVS malapposition, also taking into consideration the current limited sizes 
in scaffold diameter and length, correct scaffold sizing based on reliable assessment 
of vessel dimensions is a second important issue. Invasive imaging modalities, such as 
intravascular ultrasound (IVUS) and optical coherence tomography (OCT), have been 
proven to be superior to angiography in providing accurate morphometry, including 
for estimating vessel diameter and lesion length. OCT is particularly suited to visualize 
the scaffold struts and their interaction with the vessel wall and can greatly improve the 
quality of BVS implantation [13]. Before implantation, OCT is indicated to predetermine 
lesion characteristics, such as lesion length and the amount of calcification, to estimate 
the optimal scaffold length and to identify the optimal proximal and distal landing 
zones. OCT after scaffold implantation can be invaluable to guide post-dilatation of the 
scaffold with properly sized non-compliant balloons to perfect strut apposition, taking 
into account the expansion limit of 0.5 mm for the Absorb BVS, especially in the initial 
experience of the operator. 
Challenging lesions
Initial non-complex lesions studies had a very high procedural success rate. In a more real 
world setting lesion preparation, especially for more tortuous and calcified lesions, has 
proven to be necessary to obtain the same success rates. For truly calcified lesions, ro-
tablation smoothens the atherosclerotic segments and is an invaluable technical aid for 
procedural success. For less calcified lesions, cutting balloons and the Scoreflex balloon 
have proven to be of value to appropriately prepare the lesion with full expansion of the 
pre-dilatation balloons and percentage diameter stenosis <40% before BVS implanta-
tion. In tortuous vessels the GuideLinerTM or GuidezillaTM guide extension catheters are 
valuable to increase back-up support and device deliverability. One should keep in mind 
that these ‘aid-devices’ have smaller inner lumens. The 5-in-6F guide extension catheter 
supports the Absorb BVS 2.5 mm and 3.0 mm only after preloading. For the Absorb BVS 
3.5 mm a 6-in7F guide extension catheter is necessary. 
Bifurcation lesions
Bifurcation lesions in appropriately selected patients are potentially good candidates 
for BVS treatment. In these, provisional stenting is the preferred strategy. If side branch 
treatment is necessary, the proximal optimization technique (POT) and side branch 
fenestration with a 2.0 or 2.5 mm balloon at low pressures (max. 8 atms) and final POT 
is advocated. If balloon fenestration of the side branch is insufficient, eventual bail-out 
post-dilatation with an undersized balloon and/or scaffolding of the side branch with 
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another BVS or DES and final POT could be needed. Fenestration of side branches with 
2.0 mm and 2.5 mm non-compliant balloons has been tested in vitro without strut 
fractures and is considered safe by many operators. Just like metallic stents, scaffold 
deformation with local malapposition does happen for which post-dilatation is impor-
tant. As overexpansion capabilities of the Absorb BVS are limited, classical, simultaneous 
kissing balloon post dilatation is not recommended. Final invasive imaging optimiza-
tion is encouraged. Using BVS, we do not advocate techniques such as the culotte or 
crush techniques as these could result in ≥3 layers of stent struts (≥450 µ) with possible 
compromise of the lumen of the main branch and a high chance of delayed healing 
of intraluminal uncovered scaffold struts. At this moment the data on BVS bifurcation 
techniques are still limited compared to metal alloy stent bifurcation techniques.
antiplatelet therapy post Pci
Current guidelines for antiplatelet therapy post PCI with DES advise Dual AntiPlatelet 
Therapy (DAPT) 6 to 12 months for stable angina. For ACS patients, based on the ESC 
non-STEMI and STEMI guidelines a minimum of 12 months DAPT is advised, preferably 
with prasugrel or ticagrelor [14-15]. Some new publications suggest that for second 
generation DES, DAPT duration might be shortened [16]. However, most of these studies 
are retrospective analyses and only a limited number of patients have been analyzed 
for shorter DAPT treatment. For the ABSORB BVS a minimum of 6 months DAPT was 
stated per protocol, and the majority of patients were on DAPT for 12 months. Based on 
the design where strut thickness of the ABSORB BVS is similar to first generation DES, 
and regarding initial reports on the occurrence of early as well as late stent thrombosis, 
the best advice for the moment is to prescribe DAPT for 12 months for all patients with 
ABSORB BVS and to avoid implantation of the ABSORB BVS in patients with a strict indi-
cation for oral anticoagulation as there is currently no data for shorter DAPT in patients 
on anticoagulants.
conclusions 
At the start of this new era in interventional cardiology, treating physicians should real-
ize their responsibility for a careful introduction of the technology. This includes the 
preparation phase and a close follow-up phase for which both the NVVC and the Dutch 
Order of Medical Specialists have valuable guidelines. 
Based on currently reported data and the experience of the authors with the Absorb 
BVS, some suggestions for the selection of patient and lesion characteristics for correct 
clinical indications as well as some useful implantation tips and tricks have been made. 
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abstract
background
Limited data are currently available on the performance of everolimus-eluting biore-
sorbable vascular scaffold (BVS) for treatment of complex coronary lesions representa-
tive of daily practice. 
methods
This is a prospective, mono-center, single-arm study, reporting data after BVS implanta-
tion in patients presenting with stable, unstable angina, or non-ST segment elevation 
myocardial infarction caused by de novo stenotic lesions in native coronary arteries. No 
restrictions were applied to lesion complexity. Procedural results and 12-month clinical 
outcomes were reported.
results
A total of 180 patients have been evaluated in the present study, with 249 treated coro-
nary lesions. Device Success per-lesion was 99.2%. A total of 119 calcified lesions were 
treated. Comparable results were observed among severe, moderate and non-calcified le-
sions in term of %diameter stenosis (%DS) (20.3±10.5%, 17.8±7.7%, 16.8±8.6%; p=0.112) 
and acute gain (1.36±0.41mm, 1.48±0.44mm, 1.56±0.54 mm; p=0.109). In bifurcations 
(54 lesions), side-branch ballooning after main vessel treatment was often performed 
(33.3%) with low rate of side-branch impairment (9.3%). A total of 29 cases with coronary 
total occlusions were treated. After BVS implantation  %DS was not different from other 
lesion types (17.2±9.4%, vs 17.7±8.6%; p=0.780). At one year, all-cause mortality was 
reported in 3 cases. A total of 5 target lesion revascularizations and 4 non-target vessel 
revascularisations were reported. Four cases of definite scaffold thrombosis occurred.
conclusions
The implantation of the everolimus-eluting bioresorbable vascular scaffold in an ex-
panded range of coronary lesion types and clinical presentations was observed to be 
feasible with promising angiographic results and mid-term clinical outcomes.
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introDuction
The everolimus-eluting bioresorbable vascular scaffolds (BVS) represent a novel ap-
proach for treatment of coronary artery disease. Similarly to conventional metal stents 
the absorb BVS provide acute lumen gain, vessel scaffolding and drug elution to the 
vessel wall immediately after implantation.1 However, at variance with standard stents, 
the polymeric structure of this device allows a gradual bioresorption of the implant over 
time.2 Complete scaffold bioresorption is hypothesized to offer several advantages over 
permanent metal devices comprising re-acquirement of physiological vasomotion, late 
lumen enlargement, non-invasive imaging and future treatment with bypass grafting.3-5 
In addition the absence of a foreign body could avoid phenomena such as permanent 
side-branch jailing, late acquired malapposition and the occurrence of late and very late 
stent thrombosis.5 
The absorb BVS has been initially tested in humans in two cohort studies, both 
showing promising results in terms of surrogate and clinical endpoints.6-9 However, be-
ing those studies an early evaluation of this technology, they were characterized by a 
patient population showing stable coronary artery disease and relatively simple lesions. 
The first randomized data in selected patients (Absorb II, Absorb Japan) supported the 
further development of this technique.
At the current state of the art, very limited data are available on BVS performance 
in real-world patients, including those presenting with acute coronary syndromes and 
complex lesions. A lack of information is especially evident when considering important 
lesion subsets such as calcified plaques, long lesions, bifurcations, and total occlusions.  
Given this background, the present study aims to report angiographic and clinical 
data after an expanded clinical use of the second generation BVS, implanted in patients 
admitted with different clinical presentations including acute coronary syndromes and 
having a broad range of coronary lesion types.
methoDs
This is an investigator initiated, prospective, single-centre, single-arm post market 
study, aiming to evaluate the feasibility safety and performance of the absorb BVS for 
treatment of patients with coronary artery disease in routine clinical practice. Enrolled 
patients were subjects presenting with stable, unstable angina, or non-ST segment 
elevation myocardial infarction caused by de novo stenotic lesions in native coronary 
arteries. No restrictions were applied to lesion complexity. Due to the absorb BVS size 
availability, a Dmax (proximal and distal mean lumen diameter) within the upper limit 
of 3.8 mm and the lower limit of 2.0 mm by online QCA was required. Exclusion criteria 
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were minimal and comprised allergies or contraindications to antiplatelet medication, 
female patient with childbearing potential or currently breastfeeding, acute ST segment 
elevation myocardial infarction and post CABG patients. As per hospital policy patients 
with a previously implanted metal DES in the intended target vessel were also excluded. 
Also, although old age was not an exclusion criterion, BVS were in general reserved 
for younger patients, and left to operator’s interpretation of biological age. A hybrid 
approach combining BVS with small DES or large DES where necessary was also not 
recommended. 
All patients were treated with DAPT according to current guidelines. DAPT was 
prescribed for one year after PCI.  Prasugrel was standard therapy for ACS presenting 
patients while clopidogrel was initiated for stable angina patients only. 
To assess clinical outcomes, a questionnaire was sent to all living patients with specific 
queries on re-hospitalization and cardiovascular events. For patients who suffered an 
adverse event at another center, medical records or discharge letters from the other 
institutions were systematically reviewed. General practitioners and referring physicians 
were contacted for additional information if necessary.
ethics 
This is an observational study, performed according to the privacy policy of the Erasmus 
MC, and to the Erasmus MC regulations for the appropriate use of data in patient-
oriented research, which are based on international regulations, including the declara-
tion of Helsinki. The BVS received the CE mark for clinical use, indicated for improving 
coronary lumen diameter in patients with ischemic heart disease due to de novo native 
coronary artery lesions with no restriction in terms of clinical presentation. Therefore 
the BVS can be currently used routinely in Europe in different settings without a specific 
written informed consent in addition to the standard informed consent prior to the 
procedure. Therefore, a waiver from the hospital Ethical Committee was obtained for 
written informed consent, as according to Dutch law written consent is not required, 
if patients are not subject to acts other than as part of their regular treatment. Specific 
written informed consent post procedure was asked for a detailed follow-up program.
study device 
The device used in the present study is the second generation Absorb BVS (Abbott 
Vascular, Santa Clara, CA, USA); a balloon expandable scaffold with a polymer backbone 
of Poly-L lactide Acid (PLLA) coated with a thin layer of a 1:1 mixture of an amorphous 
matrix of Poly-D and L lactide acid (PDLLA) polymer, controlling the release of 100 mi-
crograms/cm2 of the anti-proliferative drug everolimus. Two platinum markers located 
at each Absorb BVS edge allowing for accurate visualization of the radiolucent Absorb 
BVS during angiography or other imaging modalities. Approximately 80% of the drug 
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is eluted within the first 30-days. Both PLLA and PDLLA are fully bioresorbable. The 
polymers are degraded mainly via hydrolysis resulting oligomers of lactate metabolized 
by Krebs cycle. Small particles, less than 2 μm in diameter, have also been shown to be 
phagocytised and degraded by macrophages.
Definitions 
Device Success was defined as the attainment of <30% final in segment residual stenosis 
after absorb BVS implantation, by angiographic visual estimation. Procedure Success 
was defined as device success and no major peri-procedural complications (Emergent 
CABG, coronary perforation requiring pericardial drainage, residual dissection impairing 
vessel flow – TIMI-flow II or less -). Clinical success was defined as procedural success 
and no in-hospital major adverse cardiac events (MACE). All deaths were considered 
cardiac unless an undisputed non-cardiac cause was identified. Myocardial infarction 
(MI) and scaffold thrombosis were defined according to the Academic Research Consor-
tium (ARC) definition. Any Target lesion revascularization (TLR) was defined as clinically 
driven if at repeat angiography a diameter stenosis >70% was observed, or if a diameter 
stenosis >50% was present in association with recurrent angina pectoris; objective signs 
of ischaemia (ECG changes) at rest or during exercise test, likely to be related to the 
target vessel; abnormal results of any invasive functional diagnostic test. 
Target lesion failure was defined as the composite of cardiac death, target vessel 
myocardial infarction, or ischemia driven target lesion revascularization.  Major adverse 
cardiac events (MACE), defined as the composite of cardiac death, any re-infarction 
(Q or Non Q-Wave), emergent bypass surgery (CABG), or clinically driven target lesion 
revascularization (TLR). Target vessel failure (TVF) was defined as cardiac death, target 
vessel myocardial infarction (MI), or clinically driven target vessel revascularization 
(TVR). Delivery failure was defined as opening of scaffold from its cover and insertion 
into the guiding-catheter without final implantation. 
All potential events were adjudicated by a local independent Clinical Events Commit-
tee (CEC). 
Quantitative coronary angiography 
Quantitative coronary angiography (QCA) analyses were performed using the Coronary 
Angiography Analysis System (Pie Medical Imaging, Maastricht, Netherlands). 
The QCA measurements we performed pre and post BVS implantation. The 37 μm 
platinum radio-markers located at each end of the Absorb BVS aided in the localisation 
of the non-radio-opaque scaffold for QCA. Analysed parameters included reference ves-
sel diameter (RVD) - calculated with interpolate method - percentage diameter stenosis 
(%DS) and minimal lumen diameter (MLD). Acute gain was defined as post-procedural 
MLD minus pre-procedural MLD. The angiographic analysis were performed by three 
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investigators (YI, YO and RD) who were extensively trained in an experienced core-lab 
(Cardialysis BV, Rotterdam, The Netherlands) 
A calcified coronary culprit lesion was defined as already reported10 ‘readily apparent 
densities noted within the apparent vascular wall at the site of the stenosis.’ By qualita-
tive assessment of the angiograms, target lesions were classified as severe (‘radioopaci-
ties noted without cardiac motion prior to contrast injection generally involving both 
sides of the arterial wall’), moderate (‘densities noted only during the cardiac cycle prior 
to contrast injection’), or none/mild (lesions other than severe and moderate calcified 
lesions). The Inter- and intra-observer variability in the qualitative analysis of coronary 
calcium on coronary angiograms have been already reported. 11
To provide insights on the coronary bifurcation treatment with BVS we performed a full 
analysis of techniques and material used and we reported the occurrence of side-branch 
impairment, an end-point already reported in the literature as “side-branch trouble”12 
and defined as follow: at least 1 of the following procedural parameters: 1) Side-branch 
TIMI flow grade <3 after main vessel stenting; 2) need of guide-wire(s) different from the 
workhorse wire to rewire side-branch after main vessel scaffolding; 3) failure to rewire 
the side-branch after main vessel scaffolding; or 4) failure to dilate the side-branch after 
main vessel scaffolding and side-branch rewiring.
statistical analysis
Categorical variables are reported as counts and percentages, continuous variables as 
mean ± standard deviation; p values were calculated with Fisher’s Exact test for binary 
variables, Wilcoxon’s Rank Sum test for continuous variables. Comparisons among mul-
tiple means were performed with analysis of variance (1-way ANOVA). A p value<0.05 
was considered statistically significant. Statistical analyses were performed using SPSS, 
version 15.0 for windows (IL,US).
results
From September 2012 to July 2013 a total of 1529 percutaneous coronary interven-
tions were performed in our center. A total of 180 patients have been enrolled in the 
present study, with 249 treated coronary lesions (Table 1). A total of 1157 patients were 
treated with standard second generation drug eluting stents. The remaining cases were 
treated with bare metal stents, dedicated bifurcation stents, balloon angioplasty only 
or thrombectomy only.  Baseline clinical characteristics of the patients implanted with 
bioresorbable devices compared with those of the patients implanted with second gen-
eration drug eluting metal stents are reported in the supplement (Table 4). We observed 
that patients treated with bioresorbable devices were overall younger, more frequently 
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smokers, and had a lower rate of prior myocardial infarction, PCI and CABG. Therefore, 
this patient population is slightly different from the general population treated with 
percutaneous coronary intervention in everyday practice. However, the observed differ-
ences are in line with the predefined exclusion criteria.
Seventy-three patients (40.6%) showed multivessel disease. A total of 109 lesions 
(43.8%) were classified as type B2 or C, mean lesion length was 25.86 mm, bifurcation 
lesions with side-branch ≥ 2 mm were 54, a total of 119 lesions were defined with severe 
or moderate calcification and in 29 cases was present a total occlusion (Table 1).
Lesion preparation was performed in a large part of the cases mainly through balloon 
pre-dilatation (89.2%); rotational atherectomy was necessary in 4.8% of cases. Multiple 
scaffold implantations per lesion were allowed and often performed, (31.7%) up to the 
implantation of 5 scaffolds.
table 1 Baseline clinical and lesion characteristics
clinical characteristics n = 180
Age 60.6 ± 10.6
Male n. (%) 134 (74.4%)
Hypertension n. (%) 94 (52.2%)
Hypercholesterolemia n. (%) 84 (46.7%)
Diabetes n. (%) 32 (17.8%)
Smoke n. (%) 99 (55.0%)
Peripheral vascular disease n. % 19 (10.6%)
CVA n. (%) 14 (7.8%)
Kidney disease n. (%) 11 (6.1%)
Prior MI n. (%) 30 (16.7%)
Prior PCI n. (%) 17 (9.4%)
Prior CABG n. (%) 0 (0.0%)
COPD n. (%) 11 (6.1%)
History of heart failure n. (%) 10 (5.6%)
lesion characteristics l= 249
One vessel disease 107 / 180 (59.4%)
Two vessel disease 61 / 180 (33.9%)
Three vessel disease 12 / 180 (6.7%)
number of treated lesions per vessel (%)
0 lesion 1/ 249 (0.4%)
1 lesion 189 / 249 (75.9%)
2 lesions 54 / 249 (21.7%)
3 lesions 4 / 249 (1.6%)
4 lesions 1 / 249 (0.4%)
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No scaffold dislodgment was reported. Bailout with drug eluting metal stents was 
performed in only 2 cases. Balloon post-dilatation was performed in a remarkable per-
centage of cases (45.0%) with often a balloon/scaffold ratio > 1.0 (41.8%). (Table 2) The 
overall device, procedure and clinical success rates per lesion, were respectively 99.2%, 
98.8% and 98.8%
table 1 Baseline clinical and lesion characteristics (continued)
lesion characteristics l= 249
lesion location (%)
LAD 120 / 249 (48.2%)
LCX 55 / 249 (22.1%)
RCA 66 / 249 (26.5%)
Diagonal 7 / 249 (2.8%)
LMCA 1 / 249 (0.4%)
aha/acc lesion classification (%)
A 38 / 249 (15.3%)
B1 103 / 249 (41.4%)
B2 63 / 249 (25.3%)
C 46 / 249 (18.5%)
Lesion length (mm) 25.86 ± 13.64
Range min, max (mm) 5.32 - 80.01
Bifurcation lesion n. (%) 54 / 249 (21.7%)
Total occlusion (%) 29 / 249 (11.6%)
Calcification lesion (%) 119/ 249 (47.8%)
CVA= cerebrovascular accident; PCI = percutaneous coronary intervention; CABG = coronary artery bypass 
graft; COPD = chronic obstructive pulmonary disease. Data are expressed as mean ± standard deviation or 
number and proportion
table 2 Procedural data per-lesion analysis
lesion characteristics l= 249
number of scaffold or stent – per lesion (%)
Average 1.41± 0.75
0 scaffold or stent 1 / 249 (0.4%)
1 scaffold or stent 169 / 249 (67.9%)
2 scaffolds or stents 61 / 249 (24.5%)
3 scaffolds or stents 10 / 249 (4.0%)
4 scaffolds or stents 7 / 249 (2.8%)
5 scaffolds or stents 1 / 249 (0.4%)
Overlapping  78 
Overlapping BVS-BVS 76
Overlap scaffolds diameters 3.5mm-3.5mm,n (%) 20 (26.3%)
Overlap scaffolds diameters 3.5mm-3.0mm,n (%) 15 (19.7%)
Overlap scaffolds diameters 3.5mm-2.5mm,n (%) 3 (3.9%)
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table 2 Procedural data per-lesion analysis (continued)
lesion characteristics l= 249
Overlap scaffolds diameters 3.0mm-3.0mm,n (%) 15(19.7%)
Overlap scaffolds diameters 3.0mm-2.5mm,n (%) 15 (19.7%)
Overlap scaffolds diameters 2.5mm-2.5mm,n (%)  8 (10.5%)
Overlapping BVS-Metal 2 (2.6%)
bailout scaffold/stent (%) – per lesion
with BVS 8 / 249 (3.2%)
with Metallic stent 2 / 249 (0.8%)
Pre dilatation (%) 222 / 249 (89.2%)
type of pre-dilatation balloon*
Non-compliant 16 / 203 (7.9%)
Semi-compliant 187 / 203 (92.1%) 
The usage of scoring (scoreflex or cutting) 9 / 219 (4.1%)
Average size of balloon 2.52 ± 0.36
Balloon / artery (pre-RVD)  ratio < 1 (excluding total occlusion before procedure) 100 / 184 (54.3%) 
Balloon / scaffold ratio ≤1 198 / 202 (98.0%) 
Balloon 0.5mm smaller ≤ scaffold size 172/202 (85.1%) 
Max pressure 13.95 ± 2.86
use of other devices for lesion preparation 
Rotational atherectomy 12 / 249 (4.8%)
Manual thrombectomy 11 / 249 (4.4%)
Daughter catheter 5 / 249 (2.0%)
Buddy wire 18 / 249 (7.2%)
Post-dilatation (%) 112 / 249 (45.0%)
type of post-dilatation balloon**
Compliant 32 / 110 (29.1%) 
Non-compliant 78 / 110 (70.9%) 
Average size of balloon 3.27 ± 0.46 mm
Max pressure 15.58± 3.46
Balloon / Artery < 1 25 / 110 (22.7%)
Balloon > Scaffold size 46 / 110 (41.8%)
Balloon > Scaffold size+0.25mm 15 / 110 (13.6%)
Device success per lesion (%) 247 / 249 (99.2%)
Procedure success per lesion (%) 246 / 249 (98.8%)
Clinical success per lesion 246 / 249 (98.8%)  
Qca pre-procedure 
RVD (mm) 2.63 ± 0.43
MLD (mm) 0.90 ± 0.35
% DS (%) 64.8 ± 14.5
Proximal Dmax (mm) 3.92 ± 8.28
Distal Dmax (mm) 2.89 ± 2.31
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Qca analysis 
The mean pre-procedure reference vessel diameter (RVD) was 2.63 ± 0.43 mm, with a 
mean percentage diameter stenosis (%DS) of 64.8 ± 14.5% and a mean minimal lumen 
diameter (MLD) equal to 0.90 ± 0.35 mm. Post-procedure %DS was 17.60 ± 8.65 % with a 
mean MLD equal to 2.41 ± 0.41 mm reflecting a mean acute gain of 1.51 ± 0.49 mm. TIMI 
3 flow was observed in 99.2% of the final angiograms. (Table 2, Figure 1)
bifurcation lesions 
A total of 54 lesions were located at the site of a bifurcation with a side-branch ≥ 2.0 
mm. In 51 cases a provisional side branch technique was used, in addition 1 T-stenting, 1 
culotte, 1 T-stenting with small protrusion (TAP) techniques were performed. In 18 cases 
side-branch wire protection was used, pre-dilatation and post-dilatation of the main 
vessel was often performed. Side-branch dilatation post MV stenting was necessary in 
table 2 Procedural data per-lesion analysis (continued)
lesion characteristics l= 249
Qca Post-procedure in-scaffold
RVD (mm) 2.89 ± 0.42
DS (%) 17.6 ± 8.65
MLD (mm) 2.41 ± 0.41
Scaffold length 29.44± 15.71
Acute gain (mm) 1.51 ± 0.49
TIMI grade 2 2 / 249 (0.8%)
TIMI grade 3 247 / 249 (99.2%)
*Type of pre-dilatation balloon is reported in a subgroup of 203 patients. ** Type of post-dilatation balloon 
is reported in a subgroup of 110 patients. Data are expressed as mean ± standard deviation or number and 
proportion
figure 1 Vessel and scaffold diameters and lengths
Left panel, Cumulative frequency distribution of the reference vessel diameter the proximal end distal di-
ameter in relation with the nominal size of the implanted scaffolds. Right panel, Cumulative frequency 
distribution of the lesion length in relation with the length of the implanted scaffolds 
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18 lesions. A final TIMI flow <3 in the main vessels (MV) was observed in only one case, 
in the side-branch this was reported in 3 lesions. Failure to re-wire the side-branch was 
never reported but in one case the operator was unable to re-cross the scaffold with 
a small balloon of 1.5 mm in diameter. (Table 5 Supplement) The overall rate of side-
branch impairment was 9.3% (5/54)
calcified lesions 
A total of 119 calcified lesions were treated with BVS, 33 with severe calcification, 86 
with moderate calcification, (Figure 2) and compared with non-calcified lesions.  After 
treatment no differences were observed between calcified and non-calcified lesions 
in terms of MLD (Severe calcified 2.38 ± 0.38 mm, moderate calcified 2.41 ± 0.39 mm, 
non-calcified 2.42 ± 0.43 mm; p=0.889), %DS (Severe calcified 20.3 ± 10.5 %, moder-
ate calcified 17.8 ± 7.7%, non-calcified 16.8 ± 8.6%; p=0.112) and acute gain (Severe 
calcified 1.36 ± 0.41mm, moderate calcified 1.48 ± 0.44 mm, non-calcified 1.56 ± 0.54 
mm; p=0.109). These results were achieved with an overall higher use of buddy wires 
in calcified lesions (severe calcified 18.2%, moderate calcified 9.3%, non-calcified 3.0%; 
p=0.016)
figure 2 Calcified lesion and long lesions
Right panel. Calcified lesions. Angiogram showing a long lesion in the RCA (panel A). IVUS pre-procedure 
(Panel a) shows at the MLA more than 180 degrees superficial calcium (*). Panel B shows the angiogram 
after pre-dilatation (semi-compliant balloon  3.0 x 20mm).  IVUS (panel b) shows clear “cracks” in the calcium 
(arrowheads), reducing the plaque resistance, thus sufficiently prepared for BVS implantation.  Panels C and 
c show respectively the result on angiogram and on IVUS after implanting a BVS 3.5 x 28mm. Left panel. 
Long lesions. The angiogram top left shows the long lesion in the LAD. The mid-panel shows the markers 
of the two overlapping scaffolds (a & c distal BVS 3.0 x 28mm and b & d proximal BVS 3.5 x 18mm). The top 
right shows the final result with the OCT cross-section positions indicated by a to d).  OCT (St.Jude Lightlab 
Dragonfly™) shows a well deployed scaffold. Panels B & C show the markers of respectively the proximal 
and distal scaffolds (*), indicating an overlap of approximately 1 mm. 
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Lesion preparation was more aggressive in calcified lesions with a higher use of 
rotational atherectomy (severe calcified 18.2%, moderate calcified 4.7%, non-calcified 
1.5%; p<0.001) and scoring balloons (severe calcified 15 .2%, moderate calcified 3.5%, 
non-calcified 0.8%; p=0.001). Success rates were high in calcified vessels showing no 
significant differences when compare do non-calcified ones. Device success in severe 
calcified lesions was 97.0%, in moderate calcified 100%  and in non-calcified 99.2%; 
p=0.251. (Table 3)
total occlusions 
Vessels showing a total occlusion were 29. After vessel recanalization BVS implantation 
was performed achieving a final MLD and %DS not different from other lesion types 
(MLD: 2.51 ± 0.53 mm vs 2.40 ± 0.39; p=0.163; %DS: 17.2 ± 9.4% vs 17.7 ± 8.6%; p=0.780), 
with a high rate of final device success (96.6% vs 98.2%; p=0.465) and procedure suc-
cess (96.6% vs 98.6%; p=0.393). To reach those results supportive wires were used much 
more frequently in occluded vessels (54.2% vs 2.1%; p<0.001). (Table 3, Figure 2)
table 3 BVS implantation in calcified and total occluded lesions
calcified lesions
severe 
calcification 
(l = 33)
moderate 
calcification 
(l =86 )
no calcification 
(l  =130 )
P value
Lesion preparation
Rotational atherectomy ,% (n) 18.2% (6/33) 4.7% (4/86) 1.5% (2/130) <0.001
Scoring balloon ,% (n) 15.2% (5/33) 3.5% (3/86) 0.8% (1/130) 0.001
Daughter catheter ,% (n) 3.0% (1/33) 2.3% (2/86) 1.5% (2/130) 0.886
Buddy wire,% (n) 18.2% (6/33) 9.3% (8/86) 3.0% (4/130) 0.016
Average size of balloon 2.48 ± 0.38 2.55 ± 0.35 2.52 ± 0.36 0.702
Non-compliant balloon ,% (n) 13.3% (4/30) 9.5% (7/74) 5.1% (5/99) 0.276
QCA pre-procedure
RVD (mm) 2.51 ± 0.35 2.66 ± 0.43 2.64 ± 0.46 0.256
MLD (mm) 0.97 ± 0.40 0.92 ± 0.36 0.87 ± 0.34 0.358
% DS (%) 62.3 ± 13.5 65.0 ± 12.6 65.3 ± 15.7 0.592
Lesion length 36.11 ± 2.34 27.99 ± 1.54 22.11 ± 1.16 <0.001
QCA post-procedure
RVD (mm) 2.97 ± 0.38 2.93 ± 0.39 2.85 ± 0.46 0.244
MLD (mm) 2.38 ± 0.38 2.41 ± 0.39 2.42 ± 0.43 0.889
% DS 20.3 ± 10.5 17.8 ± 7.7 16.8 ± 8.6 0.112
Acute gain (mm) 1.36 ± 0.41 1.48 ± 0.44 1.56 ± 0.54 0.109
Device success per lesion, % (n) 97.0% (32/33) 100% (86/86) 99.2% (129/130) 0.251
Procedure success per lesion, % (n) 97.0% (32/33) 98.8% (85/86) 99.2% (129/130) 0.571
Clinical success (per lesion), % (n) 97.0% (32/33) 98.8% (85/86) 99.2% (129/130) 0.571
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long lesions
 In a total of 79 lesions (31.7%) more than one device was implanted (Figure 1, Figure 3). 
The mean lesion length treated with BVS was 25.86 ± 13.64 mm. The maximum lesion 
length covered by BVS was 80.01 mm. Overlapping of BVS with BVS was often performed 
with a total of 76 overlapping scaffolds. The great majority (96%, 73/76) were performed 
using scaffold of the same diameter or with a maximum of 0.5 mm difference in nominal 
diameter. In 3 cases a 3.5 mm scaffold was placed in overlap with a 2.5 mm device.  
clinical outcomes 
Survival data at 12 months after the procedure were available for 99.4 % of patients. At 
12-month follow-up all cause-death was reported in 3 cases. A total of 5 target lesion 
revascularizations and 4 non-target vessel revascularisations were reported. Four defi-
nite, scaffold thrombosis (ST) occurred within one year after index procedure; none of 
them was acute or sub-acute. Of note, one of those cases was meeting the ARC criteria 
for ST but no clear thrombus was observed by optical coherence tomography (OCT). 
In the remaining 3 cases, severe calcification, bifurcation lesion and long overlap were 
observed but BVS underexpansion was the factor that was present in all of them. 
table 3 BVS implantation in calcified and total occluded lesions (continued)
occluded vs non-occluded
occluded
(l =29)
non-occluded
(l  = 220)
P value
QCA post-procedure 
RVD (mm) 3.01 ± 0.47 2.88 ± 0.41 0.103
MLD (mm) 2.51 ± 0.53 2.40 ± 0.39 0.163
% DS (%) 17.2 ± 9.4 17.7 ± 8.6 0.780
Acute gain (mm) - 1.51 ± 0.49 -
Procedural characteristics
Daughter catheter, % (n) 3.4% (1/29) 1.8% (4/220) 0.465
Buddy wire, % (n) 10.3% (3/29) 6.8% (15/220) 0.449
Type of first wire (after recanalization)
Supportive 54.2% (13/ 24) 2.1% (4/195) <0.001
Non-supportive 45.8% (11/24) 97.9% (191/195) <0.001
Device success after recanalization, % (n) 100% (29/29) 99.1% (218/220) 1.0
Procedure success after recanalization, % (n) 100% (29/29) 98.6% (217/220) 1.0
Clinical success after recanalization, % (n) 100% (29/29) 98.6% (217/220) 1.0
Data are expressed as mean ± standard deviation or number and proportion
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Discussion 
The present investigation represents an evaluation of the feasibility of BVS implantation 
in everyday clinical practice reflected by in a wide range of coronary lesions subsets 
including bifurcations, calcified vessels, chronic total occlusions and long lesion in pa-
tients with stable coronary artery disease and acute coronary syndromes. At variance of 
figure 3 Chronic total occlusion and bifurcation
Top panels show from left to right the angiograms pre-procedure, after recanalization and scaffold implan-
tation (BVS 3.0 x 28mm with the sequential post dilatation of the diagonal and the scaffold in the main 
branch) and 2-month follow-up with partial distal vessel positive remodelling. Characters a-c indicate the 
positions of the OCT cross-sections.  OCT (St.Jude Lightlab Dragonfly™) post procedure show distal a well 
deployed scaffold (Panel A), a well opened carina with the diagonal branch (Panel B *) and the overlap of 
the proximal marker with the septal branch (Panel C *). The 3D reconstruction (Intage realia™, Cybersys-
tems, Tokyo, Japan) shows the opening of the struts at the carina with the diagonal branch. (Arrowhead 
bottom panel).
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previous reports we also aimed to provide a detailed description of procedural data and 
techniques that were used to allow the use of this novel device in challenging subsets. 
bifurcation lesions 
A common concern regarding this technology is the fact that implantation of the BVS in 
bifurcation lesions might result in side-branch compromise due to the thick strut nature 
of this device. In keeping with this concept, a recent study performed by our group 
showed that BVS deployment could be associated with an increased small (≤0.5 mm) 
side-branch occlusion and a consequent increase of enzymes release after procedure.13
However, in the present report the effect of BVS implantation in what is commonly 
considered a bifurcation lesion (with a side branch ≥ 2 mm) was specifically investigated. 
Rewiring of the side-branch in those cases and consequent ballooning (mainly with 
small balloon 1.5-2 mm in diameter) of the SB ostium is feasible as we already reported13 
and safe also in terms of scaffold geometry and fracture.14, 15 In the present study 
side-branch ballooning was performed in one third of the patients (33%, 18/54) with 
promising results. In majority of the cases this was done with sequential ballooning and 
proximal optimization technique (POT), kissing balloon only in 3 cases.
Taking into consideration the rates of TIMI flow < 3 in the main vessel or in the side-
branch, the rate of failure to rewire the side-branch and failure to dilate the side-branch, 
the BVS performed at least as good as metallic if considering historical data. 12
In addition the rate of the composite endpoint side-branch impairment (9.3%) was 
observed to be encouraging especially when compared with data recently reported by 
Burzotta et al. with rates of side-branch impairment in sirolimus- and everolimus-eluting 
stents respectively 16% and 11%. 12 These data are supportive of the concept that BVS 
could be used safely in bifurcation lesions with side-branch ≥ 2.0 mm with a single scaf-
fold approach and could provide results similar to metallic stents.
calcified lesions 
A total of 119 calcified lesions with a considerable percentage of heavily calcified 
plaques, were treated with BVS. A large number of those lesions were located in dif-
fusely diseased vessels with an overall mean treated lesion length of more than 36 mm 
(severe calcified group). QCA analysis showed a final MLD, %DS, acute gain and device, 
procedural and clinical success not different from non-calcified lesions. These results 
were obtained at the cost of a more aggressive lesion preparation with a considerable 
use of rotational atherectomy and scoring balloons. 
Such approach is needed to facilitate the delivery of the scaffold given its slightly 
higher profile compared with second generation DES. In addition appropriate lesion 
preparation could avoid scaffold under-expansion or need for aggressive post-dilata-
tion. This strategy could be relevant also when using metallic stents. 16 Our data might 
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suggest feasibility of BVS implantation in calcified vessels with optimal results given an 
adequate lesion preparation.
Although, many of the advantages proposed for BVS, namely the restoration of the 
vasomotion and vessel physiology could be minimized in calcified artery, patients with 
diffused calcified vessels have often also a multivessel disease;17 in such scenario a tem-
porary implant would allow future surgical treatments. 
total occlusions 
Successful re-canalization of total occlusions has been previously associated with a sig-
nificant improvement in angina symptoms 18, 19 and complete coronary revascularization 
was demonstrated to have an important impact on long-term clinical outcomes.20 
Vessels with total occlusions have peculiar characteristics in terms of vascular re-
modelling; this is a dynamic process involving regulation of vascular cell migration and 
mitosis and apoptosis rates in response to several factors comprising blood flow and 
pressure, shear stress, circumferential stretch and wall tension.21 Reduction or even more 
absence of blood flow in totally occluded vessels might promote negative remodelling 
and plaque growth; on the other hand restoration of flow could have an opposite effect.
Recently, Park J.J. and colleagues reported, at 6-month follow-up after successful total 
occlusion revascularization, a flow-dependent vascular remodelling process in human 
coronary arteries, associated with increases in lumen diameter, lumen area and external 
elastic membrane area.22 This process was observed in a large part of treated vessels 
(69%) with a mean lumen diameter increase of 0.40 ± 0.34 mm. IVUS analysis of those 
vessels revealed that the amount of incomplete stent apposition increased significantly 
during 6 months in patients with positive remodelling and lumen area increase but not 
in those without lumen area increase. 
In this scenario choosing a metal stent based on the vessel diameter at the index 
procedure might lead to stent under-sizing.
Given this background a theoretical advantage of BVS implantation in patients with 
total occlusion is the fact that it might allow at mid-term follow-up, after the loss of 
scaffold mechanical integrity, late lumen enlargement without late acquired malapposi-
tion, as at that time the remnants of the bioresorbable implant can follow the vessel 
remodelling.
Long lesions and overlap 
In the present series several lesions were treated with more than one scaffold up to a 
maximum of 5 scaffolds for a maximum lesion length of 80 mm. Operators were advised 
to minimize the extension of overlapping segment using a marker-to-marker technique.
In the metal stent era, long segments treatment has been associated to an increased 
risk of stent thrombosis 23-25 and could results in prevention of future surgical revascu-
larisations. 
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Both these issues could be overcome with the use of bioresorbable technologies and 
the introduction in the near future of bioresorbable scaffold with thinner struts could 
mitigate the effect of overlap on delayed vascular healing.
clinical outcomes 
The mid-term clinical outcomes of this study revealed a relatively reassuring safety pro-
file of the BVS when used in a large range of lesion type and in patients with either stable 
symptoms or acute coronary syndromes. The event rate in this study is only minimally 
higher compared to the results in non-complex patients reported in the randomized 
Absorb II and Absorb Japan studies 26, 27. In other European registries like GHOST-EU and 
AMC registries 28, 29 reporting early experience with BVS, the event rate was in slightly 
higher compared with more recent registries like the Milan registry 30 and ASSURE BVS 
31  where more BVS specific implantation protocols where applied. Such observations 
suggest the relevance of a BVS dedicated implantation technique ensuring good lesion 
preparation and optimal scaffold deployment often facilitated by high pressure post-
dilatation.
Regarding the occurrence of scaffold thrombosis (ST), at variance with previous 
reports no acute or sub-acute STs were observed in the present investigation. These 
findings could be related to procedural characteristics including a meticulous lesion 
preparation pre-BVS implantation and a reasonably high rate of post-dilatation. 
The review of the cases with ST revealed that several factors might be associated 
with such events comprising severe lesion calcification, the presence of bifurcations, 
long overlap and antiplatelet therapy discontinuation. However, the factor that was 
particularly consistent was scaffold under-expansion. Previous investigations described 
stent underexpansion as an important predictor of ST with both bare metal stents and 
DES,32-36 with an impact on the occurrence of ST that was hypostasized to be superior 
to stent malapposition.37 The mechanisms behind these findings could be the fact that 
stent underexpansion translates into an abnormal shear stress. In particular increased 
radial transport of blood components and low wall shear stress, were described to pro-
mote platelet-dependent thrombosis.38 In addition the impact of underexpansion on 
shear stress could be potentiated by the presence of the BVS thick struts.39 
Although, given the small number of patients and events reported in the present 
study it is not possible to reach firm conclusions, our findings suggest that optimal BVS 
expansion, with lesion preparation and appropriate scaffold post-dilatation, should be 
pursued given the possible relevant clinical implications. 
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limitations
The present report is an investigator initiated, single center, single arm study. The choice 
for BVS implantation was left to operator discretion; this could be source of selection 
bias. The absence of a comparator arm is limiting the interpretation of our data. The lim-
ited number of patients does not allow reaching firm conclusions on clinical outcomes. 
The mid-term follow-up is preventing the availability of information on long-term safety 
and efficacy.
conclusion
The implantation of the everolimus-eluting bioresorbable vascular scaffold in an 
expanded range of coronary lesion types and clinical presentations was observed to 
be viable with promising angiographic results and mid-term clinical outcomes. Larger 
studies with longer follow-up and a direct comparison with currently available metallic 
drug eluting stents are needed to fully evaluate the possible additional value of the 
bioresorbable technologies an all comers setting.
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suPPlemental material
Description of the scaffold thrombosis cases  
Case 1: A 59-year old male patient, smoker, with history of cerebrovascular accident and 
stable angina pectoris, was treated after pre-dilatation of a long lesion involving the 
ostial left anterior descending (LAD) and the bifurcation with the first diagonal (D1), us-
ing a BVS 3.5 x 28mm. Despite a post-dilatation was performed with a 3.5 non-complaint 
(NC) balloon at high pressure, the BVS remained under-expanded with an impaired 
flow in the first diagonal. At day 111 post PCI the patient was re-admitted with NSTEMI, 
while being on DAPT, and angiographically was observed a total re-occlusion of the 
LAD beginning from the ostium. After pre-dilatation a DES 3.5 x32mm was implanted. 
Of note, at day 81 after the second PCI the patients was again re-admitted for instable 
angina pectoris caused by a re-occlusion also of the metal stent in the proximal LAD. The 
patient was treated with CABG.
Lesion key characteristics: Ostial lesion, long lesion, bifurcation, impaired side-branch 
TIMI flow and BVS underexpansion
Case 2: A 69-year old male with history of dyslipidaemia and hypertension was admit-
ted with NSTEMI. Angiographically was observed a long, severely calcified, chronic total 
occlusion (CTO) of the proximal and mid LAD with severe calcification and involvement 
of D1. After Pre-dilatation, 2x 3.5 x 18mm BVS were implanted. The procedure was 
complicated by pinching of D1 and thrombus formation. Additional ballooning of the 
ostium of the side-branch was performed, but at the end of the procedure remained 
BVS underexpansion and haziness in the mid LAD. Despite continued DAPT usage the 
patient developed on day 47 a non-Q wave MI due to definite scaffold thrombosis in the 
proximal LAD, which was treated with thrombectomy and DES implantation. 
Lesion key characteristics: CTO, long lesion, bifurcation, severe calcification, thrombus 
formation and BVS underexpansion 
Case 3: A 65-year old male patient, smoker, with history of hypertension was admitted 
with NSTEMI, due to a sub-occlusive lesion in the LAD located at the site of a tortuous 
trifurcation with the first and second diagonal. The initial TIMI flow was 1. After pre-
dilatation, a 3.0 x 18mm BVS was implanted and after post-dilatation a TIMI III flow was 
achieved. At day 142 on DAPT the patient was re-admitted with NSTEMI. Angiographi-
cally a proximal BVS edge sub-total restenosis was observed with a distal TIMI flow 1. A 
DES stent 3.5 x38mm was deployed covering the BVS and a large proximal segment. Of 
note, this case was meeting the ARC criteria for stent thrombosis and was adjudicated as 
such by the CEC, but should be mentioned that an OCT performed before pre-dilatation 
did not showed any clear intraluminal thrombus. 
Lesion key characteristics: tortuous trifurcation (no thrombus by OCT) 
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Case 4: A 70-year old male, with severe peripheral vascular disease, diabetes mellitus, 
dyslipidaemia, hypertension, and reduced left ventricular function was admitted with 
stable angina pectoris. Angiography revealed, a long and severely calcified lesion mid 
LAD involving two bifurcations (D1 and D2). Aggressive preparation was performed with 
rotational atherectomy and high-pressure dilatations with NC and cutting balloons. Two 
overlapping BVS were placed with a quite long segment of overlap (5 mm). Despite 
extensive post-dilatation under-expansion remained at the end of the procedure. Five 
months after index PCI, the patient underwent non-cardiac surgery. The antiplatelet 
therapy was interrupted (both aspirin and clopidogrel) and the patient developed a 
NSTEMI due to a scaffold thrombosis that was treated with balloon dilatation and eptifi-
batide. Unfortunately, the patient died few days later because of heart failure.
Lesion key characteristics: Severe calcification, bifurcation, long overlap, no antiplate-
let therapy and BVS underexpansion 
table 4 Baseline clinical characteristics
Clinical characteristics N = 180 N=1157
Age 60.6 ± 10.6 66.1 ± 11.7 <0.001
Male n. (%) 134 (74.4%) 850 (73.5%) 0.69
Hypertension n. (%) 94 (52.2%) 661 (57.1%) 0.54
Hypercholesterolemia n. (%) 84 (46.7%) 504 (43.6%) 0.18
Diabetes n. (%) 32 (17.8%) 231 (19.9%) 0.80
Smoke n. (%) 99 (55.0%) 481 (41.6%) < 0.001
Peripheral vascular disease n. % 19 (10.6%) 101 (8.7%) 0.32
CVA n. (%) 14 (7.8%) 87 (7.5%) 0.73
Kidney disease n. (%) 11 (6.1%) 122 (10.5%) 0.06
Prior MI n. (%) 30 (16.7%) 305 (26.3%) 0.01
Prior PCI n. (%) 17 (9.4%) 358 (30.9%) < 0.001
Prior CABG n. (%) 0 (0.0%) 118 (10.2%) < 0.001
COPD n. (%) 11 (6.1%) 71 (6.1%) 0.81
History of heart failure n. (%) 10 (5.6%) 70 (6.0%) 0.74
CVA= cerebrovascular accident; PCI = percutaneous coronary intervention; CABG = coronary artery bypass 
graft; COPD = chronic obstructive pulmonary disease. Data are expressed as mean ± standard deviation or 
number and proportion
table 5 BVS implantation in Bifurcation lesions 
Procedural characteristics  L=54
LAD 38
CX 12
RCA 4
Involvement of both SB and MV (Medina 111, 101, 011) 15 (27.8%)
1 Scaffold  technique 51 (94.4%)
Provisional  T 51 (94.4%)
T-stenting 1 (1.8%)
Culotte 1 (1.8%)
TAP 1 (1.8%)
MV pre-dilatation 44 (81.4%)
MV post-dilatation 26 (44.4%)
SB pre-dilatation 6 (11.1%)
SB dilatation post MV Scaffolding 18 (33.3%)
Kissing balloon 3 (5.6%)
Proximal optimization technique 26 (44.4%)
Final MV TIMI  flow <3 1 (1.8%)
Side-branch TIMI flow <3 3 (5.6%)
Failure to rewire the SB 0 (0%)
Different wire from the workhorse to rewire SB after MV scaffolding 2 (3.7%)
Failure to dilate SB 1 (1.8%)
Composite of side-branch impairment 5 (9.3%)
Data are expressed as mean ± standard deviation or number and proportion
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structureD abstract
objectives
The aim of this study was to determine if there are significant differences in curvature of 
the treated vessel after the deployment of a polymeric BRS or MPS in long lesions.
background
The impact of long polymeric Bioresorbable Absorb scaffolds (BRS) compared with 
metallic platform stents (MPS) on vessel curvature is unknown.
methods
This retrospective study compares 32 patients who received a single everolimus-eluting 
BRS with 32 patients treated with a single MPS of 28mm. Quantitative coronary angiog-
raphy (QCA) was used to evaluate curvature of the treatment and peri-treatment region 
before and after percutaneous coronary intervention (PCI). 
results
Baseline demographic and angiographic characteristics were similar between the BRS 
and MPS groups. Pre-treatment lesion length was 22.19 mm vs 20.38 mm in the BRS 
and MPS groups respectively (p=0.803). After treatment, there was a decrease in median 
diastolic curvature in the MPS group (from 0.257cm-1 to 0.199cm-1, p= 0.001).  A similar 
trend was observed in the BRS group but did not reach statistical significance (median 
diastolic curvature from 0.305cm-1 to 0.283cm-1, p= 0.056).  Median Percentage relative 
change in diastolic curvature was lower in the BRS group compared with the MPS group 
(BRS vs MPS: 7.48% vs 29.4%, p= 0.013). By univariate analysis, use of MPS was an inde-
pendent predictor of change in diastolic curvature (p = 0.022).
conclusions
In the deployment of long coronary scaffolds/ stents (28mm in length), BRS provides 
better conformability compared with MPS.
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introDuction
The everolimus-eluting Bioresorbable Absorb scaffold (BRS) (Abbott Vascular, Santa 
Clara, California) represented a novel change in the treatment of coronary artery lesions. 
The BRS is composed of a poly-L-lactic acid (PLLA) - based platform which had been 
shown to provide similar outcomes to best-in-class metallic drug eluting stents (DES) 
[1]. Besides the ability to have complete strut resorption at 36 months, there are several 
potential benefits of BRS including no trigger for thrombosis after resorption and resto-
ration of vasoreactivity [2]. Typically, implantation of hard metallic implants straightens 
the coronary artery and thus modifies its curvature. A previous computational study 
demonstrated that after implantation of a metallic implant in a coronary artery, the 
curvature of the stent edges alters significantly which correlate to the changes in shear 
stress distribution and potentially with the neointimal proliferation pattern [3]. As im-
plantation of coronary stents/ scaffolds can alter blood rheology especially at the inflow 
and outflow edge of the stents, the vessel distortion post device implantation may 
contribute to early and late stent failure such as pertaining to stent fracture. Geometric 
changes in the arteries post implantation are largely determined by the conformability 
of the stent [4]. The conformability of the stent has been described as the flexibility of a 
stent in its expanded state with adaptation to the natural shape of the vessel. A higher 
conformability of the stent is associated with less potential for vessel distortion and 
trauma [5]. 
Previous studies using BRS in short lesions demonstrate better conformability and 
favorable clinical outcomes compared to MPS in the acute setting [6, 7]. In the study 
by Gomez Lara et al, the acute change in curvature and angulation as quantified by 
quantitative coronary angiographic analysis was decreased in BRS compared to MPS 
[change in region curvature- MPS vs BRS: 0.085 cm-1 vs 0.056 cm-1, p=0.06, angulation 
MPS vs BRS 6.4° vs 4.3°, p=0.03] [7] and was shown to recover on follow up [8]. This effect 
may be more pronounced and more relevant in a long lesion in either the coronary 
or peripheral arterial system. However, the acute effects of its implantation on vessel 
geometry in long coronary lesions are yet to be investigated.  The aim of this study was 
to determine if there are any significant differences in terms of curvature of the treated 
vessel after the deployment of a polymeric scaffold device in long lesions and compare 
this to a MPS.
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study design, population, and treatment device
This is a non-randomized, 2-arm, retrospective study performed with patients from the 
onging BVS Expand and BVS STEMI First registries that received a Everolimus Eluting BRS 
(BRS- Absorb; Abbott Vascular, Santa Clara, CA, US) compared with a subset of historical 
controls from the same institutional registries (X-SEARCH) who received a Cobalt Chro-
mium- Everolimus Eluting Stent (CoCr-EES; XIENCER stent, Abbott Vascular, Santa Clara, 
CA, US).
In brief, the common inclusion criteria for this study are patients who had received a 
single BRS or CoCr EES that are 28mm in length in long coronary lesions. The patients 
in the BRS group are selected from the BVS Expand and BVS STEMI registries which are 
single centre prospective observational registries conducted at Thorax Centre, Erasmus 
Medical Centre that evaluates the long term safety and performance of the BRS-Absorb 
coronary stent in routine clinical practice post market registration. Informed, written 
consent was obtained from the patients before they undergo any procedure. The lesions 
are also more complex with more bifurcations and calcified lesions. From the X-SEARCH 
registry, patients with similar angiographic characteristics were selected for this study 
[9]. 
The BRS-Absorb vascular scaffold is a balloon-expandable device, consisting of a poly-
mer backbone of PLLA coated with a thin layer of a 1:1 mixture of an amorphous matrix 
of PLLA polymer containing 100ug/cm2 of the antiproliferative drug everolimus. The 
implant is radiolucent but has 2 platinum markers at each edge that allow visualization 
on angiography and other imaging modalities. Physically the scaffold has struts with an 
approximate thickness of 150 um, which are arranged as in-phase zigzag hoops linked 
together by 3 longitudinal links (Figure 1A).
The metallic platform of the everolimus-eluting XIENCER family stent (EES) is composed 
of a cobalt chromium (CoCr) alloy. The platform has a design similar to the Absorb plat-
form and consists of serpentine rings connected by links fabricated from a single piece 
(Figure 1B). The strut width of the CoCr-EES is 91um. The polymer and drug coating add 
a combined thickness of 7 um. The metallic platforms of the CoCr EES are constructed by 
a strut thickness of 81 um each [10]. 
treatment procedure
Lesions treated with the BRS were implanted according to the procedural steps in line 
with the accepted recommendations at the time of the study. Predilation with either 
a semi-compliant or non-compliant balloon was highly encouraged. The BRS was im-
planted at a pressure not exceeding the rated burst pressure (16 atm). Post-dilation with 
either a semi-compliant or non-compliant balloon was performed at the discretion of 
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the operator. Patients were prescribed with standard guideline recommended medical 
therapy including at least 12 months’ duration of dual antiplatelet therapy and antiangi-
nal therapy when appropriate. 
Quantitative coronary angiography (Qca) evaluation
Angiographic views with minimal foreshortening of the lesion and limited overlap with 
other vessels were used whenever possible for all phases of the treatment: pre-proce-
dural angiography, and after obtaining final result [11]. Comparison between pre and 
post treatment, were performed in matched angiographic views of 10 degrees or less. 
The 2-dimensional (2D) angiograms were analyzed with the CASS 5.10 analysis system 
(Pie Medical BV, Maastricht, the Netherlands). In each patient, the treated region and 
the peri-treated regions (defined by 5 mm proximal and distal to the device edge) were 
analyzed. The computer defined minimal luminal diameter, reference diameter obtained 
by an interpolated method, and percentage diameter stenosis in the post procedure 
angiogram. 
The definition of “Curvature” is the infinitesimal rate of change in the tangent vector 
at each point of the centerline. This measurement has a reciprocal relationship to the 
radius of the perfect circle defined by the curve at each point. The curvature of the vessel 
is calculated as 1/radius of the circle in cm-1, with a research program installed in the 
QCA Analysis software (CASS 5.10, Pie Medical Imaging) [12]. The segment of interest 
was defined as the stented/ scaffolded length. To enable analysis of curvature in the 
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peri-treated regions (defined by 5 mm proximal and distal 
to the device edge) were analyzed. The computer defined 
minimal lu inal diameter, reference diameter obtained by 
an interpolated method, and percentage diameter stenosis 
in the post procedure angiogram.
The definition of “Curvature” is the infinitesimal rate 
of change in the tangent vector at each point of the cen-
terline. This measurement has a reciprocal relationship to 
the radius of the perfect circle defined by the curve at each 
point. The curvature of the vessel is calculated as 1/radius 
of the circle in  cm−1, with a research program installed 
in the QCA Analysis software (CASS 5.10, Pie Medical 
Imaging) [13]. The segment of interest was defined as the 
stented/scaffolded length. To enable analysis of curvature 
in the same anatomical region, the scaffold position was 
superimposed on the preprocedural angiogram (Fig.  2). 
The software utomatically ete ts the lumen cont urs of 
the selected segment and configures the centerline. Three 
points are then defined according to the centerline: one at 
the proximal, one at the distal, and one at the center of the 
defined segment. Next, a perfect circle is drawn through 
these points, calculating the radius of the circle and the cur-
vature value. Prior to and after the procedure, the curvature 
of the segment of interest was repeatedly measured both 
during systole and diastole. Percentage relative change in 
curvature (Cv) was calculated as % (postCv–preCv)/preCv 
in the respective cardiac phases. Cyclic changes in vessel 
curvature were estimated as differences between systole 
and diastole at both pre-treatment and post-treatment.
Statistical analysis
The Kolmogorov–Smirnov test was used to evaluate the 
normality assumptions of all continuous variables. Descrip-
tive statistical analysis was performed with continuous var-
iables expressed as median (interquartile range) and with 
categorical variables presented as counts (%). For compari-
son between groups, Mann–Whitney U test were used for 
the continuous variables. The Chi square test has been used 
to assess differences in categorical variables. Pre and post 
treatment comparisons within groups were assessed with 
Wilcoxon signed rank tests. Because the curvature, cyclic 
changes of curvature, and difference of curvature between 
pre- and post-treatment did not have a normal distribution, 
a log transformation was performed to achieve a normal 
distribution. A univariate analysis was performed between 
curvature and angulation changes with baseline demo-
graphic and angiographic variables. Variables that were 
found to be significant at the univariate level were tested 
with a multivariate linear regression model. (The thresh-
olds for entry into and removal from the model were 0.1.) 
All statistical tests were carried out at the 5% level of sig-
nificance. All analysis was performed by SPSS version 21 
(SPSS, Inc., Chicago Illinois).
Results
The baseline clinical and angiographic characteristics are 
shown in Table 1. A total of 64 patients were involved in 
this study of which 32 were treated with the BRS and 32 
with the MPS. A flow chart summarizing patient selection 
is shown in Fig. 3. There was no difference in median age 
(BRS vs. MPS: 59.6 vs. 64.9 years, p = 0.453), gender or 
clinical presentation between the 2 device groups. There 
were no significant differences in the cardiovascular risk 
factors.
The left anterior descending artery was the most com-
monly treated vessel in the study population. Lesion cal-
cification and complexity were similar between the two 
groups (Table 1). Procedural data are as shown in Table 1. 
Lesions treated with BRS were predilated more frequently 
and at higher pressures compared to the lesions treated 
with metallic stents. Postdilation rates were similar. The 
pre treatment region length was 21.38  mm (17.67–25.58) 
in the overall group. There were no significant differences 
in reference vessel diameter, minimal lumen diameter and 
Fig. 1  a Bioresorbable scaffold: The second generation ABSORB-
BVS (Abbott Vascular, Santa Clara, CA, USA) has a strut thickness 
of 150  μm, consisting of in-phase zigzag hoops linked by bridges. 
The device is radiolucent but has two radioopaque platinum mark-
ers at each proximal and distal edge that facilitate ease of visualiza-
tion on angiography. b Cobalt chromium everolimus- eluting ste t 
(CoCr EES-  XIENCER, Abbott Vascular, Santa Clara, CA, US): The 
 XIENCER are the metal platform stents and consist of a metallic plat-
form made of cobalt chromium alloy. The struts are serpentine rings 
connected by links fabricated from a single piece. The  XIENCER is 
covered by an everolimus coating
figure 1a
a Bioresorbable scaffold: The second 
generation ABSORB-BVS (Abbott 
Vascular, Santa Clara, CA, USA) has 
a strut thickness of 150 μm, consist-
ing of in-phase zigzag hoops linked 
by bridges. The device is radiolucent 
but has two radiopaque platinum 
markers at each proximal and distal 
edge that facilitate ease of visual-
ization on angiography. b Cobalt 
chromium everolimus- eluting stent 
(CoCr EES- XIENCER, Abbott Vascular, 
Santa Clara, CA, US): The XIENCER are 
the metal platform stents and con-
sist of a metallic platform made of 
cobalt chromium alloy. The struts are 
serpentine rings connected by links 
fabricated from a single piece. The 
XIENCER is covered by an everolimus 
coating
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same anatomical region, the scaffold position was superimposed on the pre-procedural 
angiogram (Figure 2). The software automatically detects the lumen contours of the 
selected segment and configures the centerline. Three points are then defined accord-
ing to the centerline: 1 at the proximal, 1 at the distal, and 1 at the center of the defined 
segment. Next, a perfect circle is drawn through these points, calculating the radius 
of the circle and the curvature value. Prior to and after the procedure, the curvature 
of the segment of interest was repeatedly measured both during systole and diastole. 
Percentage relative change in curvature (Cv) was calculated as % (postCv- preCv)/preCv 
in the respective cardiac phases. Cyclic changes in vessel curvature were estimated as 
differences between systole and diastole at both pre-treatment and post-treatment.
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percentage diameter stenosis in both groups. Pretreat-
ment curvature was similar between the BRS and MPS 
groups in both systole and diastole phases [systole: 0.290 
(0.155–0.639)  cm−1 vs. 0.283 (0.125–0.519) respectively, 
p = 0.803 and diastole: 0.305 (0.193–0.580)  cm−1 vs. 0.257 
(0.151–0.518)  cm−1 respectively, p = 0.803].
Geometric changes within and between groups
Table  2 shows the changes in curvature in both systole 
and diastole of the treated vessel in the BRS and MPS 
groups. After implantation of MPS, there was a signifi-
cant decrease in median diastolic curvature (from 0.257 
to 0.199  cm−1, p = 0.001) and median systolic curvature 
(0.283–0.194  cm−1, p < 0.001) representing a percentage 
reduction of 16.0 and 28.6% respectively. Following an 
absorb scaffold implantation, there was a trend towards a 
decrease in the median diastolic curvature (from 0.305 to 
0.283 cm−1, p = 0.056) and median systolic curvature (from 
0.290 to 0.282 cm−1, p = 0.061) which trends towards sig-
nificance. As a result, the diastolic curvature was signifi-
cantly higher in the BRS compared with the MPS group 
post treatment [BRS vs. MPS; 0.283  cm−1 (0.150–0.541) 
vs. 0.199  cm−1 (0.089–0.357), p = 0.035] (Fig.  4). Post 
treatment, Percentage relative reduction in curvature was 
also smaller in the BRS group compared with MPS group 
in both the diastole and systole phases [BRS vs. MPS; 7.48 
vs. 29.4%, p = 0.013; 9.04 vs. 28.2%, p = 0.010 respec-
tively]. Cyclic changes in curvature (i.e. between systole 
and diastole) were similar between the BRS and the MPS 
(p = 0.271).
Predictive factors of modifying curvature
In univariate analysis, the use of MPS predicts a greater 
reduction in curvature with a coefficient of 23.33 (95% con-
fidence interval 3.81–42.85, p = 0.02).
Discussion
In summary, the major finding of this study showed that in 
the deployment of long coronary devices (28 mm in length), 
BRS showed a non-significant decrease in curvature in the 
post treated vessel compared with a significant reduction in 
curvature of the treated vessel with deployment of a MPS. 
Fig. 2  Curvature Analysis 
of the BRS and MPS: curva-
ture analysis before and after 
deployment of a BRS (Fig. 2a, 
b) and a MPS (Fig. 2c, d). 
After implantation of a BRS, 
the curvature changed from 
0.58 to 0.49 cm−1 whereas after 
the MPS was implanted, the 
curvature changed from 0.85 to 
0.23 cm−1. BRS bioresorbable 
scaffold, MPS metallic platform 
stent
figure 2 Curvature Analysis of the BRS and MPS
curvature analysis before and after deployment of a BRS (Fig. 2a, b) and a MPS (Fig. 2c, d). After implantation 
of a BRS, the curvature changed from 0.58 to 0.49 cm−1 whereas after the MPS was implanted, the curvature 
changed from 0.85 to 0.23 cm−1. BRS bioresorbable scaffold, MPS metallic platform stent
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statistical analysis
The Kolmogorov-Smirnov test was used to evaluate the normality assumptions of all 
continuous variables. Descriptive statistical analysis was performed with continuous 
variables expressed as median (interquartile range) and with categorical variables 
presented as counts (percentage). For comparison between groups, Mann-Whitney U 
test were used for the continuous variables.  The chi-square test has been used to assess 
differences in categorical variables. Pre and post treatment comparisons within groups 
were assessed with Wilcoxon signed rank tests. Because the curvature, cyclic changes of 
curvature, and difference of curvature between pre- and post-treatment did not have a 
normal distribution, a log transformation was performed to achieve a normal distribu-
tion. A univariate analysis was performed between curvature and angulation changes 
with baseline demographic and angiographic variables. Variables that were found to 
be significant at the univariate level were tested with a multivariate linear regression 
model. (The thresholds for entry into and removal from the model were 0.1.) All statisti-
cal tests were carried out at the 5% level of significance. All analysis was performed by 
SPSS version 21 (SPSS, Inc., Chicago Illinois).
results
The baseline clinical and angiographic characteristics are shown in Table 1. A total of 64 
patients were involved in this study of which 32 were treated with the BRS and 32 with 
the MPS. A flow chart summarizing patient selection is shown in Figure 3. There was 
no difference in median age [BRS vs MPS: 59.6 years vs 64.9 years, p=0.453)], gender or 
clinical presentation between the 2 device groups.  There were no significant differences 
in the cardiovascular risk factors.
table 1 Baseline clinical and angiographic characteristics
BRS (N=32) MPS (N=32) p value
Age (years) 59.6 (52.5, 67.8) 64.9 (57.7, 70.7) 0.453
Men 22 (68.8) 22 (68.8) 1.000
Hypertension 18 (56.2) 20 (62.5) 0.611
Hypercholesterolemia 15 (46.9) 17 (53.1) 0.617
Diabetes mellitus 5 (15.6) 8 (25.0) 0.351
Smoker (active) 12 (37.5) 7 ( 21.9) 0.391
Family History
Previous CVA 2 (6.2) 2 (6.2) 1.000
Previous MI 6 (18.8) 12 (37.5) 0.095
Previous PCI 5 (15.6) 9 (28.1) 0.226
Previous CABG 0 0
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The left anterior descending artery was the most commonly treated vessel in the 
study population. Lesion calcification and complexity were similar between the two 
groups (Table 1). Procedural data are as shown in Table 1. Lesions treated with BRS were 
pre-dilatated more frequently and at higher pressures compared to the lesions treated 
with metallic stents. Pos-tdilatation rates were similar.  The pre-treatment region length 
table 1 Baseline clinical and angiographic characteristics (continued)
BRS (N=32) MPS (N=32) p value
Clinical presentation
Stable or silent angina 10 (31.3) 18 (56.3) 0.074
Unstable angina 1 (3.1) 4 (12.5) 0.355
STEMI 4 (12.5) 0 0.155
NSTEMI 17(53.1) 9 (28.1) 0.074
Other 0 1 (3.1) 1.000
Target vessel 0.857
LAD 15 (46.9) 13 (40.6)
LCX 6 (18.8) 6 (18.8)
RCA 11 (34.4) 13 (40.6)
RVD (mm) 2.90 (2.49, 3.18) 2.91 (2.29, 3.26) 0.803
MLD (mm) 0.92 (0.77, 1.57) 1.20 (0.75, 1.55) 0.453
Diameter stenosis (%) 60.00 (47.25, 72.75) 56.00 (46.00, 76.75) 0.452
Bifurcation 12 (37.5) 7 (21.9) 0.274
AHA Type 0.149
A 2 (6.3) 0
B1 19 (59.4) 14 (43.8)
B2 6 (18.8) 13 (40.6)
C 5 (15.6) 5 (15.6)
Calcification
Mild 19 (59.4) 12 (37.5)
Moderate/ severe 13 (40.6) 20 (62.5)
Pre-treatment region length (mm) 22.19 (17.67, 25.08) 20.38 (17.05, 25.75) 0.803
Procedural details
Pre-dilatation performed 29 18 0.004
Pre-dilatation balloon diameter 2.50 (2.50, 2.50) 2.00 (2.00; 2.50) 0.03
Post-dilatation 18 13 0.317
Post-dilatation diameter 3.00 (2.94; 3.50) 3.50 (2.75; 4.00) 0.253
Values are presented as number (%) or median (interquartile range)
AMI acute myocardial infarct; BRS bioresorbable scaffold; CABG coronary artery bypass graft; CVA cerebro-
vascular accident; LAD left anterior descending artery; LCX left circumflex artery; MLD minimal luminal di-
ameter; MPS metallic platform stent; PCI percutaneous coronary intervention; RCA right coronary artery; 
RVD reference vessel diameter,  STEMI ST-elevation myocardial infarct.
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was 21.38mm (17.67- 25.58) in the overall group. There were no significant differences in 
reference vessel diameter, minimal lumen diameter and percentage diameter stenosis in 
both groups. Pre-treatment curvature was similar between the BRS and MPS groups in 
both systole and diastole phases [systole: 0.290 (0.155-0.639) cm-1 vs 0.283 (0.125-0.519) 
respectively, p =0.803 and diastole: 0.305 (0.193- 0.580) cm-1 vs 0.257 (0.151-0.518) cm-1 
respectively, p= 0.803]. 
Geometric changes within and between groups
Table 2 shows the changes in curvature in both systole and diastole of the treated vessel 
in the BRS and MPS groups. After implantation of MPS, there was a significant decrease 
in median diastolic curvature (from 0.257 cm-1 to 0.199 cm-1, p= 0.001) and median sys-
tolic curvature (0.283 cm-1 to 0.194 cm-1, p <0.001) representing a percentage reduction 
of 16.0% and 28.6% respectively.  Following an Absorb scaffold implantation, there was 
a trend towards a decrease in the median diastolic curvature (from 0.305 cm-1 to 0.283 
cm-1, p= 0.056) and median systolic curvature (from 0.290 cm-1 to 0.282 cm-1, p= 0.061) 
which trends towards significance.  As a result, the diastolic curvature was significantly 
higher in the BRS compared with the MPS group post treatment [BRS vs MPS; 0.283 cm-1 
(0.150-0.541) vs 0.199 cm-1 (0.089-0.357), p= 0.035] (Figure 4). Post treatment, Percent-
age relative reduction in curvature was also smaller in the BRS group compared with 
MPS group in both the diastole and systole phases [BRS vs MPS; 7.48% vs 29.4%, p= 
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in underlying material composition of the devices in that a 
polymeric bioresorbable scaffold has better conformability 
to vessel geometry compared to metallic stents. In a study 
evaluating the bending stiffness of the BRS compared to 
the MPS in-vitro, the maximum compressive load of a BRS 
from ABSORB COHORT B trial was significantly lower 
compared to the  XIENCER stent which signifies better con-
formability of the BRS (Fig.  5) [17]. This is despite the 
fact that the strut thickness of the ABSORB Cohort B stent 
is thicker than that of the  XIENCER stent (strut thickness 
Fig. 3  Flow chart of patient 
selection. BRS bioresorbable 
scaffold, CTO chronic total 
occlusion, MPS metallic plat-
form stents, STEMI ST eleva-
tion myocardial infarct
Table 2  Changes in curvature of the study population
Values are presented as numbers or median (interquartile range)
a For BRS, the p values for comparison between pre and post curvature for systole and diastole are 0.061 and 0.056 respectively. For MPS, the p 
values for comparison between pre and post curvature for systole and diastole are <0.001(*) and 0.001(*) respectively
BRS bioresorbable scaffold, MPS metallic platform stent
BRS (N = 32) MPS (N = 32) p value
Pre-treatment curvature  (cm−1)
 Systole 0.290 (0.155, 0.639) 0.283 (0.125, 0.519) 0.648
 Diastole 0.305 (0.193, 0.580) 0.257 (0.151, 0.518) 0.460
Post-treatment curvature  (cm− 1)
 Systole 0.282 (0.147, 0.549) 0.194 (0.097, 0.407) 0.077
 Diastole 0.283 (0.150, 0.541) 0.199 (0.089, 0.357) 0.035
Percentage reduction in curvature post-pretreatmenta
 Systole 2.76 28.6*
 Diastole 7.21 16.0*
Absolute reduction in curvature  (cm−1)
 Systole 0.024 (0.015, 0.087) 0.064 (0.010, 0.230) 0.034
 Diastole 0.021 (0.025, 0.098) 0.090 (0.011, 0.192) 0.066
Percentage relative change in curvature  (cm−1)
 Systole −9.035 (−22.128, 7.911) −28.17 (−46.22, −6.64) 0.010
 Diastole −7.484 (−23.193, 8.355) −29.43 (−50.31, −3.55) 0.013
Pre-treatment cyclic change in curvature  (cm−1) −0.021 (−0.072, 0.061) 0.002 (−0.086, 0.096) 0.398
Post-treatment cyclic change in curvature  (cm−1) −0.026 (−0.054, 0.023) −0.041 (−0.04, 0.125) 0.271
figure 3 Flow chart of patient selection.
BRS bioresorbable scaffold, CTO chronic total occlusion, MPS metallic platform stents, STEMI ST elevation 
myocardial infarct
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0.013; 9.04% vs 28.2%, p= 0.010 respectively]. Cyclic changes in curvature (i.e., between 
systole and diastole) were similar between the BRS than the MPS after the deployment 
in curvature (p = 0.271). 
Predictive factors of modifying curvature
In univariate analysis, the use of MPS predicts a greater reduction in curvature with a 
coefficient of 23.33 (95% confidence interval: 3.81- 42.85, p = 0.02). 
Discussion
In summary, the major finding of this study showed that in the deployment of long coro-
nary devices (28mm in length), BRS showed a non-significant decrease in curvature in 
table 2 Changes in curvature of the study population
BRS (N=32) MPS (N=32) p value
Pre-treatment curvature(cm-1) 
Systole 0.290 (0.155, 0.639) 0.283 (0.125, 0.519) 0.648
Diastole 0.305 (0.193, 0.580) 0.257 (0.151, 0.518) 0.460
Post-treatment curvature(cm-1) 
Systole 0.282 (0.147, 0.549) 0.194 (0.097, 0.407) 0.077
Diastole 0.283 (0.150, 0.541) 0.199 (0.089, 0.357) 0.035
Percentage reduction in curvature post-pre-
treatment a
Systole 2.76 28.6
Diastole 7.21 16.0
Absolute reduction in curvature (cm-1)
Systole 0.024 (0.015, 0.087) 0.064 (0.010, 0.230) 0.034
Diastole 0.021 (0.025, 0.098) 0.090 (0.011, 0.192) 0.066
Percentage relative change in curvature (cm-1)
Systole -9.035(-22.128, 7.911) -28.17 (-46.22, -6.64) 0.010
Diastole -7.484(-23.193, 8.355) -29.43 (-50.31, -3.55) 0.013
Pre-treatment cyclic change in curvature 
(cm-1)
-0.021 (-0.072, 0.061) 0.002 (-0.086, 0.096) 0.398
Post-treatment cyclic change in curvature 
(cm-1)
-0.026(-0.054, 0.023) -0.041 (-0.04, 0.125) 0.271
Values are presented as numbers or median (interquartile range).
a For BRS, the p values for comparison between pre and post curvature for systole and diastole are 0.061 and 
0.056 respectively. For MPS, the p values for comparison between pre- and post-curvature for systole and 
diastole are <0.001(*) and 0.001(*) respectively
BRS bioresorbable scaffold; MP- Metallic platform stent
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the post treated vessel compared with a significant reduction in curvature of the treated 
vessel with deployment of a MPS. Use of MPS was an independent predictor of vessel 
curvature change post deployment.
Stent conformability is dependent on both the material and design of the stent and 
differs between the commercial devices that are available [13-15]. An open cell stent de-
sign would have higher conformability compared to a closed cell design. The difference 
in curvature post treatment between BRS and MPS could be attributed to the difference 
in underlying material composition of the devices in that a polymeric bioresorbable 
scaffold has better conformability to vessel geometry compared to metallic stents.  In 
a study evaluating the bending stiffness of the BRS compared to the MPS in-vitro, the 
maximum compressive load of a BRS from ABSORB COHORT B trial was significantly lower 
compared to the XIENCER stent which signifies better conformability of the BRS (Figure 
5) [16]. This is despite the fact that the strut thickness of the ABSORB Cohort B stent is 
thicker than that of the XIENCER stent (strut thickness 152.4 µm vs 81.3 µm). A previous 
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152.4 vs. 81.3 µm). A previous study had shown that the 
use of relatively shorter (18  mm) BRS and MPS devices 
modify baseline vessel curvature but the change was more 
marked in the MPS compared with the BRS [6]. In this 
study, the median pretreatment lesion length was 16.3 and 
16.8 mm in the BRS and MPS groups respectively which 
are comparatively shorter compared to our study popula-
tion. To our knowledge, this is the first in vivo study that 
shown that BRS does not affect the curvature of the treated 
vessel significantly in the deployment of long scaffolds. 
This might be of useful significance as we treat longer 
lesions with overlap scaffold required.
Though OCT has been widely described in exist-
ing methodology [18–21] to evaluate scaffold perfor-
mance, OCT by itself is not able to measure curvature 
of the vessel, whereas QCA is available p  and post in 
almost all patients. From fluid dynamics and the result-
ing shear stress we know curvatures do have an impact 
on plaque formation in the following years where it is 
important to minimize the distortion of the natural ves-
sel course post stent or scaffold implantation. As vascu-
lar geometry is the most important determinant of local 
wall shear stress, any beneficial effect on the conform-
ability of the blood vessel might have clinical implica-
tions. Studies have demonstrated that low wall shear 
stress promotes atherosclerosis and plaque progression 
in native arteries [22] and greater intimal hyperplasia 
Fig. 4  Change in curvature post 
treatment in BRS and MPS. 
This boxplot illustrates the 
difference in median diastolic 
curvature post treatment in the 
BRS compared to the MPS 
group
Fig. 5  Maximum compressive force of ABSORB Cohort B scaffold 
and XIENCE V stent. This figure shows the maximum compres-
sive force applied to deflect the ABSORB Cohort B and XIENCE 
V 3.0 × 18  mm devices by 1.1  mm using 3 point- bend test (n = 5). 
Statistical analysis yielded p = 0.004 using One- way ANOVA and 
Tukey- Kramer HSD. Tests were performed by and data are on file 
at Abbott Vascular. (Reprinted from EuroIntervention Supplement 
(2009) Vol.5 Supplement F; Oberhauser JP, Hossainy S, Rapoza RJ. 
Design principles and performance of bioresorbable polymeric vascu-
lar scaffolds. F15-22, Copyright, with permission from Europa Digi-
tal and Publishing)
figure 4 Change in curvature post treatment in BRS and MPS.
This boxplot illustrates the difference in median diastolic curvature post treatment in the BRS compared to 
the MPS gr up
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study had shown that the use of relatively shorter (18mm) BRS and MPS devices modify 
baseline vessel curvature but the change was more marked in the MPS compared with 
the BRS [7]. In this study, the median pre-treatment lesion length was 16.3 mm and 16.8 
mm in the BRS and MPS groups respectively which are comparatively shorter compared 
to our study population. To our knowledge, this is the first in vivo study that shown that 
BRS does not affect the curvature of the treated vessel significantly in the deployment 
of long scaffolds. This might be of useful significance as we treat longer lesions with 
overlap scaffold required. 
Though OCT has been widely described in existing methodology [17-20] to evalu-
ate scaffold performance, OCT by itself is not able to measure curvature of the vessel, 
whereas QCA is available pre and post in almost all patients. From fluid dynamics and 
the resulting shear stress we know curvatures do have an impact on plaque formation in 
the following years where it is important to minimize the distortion of the natural vessel 
course post stent or scaffold implantation. As vascular geometry is the most important 
determinant of local wall shear stress, any beneficial effect on the conformability of the 
blood vessel might have clinical implications. Studies have demonstrated that low wall 
shear stress promotes atherosclerosis and plaque progression in native arteries [21] and 
greater intimal hyperplasia after stent deployment [22].  Metallic stents deployed in 
curved porcine coronary arteries were noted to cause vessel straightening in the stented 
segment and increased curvature at the stent edges [3]. A study by Gyongyosi et al had 
Int J Cardiovasc Imaging 
1 3
152.4 vs. 81.3 µm). A previous study had shown that the 
use of relatively shorter (18  mm) BRS and MPS devices 
modify baseline vessel curvature but the change was more 
marked in the MPS compared with the BRS [6]. In this 
study, the median pretreatment lesion length was 16.3 and 
16.8 mm in the BRS and MPS groups respectively which 
are comparatively shorter compared to our study popula-
tion. To our knowledge, this is the first in vivo study that 
shown that BRS does not affect the curvature of the treated 
vessel significantly in the deployment of long scaffolds. 
This might be of useful significance as we treat longer 
lesions with overlap scaffold required.
Though OCT has been widely described in exist-
ing methodology [18–21] to evaluate scaffold perfor-
mance, OCT by itself is not able to measure curvature 
of the vessel, whereas QCA is available pre and post in 
almost all patients. From fluid dynamics and the result-
ing shear stress we know curvatures do have an impact 
on plaque formation in the following years where it is 
important to minimize the distortion of the natural ves-
sel course post stent or scaffold implantation. As vascu-
lar geometry is the most important determinant of local 
wall shear stress, any beneficial effect on the conform-
ability of the blood vessel might have clinical implica-
tions. Studies have demonstrated that low wall shear 
stress promotes atherosclerosis and plaque progression 
in native arteries [22] and greater intimal hyperplasia 
Fig. 4  Change in curvature post 
treatment in BRS and MPS. 
This boxplot illustrates the 
difference in median diastolic 
curvature post treatment in the 
BRS compared to the MPS 
group
Fig. 5  Maximum compressive force of ABSORB Cohort B scaffold 
and XIENCE V stent. This figure shows the maximum compres-
sive force applied to deflect the ABSORB Cohort B and XIENCE 
V 3.0 × 18  mm devices by 1.1  mm using 3 point- bend test (n = 5). 
Statistical analysis yielded p = 0.004 using One- way ANOVA and 
Tukey- Kramer HSD. Tests were performed by and data are on file 
at Abbott Vascular. (Reprinted from EuroIntervention Supplement 
(2009) Vol.5 Supplement F; Oberhauser JP, Hossainy S, Rapoza RJ. 
Design principles and performance of bioresorbable polymeric vascu-
lar scaffolds. F15-22, Copyright, with permission from Europa Digi-
tal and P blishing)
figure 5 Maximum compressive force of ABSORB Cohort B scaffold and XIENCE V stent.
This figure shows the maximu  compressive force applied to deflect the ABSORB Cohort B and XIENCE V 
3.0 × 18 mm devices by 1.1 mm using 3 point- bend test (n = 5). Statistical analysis yielded p = 0.004 using 
One- way ANOVA and Tukey- Kramer HSD. Tests were performed by and data are on file at Abbott Vascular.
(Reprinted from EuroIntervention Supplement (2009) Vol.5 Supplement F; Oberhauser JP, Hossainy S, Rapo-
za RJ. Design principles and performance of bioresorbable polymeric vascular scaffolds. F15-22, Copyright, 
with permission from Europa Digital and Publishing)
Conformability in BVS compared with metal stents in long lesions 79
4
further showed that a longitudinal straightening of stents is an additional predictor of 
major adverse events [23]. There are possible physiological and clinical benefits arising 
from the improvement in conformability in the bioresorbable scaffolds. An increased 
conformability of the BRS platform may result in physiological wall shear stress at the 
stent edges due to less vessel distortion. This may translate to clinical benefits such as 
reduced risk of scaffold edge restenosis.  However, the clinical benefits associated with 
better conformability still needs further evaluation.  This has become more relevant in 
the setting of recent data that showed a potential lack of benefits up to 3 years [24] par-
ticular certain lesion subsets such as smaller vessels with the BRS compared with best in 
class DES, with the BRS showing either similar or increased risk of TLR and increased risks 
of scaffold thrombosis compared to DES [25, 26]. 
Stent flexibility (and conformability) is also one of the key determinants of stent 
fracture, a common cause of late stent failure. Hinge motion (i.e. rocking back and forth 
on a bend) was one of the factors that can increase the risk of stent strut fracture. Our 
results suggest that there is a subtle but certain cyclic change of curvature after device 
implantation in both groups. Although there is no difference between groups, one can 
speculate that this cyclic movement repeating greater than 86400 times a day (based on 
average heart rate of 60 beats per minute) can cause mechanical failure at the metallic 
struts. In a study looking at predictors of stent fracture, stent fracture was identified in 
2.9% of 1339 lesions treated with the XIENCER stent in only 6-9 months after placement 
[27]. In that study, the three major determinants of stent fracture in order of importance 
were hinge motion, ostial location and tortuosity. Since the BRS is programmed to get 
dismantled in the due course of the bioresorption, this might cause fewer problems with 
BRS than with MPS.  
The impact of procedural factors such as predilation on conformability is still un-
known. Although lesion pre and post-dilatation may potentially impact on outcome by 
its impact on lesion expansion (concentricity, eccentricity, final MLD/MLA, remaining 
DS% and AS%),  changes in curvature is ultimately mostly influenced by the remaining 
implanted material characteristics and the design of the stent/scaffold (Number of lon-
gitudinal connectors). In clinical practice this is manifested by the straightening of the 
vessel during balloon inflations and increase in vessel curvatures directly after balloon 
deflation. 
limitations
We acknowledge the following limitations. The study is non-randomized and popula-
tion in each group is relatively small. 2D angiographic analysis may also not be the 
most optimal imaging modality to assess the geometry of coronary vessels. However 
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the differences between the pre and post treatment angiographic views were less than 
10°, indicating that the analysis were mainly performed in the same angiographic view. 
In addition, the precise impact of subsequent procedural steps (predilation, stent im-
plantation, post-dilatation) on vascular curvature could not be entirely captured due 
to the inherent retrospective nature of our study and there was no specific protocol for 
operators to include the necessary angiographic or cinefluroscopic projections. Poten-
tially this issue is best addressed in a future prospective study with dedicated research 
protocol ensuring the angiographic projections are obtained at the procedural steps of 
predilation, stent implantation and post-dilatation.
conclusion
In the deployment of long coronary scaffolds/ stents (28mm in length), bioresorbable 
vascular scaffolds provides better conformability compared with MPS. The findings of 
this study and its clinical significance merits further evaluation.
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abstract
objectives 
To report on clinical outcomes beyond one year of the BVS Expand registry.
background
Multiple studies have proven feasibility and safety of the Absorb bioresorbable vascular 
scaffold (BVS). However, data on medium to long-term outcomes are limited and avail-
able only for simpler lesions. 
methods
This is an investigator-initiated, prospective, single-center, single-arm study evaluating 
performance of the BVS in a lesion subset representative of daily clinical practice, includ-
ing calcified lesions, total occlusions, long lesions and small vessels. Inclusion criteria 
were patients presenting with NSTEMI, stable/ unstable angina, or silent ischemia caused 
by a de novo stenotic lesion in a native previously untreated coronary artery. Procedural 
and medium to long-term clinical outcomes were assessed. Primary endpoint was major 
adverse cardiac events, defined as a composite of cardiac death, myocardial infarction 
and target lesion revascularization. 
results
From September 2012 to January 2015, 249 patients with 335 lesions were enrolled. 
Mean number of scaffolds per patient was 1.79±1.15. Invasive imaging was used in 39%. 
In 38.1% there were ACC/ AHA classification type B2/ C lesions. Mean lesion length was 
22.16±13.79 mm. Post-procedural acute lumen gain was 1.39±0.59 mm. Median follow-
up period was 622 days (interquartile range: 376-734). Using Kaplan-Meier methods, 
the MACE rate at 18 months was 6.8%. Rate of cardiac mortality, myocardial infarction 
and target lesion revascularization at 18 months were 1.8%, 5.2% and 4.0% respectively. 
Definite scaffold thrombosis rate was 1.9%.
conclusions
In our study, BVS implantation in a complex patient and lesion subset was associated 
with an acceptable rate of adverse events at longer-term, while no cases of early throm-
bosis were observed.
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introDuction
Drug-eluting stents (DES) currently form the mainstay of coronary devices used in 
percutaneous coronary interventions (PCI) in many parts of the world. Despite advan-
tages in clinical outcomes such as reduction in target lesion revascularization rates, 
shortcomings related to the use of DES still exist such as delayed arterial healing, late 
stent thrombosis (ST) and hypersensitivity reactions to the polymer, with observations 
of ongoing very late stent failure beyond one year. 1, 2 
In addition, from a physiological point of view, a vessel that is indefinitely caged in 
a metal stent may not be desirable with both short- and long-term implications and 
potentially adverse consequences such as impaired endothelial function, the reduced 
potential for vessel remodelling, interference with the normal arterial healing process 
and the risk of occlusion of covered side branches by neointima hyperplasia. Further-
more, interference with non-invasive imaging (cardiac computed tomography or mag-
netic resonance imaging) during patient follow-up and possible impairment of future 
treatment options (re-PCI or coronary artery bypass surgery) are drawbacks of metallic 
stents. 3
To overcome these issues, bioresorbable vascular scaffolds (BRS) were developed. The 
BRS most studied is the Absorb BVS (Abbott Vascular, Santa Clara, CA). The BVS provides 
transient vessel support and gradually elutes the anti-proliferative drug everolimus. 
After degradation of the polymer (after approximately three years) no foreign material 
remains and the risk for developing very late ST is potentially reduced. 
Intravascular imaging observations 5 years after BVS implantation in a simple patient 
and lesion subset have demonstrated late luminal enlargement due to plaque reduction, 
a persistent restoration of vasomotion and a fully completed bioresorption process, 4, 5 
and a low rate of  major adverse cardiac events (MACE) rate (3.4%). 6 This is consistent in 
randomized controlled trials (ABSORB II and ABSORB Japan) which showed comparable 
clinical event rates in BVS compared with best in class with metallic DES (Xience V). 7, 8 
However, as these studies included a selected group of patients, extrapolation to a more 
complex population is limited. Yet,  the registry- level clinical data on the outcomes after 
BVS implantation in more complex patient and lesion subsets have not been well docu-
mented that such data are available from registries with a relatively short follow-up of 6 
to 12 months, which have shown variable early clinical outcomes. 8-10 Thus, the medium 
to long-term outcomes beyond one year after BVS implantation in such complex ‘real-
world’ lesions remain elusive.
In the current study, we report on extended follow-up beyond one year, of the BVS 
Expand Registry. This is a single-center registry initiated in September 2012 that in-
vestigates the clinical outcomes after BVS implantation in a more complex real-world 
population. 
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Population
This is an investigator-initiated, prospective, single-center, single-arm study performed 
in an experienced, tertiary PCI center. Patients presenting with NSTEMI, stable or unstable 
angina (UA), or silent ischemia caused by a de novo stenotic lesion in a native previously 
untreated coronary artery with intention to treat with a BVS were included. Angiograph-
ic inclusion criteria included lesions with a Dmax (proximal and distal maximal lumen 
diameter) within the upper limit of 3.8 mm and the lower limit of 2.0 mm by online 
quantitative coronary angiography (QCA). Complex lesions such as bifurcation, calcified 
(as assessed by angiography), long and thrombotic lesions were not excluded. Exclusion 
criteria were patients with a history of coronary bypass grafting (CABG), presentation 
with cardiogenic shock, bifurcation lesions requiring kissing balloon post-dilatation, 
ST-elevation myocardial infarction (STEMI) patients, allergy or contra-indications to anti-
platelet therapy, fertile female patients not taking adequate contraceptives or currently 
breastfeeding and patients with expected survival of less than one year. As per hospital 
policy patients with a previously implanted metal DES in the intended target vessel were 
also excluded. Also, although old age was not an exclusion criterion, BVS were in general 
reserved for younger patients, and left to operator’s interpretation of biological age.
ethics
This is an observational study, performed according to the privacy policy of the Erasmus 
MC, and to the Erasmus MC regulations for the appropriate use of data in patient-ori-
ented research, which are based on international regulations, including the declaration 
of Helsinki. Approval of the ethical board of the Erasmus MC was obtained. All patients 
undergoing clinical follow-up provided written informed consent for the PCI and to be 
contacted regularly during the follow-up period of the study.
Procedure
PCI was performed according to current clinical practice standards. The radial or femoral 
routes were the principal routes of vascular access and 6 or 7 French catheters were 
used depending on the discretion of the operator. Pre-dilatation and post dilation were 
recommended with a balloon shorter than the planned study device length and with a 
non-compliant balloon without overexpanding the scaffold beyond its limits of expan-
sion (0.5mm > nominal diameter) respectively. Intravascular imaging with the use of 
Intravascular Ultrasound (IVUS) or Optical Coherence Tomography (OCT) was used for 
pre-procedural sizing and optimization of stent deployment on the discretion of the 
operator. All patients were treated with unfractionated heparin (at a dose of 70-100 UI/ 
kg). Patients with stable angina were preloaded with 300 mg of aspirin and 600 mg of 
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clopidogrel. Patients presenting with ACS were preloaded with 300 mg of aspirin and 60 
mg of prasugrel or 180 mg of ticagrelor.
angiographic analysis
Quantitative Coronary Analysis (QCA) was performed by three independent investiga-
tors. Coronary angiograms were analyzed with the CAAS 5.10 QCA software (Pie Medical 
BV, Maastricht, the Netherlands). The QCA measurements provided reference vessel 
diameter (RVD), percentage diameter stenosis, minimal lumen diameter (MLD), and 
maximal lumen diameter (Dmax). Acute gain was defined as post-procedural MLD mi-
nus pre-procedural MLD (in an occluded vessel MLD value was zero by default). For the 
purpose of this study we defined underexpansion as a ratio of post-procedural minimal 
lumen diameter (MLD) to the nominal device diameter of less than 0.7. The ratio of pre-
procedural reference vessel diameter (RVD) to the nominal device diameter was used to 
assess pre-procedural sizing.
follow-up
Clinical demographic data of all patients were obtained from municipal civil registries. 
Follow-up information specific for hospitalization and cardiovascular events was 
obtained through questionnaires. If needed, medical records or discharge letters from 
other hospitals were requested. Events were adjudicated by an independent clinical 
events committee (CEC). All information concerning baseline characteristics and follow-
up was gathered in a clinical data management system. 
Definitions
The primary endpoint was MACE, defined as the composite endpoint of cardiac death, 
myocardial infarction (MI) and target lesion revascularization (TLR). Deaths were con-
sidered cardiac unless a non-cardiac cause was definitely identified. TLR was described 
as any repeated revascularization of the target lesion. Target vessel revascularization 
(TVR) was defined as any repeat percutaneous intervention or surgical bypass of any 
segment of the target vessel. Non-target vessel revascularization was described as any 
revascularization in a vessel other than the target lesion. Scaffold thrombosis (ST) and 
MI were classified according to the Academic Research Consortium (ARC). 11 Clinical 
device success (lesion basis) was defined as successful delivery and deployment of 
all intended scaffolds at the target lesion and successful withdrawal of the delivery 
system with attainment of final in-scaffold residual stenosis of < 30% as evaluated by 
QCA. When bailout device was used, the success or failure of the bailout device delivery 
and deployment is not one of the criteria for device success. Clinical procedure success 
(patient basis) was described as achievement of final in-scaffold residual stenosis of less 
than 30% by QCA with successful delivery and deployment of all intended scaffolds at 
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the target lesion and successful withdrawal of the delivery system for all target lesions 
without major peri-procedural complications or in-hospital MACE (maximum of 7 days). 
In dual target lesion setting, both lesions must meet clinical procedure success criteria 
to have a patient level procedure success.
The intention-to-treat (ITT) group includes all the patients regardless of whether or 
not the scaffold was successfully implanted. The per-treatment (PT) group consists of all 
patients in whom the BVS was successfully implanted. Only events in the per-treatment 
population were analysed.
The off-registry population consisted of patients that were excluded in this study, 
mainly STEMI patients.
 statistical analysis
Categorical variables are reported as counts and percentages, continuous variables as 
mean ± standard deviation. The student’s t test and the chi square test (or Fishers’ exact 
test) were used for comparison of means and percentages. The cumulative incidence 
of adverse events was estimated according to the Kaplan-Meier method. Patients lost 
to follow-up were considered at risk until the date of last contact, at which point they 
were censored. All statistical tests were two-sided and the P value of < 0.05 was con-
sidered statistically significant. To investigate possible predictors for clinical outcomes 
MACE and ST, univariate analysis using a Cox regression model was used investigating 
variables that are frequently present. Statistical analyses were performed using SPSS, 
version 21 (IL, US).
results
From September 2012 up to January 2015, 3373 patients were treated with PCI in our 
center. The majority of patients were considered not suitable for BVS either to their 
biological age related to comorbidities, indication for stent > 3.5mm or smaller < 2.5 
mm, previous CABG, previous PCI with metal DES in the target vessel or STEMI as indica-
tion for PCI shortly after the commercial introduction of BVS in Europe. These patients 
were in general older (64.5 ± 11.6 years) and presented with more risk factors compared 
to the BVS population (previous CABG: 9.5%, previous PCI: 31.3%, previous MI: 25.6%) 
and presented more frequently with multivessel disease (57.8%). Finally, 485 patients 
were treated with one or more BVS in the registry period. Most excluded patients (N = 
169) presented with STEMI and entered a separate registry starting later, 5 had a previ-
ous CABG, 1 needed kissing balloon post-dilatation for bifurcation, 2 had a previous 
implanted metal DES in the target vessel as formal exclusion criteria for this analysis and 
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58 patients did not return their informed consent because they declined to participate, 
emigrated abroad or participated in another trial investigating BVS.
249 signed the informed consent for follow-up and were eligible based on protocol in-
clusion and exclusion criteria. In 5 patients delivery failure occurred (intention-to-treat, 
ITT group). The per-treatment (PT) group thus consisted of 244 patients. The flowchart 
of the registry is given in Figure 1.
baseline characteristics
Baseline characteristics of all BVS treated patients are presented in Table 1. Mean age was 
61.3 ± 10.2 years, 73.5% were male, 18.5% diabetic and 59.1% presented with an acute 
coronary syndrome (NSTEMI or UA; STEMI patients were excluded). Multivessel disease 
figure 1 Flowchart of the study
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was present in 45.6%. The off-registry patients were younger, with less comorbidities 
and presented more frequently with STEMI.
Lesion characteristics are presented in table 2. The left anterior descending coronary 
artery (LAD) was most commonly treated (50.0% of lesions). Moderate or severe calcifica-
tion (as assessed by angiography)  was present in 42.2% and a chronic total occlusion in 
4.2% of the lesions. Bifurcation lesions (involving lesions within 3 mm of the bifurcation 
and with side branches ≥ 2 mm by visual estimation in diameter, treated with implanta-
tion of at least one BVS) were present in 21.3% with significant side branch involvement 
(true bifurcations: Medina 1,1,1, 1,0,1 and 0,1,1 lesions) in 32% of these.  Overall, 38.1% 
table 1 Baseline characteristics
Patients characteristics ITT population Off-registry population P value
Number of patients 249 236
Gender (%) 0.57
   Men 73.5 75.6
   Women 26.5 24.4
Mean age in years (±SD) 61.3 ± 10.2 55.4 ± 10.6 P<0.001
Smoking (%) 55.0 59.0 0.24
Hypertension (%) 59.4 41.9 P<0.001
Dyslipidaemia (%) 51.0 29.9 P<0.001
Diabetes Mellitus (%) 18.5 13.2 0.14
Family history of CAD (%) 44.6 37.6 0.23
Prior MI (%) 17.7 6.0 P<0.001
Prior PCI (%) 9.2 4.7 0.05
Prior CABG (%) 0.0 2.6 0.01
Presenting with multiple vessel disease (%) 45.6 28.2 0.07
Indication for PCI (%) P<0.001
   Stable angina 40.6 9.8
   Unstable angina 16.1 2.1
STEMI 0.0 71.4
   NSTEMI 43.0 16.7
Silent ischemia 0.4 0.0
Periphery artery disease (%) 8.8 1.7 P<0.001
COPD (%) 7.2 3.9 0.10
Heart failure (%) 4.8 0.9 0.01
Renal insufficiency (%) 6.4 2.1 0.02
CVA/ TIA (%) 9.6 4.3 0.03
CAD coronary artery disease, COPD chronic obstructive pulmonary disease, CVA cerebrovascular accident, 
TIA transient ischemic attack
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of lesions were ACC/ AHA type B2 or C. Mean lesion length was 22.16 ± 13.79 mm. Pre-
procedural QCA showed a RVD of 2.42 ± 0.74 mm, a MLD of 0.91 ± 0.45 mm and a %DS 
of 59.12 ± 20.72%. 
table 2 Lesion characteristics
N= 249; L= 335
Target vessel (%)
LAD 50.0
LCX 23.7
RCA 26.0
Ramus intermedius 0.3
SVG 0.0
Lesion AHA A/B1/B2/C 16.2/ 45.8/ 24.3/ 13.8
Bifurcation (%) 21.3
Moderate/ severe calcification (%) 42.2
(Chronic) Total occlusions (%) 4.2
TIMI (%)
Pre-procedure 
TIMI 0 8.4
TIMI 1 1.8
TIMI 2 13.8
TIMI 3 75.4
Post-procedure
TIMI 0 0.0
TIMI 1 0.3
TIMI 2 3.0
TIMI 3 96.4
QCA Analysis 
Pre-procedure
Lesion length (mm) 22.10 ± 13.90
RVD (mm) 2.42 ± 0.74
MLD (mm) 0.91 ± 0.45
Diameter stenosis (%) 59.13 ± 20.72
Post-procedure 
RVD (mm) 2.77 ± 0.46
MLD (mm) 2.30 ± 0.42
Diameter stenosis (%) 16.90 ± 9.04
Acute lumen gain (mm) 1.39 ± 0.59
Values are expressed as percentages or mean ± standard deviation when appropriate. LAD left anterior 
descending artery, LCX left coronary artery, MLD minimal lumen diameter, QCA quantitative coronary angi-
ography, RCA right coronary artery, RVD reference vessel diameter, SVG saphenous vein graft
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Procedural details
Table 3 shows the procedural characteristics. Pre-dilatation was performed in 89.9% 
(pre-dilatation balloon to artery ratio of 1.05 ± 0.23). Post-dilatation was performed in 
53.3% with a balloon to scaffold ratio of 1.08 ± 0.11. Advanced lesion preparation using 
rotational artherectomy and scoring balloon was done in 3.1% and 2.7%. Pre-procedural 
evaluation and device optimization using invasive imaging with IVUS and OCT was done 
in 14.4% and 24.6% of the procedures, respectively. A total of 445 BVS were implanted 
with a mean number of 1.34 ± 0.69 scaffolds per lesion and a mean number of 1.79 
± 1.15 scaffolds per patient. For the bifurcation lesions, the provisional side branch 
treatment was standard in this study. Side branch wiring before main vessel stenting 
was employed in 37.5%. Side branch dilation after main vessel stent was performed for 
31% and bailout stenting only in one BVS. Side branch fenestration was performed in 
25%. Side branch dilation was followed by mini-kissing post-dilation of just sequential 
ballooning with proximal optimization. 
Post-procedural QCA characteristics were: RVD 2.77 ± 0.46 mm, MLD 2.30 ± 0.42 mm 
and %DS 16.90 ± 9.04. Acute lumen gain was 1.39 ± 0.59 mm.
Clinical device success was 97.3% and clinical procedural success was 96.8%. In 5 pa-
tients delivery failure of the BVS occurred because the scaffold could not pass the lesion, 
for example due to severe calcification or tortuosity. After multiple attempts, metal DES 
were placed in these cases.
 Clinical outcomes
Survival data was available in 100% with a median follow-up period of 622 days (in-
terquartile range [IQR], 376-734 days). Two patients withdrew their informed consent 
within a few weeks after the index procedure. 
One-year clinical outcomes are reported in Table 4. Event rates are described as 
Kaplan-Meier estimates. Figures 2A – 2C give an impression of the event rates during 
late follow-up. At 18 months, there were 4 fatalities (all cardiac death) with a Kaplan-
Meier estimate of 1.8%. In the per-treatment group, MACE rate at 18 months was 6.8%, 
mainly driven by the rate of MI (5.2%).  There were two cases of peri-procedural MI. TLR 
at 18 months was performed in 4.0%, TVR in 4.0%. Rate of non-TVR was 5.4%. Rate of 
overall ST at 18 months was 2.7%, with a definite ST rate of 1.9%. 
Details of ST cases are summarized in Table 5. Narratives of each case are presented in 
the supplemental material. In Figure 3 we present MACE, its components and definite/ 
probable ST rates in various subgroups. There was no increased rate of both MACE and 
definite/ probable ST in patients presenting with ACS (NSTEMI and unstable angina) 
compared to the overall population.
Bar graphs demonstrating the rate of major adverse cardiac event (MACE) rate, its 
components, and scaffold thrombosis in subgroups of population (e.g. calcification, 
bifurcation, small vessel). MI myocardial infarction, NS non-ST-segment elevation 
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table 3 Procedural characteristics
N= 249; L= 335
Treated lesion per procedure 1.35 ± 0.62
Aspiration thrombectomy (%) 4.2
Rotablation (%) 3.1
Scoring balloon (%) 2.7
Intracoronary imaging (%)
IVUS 14.4
OCT 24.6
Pre-dilation (%) 89.8
Max pre-dilation diameter (mm) 2.61 ± 0.44
Pre-dilation balloon: artery ratio 1.05 ± 0.23
Maximum pre-dilation inflation pressure (atm) 12.80 ± 5.91
Buddy wire (%) 8.1
Mean number of scaffolds/ lesion 1.34 ± 0.69
Mean number of scaffolds/ patient 1.79 ± 1.15
Number of scaffolds 445
1 (%) 72.6
2 (%) 20.3
3 (%) 4.5
4 (%) 2.5
Scaffold diameter (mm) 3.08 ± 0.35
Scaffold length implanted (mm) 28.31 ± 17.06
Lesions with Overlapping scaffolds (%) 25.4
Overlap scaffolds diameters 3.5 mm–3.5 mm (%) 24
Overlap scaffolds diameters 3.5 mm–3.0 mm 23
Overlap scaffolds diameters 3.5 mm–2.5 mm 7
Overlap scaffolds diameters 3.0 mm–3.0 mm 21
Overlap scaffolds diameters 3.0 mm–2.5 mm 29
    Overlap scaffolds diameters 2.5  mm–2.5 mm 11
Maximum scaffold implantation pressure (atm) 15.08 ± 1.82
Post-dilation (%) 53.3
Post-dilation balloon: mean scaffold diameter ratio 1.08 ± 0.11
Max post-dilation balloon (mm) 3.20 ± 0.46
Maximum post-dilation inflation pressure (atm) 15.50 ± 3.42
Procedural complications (%)
 Dissection 5.1
Slow flow/ no reflow 2.7
Clinical device success (%) 97.3
Clinical procedural success (%) 96.8
Values are expressed as percentages or mean ± standard deviation when appropriate.
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myocardial infarction, ST scaffold thrombosis, TLR target lesion revascularization, UA 
unstable angina
Univariate analysis was performed to identify predictors for the occurrence of MACE 
and definite/ probable ST (Table 6 and 7).  Due to lack of power, none of the factors 
were significant. However, regarding MACE, the following characteristics tended to be 
associated with ≥ 2 times increased risk of MACE: male (HR 4.079, P = 0.18), more than 
2 scaffolds/ lesion (HR 2.41, P = 0.19), underexpansion (HR 2.25, P = 0.16 and age > 65 
years (HR 2.11, P = 0.20) (Table 6). Regarding ST, the following characteristics tended to 
be associated with ≥ 3 times increased risk of ST: age > 65 years (HR 4.49, P = 0.19), long 
table 4 Kaplan-Meier estimates at one-year for clinical events rates
Clinical event rates at one year ITT
(N=249)
PT
(N=244)
MACE (%) 5.5 5.1
All cause death (%) 1.3 1.3
   Cardiac death 1.3 1.3
   Non-cardiac death 0.0 0.0
All myocardial infarction (%)* 3.8 3.4
Target-vessel 2.8 2.5
Target lesion revascularization (%) 3.8 3.4
Target vessel revascularization (%) 3.8 3.4
Non-target vessel revascularization (%) 3.9 3.7
Total scaffold thrombosis (%) 2.1 2.1
Definite scaffold thrombosis (%) 1.3 1.3
   Acute 0.0 0.0
   Subacute 0.0 0.0
   Late 1.3 1.3
Probable scaffold thrombosis (%) 0.4 0.4
   Acute 0.0 0.0
   Subacute 0.0 0.0
Late 0.4 0.4
Possible scaffold thrombosis (%) 0.4 0.4
   Acute 0.0 0.0
   Subacute 0.0 0.0
   Late 0.4 0.4
Bleeding (Gusto) (%) 2.1 2.2
CVA/ TIA (%) 0.9 0.9
CVA cerebrovascular accident, ITT intention-to-treat, MACE major adverse cardiac events (composite end-
point of cardiac death, myocardial infarction and target lesion revascularization), PT per-treatment, TIA 
transient ischemic attack
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lesions (HR 3.55, P = 0.27 for lesions of 20 mm and HR 3.42, P = 0.22 for lesions of 32 mm), 
calcified lesion (HR 3.55, P = 0.27) and RVD ≤ 2.5 mm (HR 3.26, P = 0.31).
Concerning intravascular imaging at baseline, patients who did not undergo baseline 
imaging had a TLR rate of 4.0%, compared to 2.3% in patients who did undergo baseline 
imaging (P Log Rank = 0.29). Intravascular imaging was performed more often in pa-
tients who had a complex lesion (AHA classification type B2/ C lesion): 44.5% vs 31.1%, 
P = 0.03.
To examine the relationship between underexpansion, sizing and MACE, a scatterplot 
of the pre-procedural sizing and post-procedural expansion divided by nominal diam-
eter was created based on QCA (Figure 4). When a cut-off value of MLD post-procedure 
/ nominal device diameter of < 0.70 is applied, the scaffold was underexpanded in 26% 
of the lesions. Patients, in whom underexpansion occurred, tended to have an increased 
rate of MACE: 8.0% versus 3.8% (P = 0.15, log rank test). 
figure 2 Kaplan-Meier curves for adverse events at 
18 months
Cumulative rates of major adverse cardiac event 
(panel A), target lesion revascularization (panel B) 
and definite/probable scaffold thrombosis (panel 
C) up to 18 months using Kaplan-Meier estimation  
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figure 3 Rate of MACE and Definite/Probable ST, divided by subgroups
Bar graphs demonstrating the rate of major cardiac adverse event (MACE) rate, its components, and scaf-
fold thrombosis in subgroups of population (e.g., calcification, bifurcation, small vessel). MI = myocardial 
infarction; NS = non-ST-segment elevation myocardial infarction; ST = scaffold thrombosis; TLR = target 
lesion revascularization; UA = unstable angina.
table 6 Univariate analysis of MACE
Hazard Ratio (95% confidence interval) P value
Male 4.07 (0.53 – 31.51) 0.18
> 2 scaffolds/ lesion 2.41 (0.66 – 8.84) 0.19
Underexpansion 2.25 (0.73 – 6.98) 0.16
Age > 65 years 2.11 (0.67 – 6.64) 0.20
Bifurcation lesion 1.97 (0.63 – 6.21) 0.25
Long lesion (>32mm) 1.73 (0.52 – 5.76) 0.37
Long lesion (>20mm) 1.67 (0.53 – 5.27) 0.38
Calcified lesion 1.64 (0.52 – 5.17) 0.39
Overlap 1.59 (0.49 – 5.17) 0.44
RVD ≤ 2.5mm 1.56 (0.49 – 4.91) 0.45
Diabetes Mellitus 1.51 (0.41 – 5.57) 0.54
Presentation with ACS 0.71 (0.23 – 2.20) 0.55
Imaging at baseline 0.55 (0.15 – 2.03) 0.37
ACS acute coronary syndrome (NSTEMI and unstable angina pectoris), MACE major adverse cardiac events 
(composite endpoint of cardiac death, myocardial infarction and target lesion revascularization), MLD mini-
mal lumen diameter, RVD reference vessel diameter (pre-procedural), Underexpansion (PostMLD/ nominal 
device diameter) < 0.7
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table 7 Univariate analysis of probable/ definite ST
Hazard Ratio (95% confidence interval) P value
Age > 65 years 4.49 (0.47 – 43.15) 0.19
Long lesion (>20mm) 3.55 (0.37 – 34.13) 0.27
Calcified lesion 3.55 (0.37 – 34.13) 0.27
Long lesion (>32mm) 3.42 (0.48 – 24.26) 0.22
RVD ≤ 2.5mm 3.26 (0.34 – 31.34) 0.31
Bifurcation lesion 2.72 (0.38 – 19.31) 0.32
Overlap 2.20 (0.30 – 15.92) 0.44
Underexpansion 2.19 (0.31 – 15.53) 0.43
> 2 scaffolds/ lesion 1.74 (0.21 – 14.70) 0.61
Diabetes Mellitus 1.52 (0.16 – 14.64) 0.72
Presentation with ACS 0.70 (0.10 – 4.96) 0.72
ACS acute coronary syndrome (NSTEMI and unstable angina pectoris), MLD minimal lumen diameter, RVD 
reference vessel diameter (pre-procedural), ST scaffold thrombosis, Underexpansion: (PostMLD/ nominal 
device diameter) < 0.7
figure 4 Relation of BVS underexpansion and MACE
BVS = bioresorbable vascular scaffold; MACE = major adverse cardiac events; MLD = minimal lumen diam-
eter; RVD = reference vessel diameter.
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Discussion
To the best of our knowledge this is the first registry reporting on the extended follow-
up beyond one year, with a median follow-up duration of 622 days. The main findings of 
our study are that: 1) 12-month MACE incidence for the per-treatment group was 5.1%, 
mainly driven by rate of MI (approximately 70% due to target vessel MI), with a further 
flattening of Kaplan-Meier after one year (6.8% at 18 months); 2) the rate of definite/ 
probable ST at one year was 1.7% which is higher compared to second generation metal 
DES; 12 3) patients with acute coronary syndrome did not have increased risk of MACE 
and ST; and 4) underexpansion of the BVS was a rather frequent finding and there was a 
trend for an increased rate of MACE. 
The BVS Expand registry describes the procedural and medium to long-term clinical 
outcomes of BVS in patients with native, de novo coronary artery disease. Other studies 
investigating clinical outcomes of BVS were often characterized by small sample size 
and inclusion of patients with non-complex lesions. In this single-center study we report 
event rates in a more complex lesions including long lesions (mean lesion length 22.10 
± 13.90 mm), calcified and bifurcated lesions, with a relatively high proportion of ACC/
AHA type B2 or C lesions (38.1%). Furthermore and different from other registries 10, 
all events were adjudicated by an independent CEC and all angiograms were analysed 
using QCA, creating a complete QCA database. Finally, in the present registry there were 
limited angiographic exclusion criteria that allowed a study population that is more 
reflective of a ‘real-world’ population.
Taking into account the complexity of the treated lesions, the one-year MACE rate of 
5.1% observed in the current registry is low and in line with previous trials using BVS 
in relatively simple lesions: 5% in the ABSORB II trial 7, 5.0% in the ASSURE BVS registry 
9, 4.3% in the BVS Extend trial. 13 Recently, several European registries reported on the 
6-month clinical outcomes after implantation of BVS in all-comer settings (Table 8). In 
our registry, 6-month MACE rate was 4.7% which is comparable to the other registries.
Recently, some concerns were raised regarding a potentially increased rate of ST after 
implantation of the Absorb BVS. 10, 14, 15 Stent thrombosis in the case of metallic DES is an 
entity with complex multifactorial pathomechanisms, something that probably applies 
to the case of BVS. 16 The importance of patient selection, lesion preparation, pre- and 
post-dilatation and the consideration of invasive imaging for optimal device deploy-
ment have to be emphasized 17, 18, while DAPT (dual antiplatelet therapy) continuation 
for at least one year is recommended. Pilot imaging observations in real-world patients 
with BVS thrombosis suggest suboptimal implantation with underexpansion, malappo-
sition, and incomplete lesion coverage, often in combination with DAPT discontinuation 
to be the major substrate both for acute and late events. 19 Although it is not clear why 
this complication is observed in high incidence with BVS, a potential explanation could 
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be the increased thickness of the BVS struts, which can cause convective flow patterns, 
potentially triggering platelet deposition and subsequent thrombosis, especially in 
settings with suboptimal flow conditions. 20 For this reason, BVS with thinner struts are 
currently being developed and animal studies are ongoing.
Rate of definite ST in the AMC registry was 3.0% at six months. 14 However, in the latter 
trial, STEMI patients were also included. The annual rate of definite/ probable ST in the 
GHOST-EU trial was 3.4% and 70% of the ST cases occurred in the first 30 days. In our 
study, there were three cases of definite ST (1.3%) within one year (table 5 and electronic 
supplements). In most of these cases, suboptimal implantation in complex lesions was 
the main finding, with also inadequate DAPT duration in one case. Notably and in con-
trast to the other registries, no cases of acute or subacute ST occurred. The lower rate 
of ST in the BVS Expand could presumably be due to the good procedural performance: 
usage of invasive imaging in almost 40% and pre-dilatation in 89%. Unlike the above-
mentioned registries, STEMI patients were excluded in our study. The enrolled patients 
were all appropriately preloaded with P2Y12 inhibitors which could attribute to the 
absence of acute and subacute ST, whereas this is not always the case in STEMI patients. 
In this study, the presence of with NSTEMI/ UA was not associated with an additional 
risk of MACE or ST. Theoretically, the lesions in patients with ACS are generally lipid-rich 
with or without thrombus which will not hinder the deployment nor the expansion of 
the BVS. 
Our analysis shows that underexpansion of BVS occurs frequently and had a non-
significant association with an increased risk of MACE and probable/definite ST. 
Compared to other BVS registries rate of post-dilatation in our study is somewhat low 
(53.3%) and this could partly explain the frequent occurrence of underexpansion. This 
low post-dilatation rate was an extension of the ABSORB-EXTEND and ABSORB II studies, 
where post-dilatation was discouraged as a reflex to a single case where strut fractures 
were observed due to severe undersizing and post-dilatation with an oversized balloon 
beyond the expansion limits of the scaffold. This is a different situation compared to 
underexpansion due to atherosclerotic disease where struts are still apposed but the 
initial lesions are difficult to dilate. It is now clear that for underexpansion high pressure 
post-dilatation do not result in strut fractures as long as non-compliant post-dilatation 
balloons are used within the maximum expansion limit of the implanted device.  
Nevertheless, the arbitrary definition of underexpansion we used for this manuscript 
was partly based on QCA measurements, which are known to underestimate vessel 
dimensions when compared to invasive imaging methods like IVUS and OCT which 
is considered the standard at the moment 21, 22. The difference for IVUS might be even 
larger compared to OCT, with an underestimation of approximately of QCA of 0.2 mm 
vs OCT and 0.3 mm vs IVUS. Use of intravascular imaging might improve pre-procedural 
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vessel sizing, whereas a more liberal use of post-dilatation has to be underlined, with the 
aim of minimizing BVS underexpansion and, eventually, improving the clinical outcome.
limitations
This is a single-center, single-arm registry with no direct comparison with metallic DES. 
The total number of patients in this study was limited. Thus, these findings warrant fur-
ther confirmation in a large-scale trial. Ongoing and upcoming trials such as the ABSORB 
III, IV and the Compare Absorb will provide data derived from larger patient cohorts and 
in direct comparison to metallic DES.
Furthermore, deciding which patient or lesion was suitable for BVS implantation could 
have led to selection bias. Almost 80% of the patients returned their study informed 
consent and thus follow-up is only investigated in these patients. The event rate is un-
known in the remaining patients. 
conclusion
In our study, BVS implantation in a more complex patient and lesion subset was associ-
ated with an acceptable rate of adverse events at the longer term, comparable to rates 
reported with contemporary second generation metallic drug-eluting stents, while no 
cases of early thrombosis were observed. This study supports a more extensive use of 
BVS and launch of randomized trials aiming to demonstrate superiority in the longer 
term, when optimal implantation strategies are used.
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suPPlement – narratives of cases with st
case 1. neointima hyperplasia and recurrent failure
A 59 year old male patient with a history of CVA and stable angina visited the outpatient 
clinic. His ECG revealed new T-top inversions. Subsequently, angiography was performed 
which revealed one vessel disease with narrowing of the proximal LAD (AHA/ACC clas-
sification type C lesion) at the origin of the first diagonal (Medina 1,1,0) and a diffusely 
diseased 2nd ramus marginalis. One BVS (3.5x28mm) was placed with a good results for 
the main branch without impact on the side branch. 112 days after in the index PCI 
the patient developed a NSTEMI due to a definite ST. Angiography with additional 
OCT showed mild scaffold underexpansion (3mm in diameter) with severe neointima 
development but also areas with late malapposition due to potential vasodilatation 
and thrombus resorption. Treatment consisted of thrombectomy, eptifibatide and a 
3.5x32mm DES (Promus). He was using DAPT (clopidogrel and aspirin) at the time of 
the event. The patient returned almost 4 months later with unstable angina. There was 
a severe ISR on angiography (DES failure) with total occlusion and collaterals suggesting 
resistance to everolimus. It was decided to perform a semi-urgent CABG, which took 
place four days later.
case 2. residual thrombus after bvs implantation
This 69 year old male patient with risk factors of dyslipidaemia and hypertension pre-
sented with a NSTEMI. Angiography showed one-vessel disease with narrowing of the 
proximal and mid LAD (AHA/ACC classification type C lesion). Three BVS (3.0x28mm, 
3.5x18mm, 3.5x18mm) were implanted. After implantation, there was pinching and 
thrombus in the 1st diagonal for which fenestration with a 2.0 mm balloon followed by 
proximal optimization was performed. Invasive imaging post-procedure revealed orga-
nized thrombus behind the struts of the proximal scaffold and thrombus protrusion at 
the overlapping scaffolds. After 47 days the patient presented with a non-Q wave MI 
due to a definite ST in the proximal LAD. OCT at the time of the event revealed areas 
of late malapposition and massive thrombosis. He was treated with thrombectomy, 
eptifibatide and PCI with a 3.5x38mm DES (Xience) with good angiographic result. The 
patient was using DAPT (clopidogrel and aspirin).  The diagnostic angiography made 
110 days later displayed good scaffold and stent apposition on OCT with good coverage 
of the struts of the new DES.
case 3. cardiac death and possible st
A 76 year old male patient with cardiac risk factors of smoking, diabetes and hyper-
tension, developed angina and dyspnea 66 days after the  baseline procedure (one 
3.0x18mm BVS in LAD) and suddenly died the next day. No autopsy was performed. The 
patient was using DAPT (clopidogrel and aspirin).
case 4. edge restenosis presenting as acute coronary syndrome
A 65 year old male patient with risk factors smoking, hypertension and a positive family 
history for CAD, presented with a NSTEMI. Angiography at baseline showed a trifurca-
tion lesion of the LAD and two diagonals treated with pre-dilatation, a single 3.0 x 18 
mm BVS and post-dilatation of the main branch only. 142 days later he returned with a 
NSTEMI. OCT imaging revealed edge restenosis as the underlying mechanism for BVS 
failure. The patient was treated with 3.5x38 mm DES (Promus) implantation. The patient 
was using DAPT (aspirin and prasugrel) at time of the event.
case 5. Discontinuation of anticoagulants
A 70 year old male patient (with extensive vascular disease (diabetes mellitus, dyslipid-
emia, and hypertension) and decreased LVF.) underwent an elective PCI because of his 
decreased LV function. Angiography showed a long and calcified lesion in the mid-LAD. 
Aggressive preparation with a 1.5mm rotablator and dilatations with NC- and cutting 
balloons were performed and two overlapping BVS (3.0x28mm and 2.5x18mm) were 
implanted. Five months after the baseline procedure he underwent iliac PTA. Post-PTA 
the patient developed pain in his back. There was a rise in cardiac enzymes. Because 
of his surgery, his anticoagulants were briefly interrupted. The patient then developed 
a NSTEMI due to thrombus in the previously treated LAD with intravascular imaging 
evidence of underexpansion. Treatment consisted of balloon dilatation and eptifibatide; 
the thrombus catheter could not approach the lesion. Four days later, the patient devel-
oped acute dyspnoea. He had alternating rhythms on ECG (first sinus tachycardia and 
later a total AV-block). He went to the CCU and was treated with CPAP and a temporary 
pacemaker. However, he became hemodynamically unstable and CPR was performed 
because of cardiogenic shock (VF). Sadly, the patient did not survive.
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abstract
objectives
To investigate one-year outcomes after implantation of a bioresorbable vascular scaffold 
(BVS) in patients presenting with acute coronary syndrome (ACS) compared to stable 
angina patients.
background
Robust data on the outcome of BVS in the setting of ACS is still scarce. 
methods
Two investigator initiated, single-center, single-arm BVS registries have been pooled for 
the purpose of this study, namely the BVS Expand and BVS STEMI registries.
results
From September 2012 - October 2014, 351 patients with a total of 428 lesions were 
enrolled. 255 (72.6%) were ACS patients and 99 (27.4%) presented with stable angina/ 
silent ischemia. Mean number of scaffold/ patient was 1.55±0.91 in ACS group versus 
1.91±1.11 in non-ACS group (P=0.11). Pre- and post-dilatation were performed less 
frequent in ACS patients, 75.7% and 41.3% versus 89.0% and 62.0% respectively (P=0.05 
and P = 0.001). Interestingly, post-procedural acute lumen gain and percentage diameter 
stenosis were superior in ACS patients, 1.62±0.65mm (versus 1.22±0.49mm, P <0.001) 
and 15.51±8.47% (versus 18.46±9.54%, P=0.04). Major adverse cardiac events (MACE) 
rate at 12 months was 5.5% in the ACS group (versus 5.3% in stable group, P=0.90). 
One-year definite scaffold thrombosis rate was comparable: 2.0% for ACS population 
versus 2.1% for stable population (P=0.94), however, early scaffold thromboses occurred 
only in ACS patients.
conclusions
One-year clinical outcomes in ACS patients treated with BVS were similar to non-ACS 
patients. Acute angiographic outcomes were better in ACS than in non-ACS, yet the 
early thrombotic events require attention and further research.  
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introDuction
Drug-eluting stents (DES) are the first choice devices in percutaneous coronary interven-
tions (PCI). Despite recent advantages, shortcomings related to the use of DES still are 
present such as delayed arterial healing, late stent thrombosis (ST), neo-atherosclerosis 
and hypersensitivity reactions to the polymer. 1, 2 
To overcome these limitations, coronary devices made of fully bioresorbable mate-
rial were developed to provide mechanical support and drug-delivery within the first 
year, followed by complete resorption. The first bioresorbable vascular scaffold (BVS) 
was commercially introduced in September 2012 as the Absorb BVS (Abbott Vascular, 
Santa Clara, CA). The BVS provides transient vessel support and gradually elutes the anti-
proliferative drug everolimus. After degradation of the polymer (after approximately two 
to three years) no foreign material remains and need for late reintervention triggered by 
foreign material should thus be reduced. 3 
First-in-man trials have proven the safety of the BVS up to five years 4, 5  with a fully 
completed bioresorption process, a late luminal enlargement due to plaque reduction 
and a persistent restoration of vasomotion. 6-8 The 1-year results of the larger ABSORB II, 
ABSORB Japan, ABSORB China and ABSORB III randomized controlled trials comparing 
BVS with DES (Xience V), confirmed the safety in relatively simple coronary lesions with 
similar clinical event rates for both devices. 9-12 
In all these early studies, ACS patients were largely excluded while BVS would com-
prise a more attractive choice in this setting as ACS patients are in general younger with 
a longer life expectancy, less previous MI and revascularizations with implantation of 
metallic stents, that would conflict with a therapy aiming at maximal recovery and res-
toration of normal anatomy of both the coronary artery and myocardium. Furthermore, 
lesions primarily consisting of soft plaque would be conceptually easy to expand thus 
facilitating BVS implantation in ACS population. On the other hand, ACS patients are in 
a much higher pro-thrombotic state which might accelerate thrombus formation on the 
larger struts of the BVS impacting much more on shear stress compared to the thinner 
struts of current metallic DES. 
Few registries focused on the performance of the BVS in patients presenting with 
ACS, mainly ST-elevation myocardial infarction (STEMI). BVS STEMI First examined the 
procedural and short-term clinical outcomes of 49 STEMI patients, revealing excellent 
results: procedural success was 97.9% and only 1 patient suffered an event (non-target 
vessel MI). 13 Kočka et al reported similar results in the Prague-19 study. 14  Extending the 
initial Prague-19 study, the BVS Examination is currently the largest registry on BVS in 
STEMI with encouraging MACE rates (Device oriented clinical endpoint: 4.1% at one year 
for both the BVS and the DES), although with a not negligible definite/ probable scaffold 
thrombosis rate (2.4% at one year for the BVS). 15 
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The recently published TROFI II randomized trial investigated arterial healing in 90 
STEMI patients treated with a BVS compared to those treated with an everolimus-eluting 
stent (EES). Based on OCT, arterial healing at 6 months after BVS implantation was non-
inferior to that after EES implantation. 16
In general, the previous studies on BVS in ACS are limited in size and procedural details 
and there is a need for more data on the efficacy of BVS in the setting of PCI for ACS. The 
aim of this study was to compare the angiographic and clinical outcomes of BVS in ACS 
patients with stable patients.
material anD methoDs
Population
Two investigator-initiated, prospective, single-center, single-arm studies performed in 
an experienced, tertiary PCI center have been pooled for the purpose of this investiga-
tion. Patients presenting with NSTEMI, stable or unstable angina (UA), or silent ischemia 
caused by a de novo stenotic lesion in a native previously untreated coronary artery with 
intention to treat with a BVS were included in BVS Expand registry. Angiographic inclu-
sion criteria were lesions with a Dmax (proximal and distal maximal lumen diameter) 
within the upper limit of 3.8 mm and the lower limit of 2.0 mm by online quantitative 
coronary angiography (QCA). Complex lesions such as bifurcation, calcified (as assessed 
by angiography), long and thrombotic lesions were not excluded. Exclusion criteria were 
patients with a history of coronary bypass grafting (CABG), presentation with cardiogenic 
shock, bifurcation lesions requiring kissing balloon post-dilatation, ST-elevation myo-
cardial infarction (STEMI) patients, allergy or contra-indications to antiplatelet therapy, 
fertile female patients not taking adequate contraceptives or currently breastfeeding 
and patients with expected survival of less than one year. As per hospital policy patients 
with a previously implanted metal DES in the intended target vessel were also excluded. 
Also, although old age was not an exclusion criterion, BVS were in general reserved for 
younger patients, and left to operator’s interpretation of biological age.
Patients presenting with STEMI, were approached to participate in the BVS STEMI 
Registry, which started two months after the BVS Expand registry. The study design has 
been described elsewhere. 13 The most important inclusion criteria were presentation 
with STEMI and complaints < 12 hours. The remaining inclusion criteria were similar to 
the BVS-EXPAND registry.
ethics
This is an observational study, performed based on international regulations, includ-
ing the declaration of Helsinki. Approval of the ethical board of the Erasmus MC was 
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obtained. All patients undergoing clinical follow-up provided written informed consent 
to be contacted regularly during the follow-up period of the study.
Procedure
PCI was performed according to current clinical practice standards. The radial or femoral 
approach using 6 or 7 French catheters were the principal route of vascular access. 
Pre-dilatation was recommended with a balloon shorter than the planned study device 
length. Advanced lesion preparation was left to the operator’s discretion. Post-dilatation 
was recommended with a non-compliant balloon without overexpanding the scaffold 
beyond its limits of expansion (by > 0.5mm larger than nominal diameter). Intravascular 
imaging with the use of Intravascular Ultrasound (IVUS) or Optical Coherence Tomogra-
phy (OCT) was used for pre-procedural sizing and optimization of scaffold deployment 
on the discretion of the operator. All patients were treated with unfractionated heparin 
(at a dose of 70-100 UI/ kg). Patients with stable angina were preloaded with 300 mg of 
aspirin and 600 mg of clopidogrel. Patients presenting with ACS were preloaded with 
300 mg of aspirin and 60 mg of prasugrel or 180 mg of ticagrelor.
angiographic analysis
The angiographic analysis was performed by three independent investigators (YI, JF 
and YO). Coronary angiograms were analyzed with the CAAS 5.10 QCA software (Pie 
Medical BV, Maastricht, the Netherlands). The QCA measurements provided reference 
vessel diameter (RVD), percentage diameter stenosis, minimal lumen diameter (MLD), 
and maximal lumen diameter (Dmax). Acute gain was defined as post-procedural MLD 
minus pre-procedural MLD (in an occluded vessel MLD value was zero by default). 
follow-up
Survival status of all patients was obtained from municipal civil registries. Follow-up 
information specific for hospitalization and cardiovascular events was obtained through 
questionnaires. If needed, medical records or discharge letters from other hospitals were 
collected. Events were adjudicated by an independent clinical events committee (CEC). 
Definitions
The primary endpoint was MACE, defined as the composite endpoint of cardiac death, 
myocardial infarction (MI) and target lesion revascularization (TLR). Deaths were consid-
ered cardiac unless a non-cardiac cause was definitely identified. TLR was described as 
any repeated revascularization of the target lesion. Target vessel revascularization (TVR) 
was defined as any repeat percutaneous intervention or surgical bypass of any segment 
of the target vessel. Non-target vessel revascularization was described as any revascular-
ization in a vessel other than the vessel(s) of the target lesion(s). Target lesion failure (TLF) 
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was defined as a composite endpoint of cardiac death, target vessel MI and TLR. Scaffold 
thrombosis (ST) and MI were classified according to the Academic Research Consortium 
(ARC). 17 Clinical device success was defined as successful delivery and deployment of 
the first study scaffold/ stent at the intended target lesion and successful withdrawal 
of the delivery system with attainment of final in-scaffold/ stent residual stenosis of < 
30% as evaluated by QCA. Clinical procedure success was described as device success 
without major peri-procedural complications or in-hospital MACE (maximum of 7 days). 
The intention-to-treat (ITT) group includes all the patients regardless of whether or 
not the scaffold was successfully implanted. The per-treatment (PT) group consists of all 
patients in whom the BVS was successfully implanted. All analyses were performed in 
the PT group.
As a measure of scaffold expansion, the expansion index was calculated as post-
procedural MLD divided by nominal device diameter. A cut-off value of < 0.70 below 
was used to define underexpansion. 
statistical analysis
Categorical variables are reported as counts and percentages, continuous variables as 
mean ± standard deviation. The student’s t test and the chi square test (or Fishers’ exact 
test) were used for comparison of means and percentages. The cumulative incidence 
of adverse events was estimated according to the Kaplan-Meier method. Patients lost 
to follow-up were considered at risk until the date of last contact, at which point they 
were censored. Kaplan-Meier estimates were compared by means of the log-rank test. 
For the endpoint MACE, a landmark survival analysis was performed with the landmark 
time point of 30 days. All statistical tests were two-sided and the P value of < 0.05 was 
considered statistically significant.  Statistical analyses were performed using SPSS, ver-
sion 21 (IL, US).
A univariate logistic regression analysis was performed to look for predictors of TLF 
and probable/ definite ST. 
results
From September 2012 up to October 2014, 452 patients were intended to be treated with 
one or more BVS. Thirteen patients were excluded based on protocol related exclusion 
criteria of the BVS Expand registry and the BVS STEMI registry and 79 patients declined 
to participate in one of the two follow-up registries. Thus 360 patients (intention-to-
treat group) remained for the purpose of this study. There were 9 cases of device failure 
in which a metallic stent was implanted and the per-treatment group consisted of 351 
patients. A flowchart of the study is given in figure 1.
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baseline characteristics
Baseline characteristics are presented in table 1. Presentation with ACS was present in 
72.6% of the patients and 27.4% were stable patients. Mean age was significantly dif-
ferent between the two groups: 57.9 ± 10.7 years for ACS patients and 63.4 ± 8.9 years 
for non-ACS patients (P < 0.001). Dyslipidemia, history of MI, history of PCI and renal 
insufficiency were factors that occurred significantly more frequent in stable patients. 
ACS patients had more single vessel disease (71.5% versus 54.2%, P = 0.02).
Lesion characteristics are presented in table 2. In both groups, the left anterior de-
scending coronary artery (LAD) was most commonly treated (48.0% in ACS group and 
54.4% in non-ACS group, P = 0.23). Lesions in stable patients were more complex, with 
a higher percentage of AHA/ ACC type B2/ C lesions. Pre-procedural TIMI flow was sig-
nificantly different (P <0.001). The mean lesion length was comparable in both groups 
(24.58 ± 14.58 mm for non-ACS versus 22.41 ± 12.24 mm for ACS, P = 0.35) (table 3). Pre-
procedural QCA analysis revealed significant differences between the groups in MLD: 
0.69 ± 0.51 mm for ACS patients versus 1.04 ± 0.40 in stable patients (P <0.001). After 
excluding the thrombotic total occlusions, this statistical difference remained (0.89 ± 
0.39 mm for ACS versus 1.06  ± 0.37 mm for non-ACS, P = 0.002). Pre-procedural %DS was 
65.45 ± 20.91% in the ACS group versus 58.62 ± 13.84% in non-ACS group (P <0.001). 
Post-procedural QCA measurements revealed a superior acute performance in the ACS 
population: remaining %DS was significant lower (15.57 ± 8.47% versus 18.46 ± 9.54%, P 
= 0.04). Final MLD was larger (2.35 ± 0.42 mm versus 2.26 ± 0.38 mm, P = 0.05) and also 
acute lumen gain was higher (1.62 ± 0.65 mm versus 1.22 ± 0.49 mm, P <0.001).
Assessed for eligibility (n=316)
September 2012 – October 2014
Assessed for eligibility (n=452)
Follow-up: patients with BVS
Survival status: 100%
Median follow-up: 597 days (IQR 427-734 days)
Lost to long-term follow-up (n=5)
Withdrew informed consent (n=2)
Died within first year (n=3)
Allocated to intervention (n=360)
Received BVS (n=351)
Device failure BVS & placement metal DES (n=9)
Declined to participate (n=79)
Not meeting inclusion criteria (n=13)
figure 1 Flowchart 
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table 1. Patient characteristics
ACS patients Non-ACS patients P value
Number of patients (%) 255 (72.6) 96 (27.4)
Mean age in years (±SD) 57.9 ± 10.7 63.4 ± 8.9 <0.001
Gender (%)
     Male 191/255 (74.9) 73/96 (76.0) 0.84
     Female 64/255 (25.1) 23/96 (24.0) 0.84
Smoking (%) 149/255 (58.4) 44/96 (45.8) 0.03
Hypertension (%) 130/253 (51.0) 55/95 (57.3) 0.29
Dyslipidemia (%) 92/251 (36.1) 49/95 (51.0) 0.01
All diabetes mellitus (%) 33/255 (12.9) 18/98 (18.8) 0.16
     Insulin dependent 7/255 (2.7) 3/96 (3.1) 1.00
Family history of CAD (%) 104/252 (40.8) 39/94 (41.5) 0.94
History of MI (%) 25/255 (9.8) 21/96 (21.9) 0.003
History of PCI (%) 12/255 (4.7) 12/96 (12.5) 0.01
Cardiogenic shock (%) 5/255 (2.0) 0/96 (0.0) 0.33
Renal insufficiency (%) 8/255 (3.1) 8/88 (8.3) 0.046
Presentation (%) <0.001
     Stable angina 0/255 (0.0) 95/96 (99.0)
     Unstable angina 40/255 (15.6) 0/96 (0.0)
     STEMI 120/255 (46.9) 0/96 (0.0)
     NSTEMI 95/255 (37.3) 0/96 (0.0)
     Silent ischemia 0/255 (0.0) 1/96 (1.0)
Single vessel disease (%) 183/255 (71.5) 52/96 (54.2) 0.02
P2Y12 inhibition use <0.001
     Clopidogrel 60/255 (23.5) 86/96 (89.6)
     Prasugrel 164/255 (64.3) 9/96 (9.4)
     Ticagrelor 30/255(11.8) 1/96 (1.0)
Values are expressed as percentages or mean ± standard deviation when appropriate. P values are based on 
Chi square test or Fishers’ exact test for categorical variables and Student’s t test for continuous variables. 
ACS: acute coronary syndrome, CAD: coronary artery disease, MI: myocardial infarction, NSTEMI: non-ST 
elevation myocardial infarction, PCI: percutaneous coronary intervention, STEMI: ST elevation myocardial 
infarction
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Procedural details
Procedural and angiographic details are summarized in table 3. In ACS patients, pre-
dilatation was performed in 75.7% of the lesions, compared to 89.0% in stable patients 
(P = 0.05). Pre-dilatation balloon to artery ratio was comparable (1.01 ± 0.21 versus 
1.05 ± 0.25, P = 0.11). Post-dilatation was significantly less frequently performed in the 
ACS group (41.3% versus 62.2%, P = 0.001). Advanced lesion preparation was less often 
performed in ACS patients than in stable patients (rotational atherectomy: 1.0% versus 
5.6%, P = 0.02; scoring balloon 1.3% versus 3.9%, P = 0.14). A total of 582 BVS were 
table 2. Lesion characteristics
ACS patients
N= 255, L=300
Non-ACS patients
N= 96, L=128
P value
Number of lesions per patient 1.18 ± 0.49 1.33 ± 0.56
Left anterior descending artery (%) 48.0 54.4 0.23
Left circumflex artery (%) 24.3 20.0 0.38
Right coronary artery (%) 27.7 25.6 0.61
Bifurcation (%) 20.3 30.7 0.009
Calcification (moderate or severe) (%) 31.8 50.4 <0.001
(Chronic) total occlusion* 26.2 8.7 <0.001
CTO 1.7 7.0 0.007
ACC/ AHA lesion classification (%)
     A 14.1 15.0 0.75
     B1 53.4 41.7 0.02
     B2 24.2 22.0 0.66
     C 7.2 19.7 <0.001
TIMI
           Pre-procedure <0.001
                                     TIMI 0   25.2 9.4
                                     TIMI I 4.6 0.8
                                     TIMI II 16.1 6.3
                                     TIMI III 52.1 81.9
           Post-procedure 0.61
                                      TIMI 0 0.0 0.0
                                      TIMI I 0.3 0.0
                                      TIMI II 4.6 3.1
                                      TIMI III 93.4 95.3
Values are expressed as percentages or mean ± standard deviation when appropriate. P values are based on 
Chi square test or Fishers’ exact test for categorical variables and Student’s t test for continuous variables. 
ACS: acute coronary syndrome (ST-elevation myocardial infarction, non-ST myocardial infarction and un-
stable angina), non-ACS: non acute coronary syndrome (stable angina and silent ischemia)
120 Chapter 6
table 3. Procedural and angiographical characteristics
ACS 
N= 255, L=300
Non-ACS 
N= 96, L=128
P value
Procedural characteristics
Aspiration (%) 34.4 0.0 <0.001
Rotablation (%) 1.0 5.6 0.02
Scoring balloon (%) 1.3 3.9 0.14
Invasive imaging at baseline (%)
     OCT 25.2 36.2 0.10
     IVUS 9.9 24.8 <0.001
Pre-dilatation (%) 75.7 89.0 0.05
     Pre-dilatation balloon : artery ratio 1.01 ± 0.21 1.05 ± 0.25 0.11
     Maximum pre-dilatation balloon diameter (mm) 2.57 ± 0.42 2.60 ± 0.34 0.49
     Maximum pre-dilatation inflation pressure (atm) 13.96 ± 3.02 14.01 ± 3.41 0.91
Buddy wire 9.8 10.2 0.74
Daughter catheter 3.6 4.0 0.80
Total number of scaffolds implanted 394 183
Mean number of scaffolds/ patient 1.55 ± 0.91 1.91± 1.11 0.11
Mean number of lesions/ patient 1.18 ± 0.49  1.33 ± 0.56 0.015
Mean scaffold diameter (mm) 3.14 ± 0.37 3.02 ± 0.38 0.003
Mean scaffold length (mm) 20.35 ± 5.67 20.75 ± 5.99
Overlap (%) 20.7 31.5 0.04
Post-dilatation (%) 41.3 62.2 0.001
     Post-dilation balloon: mean scaffold diameter ratio 1.23 ± 0.21 1.31 ± 0.23 0.11
     Maximum post-dilatation balloon diameter (mm) 3.38 ± 0.42 3.19 ± 0.42 0.003
     Maximum post-dilatation inflation pressure (atm) 15.40 ± 3.00 16.10 ±  3.31 0.17
Clinical device success (%) 98.0 97.7 0.82
Clinical procedural success (%) 95.4 96.9 0.49
Angiographical characteristics
Mean lesion length (mm) 22.41 ± 12.24 24.58 ± 14.58 0.35
Pre-procedure, overall
     RVD (mm ± SD) 2.65 ± 0.54 2.57 ± 0.45 0.22
     MLD (mm ± SD) 0.69 ± 0.51 1.04 ± 0.40 <0.001
     DS (%) 64.82 ± 42.0 47.94 ± 43.48 <0.001
Pre-procedure, non-total occlusion
     RVD (mm ± SD) 2.60 ± 0.48 2.58 ± 0.44 0.72
     MLD (mm ± SD) 0.89 ± 0.39 1.06 ± 0.37 0.002
     In-scaffold DS (%) 65.45 ± 20.91 58.62 ± 13.84 0.002
Pre-procedure, total occlusion 
(L=80 for ACS and L=11 for non-ACS)
     RVD (mm ± SD) 2.81 ± 0.69 1.78 ± 1.34 <0.001
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implanted: 399 in the ACS group (with a mean of 1.55 ± 0.91 scaffolds per patient) and 
183 in stable patients (with a mean of 1.91 ± 1.11 per patient in stable patients).
In the ACS population 6 cases of device failure occurred, all due to delivery failure. 
Main causes of these delivery failures were calcification and angulation (see table 6 
for details). Eight in-hospital MACE were reported. Whereas in the stable population 3 
device failures (placement metal DES due to dissection after BVS implantation and de-
livery failures due to severe calcification and tortuosity) and no in-hospital MACE were 
documented.. Clinical device and procedural success were 98.0% and 95.4% for the ACS 
population and 97.7 and 96.9% respectively for stable patients.
clinical outcomes
Data on survival status was available in 100% with a median follow-up period of 731 
days (interquartile range [IQR]: 550-769 days). A total of 340 (96.9%)  patients had a 
follow-up duration of at least 365 (± 2) days.
Cumulative clinical events rates are summarized in table 4. Clinical outcomes appeared 
to be comparable with no significant difference between patients presenting with ACS 
as compared to stable patients. Rate of death was 0.0% in the ACS group versus 3.1% in 
the non-ACS group (P = 0.06). Three patients died within the first year. One patient, with 
extensive cardiovascular disease died at day 166, 4 days after he went through a definite 
ST and MI, most probably due to a brief interruption of his antithrombotic medication 
during an elective surgery. The second patient died a few days after his prostate was 
surgically removed. In this case, dual antiplatelet inhibition therapy (DAPT) was also 
shortly interrupted causing a MI (probable ST). The last patient died of a sudden cardiac 
death 66 days after baseline PCI (possible ST)
table 3. Procedural and angiographical characteristics (continued)
ACS 
N= 255, L=300
Non-ACS 
N= 96, L=128
P value
Post-procedure, overall
     RVD (mm ± SD) 2.79 ± 0.48 2.77 ± 0.43 0.66
     MLD (mm ± SD) 2.35 ± 0.42 2.26 ± 0.38 0.05
     In-scaffold DS (%) 15.57 ± 8.47 18.46 ± 9.54 0.04
     Acute gain (mm ± SD) 1.62 ± 0.65 1.22 ± 0.49 <0.001
Values are expressed as percentages or mean ± standard deviation when appropriate. P values are based on 
Chi square test or Fishers’ exact test for categorical variables and Student’s t test for continuous variables. 
ACS: acute coronary syndrome (ST-elevation myocardial infarction, non-ST myocardial infarction and unsta-
ble angina), non-ACS: non acute coronary syndrome (stable angina and silent ischemia), %DS: percentage 
diameter stenosis, IVUS: intravascular imaging, OCT: optical coherence tomography, MLD: minimal lumen 
diameter, RVD: reference vessel diameter
122 Chapter 6
MACE rate in the ACS population was comparable to the non-ACS population (5.5% 
versus 5.3%, P = 0.90, figure 2). MACE was mainly driven by MI and TLR. TLR rate was 
comparable in both groups. Rate of TVR was in 3.2% in ACS patients versus 3.5% in stable 
patients (P = 0.86). Non-TVR rate was 3.2% and 5.5% in respectively ACS and non-ACS 
patients (P = 0.35). Rate of definite ST was similar in both groups: 2.0% in the ACS group 
versus 2.1% in stable patients (P = 0.94). Of note, early ST only occurred in the ACS group, 
late thrombosis was more prevalent in stable patients (table 4 and figure 3B).
A landmark survival analysis of MACE, definite/ probable ST, MI and TLR indicated a 
trend for higher event rates of the ACS population in the short-term (< 30 days). Con-
versely, mid-term event rates were higher in stable patients, although log rank test failed 
to prove significance (figure 3A-3D).
In a univariate analysis of TLF the following characteristics tended to be related by at 
least a twofold increase in odds ratio (OR): renal insufficiency, bifurcation, male gender 
and age above 65 years (table 5). The use of intravascular imaging at baseline might be 
protective for TLF (OR 0.49, P = 0.22).
table 4. Clinical outcomes at one year
ACS (N=255) Non-ACS (N=96) P value
All-cause death (%) 0.0 (0) 3.2 (3) 0.05
Cardiac 0.0 (0) 3.2 (3) 0.05
Non-Cardiac 0.0 (0) 0.0 (3) -
MACE (%) 5.5 (14) 5.3 (5) 0.90
Myocardial infarction (%) 5.1 (13) 2.1 (2) 0.22
Target lesion revascularization (%) 3.1 (8) 3.2 (3) 0.99
Target vessel revascularization (%) 3.5 (9) 3.2 (3) 0.86
Non-target vessel revascularization (%) 3.2 (8) 5.5  (5) 0.35
Overall scaffold thrombosis* (%) 2.4 (6) 4.2 (4) 0.37  
Definite scaffold thrombosis (%) 2.0 (5) 2.1 (2) 0.94
Acute 1.2 (3) 0.0 (0) 0.29
Subacute 0.4 (1) 0.0 (0) 0.54
Late 0.4 (1) 2.1 (2) 0.12
Definite/ probable scaffold thrombosis (%) 2.4 (6) 2.1 (2) 0.88
Acute 1.2 (3) 0.0 (0) 0.29
Subacute 0.4 (1) 0.0 (0) 0.54
Late 0.8 (2) 2.1 (2) 0.30
Event rates are summarized as %. P values are based on log rank test for comparing Kaplan Meier. MACE: 
major adverse cardiac events (composite endpoint consisting of cardiac death, myocardial infarction and 
target lesion revascularization). *Includes definite, probable and possible ST.
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figure 3 A - D Landmark survival analysis for MACE, probable/definite ST, MI and TLR.
124 Chapter 6
Discussion
The present study reports on the comparative procedural and the one-year clinical out-
comes of ACS patients versus non-ACS patients treated with an Absorb bioresorbable 
scaffold. The main findings of this study are summarized as follows: 1) Angiographic out-
comes were better in ACS patients despite the fact that less aggressive lesion prepara-
tion and less frequent post-dilatation were performed; 2) Overall one-year ST rate in ACS 
patients was similar to the non-ACS patients. Interestingly, early definite ST occurred 
only in the ACS population while late ST seemed more frequent in stable patients.; 3) 
Despite the higher rate of early complications in the ACS group, landmark analyses 
after one month demonstrated that event rates were lower in this group than the stable 
patient group; 4) Clinical outcomes at one year were comparable among ACS and stable 
patients.
Differences between ACS patients and stable patients exist at multiple levels. On a 
patient level, patients presenting with ACS often are younger and thus have a longer 
life expectancy. Cardiovascular disease in this group is less extensive when compared 
to stable patients. Additionally, a different plaque composition is present, featured by 
a lipid-rich necrotic core with a thin fibrous cap. All these factors make ACS patients 
very attractive for bioresorbable technologies where full expansion is important and 
acute recoil a concern. Moreover, in ACS patients DAPT pretreatment is usually short 
table 5. Univariate analysis of TLF
Odds ratio ACS vs. non ACS 
(95% confidence interval)
P value
Renal insufficiency 3.28 (0.68 – 15.83) 0.14
Bifurcation 2.68 (0.98 – 7.36) 0.06
Male gender 2.38 (0.53 – 10.69) 0.26
Age above 65 years 2.10 (0.77 – 5.75) 0.15
History of MI 1.57 (0.43 – 5.73) 0.50
Small vessel (< 2.5mm) 1.54 (0.56 – 4.20) 0.40
Post-procedural TIMI 0/1 1.45 (0.53 – 3.99) 0.47
Underexpansion 1.30 (0.46 – 3.66) 0.62
Calcification 1.26 (0.46 – 3.46) 0.66
Long lesion (>32 mm) 1.20 (0.33 – 4.36) 0.78
Smoking 1.07 (0.74 – 1.54) 0.72
Diabetes Mellitus 0.83 (0.18 – 3.78) 0.81
Presentation with ACS 0.82 (0.28 – 2.43) 0.72
Intravascular imaging at baseline 0.49 (0.15 – 1.54) 0.22
ACS: acute coronary syndrome, MI: myocardial infarction, TLF: target lesion failure (cardiac death, target 
vessel MI, ischemia driven TLR)
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(especially in STEMI patients) and frequently not yet resulting in active platelet function 
inhibition, while the thrombus burden is greater with high platelet activation and a sys-
temic inflammatory response. These factors might amplify the risk of acute thromboses 
and cause a higher risk of MACE. For these reasons studies like ours are important to 
investigate the suitability of BVS in ACS patients. To the best of our knowledge, no data 
is available comparing the performance of BVS in ACS with stable patients compared to 
stable patients.
The BVS Expand registry and the BVS STEMI registry are two single-center, single-arm 
registries describing procedural clinical outcomes of patients treated with BVS. At vari-
ance of previous studies investigating the Absorb bioresorbable scaffold, all events were 
adjudicated by an independent clinical event committee (CEC). Also, all angiograms were 
analyzed using QCA. Lastly, combining the results of the two registries, both handling 
less restrictive inclusion criteria, we were able to create a study population reflecting a 
real-world population with a considerable amount of ACS patients.
The superior acute angiographic outcome in ACS patients compared to stable pa-
tients is an important observation. In previous studies it was demonstrated that the 
acute performance of the Absorb scaffold is somewhat inferior to metallic stents for 
stable angina patients. For example, in-device acute lumen gain in the ABSORB II trial 
was 1.15 ± 0.38 mm in BVS group versus 1.46 ± 0.38 mm in the EES group (P  < 0.001). In 
the ABSORB III trial reported lumen gain was 1.45 ± 0.45 mm versus 1.59 ± 0.44 mm (P  < 
0.001). Finally, in the ABSORB Japan and ABSORB China trials acute lumen gain numbers 
were as follows: 1.46 ± 0.40 mm versus 1.65 ± 0.40mm (P  < 0.0001) and 1.51 ± 0.03 
versus 1.59 ± 0.03 (P = 0.04) respectively. Remarkably, in STEMI patients no difference in 
acute gain was observed between BVS and DES (2.16 ± 0.52 mm versus 2.21 ± 0.56 mm, 
P = 0.57). This finding also suggests that the somewhat inferior angiographic results 
only imply for stable angina patients while the current semi-compliant balloon and wide 
strut BVS design are sufficient for the general softer plaque composition of ACS patients. 
In the current study, post-dilatation was significantly less frequently performed in ACS 
patients, however angiographic outcomes were better. Post-procedural MLD, RVD, %DS 
and in-scaffold acute lumen gain were all superior compared to post-procedural QCA 
measurements in stable patients. These promising angiographic results in ACS patients 
support the use BVS in this setting as they are predictive for clinical events.
Overall, one-year ST rate in ACS patients was similar to the non-ACS patients. The 
observed rate of early ST in the ACS population might raise some concerns. Previous 
studies have stated that presentation with ACS is an independent risk factor for the 
development of (metal) stent thrombosis. 18-20 Using metal devices, multiple studies 
have documented that stenting of lesions with appeared plaque rupture are prone to 
delayed healing, characterized by higher percentages of uncovered, malapposed and 
protruding stent struts with a subsequent risk of stent thrombosis. 21-24  Furthermore, 
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underexpansion appeared to be an important predictor. 25-27 This is also the case for ST 
in BVS patients. 28, 29 In ACS patients, high thrombus burden, increased platelet activation 
and vasospasm are mechanisms that trouble optimal sizing resulting in higher rates of 
malapposition. In the acute setting, lesion preparation using pre-dilatation and intra-
vascular imaging are less frequently performed than in stable patients. Although the 
acute scaffold expansion is on average better in the ACS population than in the stable 
population, it is very important to properly size the vessel and to optimize the final scaf-
fold expansion in order to avoid early ST.
The landmark analysis beyond one month up to 12 months showed favorable results 
with regard to ST and TLR for the ACS patients (0.8% and 1.2% respectively). The some-
what higher event rates in the non-ACS group are a representation of a more complex 
non-study real world patient population. Therefore, the one-year MACE (composite of 
cardiac death, MI and TLR) rates of 5.5% (ACS) and 5.3% (non-ACS) are acceptable and 
comparable to trials using BVS in relatively simple lesions: 5.0% in the ABSORB II trial and 
3.8% in the ABSORB China trial. 9, 12. A comparable endpoint, target lesion failure (TLF: 
composite endpoint consisting of cardiac death, target vessel MI and ischemia driven 
TLR), in the ABSORB III and ABSORB Japan trials were 7.8% and 4.2% respectively. 10, 11 In 
these studies, STEMI patients were excluded. Compared to studies investigating clinical 
outcomes of metal DES in STEMI patients, event rates in our report are higher than for 
EES but for lower compared to first-generation DES. 30, 31 
Recently, few concerns were raised concerning a potentially increased incidence of ST 
after implantation of a BVS. 27, 32-34 Also, in our registry rate of definite ST (2.0% for ACS 
patients and 2.1% for stable patients) was higher compared to that of currently available 
metallic DES. 35, 36 The importance of patient selection, lesion preparation, pre- and post-
dilatation and also the consideration of intra-vascular imaging have to be underlined. 
37, 38 A pilot imaging study suggested suboptimal implantation as an important cause 
for BVS ST. 28 Use of intravascular imaging could improve pre-procedural vessel sizing, 
optimize lesion coverage and eventually reduce adverse events 
Next generation BVS with smaller scaffold struts may reduce the early event rates 
in ACS patients. For the current design, using more potent P2Y12 inhibitors such as 
ticagrelor, a direct-acting platelet inhibitor or cangrelor, an intravenous antiplatelet 
drug, could be valuable. In the ATLANTIC trial, ticagrelor was administered prehospital 
in the ambulance to STEMI patients, leading to a reduction in ST rate. 39 The CHAMPION 
PHOENIX trial assessed ischemic complications of PCI after administration of cangrelor 
and showed a decrease in these complications, with no significant increase in severe 
bleeding. 40 The upcoming HORIZONS-ABSORB AMI will compare the performance of 
BVS to DES when cangelor is used on top of heparin or bivalirudin in STEMI patients. 41
Rate of mortality in ACS patients is worse compared with patients who present with 
stable CAD. 42-45 In our patient cohort, mortality was zero percent in the ACS population 
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probably reflecting our exclusion criteria for the STEMI population (exclusion of patients 
presenting with cardiogenic shock). As shown by our landmark survival analyses, events 
in the ACS group are especially clustered in the early phase after BVS implantation. On 
the other hand, one-year Kaplan Meier curves for events are lower in ACS patients. This is 
probably due to patient selection, where ACS patients present with different patient and 
lesion factors (younger age, less extensive cardiovascular disease and more often simple 
lesions), and the higher intake of prasugrel and ticagrelor in these patients (76.1% versus 
10.4%).
In summary, our results warrant further confirmation in a large-scale trial with a high 
number of ACS patients and an optimal implantation strategy tailored at the limitation 
of this first generation fully bioresorbable scaffolds. Ongoing and upcoming trials such 
as the AIDA, Compare Absorb (NCT02486068) and HORIZON-ABSORB AMI, will provide 
data derived from larger patient cohorts and in direct comparison to metallic DES. 41, 46
limitations
These results are derived from two single-center, single-arm registries with no direct 
comparison with metallic DES. The total number of patients in this study was limited. 
Baseline differences in patient and lesion characteristics could have led to biased 
outcome in clinical event rates.
Furthermore, deciding which patient or lesion was suitable for BVS implantation could 
have led to selection bias. However, there was a fair amount of patients presenting with 
ACS and with B2/C lesions were included, indicating the complexity of the present study 
population.
conclusion
Despite the higher rate of early complications due to early ST in the ACS population, 
the one-year clinical outcomes for BVS implantations in ACS patients versus non-ACS 
patients are comparable. The early ST rate observed in ACS needs further attention and 
optimized antiplatelet therapy may play a role. Angiographic outcomes for BVS in ACS 
patients are at least as good as non-ACS patients. Therefore, ACS patients may be suit-
able candidates for the treatment with the BVS if early procedural related complications 
can be avoided.
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abstract
background
Very limited data are currently available on mid-term outcomes after implantation of 
everolimus eluting bioresorbable scaffolds (BVS) for treatment of acute myocardial 
infarction.
methods and results
Patients presenting with STEMI and undergoing primary percutaneous coronary inter-
vention, with BVS were evaluated and compared with patients treated with everolimus-
eluting metal stents (EES) by applying propensity matching. Quantitative coronary 
angiography analysis and 18-month clinical follow-up were reported. 
A total of 302 patients were analysed, 151 with BVS and 151 with EES. Baseline clinical 
characteristics were similar between groups. Final TIMI 3 flow was 87.4% vs 86.1% p= 
0.296. At 18-month follow-up, all-cause mortality was 2.8 vs 3.0 in the BVS and EES group 
respectively p=0.99, MACE rate was higher in the BVS group 9.8% vs 3.6% p=0.02. Target 
lesion revascularizations was 5.7% vs 1.3% p=0.05. The 30-day MACE rate in BVS patients 
without post-dilatation was 6.8% in patients with post-dilatation was 3.6%. Scaffold 
thrombosis (ST) occurred primarily in the acute phase (acute ST 2.1% vs 0.7%, p=0.29; 
subacute 0.7% vs 0.7%, p=0.99; late 0.0% vs 0.0%; very late1.5% vs 0.0%, p=0.18). The 
majority of the cases with acute ST had no post-dilatation at the index procedure (3/4 
cases)
conclusions
Patients implanted with BVS showed an overall higher rate of clinical events compared 
with metal stents. The majority of clinical events occurred in the early phase after im-
plantation and mainly in cases without post-dilatation. Optimisation of the implantation 
technique could be relevant also in acute patients. 
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introDuction
Bioresorbable vascular scaffolds (BVS) have been recently introduced as a novel approach 
for treatment of coronary artery disease, providing transient vascular support and drug 
delivery potentially restoring the vascular physiology after device bioresorption.1-4  
The theoretical advantages of this novel technology such as late lumen enlargement 
restoration of coronary vasomotion and plaque sealing could suggest this device as 
particularly appealing for in patients with thrombotic soft plaques._ENREF_5 5-7 Biore-
sorbable vascular scaffolds have been hypothesized to be particularly suitable for acute 
thrombotic lesion, which are frequently soft necrotic core rich plaques with a ruptured 
thin fibrotic cap.8 Vessels with such lesions, could benefit the most from a treatment with 
bioresorbable devices leading to the so-called restoration therapy, represented by late 
lumen enlargement and re-acquisition of coronary vasomotion.9, 10 Due to vasoconstric-
tion and presence of thrombus, the treatment of acute lesions is often associated with 
device under-sizing and the occurrence of malapposition after thrombus dissolution. 
Theoretically, the complete bioresorption of the device would avoid the presence of 
long-term malapposed struts. In addition the BVS wider struts have been hypothesized 
to play a role in thrombotic material entrapment with a possible impact on distal embo-
lization. In addition, polymer bioresorption and concomitant formation of a neointimal 
layer given by connective tissue and smooth muscle cells could stabilize the plaque 
creating a neo-thick fibrous cap, without the long term permanence of metallic material 
in the vessel wall. 5
Initial small cohort studies with short follow-up and relatively selected populations 
reported encouraging results after BVS implantation in acute patients; however, at the 
current state of the art limited data are available on the mid-term performance of this 
novel device in patients presenting with acute myocardial infarction.11-13 Given this 
background, we analyzed patients presenting with ST-elevation myocardial infarction 
treated with BVS and we compared angiographic and 18-month clinical results with a 
matched population implanted with everolimus- eluting stents (EES). 
methoDs
Patients presenting with ST-segment elevation myocardial infarction and treated with 
BVS at the Thoraxcenter, Erasmus MC in Rotterdam between 1 November 2012 and 
31 December 2014, were evaluated for the present analysis.  Subjects included were 
patients ≥18-years old admitted with ST-segment elevation myocardial infarction 
(STEMI). Culprit lesions were located in vessels within the upper limit of 3.8 mm and 
the lower limit of 2.0 mm by online quantitative coronary angiography (QCA). The BVS 
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was implanted according to the manufacturer’s indication for target-vessel diameter 
ranges and BVS diameters to be used. The BVS with a nominal diameter of 2.5 mm was 
implanted in vessels ≥2.0 and ≤3.0 mm by online QCA; the 3.0 mm BVS was implanted in 
vessels ≥2.5 and ≤3.3 mm by online QCA; the 3.5 mm BVS was implanted in vessels ≥3.0 
and ≤3.8 mm. For each nominal diameter a further expansion of 0.5 mm was allowed. 
All patients were treated with unfractionated heparin at the dose of 70–100 UI/kg and 
dual antiplatelet therapy after treatment was planned to have a duration of 12 months. 
Exclusion criteria comprised pregnancy, known intolerance to contrast medium, uncer-
tain neurological outcome after cardiopulmonary resuscitation, previous percutaneous 
coronary intervention with the implantation of a metal stent, left main (LM) disease, 
previous coronary artery bypass grafting (CABG), and participation in another investiga-
tional drug or device study before reaching the primary endpoints. 
Propensity score was applied to match each STEMI patient treated with BVS to a 
comparable patient treated with everolimus-eluting stent (EES) at the same institution. 
Baseline and post-scaff old/stent implantation quantitative coronary angiographic 
analysis, optical coherence tomography (when available) analyses at post- scaff old/
stent implantation were performed. Clinical outcomes at the 18-month follow-up were 
evaluated. (Figure 1)
study device 
The second-generation BVS (Absorb BVS, Abbott Vascular, Santa Clara, CA) is a balloon-
expandable scaff old consisting of a polymer backbone of poly-L-lactide (PLLA) coated 
with a thin layer of a 1:1mixture of an amorphous matrix of poly- D, L-lactide (PDLLA) 
polymer and 100 μg/cm2 of the antiproliferative drug everolimus. Two platinum mark-
figure 1 Flow chart of the study.
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ers located at each BVS edge allow for accurate visualization of the radiolucent BVS 
during angiography or other imaging modalities. The PDLLA controls the release of 
everolimus, 80% of the drug is eluted within the first 30 days. Both PLLA and PDLLA are 
fully bioresorbable. The polymers are degraded via hydrolysis of the ester bonds, and 
the resulting lactate and its oligomers are transformed to pyruvate and metabolized 
in the Krebs cycle. Small particles, less than 2 μm in diameter, have also been shown 
to be phagocytized and degraded by macrophages. According to preclinical studies, 
14 complete bioresorption of the polymer backbone occurs from is 2 to 3 years after 
implantation.15
control device 
The everolimus eluting coronary stent system is a balloon-expandable metallic platform 
stent manufactured from a flexible cobalt chromium alloy with a multicellular design 
and coated with a thin non-adhesive, durable, biocompatible acrylic, and fluorinated 
everolimus-releasing copolymer.
Quantitative coronary angiographic analysis 
Angiographic views with minimal foreshortening of the lesion and limited overlap with 
other vessels were used whenever possible for all phases of the treatment. Comparison 
between pre and post treatment, were performed in matched angiographic views. In 
case of thrombotic total occlusion, pre-procedure quantitative coronary angiographic 
analysis was performed as proximally as possible from the occlusion (in case of a side 
branch distally to the most proximal take off of the side branch), as already reported.11 
Intracoronary thrombus was angiographically identified and scored in five grades as 
previously described.16, 17 Thrombus grade was assessed before procedure and after 
thombectomy. The two-dimensional angiograms were analysed with the CASS 5.10 
analysis system (Pie Medical BV, Maastricht, the Netherlands). In each patient, the 
treated region and the peri-treated regions (defined as 5 mm proximal and distal to the 
device edge) were analysed. The QCA measurements included reference vessel diameter 
(RVD), percentage diameter stenosis, minimal lumen diameter (MLD), and maximal 
lumen diameter (Dmax). Acute gain was defined as post-procedural MLD minus pre-
procedural MLD (MLD value equal to zero was applied when culprit vessel was occluded 
pre-procedurally). 
Procedural-clinical outcomes and definitions
Device success was defined as successful delivery and deployment of the device with 
the attainment of <30% final residual stenosis, by angiographic visual estimation. Proce-
dure success was defined as device success and no major peri-procedural complications 
(Emergent CABG, coronary perforation requiring pericardial drainage, residual dissection 
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impairing vessel flow—TIMI-flow II or less). All deaths were considered cardiac unless 
an undisputed non-cardiac cause was identified. Target-lesion revascularization (TLR) 
was defined as clinically driven if at repeat angiography the diameter stenosis was 70%, 
or if a diameter stenosis 50% was present in association with (i) presence of recurrent 
angina pectoris, related to the target vessel; (ii) objective signs of ischaemia at rest (ECG 
changes) or during exercise test, related to the target vessel; and (iii) abnormal results of 
any functional diagnostic test. Scaffold/stent thrombosis was defined according to the 
Academic Research Consortium definition.18 
In BVS patients, first permission to participate in registry was obtained. A question-
naire was sent to all living patients with specific queries on re-hospitalization and 
cardiovascular events. For patients who suffered an adverse event at another centre, 
medical records or discharge letters from the other institutions were systematically 
reviewed. General practitioners and referring physicians were contacted for additional 
information if necessary.
statistical analysis
A propensity score matching was performed using a proprietary macro developed and 
tested for SPSS version 22.0 (SPSS Inc., Chicago, Illinois). First, the program performed 
a logistic regression to score all patients according to the treatment (BVS vs. EES), using 
as covariates clinical and procedural parameters: age (years), sex (male/female), cardio-
genic shock (yes/no), hypertension (yes/no), hypercholesterolemia (yes/no), smoking 
(yes/no), diabetes mellitus (yes/no), pre-procedure TIMI-flow, culprit vessel. Second, the 
macro searched and selected the best match case of the EES group for every BVS case 
according to the absolute value of the difference between the propensity score of BVS 
and EES cases under consideration. Patients in the 2 groups were matched through a 
Greedy algorithm based on local optimization.19 The control selected for a particular 
case was the one closest to the case in terms of distance. Analyses were then performed 
on the 2 matched groups (BVS vs. EES), stratified by pairs to account for propensity 
score matching. For the study, individual data were pooled on a patient-level basis. 
Categorical variables are reported as counts and percentages, continuous variables as 
mean ± standard deviation. The student’s t test and the chi square test (or Fishers’ exact 
test) were used for comparison of means and percentages. The cumulative incidence 
of adverse events was estimated according to the Kaplan-Meier method. Patients lost 
to follow-up were considered at risk until the date of last contact, at which point they 
were censored. Kaplan-Meier estimates were compared by means of the log-rank test. 
For the endpoint MACE, a landmark survival analysis was performed with the landmark 
time point of 30 days. All statistical tests were two-sided and the P value of < 0.05 was 
considered statistically significant.  
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results
A total of 1306 patients presenting with acute ST-segment elevation myocardial infarc-
tion were evaluated for the present analysis (161 patients implanted with BVS and 1145 
patients implanted with EES with at least 2-year follow-up available). After matching, 
302 patients treated with either BVS or EES (151 patients treated with BVS matched 
with 151 patients treated with EES) were analysed. Six patients (3.9%) in the BVS group 
declined to participate in follow-up.
Baseline clinical characteristics were balanced between groups as shown in Table 1.
A total of 403 devices (193 BVS) were deployed, aspiration thrombectomy was equally 
performed in the two groups (BVS 76.7% vs 76.8% EES, p=1.000). Pre-dilatation was 
performed two times more frequently in the BVS group (54.1% vs 28.4%, p<0.001) with a 
higher balloon / artery ratio (1.02 ± 0.24 vs 0.88 ± 0.21, p=0.002). Post-dilatation was also 
performed more frequently in the BVS group (and 39.7% vs 21.8%, p<0.001 respectively) 
but with a balloon / scaffold-stent ratio higher in EES group (1.07 ± 0.09 vs 1.12 ± 0.12, 
p= 0.031). The rate of post-dilatation increased over time, in the first 75 patients the rate 
of post-dilatation was 25.3% in the remaining 76 patients was 53.9%. Device success was 
similar between groups (98.7% vs 99.3%, p=1.000). (Table 2)
table 1 Baseline clinical characteristics
BVS (N=151) EES (N=151) P value
Age, years 56.31 ±10.22 54.90 ±11.52 0.263
Male 109/151 (72.2) 113/151  (74.8) 0.696
Active smoker 71/151  (41.0) 89/151  (58.9) 0.050
Diabetes mellitus 17/151  (11.3) 15/151  (9.9) 0.852
Dyslipidaemia 43/151  (28.4) 41/151  (27.1) 0.226
Hypertension 60/151  (39.7) 56/151  (37.1) 0.723
Family History 51/151  (33.8) 52/151  (34.4) 1.000
Target vessel 0.520
LAD 64/151  (42.4) 62/151  (41.1)
LCX 32/151  (21.2) 40/151  (26.5)
RCA 51/151  (33.8) 46/151  (30.5)
Diagonal 2/151  (1.3) 3/151  (2.0)
Ramus Intermedius 2/151  (1.3) 0
Left Main 0 0
SVG 0 0
Data are expressed as count and proportion (%) or mean ± standard deviation 
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Baseline culprit vessels, vessel dimensions, percentage of stenosis, TIMI flow and 
thrombotic burden were similar between patients treated with BVS and those treated 
with EES. (Table 3) 
At the end of the procedure, there were no cases of TIMI flow 0, and final TIMI 3 flow 
was achieved in 87.4% and 86.1% of BVS and EES group respectively (p= 0.296) with 
similar minimal lumen diameter and percentage stenosis. 
6-month clinical outcomes Cardiac death was observed in 1.9 vs 2.0, p=0.97; the rate 
of any myocardial infarction was 5.5% in the BVS group and 1.3% in EES group, p=0.05. 
Target lesion revascularisation rate was 3.5% and 1.3% respectively, p=0.23. Acute scaf-
fold thrombosis occurred in 2.1% of BVS implanted patients and 0.7% of EES implanted 
table 2 Procedural characteristics
BVS (N=151) EES (N=151) P value
Aspiration thrombectomy 115/151 (76.7) 116/151 (76.8) 1.000
Pre-dilatation performed 80/151 (54.1) 42/151 (28.4) <0.001
Pre-dilatation balloon / artery ratio 1.02 ± 0.24 0.88 ± 0.21 0.002
Maximal diameter balloon pre-dilatation, mm 2.54 ± 0.47 2.40 ± 0.48 0.111
Supportive wire used 18/151 (12.2) 3/151 (2.0) <0.001
Device failure 2/151 (1.5) 1/151 (0.7) 1.000
Device success 149/151 (98.7) 150/151 (99.3) 1.000
Procedure success 148/151 (98.0) 150/151 (99.3) 0.622
Mean scaffold diameter, mm 3.21 ±0.33 3.20 ± 0.46 0.827
Mean total nominal scaffold length, mm 26.32 ± 13.27 27.76 ± 14.81 0.378
Number of scaffolds deployed per treated vessel 1.28 ± 0.61 1.39 ± 0.73 0.148
  0 2 (1.3) 0 0.398
  1 115 (76.2) 108 (71.5)
  2 25 (16.6) 32 (21.2)
  3 8 (5.3) 7 (4.6)
  4 1 (0.7) 3 (2.0)
  5 0 1(0.7)
Procedures with overlapping scaffolds, n (%) 31/151 (20.7) 39/151 (25.8) 0.340
Post-dilatation performed 60/151 (39.7) 33/151 (21.8) <0.001
Post-dilatation balloon / scaffold or stent ratio 1.07 ± 0.09 1.12 ± 0.12 0.031
Maximal post-dilatation balloon diameter, mm 3.45 ± 0.41 3.54 ± 0.59 0.435
Complications occurring anytime during the procedure 
  Any dissection 10/151 (6.7) 8/151 (5.3) 0.809
  Thrombosis 0 0
  Perforation 1/151 (0.7) 0
Data are expressed as count and proportion (%)or mean ± standard deviation 
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patients, p=0.29. In both groups Subacute ST rate was 0.7%, p=0.99. Three out of 4 scaf-
fold thromboses occurred in patients without post-dilatation performed at the index 
procedure. The overall MACE rate 7.6% vs 2.7%, p=0.06. A landmark analysis showed that 
the 30-day MACE rate in BVS patients without post-dilatation was 6.8% while in patients 
with post-dilatation was 3.6%. 
12-month clinical outcomes From 6 to 12-month follow-up only a target lesion revas-
cularization and one non-target vessel revascularization occurred in the group treated 
with bioresorbable vascular scaffold.
table 3 Angiographic characteristics
BVS (N=151) EES (N=151) P value
Pre-procedure 
TIMI flow 0.213
0 80/151  (53.0) 85/151  (56.3)
1 16/151  (10.6) 12/151  (7.9)
2 31/151  (20.5) 40/151  (26.5)
3 24/151  (15.9) 14/151  (9.3)
Thrombus burden 0.551
1 24/148 (16.2) 20/150 (13.3)
2 21/148  (14.2) 16/150  (10.7)
3 12/148  (8.1) 9/150  (6.0)
4 12/148  (8.1) 18/150  (12.0)
5 79/148  (53.4) 87/150  (58.0)
Total thrombotic occlusion
RVD (mm) 2.76 ± 0.72 2.71 ± 0.47 0.608
Non-total thrombotic occlusion
RVD (mm) 2.60 ± 0.52 2.72 ± 0.54 0.179
MLD (mm) 0.82 ± 0.46 0.91 ± 0.66 0.335
Diameter stenosis (%) 68.07 ± 15.08 66.27 ± 21.57 0.571
Post-procedure 
TIMI flow 0.296
0 0 0
1 2/151 (1.3) 0/151
2 17/151 (11.3) 21/151 (13.9)
3 132/151 (87.4) 130/151 (86.1)
RVD (mm) 2.63 ± 0.54 2.98 ± 1.76 0.023
MLD (mm) 2.11 ± 0.50 2.22 ± 0.54 0.067
Diameter stenosis (%) 20.64 ± 11.02 22.28 ± 9.92 0.181
Acute lumen gain 1.98 ± 0.67 2.06 ± 0.73 0.398
Data are expressed as count and percentages or mean ± standard deviation 
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18-month clinical outcomes From 12 to 18 month 2 very late scaffold thrombosis were 
observed in the BVS group, at 416 and 449 days after implantation, in both cases the 
dual antiplatelet therapy was interrupted at the moment of the event. In both cases 
the review of intravascular imaging showed scaffold malapposition. In the EES group 2 
additional non TVR were reported one of them associated with a myocardial infarction.  
table 4 Clinical outcomes
6-month follow-up 12-month follow-up 18-month follow-up
BVS 
(n = 145)
EES 
(n = 151)
P value BVS 
(n = 145)
EES 
(n = 151)
P value BVS 
(n = 145)
EES 
(n = 151)
P value
All-cause death (%) 2.1 (3) 2.0 (3) 0.97 2.8 (4) 2.0 (3) 0.68 2.8 (4) 3.0 (4) 0.99
Cardiac 2.1 (3) 1.3 (2) 0.97 2.1 (3) 1.3 (2) 0.63 2.1 (3) 1.3 (2) 0.63
MACE (n.) % 7.6 (11) 2.7 (4) 0.06 8.1 (12) 2.7 (4) 0.03 9.8 (14) 3.6 (5) 0.03
MI (n.) % 5.5 (8) 1.3 (2) 0.05 5.5 (8) 1.3 (2) 0.05 6.3 (9) 2.3 (3) 0.07
TLR (n.) % 3.5 (5) 1.3 (2) 0.23 4.2 (6) 1.3 (2) 0.14 5.7 (8) 1.3 (2) 0.05
Non-TVR (n.) % 2.1 (3) 2.0 (3) 0.97 2.8 (4) 2.0 (3) 0.67 3.6 (5) 4.0 (5) 0.95
Definite ST (n.) % 2.8 (4) 1.3 (2) 0.38 2.8 (4) 1.3 (2) 0.38 4.3 (6) 1.3 (2) 0.15
Acute 2.1 (3) 0.7 (1) 0.29 2.1 (3) 0.7 (1) 0.29 2.1 (3) 0.7 (1) 0.29
Subacute 0.7 (1) 0.7 (1) 0.99 0.7 (1) 0.7 (1) 0.99 0.7 (1) 0.7 (1) 0.99
Late - - - - - - 0.0 (0) 0.0 (0) -
Very late - - - - - - 1.5 (2) 0.0 (0) 0.18
figure 2 Cases of very late scaffold thrombosis
Both cases were performed with satisfactory final angiographic results. Case 1 (panels A-E): A) baseline; 
B) final result of the index procedure; C) thrombosis; D) final result of the event treatment. Post-dilatation 
was performed during the index intervention, but at the end of the procedure intravascular imaging (E) 
highlighted the remaining malapposition (*). Case 2 (panels F-J): G) baseline; H) final result of the index pro-
cedure; I) thrombosis; J) final result of the event treatment. At the time of the event, intravascular imaging 
(F) showed persistent malapposition (**).
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Discussion
The feasibility of BVS implantation in patients presenting with acute myocardial infarc-
tion has been recently reported with preliminary information on short-term clinical out-
comes.11-13 However, data comparing the mid-term performance of the bioresorbable 
technology with the current generation metal DES in this specific subset are limited. 
The present study represents an early investigation evaluating the use of the second-
generation BVS for the treatment of patients presenting with STEMI in comparison with 
everolimus-eluting metal stents in terms of acute angiographic results and 18-month 
clinical outcomes.
The majority of the treated patients presented with a TIMI 0 or 1 and more than 60% 
of the lesions showed a large thrombus burden (4 or 5) in the culprit vessel, in line with 
what observed in recent large trials on myocardial infarction with minimal exclusion 
criteria.20, 21 Such data suggest a patient’s population with coronary lesions probably 
resembling the daily clinical practice in acute myocardial infarction. 
Procedural and angiographic data showed an overall comparable device success rate 
between the two groups, with similar incidence of intra-procedural complication. At the 
end of the procedure the restoration of TIMI 3 flow was achieved in a high number of 
patients and similarly in both groups with comparable acute lumen gain, percentage 
diameter stenosis and minimal lumen diameter.
On the other hand, when analysing the clinical outcomes in the BVS group was ob-
served a higher rate of events at 18-month follow-up with a larger number of TLR and 
MI an overall higher MACE rate. Although a difference became statistically significant at 
mid-term follow-up the larger component of such difference is due to events occurred 
in the very early phase after implantation. In particular three scaffolds thrombosis oc-
curred on day one after implantation. 
It should be highlighted that the devices analysed in the present study were used 
in a period when the post-dilation was not regarded as a key point during the device 
implantation especially in the acute subset. Studies reporting pooled data from differ-
ent European registries performed in the same time period of our, showed similar rates 
of scaffold thrombosis at 30 days.13 
Our group recognized the relevance of additional high-pressure post-dilation when 
implanting bioresorbable scaffolds22 and this translated into a gradual increase in the 
use of this technique during the inclusion in the present study up the point that the rate 
of post-dilation was double in the second half of the enrolment compared to the first 
half. 
This concept has been embraced by the scientific community and the current rec-
ommendations for BVS implantation suggest the high pressure post-dilatation as an 
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important action to improve scaffold deployment with a possible beneficial effect on 
clinical outcomes.22 
In a later randomized trial, the TROFI II, evaluating short-term imaging results in either 
BVS or EES in acute myocardial infarction, the rate of subacute scaffold thrombosis was 
1.1%. In this study the implantation technique was slightly different from ours, thrombus 
aspiration was mandatory in every patient with a post-dilation performed in a slightly 
higher number of cases.23 
As a matter of fact in our investigation patients without post-dilatation had a higher 
MACE rate in the first month and both the very late scaffold thrombosis was associated 
with relevant malapposition. Given this background a possible role of the implantation 
technique in the occurrence of events cannot be excluded.
The acute myocardial infarction has been classically a field where operators attempted 
to re-establish the TIMI 3 flow in the culprit vessel reducing at the minimum the amount 
of manoeuvres, including aggressive post-dilatation, at the lesion site, to minimize 
the risk of distal embolization. However, a possible association between post-dilation 
and no-reflow or slow-flow phenomenon currently remains to be clarified24, 25 and the 
seminal observation reported in the present study could support a more frequent use 
of the post-dilatation to optimize scaffold expansion even in acute patients. Large ran-
domized trials currently under preparation may add in further understand on the real 
performance of bioresorbable technologies in the acute setting.  
limitations 
The number of subject evaluated in the present study is limited and data on clinical 
outcomes should be considered descriptive and hypothesis generating. 
The two study groups were not randomized, despite the use of propensity matching, 
unadjusted confounders might remain, possibly having an impact on results
Larger patient population and longer follow-up would be needed to adequately 
compare this novel technology with current generation metal DES.
conclusion
The present study investigated the angiographic and mid-term clinical outcomes in 
patients treated with either BVS or EES. Implantation of bioresorbable vascular scaffold 
showed a higher rate of events. Procedural factors might have had a role in these find-
ings and an optimal implantation technique including high pressure post-dilatation 
should be considered also in the acute setting when using bioresorbable scaffolds.
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Everolimus-eluting bioresorbable vascular 
scaffolds implanted in coronary bifurcation 
lesions: Impact of polymeric wide struts on side-
branch impairment
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abstract
background
Limited data are available on bioresorbable vascular scaffolds (BVS) performance in 
bifurcations lesions and on the impact of BVS wider struts on side-branch impairment.
methods
Patients with at least one coronary bifurcation lesion involving a side-branch ≥2 mm in 
diameter and treated with at least one BVS were examined. Procedural and angiographic 
data were collected and a dedicated methodology for off-line quantitative coronary 
angiography (QCA) in bifurcation was applied (eleven-segment model), to assess side-
branch impairment occurring any time during the procedure. Two- and three- dimen-
sional QCA were used. Optical coherence tomography (OCT) analysis was performed in 
a subgroup of patients and long-term clinical outcomes reported.
results
A total of 102 patients with 107 lesions, were evaluated. Device- and procedural-
successes were 99.1% and 94.3%, respectively. Side-branch impairment occurring any 
time during the procedure was reported in 13 bifurcations (12.1%) and at the end of the 
procedure in 6.5%. Side-branch minimal lumen diameter (Pre: 1.45 ± 0.41 mm vs Final: 
1.48 ± 0.42 mm, p = 0.587) %diameter-stenosis (Pre: 26.93 ± 16.89% vs Final: 27.80 ± 
15.57%, p = 0.904) and minimal lumen area (Pre: 1.97 ± 0.89 mm2 vs Final: 2.17 ± 1.09 
mm2, p = 0.334), were not significantly affected by BVS implantation. Mean malapposed 
struts at the bifurcation polygon-of- confluence were 0.63 ± 1.11.
conclusions
The results of the present investigation suggest feasibility and relative safety of BVS 
implantation in coronary bifurcations. BVS wide struts have a low impact on side-branch 
impairment when considering bifurcations with side-branch diameter ≥ 2 mm.
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introDuction
Coronary artery bifurcation treatment is a frequent and challenging subset in inter-
ventional cardiology. The introduction of first generation drug eluting stents  (DES) 
was  associated  with a reduction in main vessel restenosis rate compared with balloon 
angioplasty or bare metal stent implantation [1,2], but without a clear benefit in terms 
of side branch ostium impairment and restenosis regardless the technique used [3–5]. 
Data on second-generation DES, extrapolated from post-hoc analyses of randomized tri-
als are encouraging, with similar long-term mortality after zotarolimus  and  everolimus 
DES implantation in bifurcation and non-bifurcation lesions [6]; On the other hand the 
presence of permanent metallic material at the side-branch ostia could be associated 
with delayed vascular healing and incomplete neointimal coverage [7] with a possible 
impact on late thrombotic events [8]. Given this background bioresorbable vascular 
scaffolds (BVS) could provide a novel paradigm for bifurcation treatment possibly over-
coming some of the long-term limitation of metallic DES, avoiding after bioresorption 
sidebranch ostium caging and long-term malapposition. A possible drawback of the 
BVS usage in such lesions, could be represented by the theoretical risk of an increased 
acute side-branch impairment due to the wider BVS struts, as previously hypothesized 
and demonstrated for very small (b 0.5 mm) side-branches [9]. Despite the presence of 
recently reported analyses in relatively simple lesions, [10] at the current state of the 
art, very limited data are available on BVS performance in bi- furcation lesions [11,12] 
especially when evaluating the impact of BVS implantation on side-branch impairment 
in vessels with a visually estimated diameter ≥ 2.0 mm. Therefore, we sought to report 
feasibility, procedural performance and acute angiographic results after BVS implanta-
tion in this specific subgroup with a detailed evaluation of side- branch ostium at pre-
and post-implantation and describing mid-term clinical outcomes.
methods
The present report is an investigator initiated, single-arm, single-centre study to assess 
feasibility and performance of the second- generation everolimus-eluting BVS for the 
treatment of patients with coronary bifurcation lesions.
Patients eligible for the present analysis were ≥ 18 years of age, presenting with 
stable angina or acute coronary syndromes with at least one de novo bifurcation lesion 
(regardless of morphology, number, length and angulations), involving a side-branch 
(SB) ≥ 2 mm by visual estimation in diameter treated with at least one BVS implantation. 
Exclusion criteria were minimal comprising pregnancy, known intolerance to contrast 
medium and participation to another investigational drug or device study before 
reaching the primary endpoints. Procedural details, including materials and techniques 
were collected. Pre- and post-BVS implantation off-line two-dimensional quantitative 
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coronary angiography (QCA) and, if technically feasible, off-line three- dimensional-QCA 
were performed. Optical coherence tomography (OCT) analyses at post-BVS implanta-
tion in a subgroup of patients, and clinical long-term clinical outcomes were evaluated. 
All patients included in the present analyses were part of the bioresorbable vascular 
scaffold evaluation program at the Thoraxcenter Rotterdam, The Netherlands and were 
already included in the EXPAND or in the BVS STEMI FIRST study.
Survival status information was obtained from the national population registry. A 
questionnaire was sent to all living patients with specific queries on re-hospitalization 
and cardiovascular events. Patients received the questionnaire on planned follow-up (1-, 
6-, 12-month follow-up).
For patients who suffered an adverse event at another center, medical records or 
discharge letters from the other institutions were systematically reviewed.
In case of death all possible events in that specific patient were investigated by 
reviewing our hospital records and referring hospitals or general practitioner were 
contacted to collect as much information as possible. In case patients did not send back 
the questionnaires, a second form was sent by post after one month. If this was not 
returned, patients were contacted by phone.
ethics
This is an observational study, performed according to the privacy policy of the Erasmus 
MC and to the Erasmus MC regulations for the appropriate use of data in patient-orient-
ed research, which are based on international regulations, including the declaration of 
Helsinki. The BVS received the CE mark for clinical use, indicated for improving coronary 
lumen diameter in patients with ischemic heart dis- ease due to de novo native coronary 
artery lesions with no restriction in terms of clinical presentation. Therefore, the BVS can 
be currently used routinely in Europe in different settings comprising the acute MI with-
out a specific written informed consent in addition to the standard informed consent 
to the procedure. Given this background, a waiver from the hospital Ethical Committee 
was obtained for written informed consent, as according to Dutch law writ- ten consent 
is not required, if patients are not subject to acts other than as part of their regular 
treatment.
study procedure
The procedures were performed according to standard practice. The device implanta-
tion was performed in accordance with the manufacturer’s recommendations, at a rate 
of 2 atm per 5 s up to burst pressure. Pre- and post-dilatation were encouraged but not 
mandatory. Wiring of the side-branch before main vessel stenting was per- formed at 
the operator’s discretion and mainly based on the extension of the disease and anatomi-
cal characteristics. A single scaffold approach was encouraged as preferred approach 
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for the majority of cases. Side- branch treatment was recommended only in cases with 
side-branch impairment or significant atherosclerotic disease. After the procedure, 
dual antiplatelet therapy was recommended for at least one year followed by aspirin 
indefinitely.
Definitions
Device success was defined as the attainment of a residual final stenosis b 30% in 
Main vessel (MV) or side-branch (SB) segment covered by BVS. Procedural success was 
defined as device success and no major peri-procedural complications (emergent CABG, 
coronary perforation requiring pericardial drainage, residual dissection impairing vessel 
flow with final TIMI-flow grade ≤ 2 in MV or SB). Clinical success was defined as proce-
dural success and no in-hospital major adverse cardiac events (MACEs). All deaths were 
considered cardiac unless an undisputed non-cardiac cause was identified. Myocardial 
infarction (MI) and scaffold thrombosis were defined according to the Academic Re-
search Consortium definition. Any target bifurcation revascularization was de- fined as 
clinically driven if at repeat angiography a diameter stenosis N 70% was observed, or if a 
diameter stenosis N 50% was present in the main vessel or in the daughter branches in 
association with 1) recurrent angina pectoris; 2) objective signs of ischemia (electrocar-
diogram changes) at rest or during exercise test, likely to be related to the target vessel; 
3) abnormal results of any invasive functional diagnostic test. The target bifurcation 
failure was defined as the composite of cardiac death, target vessel myocardial infarc-
tion, or clinically-driven target bi- furcation revascularization. MACEs were defined as 
the composite of cardiac death, any re-infarction (Q or Non Q-Wave) or clinically- driven 
target bifurcation revascularization.
To investigate the BVS performance in MV/SB ostium, we adopted the following pro-
cedural and angiographic parameters already reported in de the literature [7]:
“Side-branch impairment”, as previously described [7] and defined as a composite of 
1) SB TIMI flow grade b 3 after MV stenting, 2) need of guidewire(s) different from the 
default wire to rewire SB after MV stenting, 3) failure to rewire the SB after MV stenting, 
or 4) failure to dilate the SB after MV stenting and SB rewiring; “SB acute angiographic 
result”, defined as the comparison between the pre- and the post-procedure 2-dimen-
sional QCA–estimated minimal lumen diameter of 3-mm ostial SB sub-segment, accord-
ing to the modified eleven-segment model analysis [13–15].
study device
The second-generation everolimus-eluting BVS (ABSORB; Abbott Vascular, Santa Clara, 
CA, USA) consist of a backbone of semi crystalline polymer of poly-L-lactide acid, an 
amorphous matrix of poly-DL-lactide acid which controls the everolimus release (100 
micrograms/cm2) and two markers of platinum at proximal and distal edges of scaf-
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fold which are radiopaque and facilitate the correct implantation of device. The entire 
polymer is degraded to carbon dioxide and water.
Quantitative coronary angiography analysis
Off-line quantitative coronary angiography (QCA) analysis was per- formed using the 
Cardiovascular Angiography Analysis System (CAAS; Version 5.10, Pie Medical Imag-
ing, Maastricht, the Netherlands) soft- ware packages, according to methodological 
standards previously de- scribed and adopting the modified- eleven-segment model 
[13–15]. Only matched pre- and post-BVS implantation projections were considered for 
the analyses. Two-dimensional QCA (2DQCA) was performed using the angiographic 
image with the largest distal bifurcation angle. 3-dimensional QCA (3DQCA) was per-
formed if at least two projections had been acquired at least 30° apart; The following 
parameters were included: reference vessel diameter (RVD), minimal lumen diameter 
(MLD) and percentage diameter stenosis (%DS) of MV, SB and 3-mm ostial SB sub-seg-
ment (segment 8 in the eleven segment model), bifurcation proximal angle (between 
proximal MV and SB) and bifurcation distal angle (between distal MV and SB). If 3DQCA 
was feasible, minimal lumen area and percentage area stenosis of MV, SB and 3-mm 
ostial SB sub-segment were added (Fig. 1). Bifurcation lesions were classified ac- cord-
ing to the Medina classification; AHA/ACC modified lesion criteria, extent of coronary 
disease, presence of calcification, lesion length, SB and main vessel (MV) thrombolysis in 
myocardial infarction (TIMI)- flow grade.
Optical coherence tomography image acquisition and analysis
Intravascular imaging was encouraged but not mandatory and left to the operator 
discretion. The Optical coherence tomography (OCT) ex- amination was performed with 
the Illumien or Illumien Optis systems and the corresponding Dragonfly or Dragonfly 
Duo intravascular imaging catheters (St. Jude Medical, St. Paul, MN, USA). The catheter 
was advanced into the MV distally to the treated segment and then automated pullback 
(20 mm/s) and simultaneous contrast injection (flush rate 3– 4 mL/s) were performed 
to acquire the images. Off-line analysis of the OCT images was performed using the 
QCU-CMS software (Medis Medical Imaging System, Leiden, The Netherlands) at 
1-mm longitudinal intervals within the treated coronary segment, including proximal 
and distal 5-mm edge segments, after exclusion of frames with b 75% lumen contour 
visibility, using previously described methodology for the analysis of bioresorbable 
scaffolds [16]. Morphometric measurements were performed as previously described, 
using the abluminal strut points for the delineation of the scaffold contour. A scaffold 
strut was defined as incompletely apposed when there was no contact between the 
abluminal border of the strut and the vessel wall. This definition does not include struts 
located in front of SBs ostia which were defined as SB-related struts and were recorded 
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separately. The bifurcation of interest was identified in the OCT pullback and divided in 3 
sub- segments: proximal, polygon of confluence and distal (Fig. 2). Strut apposition was 
calculated separately for each of the sub-segments.
statistical analysis
Continuous variables were expressed as mean and standard deviation or as median 
and interquartile ranges if data were non-normally distributed. Dichotomous variables 
are presented as count and/or percentages. The paired t-test was used for comparison 
between pre and post-procedure QCA parameters. Statistical analysis was performed 
using SPSS, version 20.0 for Windows (SPSS Inc., Chicago, IL, US).
figure 1 Quantitative coronary analysis and 3-dimensional reconstruction. 
A. Pre-procedural angiogram of treated bifurcation was acquired at RAO34.10°CAU28.30° and 
LAO51.30°CAU29.70° (not shown). b. 3-dimensional reconstruction is shown in the optimal projection (P 
= proximal main vessel). c. 11-segment model in Cardiovascular Angiography Analysis System (CAAS); P, M 
and S = proximal main vessel, distal main vessel and side branch, respectively. d and e. Pre-procedural refer-
ence vessel diameter and area curve, respectively, for proximal main vessel into distal main vessel and side 
branch. A. Post-procedural angiogram. B and C. 3-dimensional reconstruction using 3dimensional-QCA 
and 3-dimensional OCT, respectively (white arrow indicates SB ostium). D and E. Post-procedural reference 
vessel diameter and area curve, for proximal main vessel into distal main vessel and side branch.
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results 
A total of 102 patients, with 107 bifurcation lesions, were included in this study. The 
baseline clinical characteristics are reported in Table 1. Briefly, the average age was 59.61 
± 10.79 years, 81.4% of the patients were male, 43.9% showed a multivessel disease, 
57.8% were admitted with an acute coronary syndrome and approximately one third of 
these acute patients presented with ST-segment elevation myocardial infarction (Table 
1).
figure 2 Subsegments location in the treated bifurcation lesion. 
The bifurcation of interest was identified in the OCT pullback and divided in 3 sub-segments: we defined 
the polygon of confluence as the sub-segment between the last (distally) and the first (proximally) cross 
sections (red lines) in which the contort was not distorted by the side branch. The distal and proximal sub-
segments (green lines) were defined as the 5-mm distal and the 5-mm proximal sub-segments from the last 
and the first cross sections of the polygon of confluence, respectively.
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angiographic and procedural characteristics
Angiographic characteristics of bifurcation lesions (N = 107) are listed in Table 2. The 
most frequently treated lesion was on left anterior descending/diagonal bifurcation 
(68.2%), a large part of the lesions involved both the main branch and the side-branch 
(true bifurcation lesions 42.0%), moderate or severe calcification was present in nearly 
one third of the lesions (28.9%) and long lesions were commonly observed (55.1%). In 
10 cases (9.3%) the bifurcation was located in chronically occluded coronary segments.
table 1. Baseline Clinical Characteristics
Patient characteristics N = 102
Age, yrs 59.61 ± 10.79
Gender (male) 83 (81.4)
Risk factors
     Family History of CAD 30 (29.4)
     Diabetes mellitus 16 (15.7)
     Hypercholesterolemia 53 (52.0)
     Hypertension 57 (55.9)
     Active smoking 42 (41.2)
     Kidney disease 6 (5.9)
Clinical history 
     Previous MI 23 (22.5)
     Previous PCI 15 (14.7)
     Previous CABG 2 (2.0)
     Previous TIA/stroke 4 (3.9)
     Peripheral arterial disease 7 (6.9)
     Chronic obstructive pulmonary disease 5 (4.9)
Extent of coronary artery disease
     Single vessel disease 60 (56.1)
     2-vessel disease 40 (37.4)
     3-vessel disease 6 (5.6)
     Left main 1 (0.9)
Clinical presentation
     Acute coronary syndrome 59 (57.8)
     STEMI 19 (18.6)
     Acute heart failure 2 (2.0)
     Out-hospital cardiac arrest 2 (2.0)
Values are expressed as mean ± standard deviation (SD) or count (n) and percentages (%). CABG = coronary 
artery by-pass; CAD = coronary artery disease; MI = myocardial infarction; PCI = percutaneous coronary 
intervention; STEMI = ST-segment elevation myocardial infarction; TIA = transient ischemic attack;
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Reflecting the presence of acute patients TIMI flow 0 or 1 pre- intervention was re-
ported in 17 main vessel lesions (15.9%) and with a similar rate in the side-branch (Table 
2).
table 2 Angiographic Characteristics
Number of Bifurcations N = 107
Target bifurcation
     Distal left main 2 (1.9)
     Left anterior descending/Diagonal 73 (68.2)
     Circumflex/Marginal 26 (24.3)
     Right posterior descending/posterior lateral 6 (5.6)
ACC/AHA modified lesion classification
     Type B2 73 (68.2)
     Type C 34 (31.8)
True bifurcations 45 (42.0)
Moderate or severe calcification 31 (28.9)
Length lesion > 20 mm 59 (55.1)
Chronic total occlusion 10 (9.3)
Medina bifurcation classification
     1.1.1 20 (18.7)
     1.1.0 24 (22.4)
     1.0.1 11 (10.3)
     0.1.1 14 (13.1)
     1.0.0 14 (13.1)
     0.1.0 18 (16.8)
     0.0.1 6 (5.6)
MV TIMI flow pre-procedure
     0     13 (12.1)
     1 4 (3.7)
     2 3 (2.8)
     3 87 (81.3)
SB TIMI flow pre-procedure
     0     9 (8.4)
     1 4 (3.7)
     2 2 (1.9)
     3 92 (85.9)
Values are expressed as count (n) and percentages (%). 
ACC/AHA = American College of Cardiology/American Heart Association;        MV = main vessel; SB = side 
branch; TIMI = thrombolysis in myocardial infarction.
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The most commonly performed technique was the provisional one scaffold approach 
(93.4%). A crossover from a one-scaffold to two- scaffolds technique occurred in only 
one case.
Pre-dilation was highly recommended and performed in 84.1% of the main vessels 
and 23.4% of the side-branches before treatment.
Side-branch wire protection before provisional scaffolding was per- formed in 38.0% 
of the cases, in 41 cases (38.3%) a highly supportive wire (Hi-Torque Balance Heavy-
weight or Hi-Torque Whisper ES) was the default for wiring the MV or the SB (MV 32.7%, 
SB 9.3%).
One-hundred and seventy-eight Absorb BVS were implanted, with a maximum scaf-
folded length of 102 mm (4 BVS). To achieve an optimal final angiographic result, the 
MV post-dilation was performed in 64 cases (59.8%), non-compliant balloons were 
frequently used (52/64, 81.2%) and a proximal optimization technique (POT) was per-
formed in the 59.4% of overall post-dilations.
SB ostium dilation across MV scaffold struts was performed in 39 bifurcations (36.4%), 
using balloons with mean diameter of 2.03 mm ± 0.48 and semi-compliant in the 99% 
of cases (Table 3).
table 3 Procedural Characteristics
Number of bifurcations N = 107
Technique
     Provisional  100 (93.4)
     T-stenting 5 (4.7)
     Culotte 1 (0.9)
     Mini-crush 1 (0.9)
MV direct stenting 14 (13.1)
MV pre-dilation 90 (84.1)
     Semi-compliant balloon    82 (76.6)
     Non-compliant balloon 17 (15.9)
SB wiring before MV provisional stenting 38 (38.0)*
Default supportive wire 41 (38.3)
     MV supportive wire 35 (32.7)
     SB supportive wire 10 (9.3)
Cutting balloon 1 (0.9)
Rotablator 2 (1.9)
SB ostium dilation before MV treatment 25 (23.4)
Total number of scaffolds 178
     Mean scaffolds per-bifurcation 1.66 ± 0.84
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The device success was achieved in 99.1% of the cases (106/107), in one calcified le-
sion a residual final stenosis not inferior to 30% persisted at the end of the procedure. 
The procedural success was 94.3%, in one case, a distal edge dissection caused a post-
procedure MV TIMI flow grade equal to 1 and in 4 cases the final SB TIMI flow grade was 
inferior to 3 (TIMI flow 0 in one case, after MV provisional approach without a previous 
SB wiring). The “SB impairments” occurred in 13 procedures (12.1%). The most frequently 
reported cause was a SB TIMI flow grade b 3 after MV scaffolding, reported in 10 cases. 
In 6 of those cases the final SB TIMI flow grade improved after SB ostium post-dilatation, 
with no need for SB treatment (Table 4).
Quantitative coronary angiography analysis
Two-dimensional and 3-dimensional QCA were performed in 103 patients and 40 pa-
tients, respectively (inadequate views either pre- or post- procedure were excluded).
At the end of the procedure, the side-branch was not significantly affected by the 
BVS implantation the main vessels. In the 2-dimensional and the 3-dimensional QCA 
analyses, there were no differences between the pre- and post-procedure reference ves-
sel diameter (2D RVD: 1.98 ± 0.33 mm vs 2.03 ± 0.41 mm, p = 0.718 - 3D RVD: 2.00 ± 0.28 
table 3 Procedural Characteristics (continued)
Number of bifurcations N = 107
MV Scaffold 104 (97.2)
     Scaffold diameter (mm) 3.03 ± 0.4
     Scaffold length (mm) 19.95 ± 5.6
SB Scaffold 14 (13.1)
     Scaffold diameter (mm)      2.8 ± 0.3
     Scaffold length (mm) 16.21 ± 4.8
MV post-dilation 64 (59.8)
     Semi-compliant balloon    17 (15.9)
     Non-compliant balloon 52 (48.5)
POT 38 (35.5)
Final kissing balloon inflation 5 (4.6)
SB ostium dilation after MV stent
     Balloon diameter (mm) 
39 (36.4)
2.03 ± 0.48
Vascular access
     Radial 66 (61.7)
     Femoral 42 (39.2)
Contrast media (ml) 208.15 ± 90.82
Values are expressed as mean ± standard deviation (SD) or count (n) and percentages (%).  * % calculated over all 
provisional approach. 
MV = main vessel; POT = Proximal Optimization Technique; SB = side branch. 
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mm vs 2.08 ± 0.34 mm, p = 0.28), minimal lumen diameter (2D MLD: 1.45 ± 0.41 mm vs 
1.48 ± 0.42 mm, p= 0.587 - 3D MLD: 1.54 ± 0.37 mm vs 1.61 ± 0.41 mm, p = 0.363), and 
minimal lumen area (3D MLA 1.97 ± 0.89 mm2 vs 2.17 ± 1.09 mm2, p = 0.334). In true 
bifurcation lesions the (2D) diameter stenosis appeared significant- ly increased (%DS 
pre PCI 58.7% vs 31.9%, p = 0.0001) after treatment. Additionally, also in the 3-mm ostial 
SB sub-segment, no statistically significant pre- and post-procedural variations were 
reported in terms of reference vessel diameter (2D RVD: 1.99 ± 0.33 mm vs 2.06 ± 0.38 
mm, p = 0.309 - 3D RVD: 2.03 ± 0.28 mm vs 2.10 ± 0.32 mm, p = 0.123), minimal lumen 
diameter (2D MLD: 1.51 ± 0.38 mm vs 1.53 ± 0.44 mm, p = 0.567 - 3D MLD: 1.59 ± 0.35 
mm vs 1.62 ± 0.41 mm, p = 0.760) minimal lumen area (3D MLA 2.10 ± 0.86 mm2 vs 2.19 
± 1.10 mm2, p = 0.660) (Tables 5 and 6).
optical coherence tomography findings
OCT imaging was performed in 20 bifurcations after BVS implantation (Table 7). Incom-
plete scaffold apposition (ISA) was observed in 15 patients, with a mean ISA area of 0.12 
± 0.14 mm2 and a mean percentage of malapposed struts per patient equal to 3.87 ± 
4.12%.
The sub-segments analysis was available in 19 cases (one case was excluded owing 
to incomplete pullback of treated MV). The mean percentages of malapposed struts per 
patient in distal, polygon of confluence and proximal sub-segments were 1.50 ± 2.59%, 
4.08 ± 9.45% and  6.41 ± 16.99%  respectively.
table 4 Procedural results
Number of bifurcations N = 107
Device success 106 (99.1)
Procedural succes 101 (94.3)
     Final MV TIMI flow grade 3 106 (99.1)
     Final SB TIMI flow grade 3 103 (96.3)
SB impairment 13 (12.1)
     SB TIMI flow grade < 3 after MV stenting 10 (9.3)
            SB TIMI flow grade =0 after MV stenting 4 (3.7)
            SB TIMI flow grade =1 after MV stenting 2 (1.9)
            SB TIMI flow grade =2 after MV stenting 4 (3.7)
     Need to guidewire(s) different from the default
     wire to rewire SB after MV stenting
5 (4.7)
     Failure to rewire the SB after MV stenting 1 (0.9)
     Failure to dilate the SB after MV stenting 1 (0.9)
Values are expressed as count (n) and percentages (%).
MV = main vessel; SB = side branch; TIMI = thrombolysis in myocardial infarction.
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table 5 Pre- and post-procedural vessel diameters 2D-QCA-evaluation
Number of bifurcations
Pre-PCI
(N=103)
Post-PCI
(N=103)
p value
Main vessel
     Reference diameter (mm) 2.63 ± 0.61 2.77 ± 0.55 0.286
     Minimal lumen diameter (mm)
     % diameter stenosis
1.30 ± 0.55
50.13 ± 18.86
2.35 ± 0.52
15.14 ± 8.40
<0.001
<0.001
Side branch
     Reference diameter (mm) 1.98 ± 0.33 2.03 ± 0.41 0.718
     Minimal lumen diameter (mm)
     % diameter stenosis
1.45 ± 0.41
26.93 ± 16.89
1.48 ± 0.42
27.80 ± 15.57
0.587
0.904
3-mm ostial side branch sub-segment
     Reference diameter (mm) 1.99 ± 0.33 2.06 ± 0.38 0.309
     Minimal lumen diameter (mm)
     % diameter stenosis
1.51 ± 0.38
23.97 ± 15.99
1.53 ± 0.44
25.82 ± 16.15
0.567
0.697
Angle
     Proximal Main Vessel/Side Branch (°) 143.58 ± 17.44 143.53 ± 18.04 0.282
     Distal Main Vessel/Side Branch (°)  53.47 ± 15.65 52.68 ± 17.95 0.764
Values are expressed as mean ± SD.  PCI = percutaneous coronary intervention.
table 6 Pre- and post-procedural vessels diameters and areas 3DQCA-evaluation
Number of bifurcations
Pre-PCI
(N=40)
Post-PCI
(N=40)
p value
Main vessel
     Reference diameter (mm) 2.60 ± 0.72 2.77 ± 0.48 0.128
     Minimal lumen diameter (mm) 1.48 ± 0.59 2.43 ± 0.46 <0.001
     Minimal lumen area (mm2) 1.99 ± 1.52 4.81 ± 1.70 <0.001
     Percentage area stenosis 63.47 ± 21.49 22.15 ± 12.27 <0.001
Side branch
     Reference diameter (mm) 2.00 ± 0.28 2.08 ± 0.34 0.280
     Minimal lumen diameter (mm) 1.54 ± 0.37 1.61 ± 0.41 0.363
     Minimal lumen area (mm2)    1.97 ± 0.89 2.17 ± 1.09 0.334
     Percentage area stenosis 42.25 ± 21.50 38.62 ± 21.33 0.305
3-mm ostial side branch sub-segment
     Reference diameter (mm) 2.03 ± 0.28 2.10 ± 0.32 0.123
     Minimal lumen diameter (mm) 1.59 ± 0.35 1.62 ± 0.41 0.760
     Minimal lumen area (mm2) 2.10 ± 0.86 2.19 ± 1.10 0.660
     Percentage area stenosis 34.98 ± 19.98 37.48 ± 20.28 0.798
Angle
     Proximal Main Vessel/Side Branch (°) 139.19 ± 15.94 140.86 ± 14.70 0.597
     Distal Main Vessel/Side Branch (°)  59.02 ± 12.31 55.23 ± 13.34 0.189
     Proximal Main Vessel/Distal Main Vessel (°) 152.40 ± 13.08 155.74 ± 10.27 0.128
Values are expressed as mean ± SD.  PCI = percutaneous coronary intervention.
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table 7 Optical coherence tomography (OCT) analysis post-scaffold implantation in bifurcated coronary 
lesions
OCT variables N = 20
In-segment analysis
     Minimum lumen area (mm2) 5.05 ± 1.05
     Mean lumen area (mm2) 7.36 ± 1.37
     Lumen volume (mm3) 231.49 ± 97.72
     Minimum scaffold area (mm2) 5.68 ± 1.08
     Mean scaffold area (mm2) 7.61 ± 1.45
     Scaffold volume (mm3) 236.88 ± 99.71
     Mean ISA area (mm2) 0.12 ± 0.14
     Max ISA area (mm2) 1.64 ± 1.56
     % ISA area 1.71 ± 2.22
     Mean prolapse area (mm2) 0.47 ± 0.27
     Max prolapsed area (mm2) 1.40 ± 0.75
     % prolapse 6.27 ± 3.46
     Distal dissection   (N = 15) 5 (33.3)
     Proximal dissection   (N = 17) 4 (23.5)
     Analyzed struts per patient 292 ± 117.52
     Malapposed struts per patient 10.15 ± 8.37
     % malapposed struts 3.87 ± 4.12
     Side branch struts per bifurcation 3.20 ± 2.31
5-mm proximal MV sub-segment   (N = 19)
     Malapposed struts 2.11 ± 4.53
     % malapposed struts 6.41 ± 16.99
Polygon of confluence (POC)   (N = 19)
     Malapposed struts  0.63 ± 1.11
     % malapposed struts 4.08 ± 9.45
      SB-related struts 2.0 ± 2.13
5-mm distal MV sub-segment   (N = 19) 
     Malapposed struts 0.61 ± 1.09
      % malapposed struts 1.50 ± 2.59
Values are expressed as mean ± SD, median [IQR] or n (%). ISA = incomplete scaffold apposition. MV = main 
vessel. OCT = optical coherence tomography. POC = polygon of confluence. 
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In the sub-group of patients in which a proximal optimization technique (POT) was 
performed, the percentages of malapposed struts in the polygon of confluence and 
in the proximal sub-segment were numerically lower compared with the sub-group in 
which POT was not performed (1.54 ± 3.42% vs 6.37 ± 12.49% and 3.31 ± 3.57% vs 8.33 
± 24.29% respectively).
clinical outcomes
Survival status was available in 99.0% (101/102). The overall mortality at one year was 
2.2% (2/101). Clinical follow-up rate was 91.1% (92/101) with a median follow up dura-
tion of 731 days (interquartile range, IQR: 644–762 days). 89 patients had a follow-up of 
at least one year (2 patients had a follow-up duration of 353 and 332 days respectively. 
One patient was lost to follow-up with follow-up duration of 202 days).
The remaining 9 out of 101 patients could not be approached for clinical follow-up 
the cause was refusal to participate and in one case emigration. A total of 5 patients 
were reported to have major adverse cardiac event (Fig. 4) including 1 cardiac death 
(and possible ST), 4 MI (2 ST-segment elevation MI, one peri-procedural MI caused by 
a distal scaffold dissection and one occurred after a staged procedure on a non-target 
vessel, and 2 non-ST elevation MI, both due to a late scaffold thrombosis( Table 8), 3 
ischemia-driven target bifurcation revascularizations (due to an in-scaffold restenosis 
inducing angina). At one year, 2 cases of definite ST (at day 47 and at day 142) occurred. 
(See Table  9).
table 8 Clinical outcomes at 1-year follow-up.
Clinical events N = 102
Major adverse cardiac events 5.5%
All cause death 2.2%
Cardiac death 1.1%
Myocardial infarction 4.4%
Target lesion revascularization 3.3%
Target vessel revascularization 6.6%
Non- target vessel revascularization 3.4%
Scaffold thrombosis 3.3%
Definite ST 2.2%
Probable ST 0.0%
Possible ST 1.1%
ST scaffold thrombosis
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figure 3 Treatment of a coronary bifurcation located in a diffusely disease vessel in a patient with previous 
coronary artery bypass graft.
In the upper panel angiographic appearance pre-intervention and 3-dimentional QCA reconstruction of 
the target bifurcation. In the lower panel post-procedure appearance and 3-dimentional QCA reconstruc-
tion with no side-branch impairment.
figure 4 Kaplan–Meier curves for MACE and scaffold thrombosis.
MACE: major adverse cardiac events; ST: scaffold thrombosis
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Discussion
Initial clinical experience with bioresorbable vascular scaffolds has been focused on 
simple lesions and relatively stable patients. Recent data, mainly derived from registry, 
provided additional information on safety, feasibility and performance of BVS in more 
complex lesions and patients [17,18], however specific challenging subsets such as 
bifurcation lesions remain poorly investigated.
In the present study we reported the BVS performance after implantation in bifurca-
tion lesions in wide range clinical scenarios, including patients presenting with acute 
myocardial infarction or showing multivessel disease (Fig. 3) and coronary chronic total 
occlusions.
The approach adopted in the vast majority of the cases was a T-provisional scaffolding, 
a solid amount of evidence suggests this strategy as to be the preferable in most of 
the bifurcation cases [19,20]. Such evidences are provided from studies performed with 
metal stents but it is reasonable to apply the same principles to bioresorbable devices, 
especially considering the fact that a single scaffold technique reduce the amount of 
polymer at the bifurcation site, avoids overlap and the need for multiple layer of polymer.
The scaffold sizing in bifurcation lesions could be challenging in case of remarkable 
vessel tapering distally to the side-branch.
Recently Ishibashi et al. reported that oversizing the implanted scaffold compared to 
both the proximal and distal vascular maximal diameter (Dmax) could be associated 
with clinical events. On the other hand underexpansion was also shown to increase the 
risk of scaffold thrombosis [21]. Probably a reasonable approach could be to balance the 
proximal and distal Dmax, ensuring optimal apposition proximally after post-dilatation, 
without causing high vessel stretch and injury distally.
In the present series, the size of the BVS was usually chosen on the basis of the proxi-
mal maximal diameter (Dmax) [22] but also taking into account the distal Dmax, often 
performing low-pressure deployment and thereafter performing proximal optimization. 
table 9 Cases of definite scaffold thrombosis
Case # Type of lesion Technique Device size 
(mm)
Timing (days from 
index procedure to 
scaffold thrombosis)
Dual antiplatelet therapy 
at the time of scaffold 
thrombosis 
1 LAD/1°Diagonal
Medina 1.1.1
Angulation 78°
‘’Provisional MV 
stenting’’
3.0 x 18 142 ASA (80 mg) + PRASUGREL 
(10 mg)
2 LAD/1°Diagonal
CTO
‘’Provisional MV 
stenting’’
3.0 x 28
3.5 x 18
3.5 x 18
(2 overlap)
47 ASA (80 mg) + 
CLOPIDOGREL (75 mg)
ASA = aspirin; CTO = chronic total occlusion; LAD = left anterior descending; MV = main vessel.
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In our report we observed a trend toward a reduction in malapposition at the proximal 
segment and at the polygon of confluence in the cases with performed proximal opti-
mization.
Taking into consideration the faith of the side-branches after BVS implantation, an 
initial concern associated with the larger BVS struts width and its possible impact on 
side-branch impairment has been raised [9]. Maramatsu et al. performed a post-hoc 
analysis of the ABSORB-EXTEND and SPIRIT First and II Trials [9] to assess the incidence of 
small SB occlusion (bifurcation lesions involving a SB b 2 mm) after either BVS or everoli-
mus-eluting metal stents. BVS demonstrated a higher incidence of post-procedural side 
branch occlusion compared with EES but only in small side branches with a reference 
vessel diameter ≤ 0.5 mm.
To investigate the impact of BVS wider struts on side-branch impairment when treating 
what is most commonly considered a bifurcation lesion (with a side-branch of at least 2 
mm in diameter) [20,23–27], we performed a detailed analysis taking into consideration 
both procedural and angiographic parameters.
We evaluated the composite parameter of “side-branch impairment” observing the 
TIMI flow, need for dedicated wires, or failure to re-cross or dilate the side-branch and 
we assessed the 2- and 3- dimensional QCA pre and post BVS implantation of the side-
branch.
A side-branch impairment occurred in 13 cases (12.1%) after BVS deployment, the 
most frequently reported cause was a SB TIMI flow grade b 3 after MV scaffolding, (10 
cases). Of note in 6 of those cases the final SB TIMI flow grade improved to grade TIMI 
flow 3 after SB ostium post-dilation, with no need for SB treatment and reducing the 
occurrence of final side-branch slow flow to only 4 bifurcations (3.7%). Such data are in 
line with previous investigations evaluating the impact of first- and second-generation 
drug eluting metal stents on side-branch impairment [7].
It would therefore appear that the concern of an increased side- branch damage or 
occlusion after BVS implantation may not be justified, when considering side-branches 
with a visually estimated diameter of 2 mm or more.
The OCT analysis although performed in a subgroup of patients showed a low amount 
of malapposition in the overall bifurcation segment probably also in association with a 
high rate of post-dilatation. Malapposition was distributed with a reduction from the 
proximal to the distal segment of the bifurcation, highlighting the possible need for 
proximal optimization.
Finally, although due to the small number of patients and events re- ported is not 
possible to reach firm conclusions in terms of clinical outcomes, the overall mortality 
and the MACE rate suggest a relative safety of BVS implantation in bifurcation lesions 
given a preferred single scaffold technique and a high rate of pre and post dilatation.
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limitations
The present report is an investigator initiated, single center, single arm study and is a 
retrospective analysis of the BVS evaluation program at Thoraxcenter Rotterdam, The 
Netherlands. The choice for BVS implantation was left to operator discretion; this could 
be source of selection bias. The absence of a comparator arm is limiting the interpreta-
tion of our data. In the present study side branch vessel with a visual estimated diameter 
≥ 2.0 mm was evaluated, by QCA the mean RVD of the side branch was 1.98 mm high-
lighting the well-known underestimation of vessel size by QCA. Intravascular imaging 
was encouraged but not mandatory and left to the operator discretion, such approach 
could be associated with selection bias. The limited number of patients does not allow 
reaching firm conclusions in terms of clinical outcomes, therefore clinical data should be 
considered as purely descriptive and hypothesis generating.
conclusion
The present investigation suggest the feasibility and good performance of everolimus-
eluting BVS implantation in patients with a native bifurcated coronary lesion, involving 
a SB ≥ 2 mm in diameter. Further investigations in randomized clinical trials are required 
to provide the actual impact of this novel technology on safety, efficacy and long- term 
clinical outcomes, also compared to second-generation DESs.
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abstract
background
There is limited data on the impact of calcium (Ca) on acute procedural and clinical 
outcomes in patients with lesions treated with bioresorbable vascular scaffolds (BRS). 
We sought to evaluate the effect of calcium on procedural and clinical outcomes in a 
‘real world’ population. 
methods
Clinical outcomes were compared between patients with at least 1 moderately or heav-
ily calcified lesion (Ca) and patients with no/mild calcified lesions (non-Ca) enrolled in 
our institutional BRS registry. 
results
455 patients (N) with 548 lesions (L) treated with 735 BRS were studied. Patients in the 
Ca group (N=160, L=200) had more complex (AHA B2/C lesion: 69.0% in Ca vs 14.9% 
in non-Ca, p < 0.001) and significantly longer lesions (27.80 ±15.27 vs 19.48 ±9.92mm, 
p<0.001). Overall device success rate was 99.1% with no significant differences between 
the groups. Despite more aggressive lesion preparation and post-dilatation compared to 
non Ca, acute lumen gain was significantly less in Ca lesions (1.50 ±0.66 vs 1.62 ±0.69mm, 
p= 0.040) with lower final MLD (2.28± 0.41 vs 2.36±0.43, p=0.046). There were no sig-
nificant differences in all-cause mortality, total definite scaffold thrombosis (ST), target 
lesion revascularization and myocardial infarction between the 2 groups. Late ST was 
more frequent in the Ca group compared to non Ca group (Late ST: 2.1 vs 0%, p=0.02).
conclusions
Clinical outcomes after BRS implantation in calcified and non-calcified lesions were simi-
lar.  A remarkable difference in timing of thrombosis was observed, with an increased 
rate of late thrombosis in calcified lesions.
condensed abstract
Clinical outcomes were compared between patients with at least 1 moderately or heavily calcified lesion 
(Ca) and patients with no/mild calcified lesions (non-Ca) enrolled in our institutional BRS registry. 455 pa-
tients with 548 lesions treated with 735 BRS were studied. More aggressive lesion preparation, post-dilata-
tion and the use of intracoronary imaging were more likely encountered in Ca lesions. There was a signifi-
cant increase in late ST in patients with Ca lesions compared to patients with non-Ca lesions treated with 
BRS.  However there were no significant differences in all-cause mortality and MACE between the groups.  
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introDuction
Bioresorbable scaffolds (BRS) have been devel oped as an alternative to metallic stents as 
the need for mechanical support for the treated vessel is temporary, and beyond the first 
few months there are potential disadvantages of a permanent metallic prosthesis. In 
earlier studies to demonstrate Absorb BRS feasibility and safety, severe calcification was 
an exclusion criterium [1-6].   Calcified lesions may be challenging and encountered in up 
to 35% of patients who undergo percutaneous coronary intervention (PCI) [7-8]. Lesion 
calcification has been associated with increased PCI complexity with worse procedural 
outcomes compared to non-calcified lesions [9]. Wire crossing, delivery of equipment 
during pre and post dilation and stent delivery may be more cumbersome.  In calcific 
lesions, the effect of acute plaque recoil may affect stent expansion and is associated 
with adverse clinical and angiographic outcomes [10-11].  Currently there is still limited 
data on the impact of calcium (Ca) on acute procedural and clinical outcomes in patients 
with lesions treated with BRS. We sought to determine the impact of calcification on 
acute angiographic and 2 year clini cal outcomes of a large cohort of patients treated 
solely with the Absorb Bioresorbable Vascular Scaffold (BVS) system (Abbott Vascular, 
Santa Clara, CA, USA).
methoDs
This is an investigator-initiated, prospective, single-center, single-arm study evaluating 
performance of the Absorb BVS in lesions representative of daily clinical practice, includ-
ing calcified lesions, total occlusions, long lesions and small vessels [12-13]. The study 
inclusion period was from September 2012 till January 2015. Inclusion criteria were 
patients presenting with STEMI [12], NSTEMI, stable/ unstable angina, or silent ischemia 
caused by a de novo stenotic lesion in a native previously untreated coronary artery 
[13]. Procedural and long-term clinical outcomes were assessed. The primary endpoint 
was major adverse cardiac events, defined as a composite of cardiac death, myocardial 
infarction and target lesion revascularization. 
ethics
This is an observational study, performed according to the privacy policy of the Erasmus 
MC, and to the Erasmus MC regulations for the appropriate use of data in patient-ori-
ented research, which are based on international regulations, including the declaration 
of Helsinki. Approval of the ethical board of the Erasmus MC was obtained. All patients 
undergoing clinical follow-up provided written informed consent for the PCI and to be 
contacted regularly during the follow-up period of the study.
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Quantitative coronary analysis (Qca)
The angiographic analysis was performed by three independent investigators. Coronary 
angiograms were analyzed with the CAAS 5.10 QCA software (Pie Medical BV, Maastricht, 
the Netherlands). The QCA (Quantitative Coronary Analysis) measurements provided 
reference vessel diameter (RVD), percentage diameter stenosis and minimal lumen 
diameter (MLD). Acute gain was defined as post-procedural MLD minus pre-procedural 
MLD (in an occluded vessel MLD value was zero by default). 
Angiographic Assessment of Lesion Calcification
Lesion calcification was recognized as radio-opacities within the vessel wall at the 
treated lesion. Calcification was categorized as either none/mild or moderate if the 
radio-opacities were noted only during the cardiac cycle before contrast injection and 
further classified as either none/mild or moderate based on visual assessment. Severe 
calcification was defined as having multiple persisting (that are noted even without 
cardiac motion) opacifications of the coronary wall and visible in more than one projec-
tion, surrounding the complete lumen of the coronary artery at the site of the lesion) 
as per SYNTAX definition (www.syntaxscore.com). Angiographic assessment of calcifica-
tion was conducted independently by 2 cardiologists. In cases of disagreement, a third 
independent cardiologist reviewed the films and provided a final diagnosis. 
follow-up
Clinical demographic data of all patients were obtained from municipal civil registries. 
Follow-up information specific for hospitalization and cardiovascular events was 
obtained through questionnaires. If needed, medical records or discharge letters from 
other hospitals were requested. Events were adjudicated by an independent clinical 
events committee (CEC). All information concerning baseline characteristics and follow-
up was gathered in a clinical data management system. Only patients who had given 
written consent for follow up were included in the clinical outcome assessments. 
Definitions
The primary endpoint was major adverse cardiovascular events (MACE), defined as the 
composite endpoint of cardiac death, myocardial infarction (MI) and target lesion revas-
cularization (TLR). The secondary endpoints were device oriented composite endpoints 
(DOCE: composite of cardiac death, target vessel myocardial infarct and clinically indi-
cated target lesion revascularization) and patient oriented composite endpoints (POCE: 
composite of all-cause mortality, all-cause myocardial infarct and any revascularization). 
Deaths were considered cardiac unless a non-cardiac cause was definitely identified. 
TLR was described as any repeated revascularization of the target lesion. Target ves-
sel revascularization (TVR) was defined as any repeat percutaneous intervention or 
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surgical bypass of any segment of the target vessel. Non-target vessel revascularization 
was described as any revascularization in a vessel other than the target lesion. Scaffold 
thrombosis (ST) and MI were classified according to the Academic Research Consortium 
(ARC). 1 Clinical device success was defined as successful delivery and deployment of the 
first study scaffold/ stent at the intended target lesion and successful withdrawal of the 
delivery system with attainment of final in-scaffold/ stent residual stenosis of < 30% as 
evaluated by QCA. Clinical procedure success was described as device success without 
major peri-procedural complications or in-hospital MACE (maximum of 7 days). 
statistical analysis
Categorical variables are reported as counts and percentages, continuous variables as 
mean ± standard deviation. The cumulative incidence of adverse events was estimated 
according to the Kaplan-Meier method. Patients lost to follow-up were considered at 
risk until the date of last contact, at which point they were censored. , A cox regression 
was performed to investigate clinical outcomes at two years, with the binary variable 
calcification (yes/ no). Adjusted cox regression were performed using fourteen patient 
and lesion factors (See Online supplement Table 1) to account for baseline differences 
between patients with at least 1 moderately or heavily calcified lesion (Ca) and patients 
with no/mild calcified lesions (non-Ca). Statistical analyses were performed using SPSS, 
version 21 (IL, US). All statistical tests were two-sided and the P value of < 0.05 was 
considered statistically significant.
results
Baseline clinical characteristics are shown in Table 1A. A total of 548 lesions in 455 
patients were studied of which 200 (36.5%) lesions in 160 patients (35.2%) were moder-
ately or heavily calcified (Ca group). (Table 1A). Patients in the Ca group were older, with 
more hypertension, and kidney disease. In the calcified cohort, there were 1.24 lesions 
per patient. Lesion and QCA characteristics are as shown in Table 1B. The left anterior 
table 1a Demographic Characteristics
BRS (N= 455)
Patients with at least 1 calcified 
lesion (N= 160/35.2%)
Patients with no calcified lesions
(N=295/64.8%)
Age 62.12 ± 10.64 56.54 ± 10.25 <0.001 
Male 122/160 (76.3) 220/295 (74.6) 0.734
Ex/Active smoker* 81/160 (50.7) 181/294(61.6)
Diabetes mellitus 31/160 (19.4) 40/295 (13.6) 0.107
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table 1a Demographic Characteristics (continued)
BRS (N= 455)
Patients with at least 1 calcified 
lesion (N= 160/35.2%)
Patients with no calcified lesions
(N=295/64.8%)
Dyslipidaemia* 75/158 (47.5) 109/288 (37.8) 0.056
Hypertension 93/159 (58.5) 139/290 (47.9) 0.038
Family History 55/160 (34.4) 127/295 (43.1) 0.206
CVA/TIA 13/160(8.1) 16/295 (5.4) 0.260
Prior MI 26/160 (16.3) 27/295 (9.2) 0.032
Prior PCI 10/160 (6.3) 20/295 (6.8) 1.000
Prior CABG 1/160 (0.6) 0 0.352
Kidney disease  11/160 (6.9) 8/295 (2.7) 0.048
Heart failure 7/160 (4.4) 7/295 (2.4) 0.262
Clinical presentation 0.002
Stable Angina 53/160 (33.1) 63/ 295 (21.4)
Unstable Angina 14/160 (8.8) 32/295 (10.8)
STEMI 40/160 (25.0) 118/295 (40.0)
NSTEMI 51/160 (31.9) 82/295 (27.8)
CCF 2/160 (1.3) 0
Disease Involvement 0.060
SVD 97/160 (60.6) 210/295 (71.2)
DVD 42/160 (26.3) 63/295 (21.4)
TVD 21/160 (13.1) 22/295 (7.4)
Values are expressed in numbers (percentages) or mean ± standard deviation when appropriate.
table 1b Lesion Characteristics 
BRS (L = 548)
Calcified Lesions 
 (L=200/36.5%)
Non Calcified Lesions
(L=348/ 63.5%)
P value
Target vessel 
LAD 126/200 (63.0) 128/348 (36.8) <0.001
LCX 27/200  (13.5) 96/348  (27.6) <0.001
RCA 42/200 (21.0) 111/348(31.9) 0.007
Diagonal 4/200 (2.0) 13/348(3.7) 0.314
Ramus 0 0 -
Left Main 1/200 (0.5) 0 0.365
SVG 0 0 -
Lesion AHA 
A 5/200 (2.5) 71/348 (20.4) < 0.001
B1 60/200 (30.0) 226/348 (64.9) < 0.001
B2 85/200 (42.5) 46/348 (13.2) < 0.001
C 53/200 (26.5) 6/348 (1.7) <0.001
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descending artery (n=254, 46.4%) was the most commonly treated vessel in the study 
population. Lesions in the Ca group were more complex (AHA B2/C lesion: 69.0% in Ca vs 
14.9% in non-Ca, p < 0.001) and significantly longer. Compared to non-Ca group, lesions 
in the Ca groups had smaller RVD and lower percentage diameter stenosis. 
Procedural characteristics are as shown in Table 1C. Ca lesions were treated with 
more aggressive lesion preparation compared to non Ca as evidenced by the more 
significant use of pre-dilatation, rotational atherectomy and scoring balloon. The use of 
buddy wires was higher in Ca lesions compared to non Ca lesions.  Figure 1A illustrates 
the satisfactory expansion with minimal eccentricity on OCT of a calcified LAD treated 
with a BRS. Figures 1B and 1C illustrates the acute and 2 year angiographic and IVUS 
result respectively after rotational atherectomy and lesion preparation followed by BRS 
implantation in a calcified coronary artery. A total of 735 scaffolds were implanted in 
the study population with more scaffolds per lesion for Ca lesions (1.58 vs 1.21). Scaffold 
diameter was similar in the two groups however scaffold length implanted was longer 
in the Ca group.  Post-dilatation was more frequently used in the Ca group (Ca vs non Ca: 
64.8% vs 42.1%, p<0.001). 
table 1b Lesion Characteristics  (continued)
BRS (L = 548)
Calcified Lesions 
 (L=200/36.5%)
Non Calcified Lesions
(L=348/ 63.5%)
P value
Bifurcation 61/199 (31.7) 58/347 (16.7) <0.001
CTO 13/200 (6.5) 4/348 (1.1) 0.001
Mod/Heavy calcification 133/67 0
TIMI 
Preprocedure 0.074
TIMI 0 35/200 (17.5) 87/344 (25.0)
TIMI 1 6/200 (3.0) 17/344 (4.9)
TIMI 2 50/200 (14.4) 50/344 (14.4)
TIMI 3 125/200 (62.5) 190/344 (54.6)
QCA Analysis 
Pre-procedure
Treatment length 27.80 ± 15.27 19.48 ± 9.92 <0.001
RVD (mm) 2.52±0.57 2.62 ± 0.57 0.053
MLD (mm) 0.85±0.47 0.75±0.55 0.036
Diameter stenosis (%) 65.39±18.68 70.78±20.98 0.004
Values are expressed in numbers (percentages) or mean ± standard deviation when appropriate. 
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table 1c Procedural Characteristics
BRS (L = 548)
Calcified Lesions
(L=200/36.5%)
Non Calcified Lesions 
(L=348/ 63.5%)
P value
Number of treated lesions per procedure 1.24 ± 0.48 1.17 ± 0.48 0.133
Aspiration thrombectomy 34/200 (17.1) 106/348 (30.5) 0.001
Rotablation 11/200 (5.5) 0/348 0.002
Scoring balloon 9/200 (4.5) 1/348 (0.3) 0.001
Intracoronary imaging
IVUS 30/199 (15.1) 30/348 (8.6) 0.023
OCT 62/200 (31.0) 95/348 (27.3) 0.378
Pre-dilation 177/200 (88.5) 265/348 (76.1) <0.001
Max pre-dilation diameter  2.66 ± 0.36 2.53 ± 0.42 0.002
Pre-dilation balloon: artery ratio 1.08 ± 0.25 1.01 ± 0.23 0.005
Maximum pre-dilation inflation pressure, atm 14.25 ± 3.35 13.56 ± 3.01 0.067
Buddy wire 23/199 (11.6) 22/347 (6.3) 0.036
Additional daughter catheter 3/199 (1.5) 3/348 (0.9) 0.673
Mean number of scaffolds 1.58  ± 0.823 1.21 ± 0.53 <0.001
Number of scaffolds (total 735) 315 420 <0.001
0 1/200 (0.5) 1/348 (0.3)
1 117/200 (58.5) 289/348 (83.0)
2 56/200 (28.0) 47/348 (13.5)
3 18/200 (9.0) 7/348 (2.0)
4 8/200 (4.0) 4/348 (1.1)
Scaffold diameter, mm 3.11 ± 0.32 3.12 ± 0.38 0.615
Scaffold length implanted, mm 34.65± 19.94 23.84 ± 12.20 < 0.001
Overlapping scaffolds 80/200 (40.0) 52/348 (15.0) <0.001
Maximum scaffold implantation pressure, atm 14.99 ± 1.88 14.86 ± 1.97 0.510
Post-dilatation 129/199 (64.8) 146/347 (42.1) <0.001
Post-dilatation balloon: mean scaffold diameter 
ratio
1.06 ± 0.15 1.07 ± 0.10 0.422
Max post-dilatation balloon 3.31 ± 0.43 3.31 ± 0.44 0.906
Maximum post-dilatation inflation pressure, atm 16.27 ± 3.63 15.83 ± 3.97 0.496
Values are expressed as numbers (percentages) or mean ± standard deviation when appropriate.
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Procedural outcomes are shown in Table 2A. Post procedure, acute lumen gain was 
significantly less in Ca compared to non-Ca lesions (1.50 ±0.66 vs 1.62 ±0.69mm, p= 
0.040) with lower final MLD (2.28± 0.41 vs 2.36±0.43, p=0.046).  RVD and percentage 
diameter stenosis were smaller in the Ca group compared to the non Ca group though 
the differences did not reach statistical significance.  Procedural success was high for 
both patient groups (98.7 and 99.7%, p=0.25). Overall device success rate and final TIMI 
3 flow result were similar in the two groups. 
segments, allows potential reopening of “jailed” side branches and
potential recovery of vasomotor function and vessel remodeling.
These benefits would bemore pertinent in patients with calcific lesions,
who often have widespread disease resulting in long stented segments.
However whether these will translate into long term clinical benefits in
more complex lesions such as thosewith significant calcificationswould
Table 1C
Procedural characteristics of the study population.
BRS (L = 548) p value
Calcified lesions
(L = 200/36.5%)
Non calcified lesions
(L = 348/63.5%)
Number of treated lesions per procedure 1.24 ± 0.48 1.17 ± 0.48 0.133
Aspiration thrombectomy 34/200 (17.1) 106/348 (30.5) 0.001
Rotational atherectomy 11/200 (5.5) 0/348 0.002
Scoring balloon 9/200 (4.5) 1/348 (0.3) 0.001
Intracoronary imaging
IVUS 30/199 (15.1) 30/348 (8.6) 0.023
OCT 62/200 (31.0) 95/348 (27.3) 0.378
Predilation performed 177/200 (88.5) 265/348 (76.1) b0.001
Max predilation diameter 2.66 ± 0.36 2.53 ± 0.42 0.002
Predilation balloon: artery ratio 1.08 ± 0.25 1.01 ± 0.23 0.005
Maximum predilation inflation pressure, atm 14.25 ± 3.35 13.56 ± 3.01 0.067
Buddy wire 23/199 (11.6) 22/347 (6.3) 0.036
Additional daughter catheter 3/199 (1.5) 3/348 (0.9) 0.673
Mean number of scaffold 1.58 ± 0.823 1.21 ± 0.53 b0.001
Number of scaffolds (total 735) 315 420 b0.001
0 1/200 (0.5) 1/348 (0.3)
1 117/200 (58.5) 289/348 (83.0)
2 56/200 (28.0) 47/348 (13.5)
3 18/200 (9.0) 7/348 (2.0)
4 8/200 (4.0) 4/348 (1.1)
Scaffold diameter, mm 3.11 ± 0.32 3.12 ± 0.38 0.615
Scaffold length implanted, mm 34.65 ± 19.94 23.84 ± 12.20 b0.001
Overlapping scaffolds 80/200 (40.0) 52/348 (15.0) b0.001
Maximum scaffold implantation pressure, atm 14.99 ± 1.88 14.86 ± 1.97 0.510
Postdilation performed 129/199 (64.8) 146/347 (42.1) b0.001
Postdilation balloon: mean scaffold diameter ratio 1.06 ± 0.15 1.07 ± 0.10 0.422
Max postdilation balloon, mm 3.31 ± 0.43 3.31 ± 0.44 0.906
Maximum postdilation inflation pressure, atm 16.27 ± 3.63 15.83 ± 3.97 0.496
Values are expressed as numbers (percentages) or mean ± standard deviation when appropriate.
Fig. 1.A. Implantation of Bioresorbable vascular scaffold (BRS in calcified left anterior descending artery (LAD). Panel 1. Implantation of bioresorbable vascular scaffolds (two 3.0 × 28mm
Absorb™ BVS deployed in an overlapping manner-indicated in yellow) in a calcified left anterior descending artery (LAD). Calcification marked ‘+’ in Panel 1-1. Target lesion marked ‘*’
preprocedure (Panel 1-2), after predilationwith a 2.5mmballoon at (Panel 1-3) and after postdilationwith a noncompliant 3.0mmballoon at high pressure (Panel 1-4).Panel 2A–E: Final
OCT performed showed that the scaffold was well expanded and apposed with no significant dissection seen. Proximal and distal reference areas were 7.21 mm2 and 5.52 mm2
respectively. The minimal lumen area (MLA) was 4.5 mm2 (2.83 × 1.81 mm) with an eccentricity index (EI) of 0.63. Panel 2-A–C showed the corresponding segments of the treated
vessel in Panel 1-4. Panel 2-D showed the BRS implanted in a calcified segment of the treated vessel with satisfactory expansion with minimal eccentricity. Panel 2-E showed the
longitudinal pullback of the treated vessel. B. Angiogram and intravascular ultrasound (IVUS) of the right coronary artery (RCA). Angiogram and intravascular ultrasound (IVUS) of the
right coronary artery (RCA). Panel 1-A shows the preprocedural angiogram at baseline with a severely tight lesion (circled) in the mid segment of the RCA which is heavily calcified
(see insert). Panel 1-B shows the RCA post rotational artherectomy with 1.5 mm burr (see insert) and predilation with a Trek NC 3.25 mm balloon. Panel 1-C shows the RCA after
deployment of a BRS (BVS Absorb 3.0 × 28 mm - outlined in red). The borderline lesions in the ostium and mid right posterior descending artery (RPDA) was managed conservatively
(white arrow). Panel 1-D shows the RCA at 2 years follow up which demonstrates that the previously deployed scaffold in the mid RCA was still widely patent with no significant
restenosis (outlined red). C. IVUS images of the RCA. The figure shows IVUS images of the corresponding segments of the RCA in Fig. 1B Panel 1-D at 2 years follow up demonstrating
that the scaffold struts (white arrow) remained visible in the mid RCA with good apposition and expansion with side branch (*-RPDA) patency and confirmed the scaffolded vessel
remained widely patent with no significant restenosis (Panels 2-1 and 2-2). + - Guidewire.
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figure 1a Implantation of Bioresorbable vascular scaffold (BRS in calcified left anterior descending artery 
(LAD).
Implantation of Bioresorbable vascular scaffolds (Two 3.0 x 28mm AbsorbTM BVS deployed in an overlap-
ping manner- indicated in yellow) in a calcified left anterior descending artery (LAD). Calcification marked 
‘+’ in Panel 1-1.  Target lesion marked ‘*’ reprocedure (Panel 1-2), after predilation with a 2.5mm bal oon at 
(Panel 1-3) and after postdilation with a noncompliant 3.0mm balloon at high pressure (Panel 1-4).  Panel 
2A-E: Final OCT performed showed that the scaffold was well expanded and apposed with no significant 
dissection seen. Proximal and distal reference areas were 7.21mm2 and 5.52mm2 respectively. The minimal 
lumen area (MLA) was 4.5mm2 (2.83 x 1.81mm) with an eccentricity index (EI) of 0.63. Panel 2-A-C showed 
the corresponding segments of the treated vessel in Panel 1-4. Panel 2-D showed the BRS implanted in a 
calcified segment of the treated vessel with satisfactory expansion  with minimal eccentricity. Panel 2-E 
showed the longitudinal pullback of the treated vessel. 
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segments, allows potential reopening of “jailed” side branches and
potential recovery of vasomotor function and vessel remodeling.
These benefits would bemore pertinent in patients with calcific lesions,
who often have widespread disease resulting in long stented segments.
However whether these will translate into long term clinical benefits in
more complex lesions such as thosewith significant calcificationswould
Table 1C
Procedural characteristics of the study population.
BRS (L = 548) p value
Calcified lesions
(L = 200/36.5%)
Non calcified lesions
(L = 348/63.5%)
Number of treated lesions per procedure 1.24 ± 0.48 1.17 ± 0.48 0.133
Aspiration thrombectomy 34/200 (17.1) 106/348 (30.5) 0.001
Rotational atherectomy 11/200 (5.5) 0/348 0.002
Scoring balloon 9/200 (4.5) 1/348 (0.3) 0.001
Intracoronary imaging
IVUS 30/199 (15.1) 30/348 (8.6) 0.023
OCT 62/200 (31.0) 95/348 (27.3) 0.378
Predilation performed 177/200 (88.5) 265/348 (76.1) b0.001
Max predilation diameter 2.66 ± 0.36 2.53 ± 0.42 0.002
Predilation balloon: artery ratio 1.08 ± 0.25 1.01 ± 0.23 0.005
Maximum predilation inflation pressure, atm 14.25 ± 3.35 13.56 ± 3.01 0.067
Buddy wire 23/199 (11.6) 22/347 (6.3) 0.036
Additional daughter catheter 3/199 (1.5) 3/348 (0.9) 0.673
Mean number of scaffold 1.58 ± 0.823 1.21 ± 0.53 b0.001
Number of scaffolds (total 735) 315 420 b0.001
0 1/200 (0.5) 1/348 (0.3)
1 117/200 (58.5) 289/348 (83.0)
2 56/200 (28.0) 47/348 (13.5)
3 18/200 (9.0) 7/348 (2.0)
4 8/200 (4.0) 4/348 (1.1)
Scaffold diameter, mm 3.11 ± 0.32 3.12 ± 0.38 0.615
Scaffold length implanted, mm 34.65 ± 19.94 23.84 ± 12.20 b0.001
Overlapping scaffolds 80/200 (40.0) 52/348 (15.0) b0.001
Maximum scaffold implantation pressure, atm 14.99 ± 1.88 14.86 ± 1.97 0.510
Postdilation performed 129/199 (64.8) 146/347 (42.1) b0.001
Postdilation balloon: mean scaffold diameter ratio 1.06 ± 0.15 1.07 ± 0.10 0.422
Max postdilation balloon, mm 3.31 ± 0.43 3.31 ± 0.44 0.906
Maximum postdilation inflation pressure, atm 16.27 ± 3.63 15.83 ± 3.97 0.496
Values are expressed as numbers (percentages) or mean ± standard deviation when appropriate.
Fig. 1.A. Implantation of Bioresorbable vascular scaffold (BRS in calcified left anterior descending artery (LAD). Panel 1. Implantation of bioresorbable vascular scaffolds (two 3.0 × 28mm
Absorb™ BVS deployed in an overlapping manner-indicated in yellow) in a calcified left anterior descending artery (LAD). Calcification marked ‘+’ in Panel 1-1. Target lesion marked ‘*’
preprocedure (Panel 1-2), after predilationwith a 2.5mmballoon at (Panel 1-3) and after postdilationwith a noncompliant 3.0mmballoon at high pressure (Panel 1-4).Panel 2A–E: Final
OCT performed showed that the scaffold was well expanded and apposed with no significant dissection seen. Proximal and distal reference areas were 7.21 mm2 and 5.52 mm2
respectively. The minimal lumen area (MLA) was 4.5 mm2 (2.83 × 1.81 mm) with an eccentricity index (EI) of 0.63. Panel 2-A–C showed the corresponding segments of the treated
vessel in Panel 1-4. Panel 2-D showed the BRS implanted in a calcified segment of the treated vessel with satisfactory expansion with minimal eccentricity. Panel 2-E showed the
longitudinal pullback of the treated vessel. B. Angiogram and intravascular ultrasound (IVUS) of the right coronary artery (RCA). Angiogram and intravascular ultrasound (IVUS) of the
right coronary artery (RCA). Panel 1-A shows the preprocedural angiogram at baseline with a severely tight lesion (circled) in the mid segment of the RCA which is heavily calcified
(see insert). Panel 1-B shows the RCA post rotational artherectomy with 1.5 mm burr (see insert) and predilation with a Trek NC 3.25 mm balloon. Panel 1-C shows the RCA after
deployment of a BRS (BVS Absorb 3.0 × 28 mm - outlined in red). The borderline lesions in the ostium and mid right posterior descending artery (RPDA) was managed conservatively
(white arrow). Panel 1-D shows the RCA at 2 years follow up which demonstrates that the previously deployed scaffold in the mid RCA was still widely patent with no significant
restenosis (outlined red). C. IVUS images of the RCA. The figure shows IVUS images of the corresponding segments of the RCA in Fig. 1B Panel 1-D at 2 years follow up demonstrating
that the scaffold struts (white arrow) remained visible in the mid RCA with good apposition and expansion with side branch (*-RPDA) patency and confirmed the scaffolded vessel
remained widely patent with no significant restenosis (Panels 2-1 and 2-2). + - Guidewire.
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figure 1b Angiogram and intravascular ultrasound (IVUS) of the right coronary artery (RCA).
Angiogram and intravascular ultrasound (IVUS) of the right coronary artery (RCA). Panel 1-A shows the pre-
procedural angiogram at baseline with a severely tight lesion (circled) in the mid segment of the RCA which 
is heavily calcified (see insert). Panel 1-B shows the RCA post rotational artherectomy with 1.5 mm burr (see 
insert) and predilation with a Trek NC 3.25 mm balloon. Panel 1-C shows the RCA after deployment of a BRS 
(BVS Absorb 3.0 × 28 mm - outlined in red). The borderline lesions in the ostium and mid right poste ior 
descending artery (RPDA) was managed conservatively (white arrow). Panel 1-D shows the RCA at 2 years 
follow up which demonstrates that the previously deployed scaffold in the mid RCA was still widely patent 
with no significant restenosis (outlined red).
segments, allows potential reopening of “jailed” side branches and
potential recovery of vasomotor function and vessel remodeling.
These benefits would bemore pertinent in patients with calcific lesions,
who often have widespread disease resulting in long stented segments.
However whether these will translate into long term clinical benefits in
more complex lesions such as thosewith significant calcificationswould
Table 1C
Procedural characteristics of the study population.
BRS (L = 548) p value
Calcified lesions
(L = 200/36.5%)
Non calcified lesions
(L = 348/63.5%)
Number of treated lesions per procedure 1.24 ± 0.48 1.17 ± 0.48 0.133
Aspiration thrombectomy 34/200 (17.1) 106/348 (30.5) 0.001
Rotational atherectomy 11/200 (5.5) 0/348 0.002
Scoring balloon 9/200 (4.5) 1/348 (0.3) 0.001
Intracoronary imaging
IVUS 30/199 (15.1) 30/348 (8.6) 0.023
OCT 62/200 (31.0) 95/348 (27.3) 0.378
Predilation performed 177/200 (88.5) 265/348 (76.1) b0.001
Max predilation diameter 2.66 ± 0.36 2.53 ± 0.42 0.002
Predilation balloon: artery ratio 1.08 ± 0.25 1.01 ± 0.23 0.005
Maximum predilation inflation pressure, atm 14.25 ± 3.35 13.56 ± 3.01 0.067
Buddy wire 23/199 (11.6) 22/347 (6.3) 0.036
Additional daughter catheter 3/199 (1.5) 3/348 (0.9) 0.673
Mean number of scaffold 1.58 ± 0.823 1.21 ± 0.53 b0.001
Number of scaffolds (total 735) 315 420 b0.001
0 1/200 (0.5) 1/348 (0.3)
1 117/200 (58.5) 289/348 (83.0)
2 56/200 (28.0) 47/348 (13.5)
3 18/200 (9.0) 7/348 (2.0)
4 8/200 (4.0) 4/348 (1.1)
Scaffold diameter, mm 3.11 ± 0.32 3.12 ± 0.38 0.615
Scaffold length implanted, mm 34.65 ± 19.94 23.84 ± 12.20 b0.001
Overlapping scaffolds 80/200 (40.0) 52/348 (15.0) b0.001
Maximum scaffold implantation pressure, atm 14.99 ± 1.88 14.86 ± 1.97 0.510
Postdilation performed 129/199 (64.8) 146/347 (42.1) b0.001
Postdilation balloon: mean scaffold diameter ratio 1.06 ± 0.15 1.07 ± 0.10 0.422
Max postdilation balloon, mm 3.31 ± 0.43 3.31 ± 0.44 0.906
Maximum postdilation inflation pressure, atm 16.27 ± 3.63 15.83 ± 3.97 0.496
Values are expressed as numbers (percentages) or mean ± standard deviation when appropriate.
Fig. 1.A. Implantation of Bioresorbable vascular scaffold (BRS in calcified left anterior descending artery (LAD). Panel 1. Implantation of bioresorbable vascular scaffolds (two 3.0 × 28mm
Absorb™ BVS deployed in an overlapping manner-indicated in yellow) in a calcified left anterior descending artery (LAD). Calcification marked ‘+’ in Panel 1-1. Target lesion marked ‘*’
preprocedure (Panel 1-2), after predilationwith a 2.5mmballoon at (Panel 1-3) and after postdilationwith a noncompliant 3.0mmballoon at high pressure (Panel 1-4).Panel 2A–E: Final
OCT performed showed that the scaffold was well expanded and apposed with no significant dissection seen. Proximal and distal reference areas were 7.21 mm2 and 5.52 mm2
respectively. The minimal lumen area (MLA) was 4.5 mm2 (2.83 × 1.81 mm) with an eccentricity index (EI) of 0.63. Panel 2-A–C showed the corresponding segments of the treated
vessel in Panel 1-4. Panel 2-D showed the BRS implanted in a calcified segment of the treated vessel with satisfactory expansion with minimal eccentricity. Panel 2-E showed the
longitudinal pullback of the treated vessel. B. Angiogram and intravascular ultrasound (IVUS) of the right coronary artery (RCA). Angiogram and intravascular ultrasound (IVUS) of the
right coronary artery (RCA). Panel 1-A shows the preprocedural angiogram at baseline with a severely tight lesion (circled) in the mid segment of the RCA which is heavily calcified
(see insert). Panel 1-B shows the RCA post rotational artherectomy with 1.5 mm burr (see insert) and predilation with a Trek NC 3.25 mm balloon. Panel 1-C shows the RCA after
deployment of a BRS (BVS Absorb 3.0 × 28 mm - outlined in red). The borderline lesions in the ostium and mid right posterior descending artery (RPDA) was managed conservatively
(white arrow). Panel 1-D shows the RCA at 2 years follow up which demonstrates that the previously deployed scaffold in the mid RCA was still widely patent with no significant
restenosis (outlined red). C. IVUS images of the RCA. The figure shows IVUS images of the corresponding segments of the RCA in Fig. 1B Panel 1-D at 2 years follow up demonstrating
that the scaffold struts (white arrow) remained visible in the mid RCA with good apposition and expansion with side branch (*-RPDA) patency and confirmed the scaffolded vessel
remained widely patent with no significant restenosis (Panels 2-1 and 2-2). + - Guidewire.
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figure 1c IVUS images of the RCA. 
The figure shows IVUS images of the corresponding segments of the RCA in Fig. 1B Panel 1-D at 2 years fol-
low up demonstrating that the scaffold struts (white arrow) remained visible in the mid RCA with good ap-
position and expansion with side branch (*-RPDA) patency and confirmed the scaffolded vessel remained 
widely patent with no significant restenosis (Panels 2-1 and 2-2). + - Guidewire.
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We were able to obtain written consent for the follow up program in 395 patients 
(86.8%). Clinical outcomes were available in all (100%) of these patients. (Table 2B). 
These patient had similar baseline and procedural characteristics as the total popula-
tion. Kaplan-Meier curves for MACE were parallel throughout the follow-up to two year 
(Figure 2A). Crude cumulative event rates at two years for the secondary endpoints, de-
scribed as Kaplan-Meier estimates are as shown in Table 2B. There was a slight trend for 
higher events on cardiac death and all-cause mortality for patients with calcified lesions. 
No difference was observed in POCE and DOCE. Though definite ST rates were similar 
between the two groups (Figure 2B), there was a remarkable variation in acute and late 
definite ST. For acute definite ST, the incidence was higher in the non-Ca lesions; for late 
definite ST there was a significant increase in Ca group compared to non-Ca group (Late 
ST: 2.1% vs 0, p=0.02) but not for very late ST (Table 2B). After adjusting for difference 
in baseline characteristics, Ca lesions was not found to be a significant predictor of any 
clinical events (Table 3C).
table 2a Procedural Outcomes
BRS (L = 548)
Calcified Lesions
 (L=200/36.5% )
Non-Calcified Lesions
(L=348/63.5%)
P value
TIMI post-procedure 0.850
TIMI 0 0 0
TIMI 1 1/200 (0.5) 2/348 (0.6)
TIMI 2 12/200 (6.0) 17/348 (4.9)
TIMI 3 187/200 (93.5) 329/348 (94.5)
QCA analysis post-procedure
RVD (mm) 2.75±0.48 2.78±0.45 0.401
MLD (mm) 2.28± 0.41 2.36±0.43 0.046
Diameter stenosis (%) 16.71±8.89 15.30±8.61 0.069
Acute lumen gain 1.50±0.66 1.62±0.69 0.040
Procedural outcomes
Device success 197/200 (98.5) 346/348 (99.4) 0.208
Bailout by scaffold 6/200 (3.0) 5/348 (1.4) 0.439
Bailout by metallic stent 4/200 (2.0) 5/348 (1.4) 0.547
Intra-procedural thrombosis 1/200 (0.5) 1/348 (0.3) 1.000
Significant dissection 14/200 (7.0) 16/348 (4.6) 0.444
Significant no reflow/ slow flow 9/200 (4.5) 9/348 (2.6) 0.272
MLD minimal lumen diameter; RVD reference vessel diameter. Values are expressed as numbers (percent-
ages) or mean ± standard deviation when appropriate.
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table 2b Clinical endpoints at two years, described as Kaplan-Meier estimates
Calc (n=143) No-calc (n=252) P value
MACE (%) 11.7 (17) 8.0 (19) 0.351
DOCE (%) 9.0 (12) 7.3 (17) 0.564
Cardiac death (%) 3.8 (5) 0.8 (2) 0.052
Target Vessel MI 5.3 (7) 5.1 (12) 0.945
Clinically indicated TLR (%) 4.7 (6) 5.9 (14) 0.544
Definite ST (%) 2.1 (3) 2.4 (6) 0.856
Acute 0.0 1.2 (3) 0.191
Subacute 0.0 0.4 (1) 0.450
Late 2.1 (3) 0.0 0.020
Very late 0.0 0.8 (2) 0.287
Probable ST (%) 0.7 (1) 0.4 (1) 0.682
Acute
Subacute
Late
Very late
0.0 0.0
0.0 0.0
0.7 (1) 0.4 (1) 0.682
0.0 0.0
Definite/ Probable ST (%) 2.9 (4) 2.8 (7) 0.993
Acute
Subacute
Late
Very late
0.0 1.2 (3) 0.191
0.0 0.4 (1) 0.450
2.9 (4) 0.4 (1) 0.039
0.0 0.8 (2) 0.287
POCE (%) 12.2 (23) 17.2 (29) 0.211
All-cause mortality (%) 3.8 (6) 0.8 (3) 0.052
Any revascularization 12.2 (16) 10.3 (25) 0.714
TVR (%) 5.3 (7) 6.5 (16) 0.544
Non-TVR (%) 7.7 (10) 4.7 (11) 0.260
All cause MI (%) 8.3 (11) 6.5 (15) 0.509
DOCE device oriented composite endpoints (Composite of cardiac death, target vessel myocardial infarct 
and clinically indicated target lesion revascularization); POCE patient oriented composite endpoints (Com-
posite of all- cause mortality, all cause myocardial infarct and any revascularization). (Number of composite 
endpoints does not add up as any patient may have multiple events.)
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studies may be required to evaluate if a prolonged duration of DAPT
may reduce late onset ST in calcified lesions.
5. Conclusion
Careful more elaborate lesion preparation and the use of dedicated
devices, such as scoring balloons and rotational atherectomy and
intracoronary imaging were more likely encountered in Ca lesions.
Even after more lesion preparation, acute gain and resulting final MLD
by BRS implantation was less compared to non-calcified lesion. Clinical
outcomes of calcified and non-calcified lesions treated with BRS were
otherwise similar. However this is accomplished in the setting of appro-
priate case selection, adequate lesion preparation and scaffold optimiza-
tion with attention to an adequate duration of dual antiplatelet in line
with guideline recommendations. Interestingly, a different pattern of
timing of ST was observed with no early ST but an increased late ST
rate when implanted in calcified lesions.
Table 2B
Clinical endpoints at two years, described as Kaplan-Meier estimates.
Ca (n = 143) Non-Ca (n = 252) p value
MACE (%) 11.7 (17) 8.0 (19) 0.351
DOCE (%) 9.0 (12) 7.3 (17) 0.564
Cardiac death (%) 3.8 (5) 0.8 (2) 0.052
Target vessel MI 5.3 (7) 5.1 (12) 0.945
Clinically indicated TLR (%) 4.7 (6) 5.9 (14) 0.544
Definite ST (%) 2.1 (3) 2.4 (6) 0.856
Acute 0.0 1.2 (3) 0.191
Subacute 0.0 0.4 (1) 0.450
Late 2.1 (3) 0.0 0.020
Very late 0.0 0.8 (2) 0.287
Probable ST (%) 0.7 (1) 0.4 (1) 0.682
Acute 0.0 0.0
Subacute 0.0 0.0
Late 0.7 (1) 0.4 (1) 0.682
Very late 0.0 0.0
Definite/probable ST (%) 2.9 (4) 2.8 (7) 0.993
Acute 0.0 1.2 (3) 0.191
Subacute 0.0 0.4 (1) 0.450
Late 2.9 (4) 0.4 (1) 0.039
Very late 0.0 0.8 (2) 0.287
POCE (%) 12.2 (23) 17.2 (29) 0.211
All-cause mortality (%) 3.8 (6) 0.8 (3) 0.052
Any revascularization 12.2 (16) 10.3 (25) 0.714
TVR (%) 5.3 (7) 6.5 (16) 0.544
Non-TVR (%) 7.7 (10) 4.7 (11) 0.260
All cause MI (%) 8.3 (11) 6.5 (15) 0.509
DOCE: device oriented composite endpoints (composite of cardiac death, target vessel
myocardial infarct and clinically indicated target lesion revascularization); POCE: patient
oriented composite endpoints (composite of all - cause mortality, all cause myocardial
infarct and any revascularization). (Number of composite endpoints does not add up as
any patient may have multiple events.) Ca - calcified lesions; non-Ca - non calcified lesions.
Fig. 2. Kaplan-Meier curve showing no significant difference in A) MACE and B) definite ST at 2 years in patients with calcified (Ca) and non-calcified (non-Ca) lesions treated with
bioresorbable vascular scaffolds (BRS). The primary endpoint was major adverse cardiovascular events (MACE), defined as the composite endpoint of cardiac death, myocardial
infarction (MI) and target lesion revascularization (TLR). Of note while the incidence of acute ST was higher in the non-Ca group compared to Ca group, there was a significant
increase in late ST in calcified lesions compared to non-Ca lesions. ST - scaffold thrombosis.
Table 2C
Predictors for clinical outcomes at two years follow-up (using Cox regression), calcified vs
non-calcified lesions.
Unadjusted HR (95% CI) p-Value Adjusteda HR (95% CI) p value
All-cause death
Ca vs non-Ca 4.428 (0.859–22.822) 0.075 1.7 (0.263–10.994) 0.578
Cardiac death
Ca vs non-Ca 4.428 (0.859–22.822) 0.075 1.7 (0.263–10.994) 0.578
MACE
Ca vs non-Ca 1.378 (0.700–2.712) 0.353 0.850 (0.382–1.895) 0.692
MI
Ca vs non-Ca 1.393 (0.632–3.068) 0.411 0.944 (0.366–2.433) 0.905
TLR
Ca vs non-Ca 0.754 (0.290–1.963) 0.564 0.644 (0.225–1.845) 0.644
TVR
Ca vs non-Ca 0.762 (0.314–1.853) 0.549 0.629 (0.236–1.674) 0.353
Non-TVR
Ca vs non-Ca 1.627 (0.691–3.831) 0.265 0.950 (0.342–2.634) 0.921
Definite ST
Ca vs non-Ca 0.880 (0.220–3.518) 0.856 0.930 (0.206–4.234) 0.930
Probable ST
Ca vs non-Ca 1.771 (0.111–28.307) 0.686 0.917 (0.039–21.720) 0.957
Def/prob ST
Ca vs non-Ca 1.005 (0.294–3.434) 0.993 0.935(0.242–3.610) 0.922
DOCE
Ca vs non-Ca 1.242 (0.593–2.600) 0.566 0.961 (0.416–2.218) 0.926
POCE
Ca vs non-Ca 1.416 (0.819–2.448) 0.213 1.045 (0.556–1.963) 0.891
To account for baseline differences between patients with at least 1 moderately or
heavily calcified lesion (Ca) andpatientswith no/mild calcified lesions (non-Ca), covariate
adjustment using fourteen patient and lesion factors were used (see Online Supplement).
a Adjusted for gender, age, presentation with ACS, multivessel disease, diabetes
mellitus, dyslipidemia, smoking, hypertension, peripheral artery disease, small vessel,
bifurcation, average scaffold diameter per patient, total scaffold length per patient. DOCE:
device oriented composite endpoints (composite of cardiac death, target vesselmyocardi-
al infarct and clinically indicated target lesion revascularization); POCE: patient oriented
composite endpoints (composite of all - cause mortality, all cause myocardial infarct and
any revascularization). (Number of composite endpoints does not add up as any patient
may have multiple events.) Ca - calcified lesions; non-Ca - non calcified lesions; MACE -
major adverse cardiovascular events; MI - myocardial infarct; TLR - target lesion revascu-
larization; TVR - target vessel revascularization; ST - scaffold thrombosis.
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studies may be required to evaluate if a prolonged duration of DAPT
may reduce late onset ST in calcified lesions.
5. Conclusion
Careful more elaborate lesion preparation and the use of dedicated
devices, such as scoring balloons and rotational atherectomy and
intracoronary imaging were more likely encountered in Ca lesions.
Even after more lesion preparation, acute gain and resulting final MLD
by BRS implantation was less compared to non-calcified lesion. Clinical
outcomes of calcified and non-calcified lesions treated with BRS were
otherwise similar. However this is accomplished in the setting of appro-
priate case selection, adequate lesion preparation and scaffold optimiza-
tion with attention to an adequate duration of dual antiplatelet in line
with guideline recommendations. Interestingly, a different pattern of
timing of ST was observed with no early ST but an increased late ST
rate when implanted in calcified lesions.
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Acute 0.0 1.2 (3) 0.191
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Late 2.1 (3) 0.0 0.020
Very late 0.0 0.8 (2) 0.287
Probable ST (%) 0.7 (1) 0.4 (1) 0.682
Acute 0.0 0.0
Subacute 0.0 0.0
Late 0.7 (1) 0.4 (1) 0.682
Very late 0.0 0.0
Definite/probable ST (%) 2.9 (4) 2.8 (7) 0.993
Acute 0.0 1.2 (3) 0.191
Subacute 0.0 0.4 (1) 0.450
Late 2.9 (4) 0.4 (1) 0.039
Very late 0.0 0.8 (2) 0.287
POCE (%) 12.2 (23) 17.2 (29) 0.211
All-cause mortality (%) 3.8 (6) 0.8 (3) 0.052
Any revascularization 12.2 (16) 10.3 (25) 0.714
TVR (%) 5.3 (7) 6.5 (16) 0.544
Non-TVR (%) 7.7 (10) 4.7 (11) 0.260
All cause MI (%) 8.3 (11) 6.5 (15) 0.509
DOCE: device oriented composite endpoints (composite of cardiac death, target vessel
myocardial infarct and clinically indicated target lesion revascularization); POCE: patient
oriented composite endpoints (composite of all - cause mortality, all cause myocardial
infarct and any revascularization). (Number of composite endpoints does not add up as
any patient may have multiple events.) Ca - calcified lesions; non-Ca - non calcified lesions.
Fig. 2. Kaplan-Meier curve showing no significant difference in A) MACE and B) definite ST at 2 years in patients with calcified (Ca) and non-calcified (non-Ca) lesions treated with
bioresorbable vascular scaffolds (BRS). The primary endpoint was major adverse cardiovascular events (MACE), defined as the composite endpoint of cardiac death, myocardial
infarction (MI) and target lesion revascularization (TLR). Of note while the incidence of acute ST was higher in the non-Ca group compared to Ca group, there was a significant
increase in late ST in calcified lesions compared to non-Ca lesions. ST - scaffold thrombosis.
Table 2C
Predictors for clinical outcomes at two years follow-up (using Cox regression), calcified vs
non-calcified lesions.
Unadjusted HR (95% CI) p-Value Adjusteda HR (95% CI) p value
All-cause death
Ca vs non-Ca 4.428 (0.859–22.822) 0.075 1.7 (0.263–10.994) 0.578
Cardiac death
Ca vs non-Ca 4.428 (0.859–22.822) 0.075 1.7 (0.263–10.994) 0.578
MACE
Ca vs non-Ca 1.378 (0.700–2.712) 0.353 0.850 ( .382–1.895) 0.692
MI
Ca vs non-Ca 1.393 (0.632–3.068) 0.411 0.944 (0.366–2.433) 0.905
TLR
Ca vs non-Ca 0.754 (0.290–1.963) 0.564 0.644 (0.225–1.845) 0.644
TVR
Ca vs non-Ca 0.762 (0.314–1.853) 0.549 0.629 (0.236–1.674) 0.353
Non-TVR
Ca vs non-Ca 1.627 (0.691–3.831) 0.265 0.950 (0.342–2.634) 0.921
Definite ST
Ca vs non-Ca 0.880 (0.220–3.518) 0.856 0.930 (0.206–4.234) 0.930
Probable ST
Ca vs non-Ca 1.771 (0.111–28.307) 0.686 0.917 (0.039–21.720) 0.957
Def/prob ST
Ca vs non-Ca 1.005 (0.294–3.434) 0.993 0.935(0.242–3.610) 0.922
DOCE
Ca vs non-Ca 1.242 (0.593–2.600) 0.566 0.961 (0.416–2.218) 0.926
POCE
Ca vs non-Ca 1.416 (0.819–2.448) 0.213 1.045 (0.556–1.963) 0.891
To account for baseline differences between patients with at least 1 moderately or
heavily calcified lesion (Ca) andpatientswith no/mild calcified lesions (non-Ca), covariate
adjustment using fourteen patient and lesion factors were used (see Online Supplement).
a Adjusted for gender, age, presentation with ACS, multivessel disease, diabetes
mellitus, dyslipidemia, smoking, hypertension, peripheral artery disease, small vessel,
bifurcation, average scaffold diameter per patient, total scaffold length per patient. DOCE:
device oriented composite endpoints (composite of cardiac death, target vesselmyocardi-
al infarct and clinically indicated target lesion revascularization); POCE: patient oriented
composite endpoints (composite of all - cause mortality, all cause myocardial infarct and
any revascularization). (Number of composite endpoints does not add up as any patient
may have multiple events.) Ca - calcified lesions; non-Ca - non calcified lesions; MACE -
major adverse cardiovascular events; MI - myocardial infarct; TLR - target lesion revascu-
larization; TVR - target vessel revascularization; ST - scaffold thrombosis.
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figure 2 Kaplan-Meier curve showing no significant difference in A) MACE and B) definite ST at 2 years in 
patients with calcified (Ca) and non-calcified (non-Ca) lesions treated with bioresorbable vascular scaffolds 
(BRS). 
The primary endpoint was major adverse cardiovascular events (MACE), defined as the composite endpoint 
of cardiac death, myocardial infarction (MI) and target lesion revascularization (TLR). Of note while the inci-
dence of acute ST was higher in the non-Ca group compared to Ca group, there was a significant increase 
in late ST in calcified lesions compared to non-Ca lesions. ST- Scaffold thrombosis.
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Discussion
In our study, the key finding was that despite Ca lesions were more complex, required 
more lesion preparation, and encountered more deliverability issues with lower acute 
luminal gain and smaller final MLD, acute procedural and 24 month clinical outcomes 
were similar regardless of the calcification group with the exception of a higher rate of 
late ST at 2 years in the Ca group compared to non-Ca group.  While there have been 
earlier studies evaluating the use of BRS in calcified lesions.  [16-18], this is the first large 
clinical prospective registry study involving BRS scaffolds that look at the impact of le-
sion calcification on long term clinical outcomes at 2 years.
table 2c Predictors for clinical outcomes at two years follow-up (using Cox regression), calc vs no calc
Unadjusted HR (95% CI) p-value Adjusted* HR(95% CI) p value
All-cause death
Calc vs non-calc 4.428 (0.859 – 22.822) 0.075 1.7 (0.263 – 10.994) 0.578
Cardiac death
Calc vs non-calc 4.428 (0.859 – 22.822) 0.075 1.7 (0.263 – 10.994) 0.578
MACE
Calc vs non-calc 1.378 (0.700 – 2.712) 0.353 0.850 (0.382 – 1.895) 0.692
MI
Calc vs non-calc 1.393 (0.632 – 3.068) 0.411 0.944 ( 0.366 – 2.433) 0.905
TLR
Calc vs non-calc 0.754 (0.290 – 1.963) 0.564 0.644 (0.225 – 1.845) 0.644
TVR
Calc vs non-calc 0.762 (0.314 – 1.853) 0.549 0.629 ( 0.236 – 1.674) 0.353
Non-TVR
Calc vs non-calc 1.627 (0.691 – 3.831) 0.265 0.950 (0.342 – 2.634) 0.921
Definite ScT
Calc vs non-calc 0.880 (0.220 – 3.518) 0.856 0.930 (0.206 – 4.234) 0.930
Probable ScT
Calc vs non-calc 1.771 (0.111 – 28.307) 0.686 0.917 (0.039 -21.720) 0.957
Def/ Prob ScT
Calc vs non-calc 1.005 (0.294 – 3.434) 0.993 0.935(0.242- 3.610) 0.922
DOCE
Calc vs non-calc 1.242 (0.593 – 2.600) 0.566 0.961 (0.416-  2.218) 0.926
POCE
Calc vs non-calc 1.416 (0.819 – 2.448) 0.213 1.045 (0.556 – 1.963) 0.891
*Adjusted for gender, age, presentation with ACS, multivessel disease, diabetes mellitus, dyslipidemia, 
smoking, hypertension, peripheral artery disease, small vessel, bifurcation, average scaffold diameter per 
patient, total scaffold length per patient (See Data supplement for tabulation of propensity score).
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Our findings,  which showed that Ca lesions were more complex and required more 
careful and elaborate lesion preparation including rotational atherectomy (in 5.5% of 
the lesions), were consistent with similar findings published elsewhere [9, 19]. The use 
of intracoronary imaging like IVUS was also increased in Ca lesions compared to non Ca 
lesions. The more frequent use of buddy wires in the Ca group suggested that difficult 
deliverability issues may be encountered more commonly in Ca lesions thus potentially 
prolonging procedure times. Despite the advances in interventional techniques, cal-
cific lesions still pose a challenge for the procedurist. Due to their inherent polymeric 
structural composition and increased strut thickness, BRS have been shown to have less 
favourable mechanical characteristics including less deliverability and radial strength 
compared to current second generation DES [19-20]. There have been concerns as to 
whether such mechanical characteristics may result in less optimal stent performance 
which may be more pronounced in calcified lesions where focal areas of calcification 
limit expansion of the BRS more compared to DES [19]. This may have practical clinical 
implications since suboptimal stent expansions has been known to contribute to metal-
lic stent failure [21] and there have been reports of inadequate scaffold expansion in BRS 
failure [22-3]. 
Our findings are also consistent with clinical [24-5] data addressing the feasibility of 
BRS in calcified lesions. In a recent study looking at specific procedural outcomes in 62 
calcified lesions by Panoulas et al [24], expansion of BRS as measured in terms of lu-
men gain on QCA and intravascular ultrasound (IVUS) was similar between calcified and 
non-calcified lesions. Acute luminal gain (1.83±0.6 vs. 1.86±0.6mm, p=0.732) and angio-
graphic success were similar (98% non-calcific vs. 95.2% calcific, p=0.369), whereas pro-
cedural success was reduced in patients with calcific lesions (94.1% vs. 83.9%, p=0.034) 
due to higher rates of periprocedural myocardial infarction (MI) (5% vs. 13.1%, p=0.067). 
MACE rates (10.9% non-calcific vs. 12.9% calcific, p log-rank=0.546) were similar in the 
median follow-up time of 14 months. However a greater degree of lesion preparation in 
calcified lesions was also required. OCT was not used and a comparison of the expansion 
of BRS compared with DES was not performed. In our study, we report 2 year clinical 
outcomes in a larger study population which showed MACE rates were similar between 
Ca and non-Ca groups. In another study conducted by Kawamoto et al [25], though 
eccentric calcium distribution resulted in asymmetric expansion of BRS, the final MSA 
was still comparable irrespective of calcium distribution, and the use of IVUS for scaffold 
optimization led to favorable clinical outcomes even in calcified lesions. Earlier OCT 
findings published from our centre [26] also suggest that regardless of the degree of 
angiographic calcification, BRS can achieve a similar expansion as DES, in the context of 
an imaging-guided strategy with adequate lesion preparation. Our findings were also 
consistent with recent published literature showing that the presence of moderate or 
severe lesion calcification does not negatively affect angiographic outcomes at both 
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post-procedure and 13-month follow-up after BVS implantation [27]. However, in this 
study [27], heavily calcified lesions or those requiring extensive lesion preparation such 
as rotational atherectomy were excluded according to the study protocol wheras our 
study included “all comers” lesions with various degrees of calcification or that require 
rotational atherectomy.
However, BRS deployment requires more lesion preparation and decalcification strat-
egy particularly for moderately or heavily calcified lesions. Further studies are needed 
to ascertain if in such lesions the use of such a strategy may impact on long term clinical 
outcomes such as increased TLR rates such as seen in DES deployment after lesion deb-
ulking or decalcification using rotational atherectomy [28, 29]. In addition, the postdila-
tion rate reported in our study (Table 1C) was comparable to other studies considering 
that systematic postdilation was implemented on average in less than 50% of previously 
published studies [30]. It is still debatable if pursuing a systematic postdilation strategy 
will have an impact on long term results particularly the risk of very late ST (VLST). Given 
the results of this study, an analysis of BRS specific implantation technique such as 
PSP (Prepare the lesion to be reengineered; Size the vessel appropriately; Postdilate to 
embed scaffold struts into the vessel wall) would be timely and of interest [31].Though 
the lesions treated in the Ca group were more complex, requiring  longer and more 
overlapping scaffolds and the post dilatation rate of 64.8% was considered relatively low 
for calcific lesions, the procedural and clinical results were still similar between the Ca 
and non Ca groups. This may be reassuring since the current practice suggest a large use 
of postdilation especially in stable patients with complex lesions.
BRS offers several unique potential advantages over DES. The future bioresorption of 
BRS permits potential future grafting of treated segments, allows potential reopening of 
“jailed” side branches and potential recovery of vasomotor function and vessel remodel-
ing. These benefits would be more pertinent in patients with calcific lesions, who often 
have widespread disease resulting in long stented segments. However whether these 
will translate into long term clinical benefits in more complex lesions such as those with 
significant calcifications would still require further evaluation. Previous studies have 
highlighted a higher rate of ST related to the use of BRS [4, 32-34], but did not provide 
details on the effect of calcification. In our study, we see an observation pattern of 
higher early ST cases in the non-Ca group followed by a significantly higher rate of late 
ST in the Ca group. To the best of our knowledge, we believe the difference in timing on 
ST observed in the two groups is notable and interesting which warrant further studies. 
The observation of early ST in the non-Ca group (a group with a higher number of acute 
coronary syndromes; ACS) patients might be related to scaffold under sizing and to 
increased platelets activation. Predisposing factors of scaffold undersizing include the 
increased thrombus burden and vasoconstriction in the setting of acute STEMI leading 
to underestimation of the actual size of the infarct-related artery, thus increasing the 
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risk of the implantation of undersized scaffolds which can be seen even in the setting of 
metallic drug eluting stents [35]. Implantation of a relatively small scaffold in a relatively 
larger vessel can result in incomplete apposition, predisposing to ST [36]. Higher rates 
of ST were also previously noted in patients with ACS which could be due to reduction 
of early neointimal growth and strut coverage [37, 38]. Reasons for the increase in late 
ST in the Ca compared to the non Ca group include a role for technical factors such 
as suboptimal implantation with incomplete lesion coverage, underexpansion and 
malapposition [36, 39] and possibly greater impact on the scaffold endothelization and 
resorption process from a reduced MLD in the Ca group. The additional risks of late ST in 
the Ca lesions may arise from either the loss of radial strength after scaffold resorption 
(which typically commences 6 months to more than 1 year after scaffold implantation) 
or the scaffold ‘dismantling’ around calcified lesions which will have forces localized at 
the edge of the calcified areas where expansion tends to be asymmetrical [25].  Scaffold 
‘dismantling’ might result in rapid changes in vessel wall architecture and therefore exert 
localized forces on the neo-intimal coverage potentially resulting in microdissections, 
triggering the thrombosis. 
In our current study, though the event rate is similar between the Ca and non Ca 
groups, this may also be partially attributed to a higher ACS population in the non Ca 
group which is known to have higher risk of clinical events at follow up. In an earlier study 
evaluating the one-year outcomes in patients presenting with ACS compared to stable 
angina patients after implantation of a BRS from our centre, one-year clinical outcomes 
in ACS patients treated with BRS were similar to non-ACS patients. One-year definite 
ST rate was comparable: 2.0% for ACS population versus 2.1% for stable population 
(P=0.94), however, early ST occurred only in ACS patients [40]. Comparatively, overall 
ST rates were similar between the two groups in this study and further analysis did not 
show that Ca lesions were a significant predictor of ST (Table 2C). Of note, there was no 
difference in VLST between the Ca and non-Ca groups. 
Though recent guidelines have supported a shift towards a shorter duration of DAPT 
[41], our findings on an increased late ST rate in Ca lesions may suggest that a longer 
duration of DAPT may still be necessary if BRS is to be implanted before the patient is 
to derive the potential benefits of BRS resorption. In our study, data on the use of dual 
antiplatelets therapy (DAPT) were available in the 395 patients whose follow up were 
available. All patients were prescribed aspirin during the duration of the study. Second 
generation P2Y12 antiplatelet medications were used; clopidogrel (n=157, 39.7%), pra-
sugrel (n=187, 47.3%) and ticagrelor (n=51, 12.9%). The median duration of DAPT was 
365.00 (IQR 364.00 - 394.50) days and was similar between the 2 groups. In a study to 
evaluate the impact of DAPT termination on late and very late ST in patients treated 
with the Absorb BRS, the incidence of ST was low while on DAPT but potentially higher 
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when DAPT was terminated before 18 months [42, 43]. Further studies may be required 
to evaluate the effect of a prolonged duration of DAPT on the rate of late ST. 
The findings showing a lesser acute lumen gain and similar 2 year MACE were con-
sistent with previous research involving metallic DES in calcified versus non calcified 
lesions [8]. Moussa et al reported in a subanalysis of the TAXUS IV trial [8] a signifi cant re-
duction in late lumen loss in calcific lesions (n=247) treated with PES vs. BMS (0.26±0.56 
vs. 0.51±0.48 mm, p=0.015). In a study from the SPIRIT II trial by Onuma et al [44], the 
efficacy of EES in patients with at least one angiographically defined moderate calcific 
lesion (68 patients), was compared to those without any calcific lesion (144 patients). 
Late lumen loss was similar between the two groups at two years. No significant differ-
ence in two-year MACE rates was observed between the two groups (calcific vs. non-
calcific: 10.9% vs. 4.4%, p=0.12). The numerically increased MACE rate was attributed 
to an increased ischaemia-driven TLR (7.8% vs. 1.5%, p=0.03). However TLR rates were 
similar between the Ca and non Ca groups in our study. 
In summary, clinical outcomes of calcified and non-calcified lesions treated with BRS 
are in general similar except for late ST. Overall two-year MACE rates appear acceptable 
in patients with and without calcific lesions treated with BRS. Further larger randomized 
controlled trials comparing clinical outcomes of DES to BRS in calcified lesions may be 
required to evaluate the full impact of calcium on BRS outcomes compared to DES.
stuDy limitations
This is a single-center, single-arm registry with no direct comparison with metallic DES. 
The total number of patients in this study was still limited. In addition, calcification 
assessment was based on angiographic classification alone rather than characteriza-
tion of coronary calcification using alternative imaging modality such as intravascular 
ultrasound. Thus, these findings warrant further confirmation in a large-scale trial. Fur-
thermore, deciding which patient or lesion was suitable for treatment with BRS could 
have resulted in selection bias. The event rate is unknown in the patients (n= 60, 13.2%) 
who did not agree to participate in further follow up and hence excluded from clinical 
outcome analysis. We further evaluated the population who did not agree to further 
follow up and compared the baseline demographic, lesion and procedural characteris-
tics between the cases with calcified lesions and non- calcified lesions. There were sig-
nificant differences in terms of age and use of predilation between the 2 groups which 
were similarly observed in the main population. Overall, the results are similar which 
provide support to our inference that the clinical outcomes reported in our study may 
be extrapolated to the patients whose clinical outcomes were not available.  In addition, 
as our study was not powered to study clinical outcomes in relation to DAPT, we believe 
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that further studies may be required to evaluate if a prolonged duration of DAPT may 
reduce late onset ST in calcified lesions. 
conclusion
Careful more elaborate lesion preparation and the use of dedicated devices, such as 
scoring balloons and rotational atherectomy and intracoronary imaging were more 
likely encountered in Ca lesions.  Even after more lesion preparation, acute gain and re-
sulting final MLD by BRS implantation was less compared to non-calcified lesion. Clinical 
outcomes of calcified and non-calcified lesions treated with BRS were otherwise similar. 
However this is accomplished in the setting of appropriate case selection, adequate 
lesion preparation and scaffold optimization with attention to an adequate duration 
of dual antiplatelet in line with guideline recommendations. Interestingly, a different 
pattern of timing of ST was observed with no early ST but an increased late ST rate when 
implanted in calcified lesions.  
clinical Perspectives 
Data on the impact of calcium (Ca) on outcomes in patients with lesions treated with 
bioresorbable vascular scaffolds (BRS) is limited, particularly in a “real world” study popu-
lation. Careful more elaborate lesion preparation and the use of dedicated devices, such 
as scoring balloons and rotational atherectomy and intracoronary imaging were more 
likely encountered in Ca lesions.  Late ST was more frequent in the Ca group compared 
to non-Ca group and no difference for VLST was observed. The findings merit further 
evaluation of clinical outcomes of BRS and the impact of implantation techniques in 
complex calcified lesions. 
196 Chapter 9
references
 1.  Simsek C, Karanasos A, Magro M, Garcia-Garcia HM, Onuma Y, Regar E, Boersma E, Serruys PW, 
van Geuns RJ.  Long-term invasive follow-up of the everolimus-eluting bioresorbable vascular 
scaffold: five-year results of multiple invasive imaging modalities. EuroIntervention. 2014 Oct 28. 
doi: 10.4244/EIJY14M10_12. [Epub ahead of print]
 2.  Karanasos A, Simsek C, Gnanadesigan M, van Ditzhuijzen NS, Freire R, Dijkstra J, Tu S, Van Mieghem 
N, van Soest G, de Jaegere P, Serruys PW, Zijlstra F, van Geuns RJ, Regar E.  OCT assessment of 
the long-term vascular healing response 5 years after everolimus-eluting bioresorbable vascular 
scaffold. J Am Coll Cardiol. 2014 Dec 9;64(22):2343-56
 3.  Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining 
N, Dorange C, Miquel-Hébert K, Veldhof S, Webster M, Thuesen L, Dudek D. A bioabsorbable 
everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple 
imaging methods. Lancet 2009;373:897–910.
 4.  Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, 
Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C, Stone GW; ABSORB III Investigators. 
Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.N Engl J Med. 2015 Nov 
12;373(20):1905-15. doi: 10.1056/NEJMoa1509038. Epub 2015 Oct 12.
 5.  Gao R, Yang Y, Han Y, Huo Y, Chen J, Yu B, Su X, Li L, Kuo HC, Ying SW, Cheong WF, Zhang Y, Su X, 
Xu B, Popma JJ, Stone GW. ABSORB China Investigators. Bioresorbable Vascular Scaffolds Versus 
Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial. J Am Coll Cardiol. 
2015 Dec 1;66(21):2298-309. doi: 10.1016/j.jacc.2015.09.054. Epub 2015 Oct 12.
 6.  Kimura T, Kozuma K, Tanabe K, Nakamura S, Yamane M, Muramatsu T, Saito S, Yajima J, Hagiwara 
N, Mitsudo K, Popma JJ, Serruys PW, Onuma Y, Ying S, Cao S, Staehr P, Cheong WF, Kusano H, 
Stone GW. ABSORB Japan Investigators. A randomized trial evaluating everolimus-eluting Absorb 
bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery 
disease: ABSORB Japan. Eur Heart J. 2015 Dec 14;36(47):3332-42. doi: 10.1093/eurheartj/ehv435. 
Epub 2015 Sep 1.
 7.  Kawaguchi R, Tsurugaya H, Hoshizaki H, Toyama T, Oshima S, Taniguchi K. Impact of lesion 
calcification on clinical and angiographic outcome after sirolimus-eluting stent implantation in 
real-world patients. Cardiovasc Revasc Med. 2008;9:2-8. 
 8.  Moussa I, Ellis SG, Jones M, Kereiakes DJ, McMartin D, Rutherford B, Mehran R, Collins M, Leon MB, 
Popma JJ, Russell ME, Stone GW. Impact of coronary culprit lesion calcium in patients undergoing 
paclitaxel-eluting stent implantation (a TAXUS-IV sub study). Am J Cardiol. 2005;96:1242-7.
 9.  Bourantas CV, Zhang YJ, Garg S, Iqbal J, Valgimigli M, Windecker S, Mohr FW, Silber S, Vries 
Td, Onuma Y, Garcia-Garcia HM, Morel MA, Serruys PW. Prognostic implications of coronary 
calcification in patients with obstructive coronary artery disease treated by percutaneous 
coronary intervention: a patient-level pooled analysis of 7 contemporary stent trials. Heart. 2014 
Aug;100(15):1158-64.
 10.  de Jaegere P, Mudra H, Figulla H, Almagor Y, Doucet S, Penn I, Colombo A, Hamm C, Bartorelli A, 
Rothman M, Nobuyoshi M, Yamaguchi T, Voudris V, DiMario C, Makovski S, Hausmann D, Rowe S, 
Rabinovich S, Sunamura M, van Es GA. Intravascular ultrasound-guided optimized stent deploy-
ment. Immediate and 6 months clinical and angiographic results from the multicenter ultrasound 
stenting in coronaries study (MUSIC Study). Eur Heart J 1998;19:1214–1223
 11.  Otake H, Shite J, Ako J, Shinke T, Tanino Y, Ogasawara D, Sawada T, Miyoshi N, Kato H, Koo BK, 
Honda Y, Fitzgerald PJ, Hirata K. Local determinants of thrombus formation following sirolimus-
Impact of calcium on procedural and clinical outcomes in lesions treated with BVS 197
9
eluting stent implantation assessed by optical coherence tomography. J Am Coll Cardiol Intv 
2009;2: 459–66.
 12.  Diletti R, Karanasos A, Muramatsu T, Nakatani S, Van Mieghem NM, Onuma Y, Nauta ST, Ishibashi 
Y, Lenzen MJ, Ligthart J, Schultz C, Regar E, de Jaegere PP, Serruys PW, Zijlstra F, van Geuns RJ. 
Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-
segment elevation myocardial infarction: BVS STEMI first study. Eur Heart J. 2014 Mar;35(12):777-
86. doi: 10.1093/eurheartj/eht546. Epub 2014 Jan 6.
 13.  Felix CM, Fam JM, Diletti R, Ishibashi Y, Karanasos A, Everaert BR, van Mieghem NM, Daemen J, 
de Jaegere PP, Zijlstra F, Regar ES, Onuma Y, van Geuns R. Mid- to Long-Term Clinical Outcomes 
of Patients Treated With the Everolimus-Eluting Bioresorbable Vascular Scaffold: The BVS Expand 
Registry. JACC Cardiovasc Interv. 2016 Aug 22;9(16):1652-63. doi: 10.1016/j.jcin.2016.04.035. 
Epub 2016 Jul 27.
 14.  Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in 
coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-51.
 15.  Cortese B, Ielasi A, Romagnoli E, Varricchio A, Cuculo A, Loi B, Pisano F, Corrado D, Sesana M, La 
Vecchia L, Summaria F, Tespili M, Silva Orrego P, Tognoni G, Steffenino G. Clinical Comparison 
With Short-Term Follow-Up of Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Stent 
in Primary Percutaneous Coronary Interventions. Am J Cardiol. 2015 Sep 1;116(5):705-10. doi: 
10.1016/j.amjcard.2015.05.049. Epub 2015 Jun 3.
 16.  Basavarajaiah S, Naganuma T, Latib A, Colombo A. Can bioabsorbable scaffolds be used in calci-
fied lesions? Catheter Cardiovasc Interv. 2014 Jul 1;84(1):48-52. doi: 10.1002/ccd.24939. Epub 
2013 Aug 31.
 17.  Seth A, Ravisekar V, Kaul U. Use of ‘Guideliner’ catheter to overcome failure of delivery of Absorb™ 
Bioresorbable Vascular Scaffold in calcified tortuous coronary lesions: technical considerations in 
‘Real World Patients’. Indian Heart J. 2014 Jul-Aug;66(4):453-8. doi: 10.1016/j.ihj.2014.05.019.
 18.  Miyazaki T, Panoulas VF, Sato K, Latib A, Colombo A1. Bioresorbable Vascular Scaffolds for Heavily 
Calcified Lesions: How to Tackle the Rugged Passage? J Invasive Cardiol. 2015 Aug;27(8):E167-8.
 19.  Tanimoto S, Serruys PW, Thuesen L, Dudek D, de Bruyne B, Chevalier B, Ormiston JA. Comparison 
of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and 
the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT 
trials. Catheter Cardiovasc Interv 2007; 70: 515–523.
 20.  Ormiston JA, Webber B, Ubod B, Webster MW, White J. Absorb everolimus-eluting bioresorbable 
scaffolds in coronary bifurcations: a bench study of deployment, side branch dilatation and post-
dilatation strategies. EuroIntervention. 2015;10:1169-77.
 21.  Choi SY, Witzenbichler B, Maehara A, Lansky AJ, Guagliumi G, Brodie B, Kellett MA Jr, Dressler 
O, Parise H, Mehran R, Dangas GD, Mintz GS, Stone GW. Intravascular ultrasound findings of 
early stent thrombosis after primary percutaneous intervention in acute myocardial infarction: 
a Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction 
(HORIZONS-AMI) substudy. Circ Cardiovasc Interv. 2011 Jun;4; 3: 239-47.
 22.  Antonios Karanasos, Nicolas M. Van Mieghem, Nienke van Ditzhuijzen, Cordula Felix, Joost Dae-
men, Anouchska Autar, Yoshinobu Onuma, Mie Kurata, Roberto Diletti, Marco Valgimigli, Floris 
Kauer, Heleen van Beusekom, Peter de Jaegere, Felix Zijlstra, Robert-Jan van Geuns, Evelyn Regar. 
Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombo-
sis. A single-center experience. Circ Cardiovasc Interv. 2015 May;8(5). pii: e002369. doi: 10.1161/
CIRCINTERVENTIONS.114.002369.
198 Chapter 9
 23.  Longo G, Granata F, Capodanno D, Ohno Y, Tamburino CI, Capranzano P, La Manna A, Francaviglia 
B, Gargiulo G, Tamburino C. Anatomical Features and Management of Bioresorbable Vascular 
Scaffolds Failure: A Case Series from the GHOST Registry. Catheter Cardiovasc Interv. 2015 Jan 8. 
doi: 10.1002/ccd.25819. [Epub ahead of print].
 24.  Panoulas VF, Miyazaki T, Sato K, Naganuma T, Sticchi A, Kawamoto H, Figini F, Chieffo A, Carlino 
M, Montorfano M, Latib A, Colombo A. Procedural outcomes of patients with calcified lesions 
treated with bioresorbable vascular scaffolds. EuroIntervention. 2016 Mar;11(12):1355-62. doi: 
10.4244/EIJY15M03_11.
 25.  Kawamoto H, Ruparelia N, Latib A, Miyazaki T, Sato K, Tanaka A, Naganuma T, Sticchi A, Chieffo A, 
Carlino M, Montorfano M, Colombo A. Expansion in calcific lesions and overall clinical outcomes 
following bioresorbable scaffold implantation optimized with intravascular ultrasound. Catheter 
Cardiovasc Interv. 2016 Aug 22. doi: 0.1002/ccd.26725. [Epub ahead of print]
 26.  Ming Jiang Fam, van Der Sijde JN, Karanasos A, Felix C, Diletti R, van Mieghem N, de Jaegere P, 
Zijlstra F, Jan van Geuns R, Regar E. Comparison of acute expansion of bioresorbable vascular 
scaffolds versus metallic drug-eluting stents in different degrees of calcification: An Optical 
Coherence Tomography Study. Catheter Cardiovasc Interv. 2016 Oct 7. doi: 10.1002/ccd.26676.
 27.  Ohya M, Kadota K, Sotomi Y, Kozuma K, Tanabe K, Uematsu M, Kawasaki T, Morino Y, Tobaru T, 
Nakao K, Tachibana K, Kishi K, Shibata Y, Ying S, Kusano H, Stone GW, Popma JJ, Onuma Y, Serruys 
PW, Kimura T. Impact of lesion calcification on angiographic outcomes after Absorb everolimus-
eluting bioresorbable vascular scaffold implantation: an observation from the ABSORB Japan 
trial. EuroIntervention. 2016 Nov 8. pii: EIJ-D-16-00359. doi: 10.4244/EIJ-D-16-00359. [Epub ahead 
of print]
 28.  Colombo A, Panoulas VF. After 3 decades, at long last, a new device to deal with calcific lesions. 
JACC Cardiovasc Interv. 2014;7:519-20.
 29.  Basavarajaiah S, Naganuma T, Latib A, Colombo A. Can bio absorbable scaffolds be used in calci-
fied lesions? Catheter Cardiovasc Interv. 2014;84:48-52.
 30.  Yamaji K, Räber L, Windecker S. What determines long-term outcomes using fully bioresorbable 
scaffolds - the device, the operator or the lesion? EuroIntervention. 2017 Jan 26. pii: EIJV12I14A277. 
doi: 10.4244/EIJV12I14A277. [Epub ahead of print]
 31.  Patrick W. Serruys, MD, PhD; Yoshinobu Onuma, MD, PhD. Dmax for sizing, PSP-1, PSP-2, PSP-3 
or OCT guidance: interventionalist’s jargon or indispensable implantation techniques for short- 
and long-term outcomes of Absorb BRS? EuroIntervention. 2017 Mar 2. pii: EIJY17M02_01. doi: 
10.4244/EIJY17M02_01. [Epub ahead of print]
 32.  Cassese S, Byrne RA, Ndrepepa G, Kufner S, Wiebe J, Repp J, Schunkert H, Fusaro M, Kimura T, 
Kastrati A. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metal-
lic stents: a meta-analysis of randomised controlled trials. Lancet. 2016 Feb 6;387(10018):537-44. 
doi: 10.1016/S0140-6736(15)00979-4. Epub 2015 Nov 17.
 33.  Stone GW, Gao R, Kimura T, et al. 1-year outcomes with the Absorb bioresorbable scaffold in 
patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet 2016; 387: 
1277-89
 34.  Joanna J. Wykrzykowska, Robin P. Kraak, Sjoerd H. Hofma,., Rene J. van der Schaaf,, E. Karin Arken-
bout,., Alexander J. IJsselmuiden,, Joëlle Elias, Ivo M. van Dongen, M.D., Ruben Y.G. Tijssen, Karel 
T. Koch, Jan Baan, Jr., M. Marije Vis, Robbert J. de Winter, Jan J. Piek, Jan G.P. Tijssen, , and Jose P.S. 
Henriques, for the AIDA Investigators*.Bioresorbable scaffolds versus metallic stents in routine 
PCI. N Engl J Med. DOI: 10.1056/NEJMoa1614954.
Impact of calcium on procedural and clinical outcomes in lesions treated with BVS 199
9
 35.  van Geuns RJ, Tamburino C, Fajadet J et al. Self-expanding versus balloon-expandable stents in 
acute myocardial infarction: results from the APPOSITION II study: self-expanding stents in ST-
segment elevation myocardial infarction. JACC Cardiovasc Interv 2012;5:1209-19.
 36.  Puricel S, Cuculi F, Weissner M, Schmermund A, Jamshidi P, Nyffenegger T, Binder H, Eggebrecht H, 
Münzel T, Cook S, Gori T. Bioresorbable Coronary Scaffold Thrombosis: Multicenter Comprehen-
sive Analysis of Clinical Presentation, Mechanisms, and Predictors. J Am Coll Cardiol. 2016 Mar 
1;67(8):921-31. doi: 10.1016/j.jacc.2015.12.019.
 37.  Giblett JP, Brown AJ, Keevil H, Jaworski C, Hoole SP, West NE. Implantation of bioresorbable vascular 
scaffolds following acute coronary syndrome is associated with reduced early neointimal growth 
and strut coverage. EuroIntervention. 2016 Aug 20;12(6):724-33. doi: 10.4244/EIJV12I6A117.
 38.  Capodanno D, Angiolillo DJ. Antiplatelet Therapy After Implantation of  Bioresorbable Vascular 
Scaffolds: A Review of the Published Data, Practical Recommendations, and  Future Directions. 
JACC Cardiovasc Interv. 2017 Mar 13;10(5):425-437. doi: 10.1016/j.jcin.2016.12.279. 
 39.  Karanasos A, Van Mieghem N, van Ditzhuijzen N, Felix C, Daemen J, Autar A, Onuma Y, Kurata 
M, Diletti R, Valgimigli M, Kauer F, van Beusekom H, de Jaegere P, Zijlstra F, van Geuns RJ, Re-
gar E. Angiographic and optical coherence tomography insights into bioresorbable scaffold 
thrombosis: single-center experience. Circ Cardiovasc Interv. 2015 May;8(5). pii: e002369. doi: 
10.1161/.114.002369.
 40.  Felix CM, Onuma Y, Fam JM, Diletti R, Ishibashi Y, Karanasos A, Everaert BR, van Mieghem NM, Dae-
men J, de Jaegere PP, Zijlstra F, Regar ES, van Geuns RJ. Are BVS suitable for ACS patients? Support 
from a large single center real live registry. Int J Cardiol. 2016 Sep 1;218:89-97. doi: 10.1016/j.
ijcard.2016.05.037. Epub 2016 May 13.
 41.  Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, 
Mauri L, Mehran R, Mukherjee D, Newby LK, O’Gara PT, Sabatine MS, Smith PK, Smith SC Jr 2016 
ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With 
Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Asso-
ciation Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016 Sep 6;68(10):1082-115. 
doi: 10.1016/j.jacc.2016.03.513. Epub 2016 Mar 29
 42.  C.M. Felix, G. J. Vlachojannis, A.J.J. IJsselmuiden, J.M. Fam, P.C. Smits, W. Lansink, R. Diletti, F. 
Zijlstra, E.S. Regar, Eric Boersma, Y. Onuma, R.J.M van Geuns;  Potentially increased incidence of 
scaffold thrombosis in patients treated with Absorb BVS who terminated DAPT before 18 months. 
EuroIntervention [In press] 
 43.  Felix CM, Vlachojannis GJ, IJsselmuiden AJ, Onuma Y, van Geuns RJ. Very Late Scaffold Throm-
bosis in Absorb BVS: Association With DAPT Termination? JACC Cardiovasc Interv. 2017 Mar 
27;10(6):625-626. doi: 10.1016/j.jcin.2017.01.015.
 44.  Onuma Y, Tanimoto S, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ, Richardt G, Wiemer M, Carrie 
D, Thuesen L, Dorange C, Miquel-Hebert K, Veldhof S, Serruys PW. Efficacy of everolimus eluting 
stent implantation in patients with calcified coronary culprit lesions: two-year angiographic and 
three-year clinical results from the SPIRIT II study. Catheter Cardiovasc Interv. 2010;76:634-42.
200 Chapter 9
online supplement
After exclusion criteria BVS STEMI and BVS Expand: 395 patients remain for analysis: 252 (63.8%) without 
calcification and 143 (36.2%) with a calcified lesion. 
Univariate analysis (logistic regression) for calcification (yes/ no) to compute propensity score
Variables OR (95% CI) p value
Age 1.052 (1.030 – 1.075) <0.001
Gender 1.125 (0.698 – 1.812) 0.630
DM 1.602 (0.923 – 2.781) 0.094
Dyslipidemia 1.552 (1.001 – 2.313) 0.050
Smoking 0.839 (0.721 – 0.977) 0.024
Presentation with ACS 0.465 (0.293 – 0.739) 0.001
HT 1.649 (1.086 – 2.504) 0.019
PAD 2.679 (1.116 – 6.434) 0.027
Previous MI 2.092 (1.139 – 3.842) 0.017
Multivessel disease 1.702 (1.108 – 2.615) 0.015
Small vessel 1.137 (0.721 – 1.792) 0.580
Bifurcation 2.253 (1.432 – 3.545) <0.001
Total scaffold length per patient 1.029 (1.019 – 1.039) <0.001
Average scaffold diameter per patient 0.701 (0.380 – 1.294) 0.256
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abstract
objectives
To evaluate the mid-term coronary computed tomography angiography (CCTA) out-
comes of the Absorb bioresorbable vascular scaffold (BVS) by non-invasive CT imaging 
in combination with CT perfusion.
background
BVS were introduced with the aim of overcoming some of late events of metal drug-
eluting stent (DES). Data regarding follow-up of BVS by use of CT is limited.
methods
BVS-EXPAND, a single-centre study includes selected, real-world patients. Complex lesions 
such as bifurcation and long lesions were not excluded. Eighteen to 24 months after in-
dex procedure, consecutive suitable patients underwent CT. Main exclusion criteria were: 
contrast medium allergy, severe renal insufficiency, Target lesion revascularization (TLR) 
before CCTA. Additional CT perfusion was performed when a significant non-occlusive 
stenosis (> 50%) in the target lesion was identified on CCTA. CT-defined BVS success was 
defined as: stenosis< 50% on CCTA or CT perfusion without perfusion deficits. 
results:
The CCTA cohort consisted of 164 patients. CCTA’s were assessable in 160 patients with 215 
lesions and within that group, rate of BVS patency was 98.6% of the lesions. CT perfusion 
was necessary in 9 patients (lesions) with degree of stenosis > 50% and ruled out func-
tionally significant restenosis in five. CT-defined BVS success was achieved in 207 lesions 
(96.7%); CT-derived failure occurred in 7 lesions (3.3%). Complete quantitative CCTA mea-
sures were available in 144 patients with in-scaffold minimal lumen area of 4.2 (± 1.7) mm2, 
% area stenosis 10.3 ± 32.1%. Following CCTA three participants required revascularization.
conclusions
CCTA was able to evaluate most BVS treated patients at mid-term follow-up, where ad-
ditional perfusion imaging was a valuable addition, needed only in a small group of 
patients.  
condensed abstract 
This study investigated the CCTA outcomes to describe the mid-term performance of the Absorb BVS in 
more complex coronary lesions when examined by means of CCTA. Due to the invasiveness, costs of an-
giography and excellent performance of second-generation drug-eluting stents, routine follow-up after 
index PCI by invasive coronary angiography has disappeared from the spectrum. CCTA is a non-invasive 
method to investigate coronary lesions and CT perfusion is a valuable addition. CCTA was able to evaluate 
most BVS-treated patients at mid-term follow-up. 
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introDuction
Currently, percutaneous coronary intervention (PCI) with drug-eluting stents (DES) is 
the gold standard for the treatment of coronary artery disease (CAD). In comparison 
with balloon angioplasty alone or PCI using bare metal stents (BMS), PCI with DES drasti-
cally decreased the rate of restenosis and revascularization. However on the long-term, 
DES with their permanent presence of foreign material are not devoid of drawbacks 
and have a stable average rate of reintervention of 2-4% after the first year. [1, 2] In an 
attempt to eliminate the potential (late) limitations of DES (neoatherosclerosis, very late 
stent thrombosis), bioresorbable scaffolds have been developed. The concept consists 
of a temporary device that restores the blood flow and temporally supports the vessel 
but that will fully resorb over time. The bioresorbable device most intensely investigated, 
is the ABSORB bioresorbable vascular scaffold (BVS. Abbott vascular, Santa Clara, CA, 
USA), which received both CE mark and FDA approval. It is a fully resorbable everolimus-
eluting device made of a poly-L-lactide backbone with a poly-D, L-lactide coating. With 
the exception of two platinum markers at each end of the scaffold, this device is radio-
lucent and therefore does not interfere with non-invasive computed tomography of the 
coronary arteries. This is in contrast to metal stents, which cause blooming artefacts with 
subsequent hampering of luminal assessment. [3] Recently, mid-term outcomes RCTs 
that compared BVS with Xience, a second-generation everolimus eluting metal DES, 
showed that the BVS was associated with worse outcomes.[4] [5-7]  These results were 
mainly driven by early scaffold thrombosis (ScT), triggered by the relatively thick struts 
of the first generation. Development of thin strut BVS is complex and expensive which 
first requires positive signals from long-term imaging and clinical follow-up. 
Coronary computed tomography angiography (CCTA) could be such a technology 
and greatly improved over the last 20 years with an important increase in spatial and 
temporal resolution. The enhancement in CT technology enabled a reliable visualisation 
of the vessel lumen and also detection of significant coronary lesions.  
A study by Collet and colleagues investigated the diagnostic accuracy of CCTA in 
ABSORB II and reported that accuracy regarding identification of presence and severity 
of obstructive CAD was similar between CCTA and coronary angiography at three years 
of follow-up. [8]
The aim of our study was to report mid-term CCTA outcomes to describe the mid-term 
performance of the Absorb BVS in more complex coronary lesions when examined by 
means of CCTA. 
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Population
The BVS Expand registry is an investigator-initiated, prospective, single-centre, single-
arm study performed in an experienced, tertiary PCI centre. In- and exclusion criteria 
have been described elsewhere. [9] In brief, patients presenting with NSTEMI, stable or 
unstable angina (UA), or silent ischemia caused by a de novo stenotic lesion in a native 
coronary artery treated with a BVS were included. Main exclusion criteria were patients 
with a history of coronary bypass grafting (CABG), presentation with ST-elevation 
myocardial infarction (STEMI) and patients with expected survival of less than one year. 
Complex lesions such as bifurcation, calcified (as assessed by angiography), long and 
thrombotic lesions were not excluded. As per hospital policy patients with a previously 
implanted metal DES in the intended target vessel were also excluded. Also, although 
old age was not an exclusion criterion, BVS were in general reserved for younger pa-
tients, and left to operator’s interpretation of biological age.
For hospital quality control purposes of this new technique within the field of inter-
ventional cardiology, CCTA at mid-term follow-up (between 18 months and two years) 
was offered to all consecutive suitable patients. Exclusion criteria for undergoing a CCTA 
were contrast medium allergy, severe renal insufficiency, target lesion revascularization 
(TLR) performed before CCTA, severe calcification and patients who underwent cardiac 
imaging during the same time point.
ethics
This is an observational study, performed according to the privacy policy of the Erasmus 
MC, and to the Erasmus MC regulations for the appropriate use of data in patient-ori-
ented research, which are based on international regulations, including the declaration 
of Helsinki. Approval of the ethical board of the Erasmus MC was obtained. All patients 
undergoing clinical follow-up provided written informed consent for the PCI and to be 
contacted regularly during the follow-up period of the study.
Procedure
PCI was performed according to current clinical practice standards. The radial or femoral 
routes were the principal routes of vascular access and 6 or 7 French catheters were 
used depending on the discretion of the operator. Pre-dilatation and post dilation were 
recommended with a balloon shorter than the planned study device length and with a 
non-compliant balloon without overexpanding the scaffold beyond its limits of expan-
sion (0.5mm > nominal diameter) respectively. Intravascular imaging with the use of 
Intravascular Ultrasound (IVUS) or Optical Coherence Tomography (OCT) was used for 
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pre-procedural sizing and optimization of stent deployment on the discretion of the 
operator. 
angiographic analysis
Baseline quantitative Coronary Analysis (QCA) was performed by a total of three differ-
ent independent investigators. Coronary angiograms were analysed with the CAAS 5.10 
QCA software (Pie Medical BV, Maastricht, the Netherlands). The QCA measurements 
provided reference vessel diameter (RVD), percentage diameter stenosis and minimal 
lumen diameter (MLD).  
ccta 
Second and third-generation dual source CT scanners (SOMATOM Definition Flash and 
SOMATOM Force, Siemens Medical Solutions, Forchheim, Germany) were used. Standard 
acquisition techniques for coronary techniques were used: Sublingual nitroglycerin was 
given to all patients. Beta-blockers were optional in patients with a fast heart rate.  
A prospective electrocardiographically triggered axial scan mode was used, with an 
exposure window during diastole and/or systole depending on the heart rate. Tube 
current and tube voltage were selected semi-automatically on the basis of body size. 
For CCTA imaging, a contrast bolus of approximately 50 to 60 ml (depending on iodine 
concentration and expected scan duration) was injected, followed by a saline bolus 
chaser. Images were reconstructed with a medium smooth kernel (B26, Bv40) and a slice 
thickness of 0.5-0.7 mm at 5% intervals of the acquired R-R segment. [10]
Scaffold patency was described as a scaffolded tract with a visible lumen and the 
possibility to evaluate contrast attenuation. First and according to normal practice, the 
CCTA was evaluated by a radiologist. Lesions were then divided into three groups: no ab-
normalities identified in target lesion, abnormalities seen but non-significant, significant 
stenosis (suspected) or total occlusion.
CT perfusion
Experienced CT readers (KN or RB) evaluated the CT angiograms, using PCI proce-
dural information on BVS sizes and location but blinded to all other modalities. They 
set indication for any additional CT myocardial perfusion scans in case of a significant, 
non-occlusive stenosis on CCTA. This CT myocardial perfusion scan was performed in a 
separate session.
The dynamic CT myocardial perfusion scan was performed to further determine the 
functional significance of a morphological significant stenosis detected on CCTA. In a 
dynamic CT myocardial perfusion scan a series of acquisitions is made during the first 
pass of a contrast bolus, while the patient is in a hyperaemic state. After 3 min of adenos-
ine infusion (at 140 μg/kg/min) the dynamic CT myocardial perfusion scan was started. 
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Fifty ml of contrast medium (Ultravist, 370 mgI/ml; Bayer, Berlin, Germany) was injected 
at 6 ml/s, followed by a saline bolus of 40 ml. A shuttle mode was used to cover the left 
ventricle acquiring images in alternating cranial and caudal table positions. CT dynamic 
myocardial perfusion acquisition was started 5 seconds after the start of the contrast 
medium injection and patients were asked to hold their breath during the entire acquisi-
tion (30-35 seconds) [10, 11]. The change in attenuation of the myocardium due to the 
first pass of the contrast bolus was used to compute myocardial blood flow maps using 
a hybrid deconvolution model. A functionally significant coronary (re)stenosis would 
result in a reduction of the myocardial blood flow in the associated myocardial territory 
[12]. By visual inspection, the myocardial blood flow maps in combination with the CTA 
potential ischemia causing (re)stenosis of the BVS were identified by an expert CCTA 
reader (KN). 
Quantitative CCTA analysis
In a subgroup of patients, quantitative data of the lesion of interest were analysed off-line 
by a radiologist on a dedicated workstation using commercially available software Syngo.
Via (Siemens, Forchheim, Germany) to perform a quantitative CTA analysis. The optimal 
imaging phase and the centre lumen line through the treated vessel was automatically 
selected by the software and manually adjusted when needed. Cross-sections of the 
vessel were reconstructed, extending approximately 5 mm beyond the device (proximal 
and distal segments), using the platinum scaffold markers as landmarks. Every BVS was 
evaluated at three locations: 1. the proximal scaffold segment (defined as the segment 
extending from the platinum marker to five mm proximal to the marker, was evaluated 
first by using Syngo.Via to detect the minimal lumen and to determine the lumen areas. 
An automatic tracer was used and in case of insufficient contrast lumen opacification, it 
was manually adjusted; 2. the distal scaffold segment (defined as the segment extending 
from the platinum marker to five mm distal to the marker), was evaluated in the same 
fashion; 3. the minimal scaffold lumen was assessed by visually selecting the minimal 
lumen area inside the scaffold (Figure 1). At each location the cross-sectional lumen 
area surface was measured.  If multiple overlapping scaffolds were inserted, they were 
considered as one lesion; if none were overlapping, they were considered as separate. 
Reference vessel area was calculated as the average of the proximal and distal lumen 
reference area segments. The lumen area stenosis was calculated as follows: reference 
lumen area minus the minimal lumen area as a percentage of reference lumen area. In 
case of a bifurcation lesion with a large side branch elucidating a significant step down, 
the reference lumen diameter was based on measures of the distal end only. 
Quantitative CTA analysis could not (completely) be performed in case of poor image 
quality (motion artefacts, insufficient contrast lumen opacification), ostial lesion, too 
small vessel calibre and total occlusion.
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follow-up
Follow-up information specific for hospitalization and cardiovascular events was ob-
tained through questionnaires or telephone interviews at multiple time points (1 month, 
6 months, 1, 2, 3 and in the end: 4 and 5 years). If needed, medical records or discharge 
letters from other hospitals were requested. Events were adjudicated by an independent 
clinical events committee (CEC). All information concerning baseline characteristics and 
follow-up was gathered in a clinical data management system. 
Figure 1. Example QCT measurement 
 
figure 1 Example QCT measurement 
Example of a normal QCT measurement: the blue line shows the proximal reference (5-10 mm distance 
from proximal scaffold edge), the red line indicates the proximal scaffold border (0.3mm distance from 
proximal scaffold edge). The green line is the distal reference (5-10 mm distance from distal scaffold edge). 
The white arrows indicate the two pairs of  platinum scaffold markers.
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Definitions
CCTA feasibility was the percentage of patients with sufficient image quality to assess 
the target lesion on CCTA. BVS patency was defined as an open vessel at the site of 
BVS implantation. CT-defined BVS success was described as no stenosis of target lesion, 
diameter stenosis of < 50% on CCTA or (possible) stenosis of ≥ 50% but with a normal 
additional myocardial perfusion scan. CT-defined BVS failure was defined as stenosis ≥ 
50% on CCTA combined with perfusion deficits during perfusion CT or complete occlu-
sion on CCTA. Definitions of events were as in our previous publication. [9]
statistical analysis
Categorical variables are reported as counts and percentages, continuous variables as 
mean ± standard deviation. Quantitative CCTA measures are described as median with 
interquartile range (IQR). The cumulative incidence of adverse events was estimated ac-
cording to the Kaplan-Meier method. Patients lost to follow-up were considered at risk 
until the date of last contact, at which point they were censored. All statistical tests were 
two-sided and the P value of < 0.05 was considered statistically significant. Statistical 
analyses were performed using SPSS, version 21 (IL, US).
results
After applying the exclusion criteria, 195 consecutive patients were invited as suitable 
for follow-up CCTA, of which 164 accepted the offer. In four patients, poor CCTA quality 
made any image assessment impossible and thus 160 patients with 215 lesions remained 
for analysis (Figure 2). In one lesion, patency was assessable but detailed information of 
degree of stenosis could not be provided. 
Figure 3 is an example of a patient with two sequential lesions in the RCA treated 
with two 28 mm long overlapping BVS with excellent acute outcome. Follow-up CCTA 
identified an excellent result, even at the location of the overlap. 
baseline characteristics
Table 1 summarizes baseline characteristics of patients, lesions and certain procedural 
factors of the whole CCTA cohort (n=160). Mean age was 59.9 ±10.0 years, 76.3% were 
male, 11.9% diabetics and 60.0 % presented with ACS. 
The LAD was the coronary artery most frequently treated (53.2%). AHA/ ACC lesion 
type B2/ C was present in 37.2%, bifurcation in 22.5%, calcification (moderate or severe 
on angiography) in 39.0%. Pre-dilatation was performed in 89.4%, with a balloon to ar-
tery ratio of 1.07. Intravascular imaging using OCT or IVUS was carried out in 58%. Post-
dilatation was performed in 51.8% with a maximum post-dilatation balloon inflation 
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pressure of 15.5 (±3.24) atm. Post-procedural MLD was 2.3 (±0.4) mm, post-procedural 
% diameter stenosis was 16.5 (±9.3) %.
CTCA: no abnormalities 
 
72.0% (n=154)
CTCA: 100% occlusion or 
CT perfusion: ischemia
3.3% (n=7)
CTCA: possible stenosis > 
50%, normal CT Perfusion
2.3% (n=5)
CTCA: stenosis <50% or 
borderline
22.4% (n=48)
Mid-term BVS CT Success 
96.7% (n=207)
BVS CT Failure
3.3% (n=7)
See Online Material
160 patients, 215 lesions with patency in 98.6% of the lesions
(Qualitative analysis possible in 144/160 patients) 
Figure 2. Flowchart
In 1/215 lesion: degree of stenosis could not be assessed
CTCA cohort (N=164 patients)
CT Assessment impossible in 4/164
figure 2 Flowchart of the study
Figure 3. Case 1 
 
Figure 3 is an example of a successful case. It concerns a 40-year old male, smoking patient 
with diabetes, dyslipidaemia and a positive family history for CAD. He presented with NSTEMI 
due to two-vessel disease of the RCA (A) and LAD. The RCA was treated with pre-dilatation, 
BVS (2x 3.5*28) and post-dilatation (B) The LAD showed a positive FFR (0.75) and one 
2.5*18mm BVS was implanted, followed by post-dilatation. He underwent his CCTA 861 days 
after baseline PCI and all BVS were patent without signs of stenosis (See C for CCTA result of 
RCA during follow-up).  
 
 
 
 
figure 3 Case description 1
Figure 3 is an example of a successful case. It concerns a 40-year old male, smoking patient with diabetes, 
dyslipidaemia and a positive family history for CAD. He presented with NSTEMI due to two-vessel disease 
of the RCA (A) and LAD. The RCA was treated with pre-dilatation, BVS (2x 3.5*28) and post-dilatation (B) The 
LAD showed a positive FFR (0.75) and one 2.5*18mm BVS was implanted, followed by post-dilatation. He 
underwent his CCTA 861 days after baseline PCI and all BVS were patent without signs of stenosis (See C for 
CCTA result of RCA during follow-up). 
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ccta
Median duration from index procedure until CCTA was 714 (IQR: 639 – 754) days. See 
Table 2 for median dose length product (DLP) and effective dose. 
When assessed by CCTA, in 98.6 % of the 215 lesions BVS patency was achieved. In one 
lesion, degree of stenosis could not be assessed.
table 1. Baseline characteristics
Patient (n=160 )
    Age (mean ± SD), years 59.86 (±10.0)
    Male gender, % 76.3 
    Diabetes mellitus, % 11.9 
    Current smoker, % 33.8 
    Dyslipidaemia, % 51.9 
    Hypertension, % 55.0 
    Family history of CAD, % 46.9 
    Prior myocardial infarction, % 17.5 
    Prior PCI, % 10.6 
    Presentation with ACS, % 60.0 
Lesion (n= 215 lesions)
    Treated vessel , %
          LAD 53.2
          LCX 22.5
          RCA 24.3
    AHA/ ACC lesion classification type B2 /C, % 37.2
    Calcification 39.0
    Bifurcation 22.5
    CTO 4.1
Procedure
    Pre-dilatation (%) 89.4
    Max pre-dilation balloon diameter (mean ± SD), mm 2.62 (±0.39)
    Pre-dilation balloon: artery ratio 1.07 (±0.23)
    Post-dilatation (%) 51.8
    Maximum post-dilatation inflation pressure (mean ± SD), atm 15.50 (±3.24)
    Intravascular imaging (%) 58.1
    Pre-procedural RVD (mean ± SD), mm 2.54 (±0.47)
    Post-procedural MLD (mean ± SD), mm 2.30 (±0.40)
    Post-procedural diameter stenosis, % 16.54 (±9.25)
    Lesion length (mean ± SD),  mm 23.97 (±13.10)
CAD: coronary artery disease, CTO: chronic total occlusion, MLD: minimum lumen diameter, PCI: percutaneous 
coronary intervention, RVD: reference vessel diameter. Values are mean (±SD) or median (interquartile range)
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In 154/ 214 lesions (72%) no target lesion abnormalities were seen on CCTA. In 53 
lesions (24.7%) some non-significant changes, representing minor neo-intima hyperpla-
sia, were seen. In 12 lesions (5.6%, 12 patients) an anatomical significant stenosis of the 
target lesion was reported. Three of them showed total occlusion. 
CT Perfusion
In four patients, BVS failure was identified by additional CT perfusion. Figure 4 demon-
strates an example of a patient with two BVS (2.5*28mm) in the LAD for spontaneous 
coronary artery dissection. CCTA showed ISR at level of the second scaffold and the 
additional CT perfusion revealed a small area of ischemia. Therefore, CT-defined BVS 
success was 96.7% of the lesions (Figure 2).
Two patients were subsequently treated by PCI. The other patients were initially treated 
conservatively, of whom one was treated through PCI during follow-up (> two years post-
CCTA). However, during this re-intervention, only a non-target vessel was treated. FFR of 
the target-vessel was negative and the BVS was patent. In patients who did not have 
anatomically or functionally significant stenosis, no events occurred during follow-up. 
Quantitative CCTA
Complete quantitative analysis was available in a subgroup of 144/160 patients with 
194 lesions (Table 3). Quantitative analysis of the lesion was not possible in case of the 
presence of total occlusion (n= 3 patients), vessel calibre of too small diameter (n=3), too 
much calcification (n=3), insufficient amount of contrast (n=4) or motion artefacts (n=8).
In-scaffold minimal lumen area was 4.2 ± 1.7 mm2. In-scaffold percentage area ste-
nosis was 10.3 ± 32.1. In-segment area stenosis was 30.6 ± 25.2 %. Lesions that showed 
significant abnormalities on CCTA had smaller but non-significant reference areas: 4.3 vs 
5.8 mm2, p=0.69. Out of the seven patients with CT-defined BVS failure, five had MLD < 
table 2. CCTA (perfusion)  acquisition
CCTA (n= 160)
    CTDIvol (mGy) 19.52 (13.36 – 35.17)
    DLP (mGy-cm) 288.15 (186.15 – 473.55)
    Radiation effective dose (mSv) 4.09 (2.63 – 6.73)
  CT perfusion (n = 9)
    CTDIvol (mGy) 37.24 (25.00 – 45.06)
    DLP (mGy-cm) 338.10 (238.93 – 441.83)
    Radiation effective dose (mSv) 5.51 (3.70 – 6.44)
    Tube voltage (KV) 70 (70 – 70)
CCTA: Computed tomography coronary angiography, CTDI: CT dose index, DLP: dose length product. Val-
ues expressed as median (interquartile range) 
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2.4 mm at baseline. Patients with a suboptimal result post-PCI (MLD <2.4 mm), showed 
smaller MLA during follow-up CT: 3.9 vs 4.7 mm2 (p=0.03).
Figure 4. Case 2 
 
Figure 4 A 53-year old female patient presented with an anterior STEMI based on an intramural 
haematoma. (A) For TIMI I flow, initial balloon angioplasty did not result in stable TIMI III 
flow due to acute recoil for which two overlapping 2.5 x 28 mm BVS scaffolds were implanted 
(B). Follow-up CTCA (C and D for 3D image) showed a well patent proximal scaffold with 
minimal contrast in the distal scaffold suggestive for scaffold failure. CT-perfusion (E) 
demonstrated localised ischemia in the territory of the distal LAD. Subsequent angiography (F) 
confirmed target lesion failure, mainly due to late recoil and minimal neo-intima on IVUS which 
was successfully treated with balloon angioplasty only. Subsequent follow-up for one year was 
without recurrent events. 
figure 4 Case description 2
A 53-year old female patient presented with an anterior STEMI based on an intramural haematoma. (A) For 
TIMI I flow, initial balloon angioplasty did not result in stable TIMI III flow due to acute recoil for which two 
overlapping 2.5 x 28 mm BVS scaffolds were implanted (B). Follow-up CTCA (C and D for 3D image) showed 
a well patent proximal scaffold with minimal contrast in the distal scaffold suggestive for scaffold failure. 
CT-perfusion (E) demonstrated localised ischemia in the territory of the distal LAD. Subsequent angiog-
raphy (F) confirmed target lesion failure, mainly due to late recoil and minimal neo-intima on IVUS which 
was successfully treated with balloon angioplasty only. Subsequent follow-up for one year was without 
recurrent events.
table 3. Quantitative CCTA Assessment
Total
In-scaffold, mm2
    Minimal lumen area (mean ± SD) 4.2 ± 1.7
    Median reference area (mean ± SD) 5.0 ± 2.1
   Area stenosis, % (mean ± SD) 10.3 ± 32.1
In-segment, mm2 
    Area stenosis, % (mean ± SD) 30.6 ± 25.2
Values described as mean ± standard deviation (SD) or median (interquartile range [IQR]) 
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clinical outcomes
Clinical outcomes (reported as Kaplan-Meier estimates) are described in Table 4. Median 
duration of follow-up after baseline PCI was 1456.50 (IQR: 1098.25 – 1472.50) days and 
follow-up of at least three years post-PCI was available in 85.6%. We focussed on events 
that took place after CCTA and up to three years after baseline PCI. Those event rates 
were as follows: rate of death was 0.7% (one patient, non-cardiac cause); rate of MI was 
0% and TLR rate was 3.5%. There were no cases of scaffold thrombosis. In three patients, 
TLR occurred after CCTA 
Discussion
In this sub-cohort of the BVS Expand registry, we have reported on the mid-term CCTA 
and clinical outcomes of a sub-cohort of patients treated with the ABSORB BVS for a 
variety of lesion complexity. The main findings were as follows: 1) CCTA was a success-
ful tool to establish non-invasively CT-derived BVS success at mid-term follow-up in 
almost all patients including more complex lesions. 2). Additional CT perfusion imaging 
provides important functional information in moderate or severe restenotic lesions. 3) 
Non-clinical CT-derived BVS failure is a rare event. 4) Patients with CT-derived BVS suc-
cess at mid-term were free from thrombosis or TLR during follow-up after CT imaging.
Our study demonstrated that even in patients with more complex anatomy, CCTA 
could be routinely used to follow-up the patients after BRS implantation. Patency was 
98.6% and the rate of adverse events after CT, was low. When compared to the ABSORB 
Cohort A and B studies in which CCTA was also performed [13, 14], the percentage of 
calcification, longer lesion length and AHA/ ACC lesion classification type B2/C illustrates 
the higher complexity of our patient population. Polymeric BRS technology, through its 
radiolucency and complete resorption, could be very suitable for non-invasive follow-
up. Evaluation of newly introduced technologies in medicine after initial approval is es-
sential. Patients in routine practice differ importantly from patients studied in approval 
studies where success rates reported in first-in-man studies and RCT including highly 
table 4. Clinical outcomes, described as Kaplan-Meier estimates (n =160 patients)
Post-ccta 
Death, % (n) 0.7 (1)
Cardiac death, % (n) 0.0 (0)
Myocardial infarction, % (n) 0.0 (0)
Target lesion revascularization % (n) 3.5 (3)
Target vessel revascularization, % (n) 3.5 (3)
Non-target vessel revascularization, % (n) 2.8 (4)
Definite/ probable scaffold thrombosis, % (n) 0.0 (0)
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selected patients, are generally higher. Most post-approval investigator-initiated stud-
ies rely only on clinical follow-up specific protocols and, in the best case, independent 
event adjudication by experienced investigators. Invasive coronary angiography has 
been the objective standard to establish metallic stent patency and presence of in-stent 
restenosis. Due to the invasiveness, costs of angiography and excellent performance of 
second-generation DES, routine follow-up after index PCI by invasive coronary angiog-
raphy (ICA) has disappeared from the spectrum. CCTA is a non-invasive image modality 
with a high sensitivity and relatively low specificity, particularly for identification of 
hemodynamically significant CAD. Evaluation of BVS using CCTA was described in sev-
eral publications and appeared to have a high diagnostic accuracy. [8, 13, 15] [16] Our 
study lacked validation with angiography; however, a recent study concluded that the 
accuracy of the Absorb BVS to detect in-scaffold luminal obstruction, when angiography 
and IVUS were used as references, was high. [17] 
Investigation of efficacy after local introduction of new technology with the best 
feasible techniques should be routine for every hospital. [18]  
In our cohort, in only four patients image quality was not sufficient to assess scaffold 
patency, let alone severity of stenosis or even quantitative CT measures. Rate of patency 
and also mid-term CT-defined BVS success were high. Our study showed that when a 
CT perfusion was performed, perfusion deficits were seen in approximately 50% of the 
cases. The advantage of CT perfusion is the possibility to perform it on-site and in the 
same session as CCTA. CT perfusion improves the performance of CCTA in the identifica-
tion of functionally significant CAD and also improves specificity. [10, 19] 
In order to discriminate between lesions that are hemodynamically significant and 
those who are not and with the aim of diminishing unnecessary referrals for ICA, physi-
ological assessment of the target lesion is of importance. One of the possibilities is by 
using quantitative vessel analysis [20] or MR perfusion[21] and CT-derived fractional 
flow reserve (FFRCT).[10, 19] Quantitative CTA analysis improved specificity from 41% 
- 76% for percentage area stenosis [22] and accuracy from 49% - 71% for percentage 
diameter stenosis. [20]
FFRCT  has been advocated as additional technology to improve specificity of CCTA, 
revealing good diagnostic accuracy. [23] Several studies have investigated FFRCT. [19, 24-27] 
Currently, the HeartFlow FFRCT is the only the FDA-approved CCTA derived FFR platform, 
which can be used off-site only and at significant costs. As so, we selected CT perfusion 
for our research.
Post-CCTA adverse events up to three years after baseline PCI occurred in only three 
patients. In all of the other patients, no adverse events of the target lesion were reported 
after CCTA was performed and therefore this appeared as a rare event. In comparison to 
other mid-term clinical results [28], outcomes at three years are good with a low rate of 
death and no cases of ScT.
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Findings of our study show that CCTA is feasible in patients treated with Absorb BVS, 
which can be useful information also for other bioresorbable devices, as the current 
generation BVS has been taken out of the market.
conclusion
CCTA was able to evaluate most BVS-treated patients at mid-term follow-up. Rates of 
patency and CT-defined BVS success were high. Additional perfusion imaging was a 
valuable addition, needed only in a small group of patients. Clinical outcomes at three 
years were promising without cases of scaffold thrombosis and no TLR post-CT when 
CCTA results were good.
limitations
The size of our CCTA cohort was relatively limited. There might have been selection bias 
at the moment patients were included in the CCTA cohort. Quantitative assessment was 
not possible in all of the patients. Variations in image quality occurred due to calcifica-
tion and platinum markers causing blooming, motion artefacts. Lastly, there was no 
validation with angiography or intravascular imaging.
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abstract
background
As bioresorbable vascular scaffolds (BVSs) are being increasingly used in complex real-
world lesions and populations, BVS thrombosis cases have been reported. We present 
angiographic and optical coherence tomography (OCT) findings in a series of patients 
treated in our center for definite bioresorbable scaffold thrombosis.
methods and results
Up to June 2014, 14 patients presented with definite BVS thrombosis in our centre.  OCT 
was performed in 9 patients at the operator’s discretion. Angiographic and OCT findings 
were compared with a control group comprising 15 patients with definite metallic stent 
thrombosis. In the BVS group, time interval from index procedure to scaffold thrombosis 
ranged from 0 to 675 days. Incomplete lesion coverage by angiography was identified in 
4 of 14 cases, malapposition by OCT in 5 of 9 cases, strut discontinuity in 2 of 9 cases, and 
underexpansion in 2 of 9 cases. Five patients had discontinued dual antiplatelet therapy, 
and in 3 of them discontinued dual antiplatelet therapy discontinuation had occurred 
the week preceding the event. There were no significant differences in angiographic or 
OCT findings between BVS and metallic stent thrombosis.
conclusions
Suboptimal implantation with incomplete lesion coverage, underexpansion, and malap-
position comprises the main pathomechanism for both early and late BVS thrombosis, 
similar to metallic stent thrombosis. Dual antiplatelet therapy discontinuation seems to 
also be a secondary contributor in several late events. Our observations suggest that 
several potential triggers for BVS thrombosis could be avoided. 
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introDuction
Metallic drug-eluting stents (DESs) are the current standard for invasive treatment of 
coronary artery disease. However, metallic DES have been associated with late complica-
tions such as neoatherosclerosis and incomplete healing that can lead to failure even 
at long-term follow-up.1–3 Bioresorbable vascular scaffolds (BVSs) are a new treatment 
for coronary artery disease that could potentially alleviate such problems.4,5  To date, 
bioresorbable scaffolds have been evaluated in first-in-man or highly selected study co-
horts with simple lesions in low-risk patient populations,4–7 whereas vascular response 
in lesions of real-world patients might differ. As BVSs are being increasingly used in more 
complex lesions, several cases of BVS thrombosis have been reported.8–10
In metallic DES, intravascular imaging has elucidated pathophysiologic mechanisms 
of stent thrombosis, underscoring the significance of procedural factors such as inad-
equate stent expansion and vascular trauma for acute thrombosis11, 12 or delayed 
healing and neoatherosclerosis for late thrombosis.1, 2 Whether BVS thrombosis is 
amenable to the same factors remains unknown.
We aimed to present angiographic and optical coherence tomography (OCT) find-
ings in a series of patients with definite bioresorbable scaffold thrombosis treated in 
our catheterization laboratory and compare them with a control group of patients with 
definite metallic stent thrombosis.
methoDs
study Population
The everolimus-eluting BVS (Absorb; Abbott Vascular, Santa Clara, CA) has been used 
in clinical trials in our centre since 2006.4–7 Since September 2012, Absorb BVS was 
approved for commercial use in the Netherlands and has been used in our centre also 
in more complex patients and lesions, while outcomes of these patients are recorded 
in the Expanded Clinical Use of Everolimus Eluting Bioresorbable Vascular Scaffolds for 
Treatment of Coronary Artery Disease (BVS- Expand) and Everolimus-Eluting Bioresorb-
able Vascular Scaffolds for Treatment of Patients Presenting With ST-Segment–Elevation 
Myocardial Infarction (BVS-STEMI) registries.13, 14 Up to June 1, 2014, a total of 733 
everolimus-eluting BVS had been implanted in 469 patients in our centre.
Since 2006 and up to June 2014, 14 patients were admitted to our laboratory because 
of definite BVS thrombosis. Definite BVS thrombosis was identified using the Aca-
demic Research Consortium definition requiring both angiographic evidence of scaffold 
thrombosis (including 5-mm edge segments) and clinical evidence of acute coronary 
syndrome and were classified as acute, subacute, late, or very late.15 Treatment of BVS 
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thrombosis, including thrombus aspiration or invasive imaging, was performed at the 
operator’s discretion. All patients have provided informed consent.
To understand potential differences and similarities between BVS and metallic stent 
thrombosis, we used consecutive patients with definite metallic stent thrombosis 
as control. Between September 1, 2012 and June 1, 2014, 55 patients presented with 
definite metallic stent thrombosis. We excluded patients with stent thrombosis in left 
main or in graft (n=4), as these typically large vessels are not suited for BVS with its 
currently limited diameter range, and patients with very late stent thrombosis >2 years 
since implantation (n=36), as the available follow-up period in BVS does not allow a 
meaningful comparison of very late thrombosis at that interval. Thus, 15 patients with 
definite metallic stent thrombosis were included as control (2 acute, 4 subacute, 5 late, 
and 4 very late between 1 and 2 years). 
angiographic analysis
Angiographic analysis was performed for baseline implantation and for stent/scaffold 
thrombosis, including quantitative coronary angiography and assessment of intra-
procedural complications. Incomplete lesion coverage (also called geographical miss) 
was defined as the longitudinal mismatch between implantation site and diseased 
coronary segment or coronary segment subjected to balloon dilatation, and its identifi-
cation required a consensus characterization by 2 observers that reviewed the baseline 
angiography, applying established methodology.16 Angiographic analysis at the event 
included assessment of thrombolysis in myocardial infarction flow grade, thrombus 
burden,17 and quantitative coronary angiography measurements.
oct image acquisition
OCT was performed at the operator’s discretion, after thrombus aspiration, in 9 patients 
with BVS thrombosis and in 5 patients with metallic stent thrombosis. OCT acquisition 
was performed with the Lightlab/St Jude (C7XR/Illumien, St Jude/Lightlab, St Paul, MN) 
or the Terumo Lunawave (Terumo Corporation, Tokyo, Japan) frequency-domain imag-
ing systems, as previously described.4, 14
OCT Image Analysis
OCT image analysis was performed offline in 1-mm intervals within the treated segment, 
including proximal and distal 5-mm long edge segments, after excluding frames with 
<75% lumen contour visibility, as previously described.1,7,14 Scaffold struts were de-
fined malapposed in the absence of contact with the vessel wall, whereas metallic stent 
struts were malapposed when the distance of the adluminal strut reflection from the 
vessel wall exceeded the nominal strut thickness (metal backbone plus coating). These 
definitions do not include struts in front of side-branches or their ostium (polygon of 
Angiographic and OCT insights into BVS 227
11
confluence), which are defined as side- branch–related struts. Intraluminal struts belong-
ing to adjacent clusters of apposed struts in overlapping scaffolds were not considered 
malapposed. Thrombus was defined as irregular endoluminal or mural mass and scaf-
fold discontinuity (in BVS) as struts overhanging each other at the same angular sector, 
with or without malapposition, or isolated struts at the luminal centre without obvious 
connection to other surrounding struts,7,18 further classified  as fracture (present at 
baseline and follow-up) or late discontinuity (present only at follow-up). OCT findings in 
BVS thrombosis were compared between frames with and without thrombus.
statistical analysis
All analyses were performed with SPSS 20.0 (IBM, Chicago, IL). Continuous variables 
are presented as mean ± SD, median [inter- quartile range], or estimated means (95% 
confidence interval), whereas categorical variables are reported as count and percent-
ages. Differences in continuous baseline or angiographic variables were assessed with t 
test, whereas in categorical variables with the χ2 or Fisher exact test. Differences in OCT 
variables were assessed with Mann–Whitney and paired comparisons with Wilcoxon, be-
cause of the small sample size and skewed nature of these variables. Frame- or strut-level 
analysis was performed with mixed linear or logistic regression, as struts are clustered 
within each frame within each patient. Strut-level malapposition was assessed by mixed 
logistic regression using within-frame and within-patient intercepts as random effects. 
Frame-level differences were assessed with mixed linear or logistic regression analysis 
using within-patient intercepts as random effect. All P values are 2-sided with a value 
<0.05 indicating significance.
results
Baseline Characteristics and Concomitant Therapy Baseline characteristics for BVS 
(n=14) and metallic stents (n=15) are reported in Table 1. There were no significant dif-
ferences in baseline characteristics with the exception of a higher proportion of men in 
BVS (100% versus 67%; P=0.042).
At the time of BVS thrombosis, 5 patients were not receiving dual antiplatelet therapy 
(DAPT) (2 with premature dis- continuation <1 year and 3 with planned discontinuation 
>1 year). In three patients, DAPT discontinuation had occurred the week preceding the 
event. In metallic stents, complete DAPT discontinuation <1 year was confirmed in 1 pa-
tient and BVS compared with metallic stents (predilation:  92.9% versus 50.0%; P=0.033 
and post-dilation: 50.0% versus 0%; P=0.006), with a trend for higher scaffold diameter 
in (3.18±0.27 versus 2.90±0.47; P=0.06). OCT post implantation had been performed in 5 
of 14 patients in BVS and in none of the metallic stents. Incomplete lesion coverage was 
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observed in four BVS cases, and in one case with metallic stent. Two patients with BVS 
had an angiographically visible edge dissection (one proximal, one distal) after baseline 
implantation, left untreated.
table 1. Clinical and demographic characteristics
n=14
Age (years) 60.2±10.5
Male n(%) 14(100)
Clinical syndrome at baseline
Stable angina  n(%) 5(35.7)
Unstable angina  n(%) 1(7.1)
NSTEMI  n(%) 3(21.4)
STEMI  n(%) 5(35.7)
Clinical syndrome at scaffold thrombosis
NSTEMI  n(%) 7(50.0)
STEMI  n(%) 7(50.0)
Antiplatelet therapy at scaffold thrombosis
Aspirin  n(%) 11(78.6)
Clopidogrel  n(%) 3(21.4)
Prasugrel  n(%) 5(35.7)
Ticagrelor n(%) 1(7.1)
Oral anticoagulation  n(%) 3(21.4)
CAD risk factors
Hypertension n(%) 9(64.3)
Dyslipidemia n(%) 6(42.9)
Diabetes n(%) 1(7.1)
Smoking n(%) 6(42.9)
Family history of CAD n(%) 5(35.7)
Comorbidities
Prior cerebrovascular accident n(%) 3(21.4)
Peripheral vascular disease n(%) 1(7.1)
Kidney disease n(%) 0(0.0)
Prior MI n(%) 2(14.3)
Prior PCI n(%) 2(14.3)
Prior CABG n(%) 0(0.0)
COPD n(%) 1(7.1)
Abbreviations: NSTEMI=non-ST-elevation myocardial infarction; STEMI=ST-elevation myocardial infarc-
tion; CAD=coronary artery disease; MI=myocardial infarction; PCI=percutaneous coronary intervention; 
CABG=coronary artery bypass graft; COPD=chronic obstructive pulmonary disease
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oct findings
OCT at thrombosis was performed in 9 of 14 patients with BVS and in 5 of 15 patients 
with metallic stents. There was no significant difference in OCT findings between BVS 
and metallic stent thrombosis (Table 4). In (very) late thrombosis, the incidence of 
malapposed struts was 1.9%±2.2% for BVS versus 5.6%±6.2% for metallic stents (P=0.31), 
and malapposition distance 486±225 μm for BVS versus 265±151 μm for metallic stents 
(P=0.17).
In BVS thrombosis, frames with thrombus had lower lumen (4.35 mm2 [2.61–6.08 
mm2] versus 5.84 mm2 [4.11–7.58 mm2]; P<0.001) and scaffold area (7.63 mm2 [6.32–
8.95 mm2] versus 8.14 mm2 [6.83–9.46 mm2]; P<0.001) com- pared with frames without 
thrombus (Table I in the Data Supplement). No difference was found in frame-level 
malapposition incidence (P=0.75), whereas malapposition area was numerically higher 
in frames with thrombus, without reaching significance (1.54 mm2 [0–3.44 mm2] versus 
0.44 mm2 [0.00–6.70 mm2]; P=0.18). 
Patient-specific substrates of thrombosis
Tables II and III in the Data Supplement present patient-specific clinical, procedural, 
angiographic and OCT characteristics in BVS thrombosis.
(Sub)acute Thrombosis
In (sub)acute scaffold thrombosis, suboptimal implantation was the main mechanism. 
Incomplete lesion coverage was observed in three patients (Figure I in the Data 
Supplement), either because of mismatch of the pre-dilated segment and the scaf-
folded segment or because of incomplete coverage of the thrombosed segment in 
ST-segment–elevation myocardial infarction (Figure 1). In 2 cases with BVS implantation 
in ostial left anterior descending artery, angiography demonstrated scaffold protrusion 
into left main suggesting malapposition, also with underexpansion in one. Finally, in 1 
case, thrombus was observed in a long overlap segment (7 mm by OCT), together with 
compact fibrin and Zahn-lines in aspirate histology (Figure 2), despite good expansion 
and apposition. In metallic stents, (sub)acute thrombosis was attributed to edge dissec-
tions in 3 cases, strut protrusion into left main with associated malapposition in 1 case, 
and extensive under- expansion in 1 case (minimal stent area, 1.19 mm2). In 1 case, there 
were no findings suggesting suboptimal implantation, but there was suspicion of poor 
compliance with DAPT.
(Very) Late Thrombosis
In 1 case, despite meeting Academic Research Consortium criteria for definite thrombo-
sis, OCT disclosed the absence of thrombus and occlusive edge restenosis as substrate 
(Figure II in the Data Supplement). In most patients, (very) late BVS thrombosis was 
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OCT), together with compact fibrin and Zahn-lines in aspi-
rate histology (Figure 2), despite good expansion and apposi-
tion. In metallic stents, (sub)acute thrombosis was attributed 
to edge dissections in 3 cases, strut protrusion into left main 
with associated malapposition in 1 case, and extensive under-
expansion in 1 case (minimal stent area, 1.19 mm2). In 1 case, 
there were no findings suggesting suboptimal implantation, 
but there was suspicion of poor compliance with DAPT.
(Very) Late Thrombosis
In 1 case, despite meeting Academic Research Consortium 
criteria for definite thrombosis, OCT disclosed the absence of 
thrombus and occlusive edge restenosis as substrate (Figure 
Figure 1. Acute thrombosis because of incomplete lesion coverage. A, Preprocedural and (B) postprocedural angiogram after bioresorb-
able vascular scaffold implantation in a ST-segment–elevation myocardial infarction patient undergoing primary percutaneous coronary 
intervention. Mild haziness at the proximal edge postprocedure (arrow). C, Angiogram at event after thrombus aspiration. Red and white 
thrombus at the proximal scaffold segment (D) and proximal edge segment (E) extending >5 mm. The thrombus is overlying a thin-cap 
fibroatheroma, with possible rupture (arrow). Thrombus aspirate histology (F and G) demonstrates platelet-rich thrombus.
Figure 2. Subacute bioresorbable vascular scaffold thrombosis in extensive strut overlap. A, Preprocedural and (B) postprocedural angio-
gram at baseline. C, Angiogram at event showing contrast deficit in the scaffolded segment. D and E, Optical coherence tomography 
demonstrates thrombus mainly at the overlap (D). F and G, Thrombus aspirate histology shows compact fibrin with Zahn-lines (arrows).
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table 2. Angiographic and procedural characteristics at baseline implantation
Angiographic characteristics n=14
Vessel
LAD n,(%) 9(64.3)
RCA n,(%) 2(14.3)
LCX n,(%) 3(21.4)
Bifurcation 3(21.4)
Ostial LAD/LCx lesion 6(42.9)
AHA/ACC classification
A/B1 3(21.4)
B2/C 11(78.6)
Pre-procedure
TIMI flow grade n,(%)
0 5(35.7)
1 0(0)
2 1(7.1)
3 8(57.1)
Total occlusion (n=5)
   RVD, mm 2.98±0.22
Non-total occlusion (n=9)
RVD, mm 2.61±0.35 
Minimal lumen diameter, mm 0.94± 0.26
Diameter stenosis, % 64.1±9.8
Lesion length, mm 22.08±10.78
Post-procedure
TIMI flow grade  n,(%)
   0 0(0)
   1 0(0)
   2 0(0)
   3 14(100)
RVD, mm 2.68± 0.33
Minimal lumen diameter, mm 2.32±0.26 
Diameter stenosis, % 13.0±6.4 
Dissection  n,(%) 2(14.3)
Side-branch occlusion 1(7.1)
Procedural data
Pre-dilatation  n,(%) 13(92.9)
Post-dilatation  n,(%) 7(50.0)
Thrombus aspiration  n,(%) 4(28.6)
OCT guidance  n,(%) 5(35.7)
Overlap  n,(%) 3(21.4)
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observed in the presence of regional suboptimal flow conditions, such as strut malap-
position, scaffold fracture, and underexpansion. Four of 7 patients with (very) late BVS 
thrombosis undergoing OCT had malapposed struts. In 2 patients, malapposition was 
observed in the absence of scaffold discontinuity (Figure 3), also with underexpansion 
and restenosis in one of them. In the other 2 patients, malapposition was observed 
because of strut discontinuity: 1 with late discontinuity and intraluminal thrombus, 
19 possibly resulting from balloon dilation of the scaffolded segment after the index 
table 2. Angiographic and procedural characteristics at baseline implantation (continued)
Angiographic characteristics n=14
Bifurcation scaffolding
T-stenting  n,(%) 1(7.1)
Balloon dilation of side-branch ostium  n,(%) 1(7.1)
Mean scaffolds per patient,  n 1.36±0.63
Total scaffold length per patient, mm 28.57±14.56
Mean scaffold diameter per patient, mm 3.18±0.27
All values presented as n(%) or mean±SD. Abbreviations: RVD=reference vessel diameter; OCT=optical co-
herence tomography
table 3. Angiographic characteristics at BVS thrombosis
Angiographic characteristics n=14
TIMI flow grade, n,(%)
   0 10(71.4)
   1 1(7.1)
   2 2(14.3)
   3 1(7.1)
Thrombus burden index, n,(%)
   0 0(0)
   1 0(0)
   2 1(7.1)
   3 3(21.4)
   4 0(0)
   5 10(71.4)
Total occlusion (n=10)
   RVD, mm 2.94±0.30
Non-total occlusion (n=4)
   RVD, mm 2.23±0.65
   Minimal lumen diameter, mm 0.86±0.18
   Diameter stenosis, % 58.5±16.9
All values presented as n(%) or mean±SD. Abbreviations: RVD=reference vessel diameter
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procedure, whereas acute fracture had been detected in a second case. In this second 
case, late thrombosis occurred 2 days after both aspirin and clopidogrel discontinuation; 
however, there was no thrombus in the fracture site, but in an under expanded long 
overlap segment (Figure 4). In 3 cases, the substrate was not clearly identified: 1 very 
late thrombosis case where late discontinuity was suspected but not clearly identified 
because of thrombus (Figure III in the Data Supplement), 1 very late thrombosis case 
with extensive baseline malapposition (8.6% malapposed struts) and intra-scaffold 
dissections (no imaging at the event), and 1 late thrombosis case with T-stenting with 
BVS in a left anterior descending artery- diagonal bifurcation. The 2 latter patients were 
not receiving any antiplatelet agent at the time of late scaffold thrombosis. In metallic 
stents, late thrombosis was associated with malapposition in 2 cases and with strut pro-
trusion into left main in another case. Complete DAPT discontinuation was confirmed in 
an additional patient and suspected in another with late thrombosis. In 4 patients with 
6  Karanasos et al  OCT Findings in BVS Thrombosis 
II in the Data Supplement). In most patients, (very) late BVS 
thrombosis was observed in the presence of regional subop-
timal flow conditions, such as strut malapposition, scaffold 
fracture, and underexpansion. Four of 7 patients with (very) 
late BVS thrombosis undergoing OCT had malapposed struts. 
In 2 patients, malapposition was observed in the absence 
of scaffold discontinuity (Figure 3), also with underexpan-
sion and restenosis in one of them. In the other 2 patients, 
malapposition was observed because of strut discontinuity: 1 
with lat  discontinuity and intraluminal thrombu ,19 possibly 
resulting from balloon dilation of the scaffolded segment after 
the index procedure, whereas acute fracture had been detected 
in a second case. In this second case, late thrombosis occurred 
2 days after both aspirin and clopidogrel discontinuation; 
however, there was no thrombus in the fracture site, but in an 
underexpanded long overlap segment (Figure 4). In 3 cases, 
the substrate was not clearly identified: 1 very late thrombosis 
case where late discontinuity was suspected but not clearly 
identified because of thrombus (Figure III in the Data Supple-
ment), 1 very la e thrombosis case with extensive baseline 
Figure 3. Late bioresorbable vascular scaffold (BVS) thrombosis and malapposition. BVS implantation in a total left anterior descending 
artery occlusion with postdilation (A), resulting in acceptable angiographic result with mild haziness (B), but residual thrombus by optical 
coherence tomography (OCT; C and D) and residual plaque burden by intravascular ultrasound (E). Postdilation was not repeated, consid-
ering the risk of side-branch occlusion. F, Angiogram at event after thrombus aspiration. G through I, OCT shows massive red thrombus, 
and late malapposition (arrows).
Figure 4. Late scaffold thrombosis after dual antiplatelet therapy discontinuation in overlapping bioresorbable vascular scaffold (BVS) 
with underexpansion. Overlapping BVS implantation in a diffuse calcified left anterior descending artery lesion (A), with acceptable angio-
graphic result (B), but underexpansion by intravascular ultrasound (C), and scaffold fracture at the proximal edge by optical coherence 
tomography (OCT; D), possibly because of deep catheter intubation. The patient experienced late thrombosis 161 days post implantation 
(E), 2 days after aspirin and clopidogrel discontinuation. OCT shows thrombosis mainly at the overlap region, with low minimal scaffold area 
(4.21 mm2; F), whereas the fracture site remains free of thrombus (G).
 by guest on N
ovem
ber 13, 2017
http://circinterventions.ahajournals.org/
D
ow
nloaded from
 
figure 3 Late bioresorbable vascular scaffold (BVS) thromb is and malapposition.
BVS implantation in a total left anterior desc nding artery occlusion with post-dilati  (A), resulting in ac-
ceptable angiographic result with mild haziness (B), but residual thrombus by optical coherence tomog-
raphy (OCT; C and D) and residual plaque burden by intravascular ultrasound (E). Post-dilation was not 
repeated, considering the risk of side-branch occlusion. F, Angiogram at event after thrombus aspiration. G 
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table 4. Optical coherence tomography findings in frames with and without thrombus
Frames with thrombus
(n=140)
Frames without 
thrombus
(n=112)
p-value
Lumen area, mm2 4.35(2.61-6.08) 5.84(4.11-7.58) 0.001
Scaffold area, mm2 7.63(6.32-8.95) 8.14(6.83-9.46) 0.001
Malapposition area, mm² (n=16) 1.54(0-3.44) 0.44(0.00-6.70) 0.182
Frames with malapposition, % 7.6(0.0-16.2) 8.9(0.2-17.6) 0.752
Frames with overlap, % 8.3(1.5-15) 3.5(0.0-10.4) 0.196
All values presented as estimated marginal means (95% confidence intervals). 
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very late metallic stent thrombosis, baseline or follow-up angiography did not suggest 
any mechanical issues, while intravascular imaging was not performed.
Discussion
This real-world case series provides unique insights in the mechanisms of BVS throm-
bosis. The main findings of our study are (1) device thrombosis remains an issue with 
BVS, with the timing of the event evenly distributed from acute to very late thrombosis; 
(2) similar to metallic stents, acute and subacute BVS thrombosis is predominantly as-
sociated with suboptimal implantation; and (3) late and very late scaffold thrombosis 
is frequently observed in the presence of regional suboptimal flow conditions, often in 
combination with cessation of DAPT.
Notwithstanding promising results from first-in-man studies showing favourable 
BVS long-term healing response 4, 7 and clinical results comparable with metallic DES, 
5, 6 little is known about vascular healing after BVS implantation in complex lesions. 
Real-world registries have reported high 6-month BVS thrombosis rates, driven mainly 
by increased early thrombosis, 8, and 9 implying a possible role of suboptimal implanta-
tion. In our series, we report on 14 cases of definite BVS thrombosis at different intervals 
since implantation and compare the imaging findings with a control group of metallic 
6  Karanasos et al  OCT Findings in BVS Thrombosis 
II in the Data Supplement). In most patients, (very) late BVS 
thrombosis was observed in the presence of regional subop-
timal flow conditions, such as strut malapposition, scaffold 
fracture, and underexpansion. Four of 7 patients with (very) 
late BVS thrombosis undergoing OCT had malapposed struts. 
In 2 patients, malapposition was observed in the absence 
of scaffold discontinuity (Figure 3), also with underexpan-
sion and restenosis in one of them. In the other 2 patients, 
malapposition was observed because of strut discontinuity: 1 
with late discontinuity and intraluminal thrombus,19 possibly 
resulting from balloon dilation of the scaffolded segment after 
the index procedure, whereas acute fracture had been detected 
in a second case. In this second case, late thrombosis occurred 
2 days after both aspirin and clopidogrel discontinuation; 
however, there was no thrombus in the fracture site, but in an 
underexpanded long overlap segment (Figure 4). In 3 cases, 
the substrate was not clearly identified: 1 very late thrombosis 
case where late discontinuity was suspected but not clearly 
identified because of thrombus (Figure III in the Data Supple-
ment), 1 very late thrombosis case with extensive baseline 
Figure 3. Late bioresorbable vascular scaffold (BVS) thrombosis and malapposition. BVS implantation in a total left anterior descending 
artery occlusion with postdilation (A), resulting in acceptable angiographic result with mild haziness (B), but residual thrombus by optical 
coherence tomography (OCT; C and D) and residual plaque burden by intravascular ultrasound (E). Postdilation was not repeated, consid-
ering the risk of side-branch occlusion. F, Angiogram at event after thrombus aspiration. G through I, OCT shows massive red thrombus, 
and late malapposition (arrows).
Figure 4. Late scaffold thrombosis after dual antiplatelet therapy discontinuation in overlapping bioresorbable vascular scaffold (BVS) 
with underexpansion. Overlapping BVS implantation in a diffuse calcified left anterior descending artery lesion (A), with acceptable angio-
graphic result (B), but underexpansion by intravascular ultrasound (C), and scaffold fracture at the proximal edge by optical coherence 
tomography (OCT; D), possibly because of deep catheter intubation. The patient experienced late thrombosis 161 days post implantation 
(E), 2 days after aspirin and clopidogrel discontinuation. OCT shows thrombosis mainly at the overlap region, with low minimal scaffold area 
(4.21 mm2; F), whereas the fracture site remains free of thrombus (G).
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figure 4. Late scaffold thrombosis after dual antiplatelet therapy discontinuation in overlapping biore-
sorbable vascular scaffold (BVS) with underexpa sion. Overlapping BVS implantation in a diffuse calcifi d 
left anterior desce ding art ry lesio  (a), with acceptable angiographic result (b), but underexpansion by 
intravascular ultrasound (c), and scaffold fracture at the proximal edge by optical coherence tomography 
(OCT; D), possibly because of deep catheter intubation. The patient experienced late thrombosis 161 days 
post implantation (e), 2 days after aspirin and clopidogrel discontinuation. OCT shows thrombosis mainly 
at the overlap region, with low minimal scaffold area (4.21 mm2; f), whereas the fracture site remains free 
of thrombus (G).
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stents with definite stent thrombosis from the same time period, thus providing imaging 
insights into this complication. Importantly, suboptimal implantation was identified in 
both groups in a similar extent, suggesting that achieving an optimal implantation result 
might be more crucial than the type of implanted device in avoiding device thrombosis.
(Sub)acute BVS Thrombosis: Impact of Suboptimal Implantation
In acute and subacute BVS thrombosis, suboptimal implantation, comprising incom-
plete lesion coverage, malapposition, and underexpansion, was identified as the leading 
morphological substrate. This finding is in line with established substrates for metallic 
stent thrombosis12 and confirmed by observations in our control group. As the cur-
rent BVS generation has a relatively high crossing profile, BVSs require rigorous lesion 
preparation, potentially translating to higher risk for incomplete coverage of the injured 
segment, compared with direct stenting often applied with metallic stents. Thus, our 
findings might urge the operator to specifically ensure complete cover- age of the lesion 
and injured segments, including angiographically apparent edge dissections.
Furthermore, the development of acute and subacute BVS thrombosis in 2 ST-
segment–elevation myocardial infarction patients, after BVS implantation in ostial left 
anterior descending artery with scaffold protrusion into the left main, raises specula-
tion that hemodynamic disturbances resulting from the protrusion and the associated 
malapposition could be a substrate for thrombosis.20–22 This was also documented 
by OCT in 2 metallic stent thrombosis cases, suggesting a similar contribution of this 
mechanism.
Finally, 1 case of subacute thrombosis occurred despite good expansion and apposi-
tion, in the presence of long strut overlap. The high strut thickness of Absorb BVS (150 
μm) and bench observations of increased thrombogenicity of thick-strut stents which is 
more pronounced at overlap sites, 21 together with histological observations of Zahn-
lines in the aspirates, indicate a potential involvement of flow disturbances induced by 
long overlap and make a case for minimizing over- lap length in treatment of long le-
sions by BVS. Whether this increased strut thickness could translate to increased throm-
bogenicity in vivo in the presence of an optimal implantation result remains unknown.
These findings underscore the significance of a meticulous BVS implantation tech-
nique, potentially including invasive imaging guidance, which has proven advantages 
over angiography for achieving optimal lesion treatment, in terms of coverage and 
expansion.23 It is important however to note that imaging guidance during the proce-
dure might drive the opera- tor to excessive post-dilation, potentially leading to scaffold 
fracture. Therefore, thorough lesion evaluation before implantation might help avoid 
situations with pronounced mismatch between scaffold and artery size.
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late and very late bvs thrombosis: Prominent role of suboptimal flow 
conditions
(Very) late thrombosis events in our series were attributed to factors potentially affect-
ing flow conditions. These include underexpansion and pronounced strut protrusion 
into the lumen as a result of malapposition, bifurcation intervention, or strut discon-
tinuity. Underexpansion has been identified as an important predictor of metallic DES 
thrombosis.3, 12 the significance of optimal expansion in avoiding BVS thrombosis is 
underscored by the finding of lower scaffold area in sites with thrombus compared with 
sites without thrombus.
The role of malapposition in late metallic DES thrombosis is debated 24; however, there 
is high prevalence in patients with events,1 and late malapposition in first-generation 
DES has been identified as predictor of very long-term adverse outcome.25 In our series, 
malapposition in (very) late BVS thrombosis (1.9±2.2%) did not differ significantly from 
late metallic stent thrombosis and was higher than the range reported for follow-up of 
second-generation metallic DES.26 Likewise, malapposition distance (486 ± 225 μm) was 
similar to metallic stents (265 ± 151 μm) and at the range of previously reported values 
in metallic DES thrombosis (mean: 350 μm).1 Therefore, malapposition of such extent, 
either persistent or late-acquired, might contribute to (very) late scaffold thrombosis.
As opposed to metallic DES, extensive malapposition in BVS might also result from 
strut discontinuity, which was associated with extensive thrombosis in a very late event 
in our series, possibly triggered by DAPT cessation.19 Whether small discontinuities, 
resulting from normal scaffold resorption, are associated with thrombosis is unclear. 
Notwithstanding this poorly documented association of discontinuity with thrombo-
sis,18 precautionary measures such as respecting the post-dilation limits and cautious 
catheter recrossing or reintervention at later time points should be considered.
role of DaPt Discontinuation
In addition to suboptimal implantation, DAPT cessation seems to play a role in BVS 
thrombosis, as in metallic DES.27 In 3 cases, there was a close temporal association of 
DAPT cessation with clinical manifestation of BVS thrombosis, tracking with observa-
tions in first-generation metallic DES, where scheduled P2Y12 inhibitor withdrawal was 
associated with increased ischemic events.28 As we assume concomitant suboptimal 
flow conditions in these patients, caused by underexpansion or extensive malapposi-
tion, we speculate on a possible synergistic effect of these factors in scaffold thrombosis. 
Consequently, these observations might raise questions about the need for platelet 
reactivity testing in patients with complex procedures or where optimal expansion can-
not be achieved. Furthermore, the impact of DAPT cessation could be more pronounced 
when both aspirin and P2Y12 inhibitor are with- drawn in patients receiving chronic oral 
anticoagulation, as in 3 patients in our BVS series. Therefore, considering our observa-
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tions of ongoing thrombotic risk even beyond 1 year, BVS implantation in such patients 
should be accompanied by adequate antiplatelet therapy or avoided in case of high 
bleeding risk.
clinical implications
Collectively, our findings underscore the significance of an optimal implantation result 
for minimizing the incidence of BVS thrombosis. Intravascular imaging at baseline could 
allow for early recognition and treatment of incomplete lesion coverage, better proce-
dural planning in ostial lesions, 29 and optimal BVS sizing and post-dilating, thus avoid-
ing underexpansion 23 or scaffold fracture. Moreover, similar to metallic DES, proper 
DAPT administration must be emphasized.27 Therefore, future studies should focus on 
optimal DAPT duration in patients with BVS, whereas platelet reactivity testing might be 
considered in selected patients with suboptimal implantation or complex intervention. 
Finally, in patients concomitantly receiving anticoagulants, administration of at least 1 
antiplatelet agent until resorption or for life should be considered, pending appropriate 
studies.
limitations
This study is focusing on a mechanistic understanding of BVS thrombosis. The study de-
sign and its single-centre nature preclude firm estimations of BVS thrombosis incidence 
and predictors in real-world populations, considering the inclusion of patients treated 
for BVS thrombosis in our centre, leading to possible underestimation. As OCT was not 
systematically performed, it was only available for 9 of 14 patients. Rou- tine OCT use 
could have provided further insights into the pathomechanisms of BVS thrombosis, 
whereas the small number of patients undergoing OCT might be a limitation in the 
mixed model analysis of OCT variables. Moreover, the lack of a control group of BVS 
without thrombosis precludes assessment of morphological predictors of BVS throm-
bosis. Residual thrombus might have underestimated our results, hampering complete 
substrate visualization, while precluding coverage assessment, which is based on thick-
ness measurements for BVS, that are inaccurate in the presence of attached thrombus, 
rather than on visual confirmation of overlying tissue as in metallic stents.1, 7 Therefore, 
a possible contribution of incomplete strut coverage could not be systematically evalu-
ated. Finally, no platelet function tests were performed that could evaluate a possible 
contribution of increased platelet reactivity to BVS thrombosis.
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conclusions
Suboptimal implantation with underexpansion, malapposition, and incomplete lesion 
coverage comprised the main pathomechanisms for both early and late BVS thrombosis 
in our series, similar to metallic stent thrombosis. DAPT discontinuation seems to also be 
a secondary contributor in several late events. Our observations suggest that a number 
of potential triggers for BVS thrombosis could be avoided and might warrant prospec-
tive validation.
Angiographic and OCT insights into BVS 239
11
references
 1. Guagliumi G, Sirbu V, Musumeci G, Gerber R, Biondi-Zoccai G, Ikejima H, Ladich E, Lortkipanidze 
N, Matiashvili A, Valsecchi O, Virmani R, Stone GW. Examination of the in vivo mechanisms of late 
drug-eluting stent thrombosis: findings from optical coherence tomography and intra- vascular 
ultrasound imaging. JACC Cardiovasc Interv. 2012;5:12–20. doi: 10.1016/j.jcin.2011.09.018.
 2. Amabile N, Souteyrand G, Ghostine S, Combaret N, Slama MS, Barber- Chamoux N, Motreff P, 
Caussin C. Very late stent thrombosis related to incomplete neointimal coverage or neoath-
erosclerotic plaque rupture iden- tified by optical coherence tomography imaging. Eur Heart J 
Cardiovasc Imaging. 2014;15:24–31. doi: 10.1093/ehjci/jet052.
 3. Alfonso F, Dutary J, Paulo M, Gonzalo N, Pérez-Vizcayno MJ, Jiménez- Quevedo P, Escaned J, 
Bañuelos C, Hernández R, Macaya C. Combined use of optical coherence tomography and intra-
vascular ultrasound imaging in patients undergoing coronary interventions for stent thrombosis. 
Heart. 2012;98:1213–1220. doi: 10.1136/heartjnl-2012-302183.
 4. Karanasos A, Simsek C, Gnanadesigan M, van Ditzhuijzen NS, Freire R, Dijkstra J, Tu S, Van Mieghem 
N, van Soest G, de Jaegere P, Serruys PW, Zijlstra F, van Geuns RJ, Regar E. OCT assessment of 
the long-term vascular healing response 5 years after everolimus-eluting bioresorbable vascular 
scaffold. J Am Coll Cardiol. 2014;64:2343–2356. doi: 10.1016/j. jacc.2014.09.029.
 5. Serruys PW, Chevalier B, Dudek D, Cequier A, Carrié D, Iniguez A, Dominici M, van der Schaaf 
RJ, Haude M, Wasungu L, Veldhof S, Peng L, Staehr P, Grundeken MJ, Ishibashi Y, Garcia-Garcia 
HM, Onuma Y. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus- eluting 
stent for ischaemic heart disease caused by de-novo native coro- nary artery lesions (ABSORB 
II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised 
controlled trial. Lancet. 2015;385:43–54. doi: 10.1016/S0140-6736(14)61455-0.
 6. Abizaid A, Costa JR Jr, Bartorelli AL, Whitbourn R, van Geuns RJ, Chevalier B, Patel T, Seth A, Stute-
ville M, Dorange C, Cheong WF, Sudhir K, Serruys PW. The ABSORB EXTEND study: preliminary 
report of the twelve-month clinical outcomes in the first 512 patients enrolled. EuroIntervention. 
2015;10:1396–1401. doi: 10.4244/EIJV10I12A243.
 7. Serruys PW, Onuma Y, Garcia-Garcia HM, Muramatsu T, van Geuns RJ, de Bruyne B, Dudek D, Thue-
sen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange 
C, Veldhof S, Hebert KM, Rapoza R, Ormiston JA. Dynamics of vessel wall changes fol- lowing the 
implantation of the absorb everolimus-eluting bioresorbable vas- cular scaffold: a multi-imaging 
modality study at 6, 12, 24 and 36 months. EuroIntervention. 2014;9:1271–1284. doi: 10.4244/
EIJV9I11A217.
 8. Capodanno D, Gori T, Nef H, Latib A, Mehilli J, Lesiak M, Caramanno G, Naber C, Di Mario C, 
Colombo A, Capranzano P, Wiebe J, Araszkiewicz A, Geraci S, Pyxaras S, Mattesini A, Naganuma 
T, Münzel T, Tamburino C. Percutaneous coronary intervention with everolimus-eluting biore- 
sorbable vascular scaffolds in routine clinical practice: early and mid- term outcomes from the 
European multicentre GHOST-EU registry. EuroIntervention. 2015;10:1144–1153. doi: 10.4244/
EIJY14M07_11.
 9. Kraak RP, Hassell ME, Grundeken MJ, Koch  KT,  Henriques  JP, Piek JJ, Baan J Jr, Vis MM, Arkenbout 
EK, Tijssen JG, de Winter RJ, Wykrzykowska JJ. Initial experience and clinical evaluation of the 
Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real 
World PCI Registry. EuroIntervention. 2015;10:1160– 1168. doi: 10.4244/EIJY14M08_08.
 10. Ishibashi Y, Onuma Y, Muramatsu T, Nakatani S, Iqbal J, Garcia-Garcia HM, Bartorelli AL, Whitbourn 
R, Abizaid A, Serruys PW; ABSORB EXTEND Investigators. Lessons learned from acute and late 
240 Chapter 11
scaffold fail- ures in the ABSORB EXTEND trial. EuroIntervention. 2014;10:449–457. doi: 10.4244/
EIJV10I4A78.
 11. Regar E, Lemos PA, Saia F, Degertekin M, Tanabe K, Lee CH, Arampatzis CA, Hoye A, Sianos G, de 
Feyter P, van der Giessen WJ, Smits PC, van Domburg RT, Serruys PW. Incidence of thrombotic 
stent occlusion dur- ing the first three months after sirolimus-eluting stent implantation in 500 
consecutive patients. Am J Cardiol. 2004;93:1271–1275. doi: 10.1016/j. amjcard.2004.02.013.
 12. Choi SY, Witzenbichler B, Maehara A, Lansky AJ, Guagliumi G, Brodie B, Kellett MA Jr, Dressler 
O, Parise H, Mehran R, Dangas GD, Mintz GS, Stone GW. Intravascular ultrasound findings of 
early stent thrombosis after primary percutaneous intervention in acute myo- cardial infarction: 
a Harmonizing Outcomes with  Revascularization and Stents in Acute Myocardial Infarction 
(HORIZONS-AMI) sub- study. Circ Cardiovasc Interv. 2011;4:239–247. doi: 10.1161/ CIRCINTERVEN-
TIONS.110.959791.
 13. Van Geuns RJ, De Jaegere P, Diletti R, Karanasos A, Muramatsu T, Nauta ST, Onuma Y, Regar E, 
Schultz CJ, Serruys PW, Van Mieghem NM, Zijlstra F. Short- and intermediate- term clinical out-
comes after implantation of evero- limus-eluting bioresorbable scaffold in complex lesions: a 
prospective single- arm study - ABSORB Expand trial. J Am Coll Cardiol. 2013;62:B133–B133.
 14. Diletti R, Karanasos A, Muramatsu T, Nakatani S, Van Mieghem NM, Onuma Y, Nauta ST, Ishibashi 
Y, Lenzen MJ, Ligthart J, Schultz C, Regar E, de Jaegere PP, Serruys PW, Zijlstra F, van Geuns RJ. 
Everolimus- eluting bioresorbable vascular scaffolds for treatment of patients present- ing with 
ST-segment elevation myocardial infarction: BVS STEMI first study. Eur Heart J. 2014;35:777–786. 
doi: 10.1093/eurheartj/eht546.
 15. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, 
Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consor-
tium. Clinical end points in coronary stent trials:  a  case  for  standard- ized definitions. Circulation. 
2007;115:2344–2351. doi: 10.1161/ CIRCULATIONAHA.106.685313.
 16. Sianos G, Kay IP, Costa MA, Regar E, Kozuma K, de Feyter PJ, Boersma E, Disco C, Serruys PW. 
Geographical miss during catheter-based intra- coronary beta-radiation: incidence and implica-
tions in the BRIE study. Beta-Radiation In Europe. J Am Coll Cardiol. 2001;38:415–420.
 17. Sianos G, Papafaklis MI, Daemen J, Vaina S, van Mieghem CA, van Domburg RT, Michalis LK, 
Serruys PW. Angiographic stent throm- bosis after routine use of drug-eluting stents in ST-
segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol. 
2007;50:573–583. doi: 10.1016/j.jacc.2007.04.059.
 18. Onuma Y, Serruys PW, Muramatsu T, Nakatani S, van Geuns RJ, de Bruyne B, Dudek D, Christiansen 
E, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Garcia-Garcia 
HM, Veldhof S, Rapoza R, Ormiston JA. Incidence and imaging outcomes of acute scaffold dis-
ruption and late structural discontinuity after implanta- tion of the absorb Everolimus-Eluting 
fully bioresorbable vascular scaf- fold: optical coherence tomography assessment in the ABSORB 
cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent Sys-
tem in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc 
Interv. 2014;7:1400–1411. doi: 10.1016/j.jcin.2014.06.016.
 19. Karanasos A, van Geuns RJ, Zijlstra F, Regar E. Very late bioresorbable scaffold thrombosis after 
discontinuation of dual antiplatelet therapy. Eur Heart J. 2014;35:1781. doi: 10.1093/eurheartj/
ehu031.
 20. Foin N, Gutiérrez-Chico JL, Nakatani S, Torii R, Bourantas CV, Sen S, Nijjer S, Petraco R, Kousera 
C, Ghione M, Onuma Y,  Garcia- Garcia HM, Francis DP, Wong P, Di Mario C, Davies JE, Serruys 
PW. Incomplete stent apposition causes high shear flow disturbances and delay in neointimal 
Angiographic and OCT insights into BVS 241
11
coverage as a function of  strut  to  wall  detach- ment distance: implications for the management 
of incomplete stent apposition. Circ Cardiovasc Interv. 2014;7:180–189. doi: 10.1161/ CIRCINTER-
VENTIONS.113.000931.
 21. Kolandaivelu K, Swaminathan R, Gibson WJ, Kolachalama VB, Nguyen-Ehrenreich KL, Giddings 
VL, Coleman L, Wong GK, Edelman ER.  Stent  thrombogenicity  early  in  high-risk  interventional 
set- tings is driven by stent design and deployment and protected by poly- mer-drug coatings. 
Circulation. 2011;123:1400–1409. doi: 10.1161/ CIRCULATIONAHA.110.003210.
 22. Karanasos A, Li Y, Tu S, Wentzel JJ, Reiber JH, van Geuns RJ, Regar E. Is it safe to implant bioresorb-
able scaffolds in ostial side-branch le- sions? Impact of ‘neo-carina’ formation on main-branch 
flow pattern. Longitudinal clinical observations. Atherosclerosis. 2015;238:22–25. doi: 10.1016/j.
atherosclerosis.2014.11.013.
 23. Witzenbichler B, Maehara A, Weisz G, Neumann FJ, Rinaldi MJ, Metzger DC, Henry TD, Cox DA, 
Duffy PL, Brodie BR, Stuckey TD, Mazzaferri EL Jr, Xu K, Parise H, Mehran R, Mintz GS, Stone GW. Re-
lationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting 
stents: the assessment of dual antiplatelet therapy with drug- eluting stents (ADAPT-DES) study. 
Circulation. 2014;129:463–470. doi: 10.1161/CIRCULATIONAHA.113.003942.
 24. Karanasos A, Regar E. Standing on solid ground?: Reassessing the role of incomplete strut ap-
position in drug-eluting stents. Circ Cardiovasc Interv. 2014;7:6–8. doi: 10.1161/CIRCINTERVEN-
TIONS.114.001173.
 25. Cook S, Eshtehardi P, Kalesan B, Räber L, Wenaweser P, Togni M, Moschovitis A, Vogel R, Seiler C, 
Eberli FR, Lüscher T, Meier B, Jüni P, Windecker S. Impact of incomplete stent apposition on long-
term clinical outcome after drug-eluting stent implantation. Eur Heart J. 2012;33:1334–1343. doi: 
10.1093/eurheartj/ehr484.
 26. Papayannis AC, Cipher D, Banerjee S, Brilakis ES. Optical coherence to- mography evaluation 
of drug-eluting stents: a systematic review. Catheter Cardiovasc Interv. 2013;81:481–487. doi: 
10.1002/ccd.24327.
 27. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, Suddath WO, Weissman NJ, Tor-
guson R, Kent KM, Pichard AD, Satler LF, Waksman R, Serruys PW. Late thrombosis in drug-eluting 
coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364:1519–1521. doi: 
10.1016/S0140-6736(04)17275-9.
 28. Garratt KN, Weaver WD, Jenkins RG, Pow TK, Mauri L, Kereiakes DJ, Winters KJ, Christen T, Allocco 
DJ, Lee DP. Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after 
TAXUS Liberté paclitaxel-eluting coronary stent placement. Circulation. 2015;131:62–73. doi: 
10.1161/CIRCULATIONAHA.114.013570.
 29. Patel Y, Depta JP, Patel JS, Masrani SK, Novak E, Zajarias A, Kurz HI, Lasala JM, Bach RG, Singh 
J. Impact of intravascular ultrasound on the long-term clinical outcomes in the treatment of 
coronary ostial lesions [published online ahead of print June 1, 2013]. Catheter Cardiovasc Interv. 
doi: 10.1002/ccd.25034.
242 Chapter 11
Supplemental Material
methoDs
Quantitative coronary angiography
Quantitative coronary angiography was performed using CAAS 5.11 (Pie Medical Imag-
ing, Maastricht, Netherlands) and included reference vessel diameter (RVD), diameter 
stenosis (DS%), and minimal lumen diameter (MLD).
histopathological analysis of thrombus aspirates
Thirteen patients underwent thrombus aspiration. Aspiration samples were success-
fully retrieved in four (30.8%) and were collected after filtering (40μm cell strainer BD 
Biosciences), snap-frozen and stored at -80°C. Macroscopic characteristics such as color, 
size and number of particles were documented. The frozen samples were cryosectioned 
(5μm serial sections), fixed with buffered paraformaldehyde 4%, and stained with 
hematoxylin-eosin as a routine stain, rosorcin-fuchin as an elastin stain and alcian blue 
for proteoglycans. Polarized light was used to detect birefringence.
results
histopathological findings of thrombus aspirates
Four thrombus specimens were submitted for histopathology analysis. One sample did 
not contain any thrombus. One case contained only micro-thrombi [mean length 36µm 
(25-52μm)] without cellular elements. Two cases contained overt thrombi: one being 
platelet-rich and one containing compact fibrin with Zahn-lines. Eosinophilic granulo-
cytes were observed in both but comprised <10% of all granulocytes, reflecting normal 
distribution. There was no evidence of hypersensitivity towards scaffold material. Vessel 
wall components and atheroma were not observed. There was no birefringence indica-
tive of polymeric scaffold material in the aspirates.
treatment of bvs thrombosis
Seven of 14 patients were treated by implantation of a metallic DES. Two patients with 
acute thrombosis due to edge problems were treated by additional BVS implantation. 
Four patients were treated by combination of thrombectomy and balloon dilation, while 
in one patient the attempt for treatment of acute thrombosis failed. This patient devel-
oped a large myocardial infarction (CKpeak: 4358U/L), which led to poor left ventricular 
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11systolic function and implantation of an implantable cardioverter-defibrillator for non-sustained ventricular tachycardia. In all patients, antiplatelet therapy after thrombosis 
was recommended for at least one year, continued by aspirin alone, including patients 
concomitantly receiving oral anticoagulation.
outcome after treatment of bvs thrombosis
In 11 patients, follow-up was uneventful, while 3 patients suffered a recurrent event: 
One patient died of cardiac cause 4 days after the procedure. Another patient receiving 
a metallic DES for the treatment of BVS thrombosis, had an invasive follow-up 6 months 
after the thrombosis. OCT showed an overall good healing result with nevertheless 
sporadic clusters of uncovered struts. This patient suffered recurrent thrombosis, one 
year after the initial event, and 5 days after scheduled prasugrel discontinuation. An-
other patient had a repeat target vessel revascularization 4 months after thrombosis by 
coronary artery bypass graft (CABG), due to restenosis of the metal DES implanted for 
the treatment of BVS thrombosis.
table 1. OCT findings at scaffold thrombosis
OCT findings n=9
Analyzed struts, n 208±145
Minimum lumen area, mm2 2.26±1.56
Mean lumen area, mm2 5.00±2.21
Minimum scaffold area, mm2 6.21±1.20
Mean scaffold area, mm2 7.88±1.42
Ratio of minimum scaffold area to reference area 0.93±0.20
Ratio of minimum scaffold diameter to nominal diameter 0.87±0.06
Malapposition area, mm2 (n=3) 0.184±0.181
Mean neointimal/attached thrombus area, mm2 1.99±0.78
Mean non-attached thrombus area, mm2 0.017±0.028
Malapposed struts, % 2.8(1.5-4.1)
Malapposition distance(μm) 348(214-482)
Scaffolds with at least 1 malapposed strut, n,(%) 5(55.5)
Scaffolds with >5% malapposed struts, n,(%) 2(22.2)
Thrombus n,(%) 8(88.8)
Scaffold discontinuity n,(%) 2(22.2)
Values presented as n(%) or mean±SD. Malapposed struts and distance presented as estimated marginal 
mean (95% confidence intervals). Abbreviations: OCT=optical coherence tomography 
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Supplementary Figures 
 
 
Supplementary Figure 1. Summary of the cases with acute thrombosis due to incomplete lesion 
coverage 
Black arrows indicate the scaffold markers and white arrows indicate the uncovered edge segment. 
   
supplementary figure 1 Summary of the cases with acute thrombosis due to incomplete lesion coverage
Black arrows indicate the scaffold markers and white arrows indicate the uncovered edge segment.
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Supplementary Figure 2. Late stent thrombosis re-classified by OCT as edge restenosis resulting from 
incomplete lesion coverage. 
A. Pre-procedural and B. post-procedural angiogram at baseline showing proximal edge dissection (white 
arrow). C. Angiogram at event (142 days) shows contrast deficit at the proximal edge, extending within the 
scaffold with TIMI I flow. OCT discloses occlusive edge restenosis (D) and restenosis within the scaffold 
with layered pattern (E), without luminal thrombus. F. Angiographic review demonstrating incomplete 
lesion coverage. Black arrows indicate the scaffold markers and white arrows the uncovered edge segment. 
supplementary figure 2 Late stent thrombosis re-classified by OCT as edge restenosis resulting from in-
complet  lesion coverage.
A. Pre-procedural and B. post-procedural angiogram at baseline showing proximal edge dissection (white 
arrow). C. Angiogram at event (142 days) shows contrast deficit at the proximal edge, extending within the 
scaffold with TIMI I flow. OCT discloses occlusive edge restenosis (D) and restenosis within the scaffold with 
laye d pattern (E), without luminal thrombus. F. Angiographic review demonstrating incomplete lesion 
coverage. Black arrows indicate the scaffold markers and white arrows the uncovered edge segment.
248 Chapter 11
10 
 
 
 
Supplementary Figure 3. Very late scaffold thrombosis without definite substrate. 
BVS implantation in a proximal RCA lesion due to STEMI (A), with good post-procedural angiographic (B) 
and OCT (C-D) result. The patient suffered very late scaffold thrombosis 478 days post implantation, while 
only on aspirin (E). OCT shows suspected scaffold discontinuity (F; white arrow) and uncovered and 
possibly malapposed struts (G; yellow arrow) proximally to the thrombosed segment. 
 
supplementary figure 3 Very late scaffold thrombosis without definite substrate.
BVS implantation in a proximal RCA lesion due to STEMI (A), with good post-procedural angiographic (B) 
and OCT (C-D) result. The patient suffered very late scaffold thrombosis 478 days post implantation, while 
only on aspirin (E). OCT shows suspected scaffold discontinuity (F; white arrow) and uncovered and pos-
sibly malapposed struts (G; yellow arrow) proximally to the thrombosed segment.
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introDuction
Bioresorbable scaffolds (BRS) are a promising new interventional treatment strategy for 
coronary artery disease. They were developed to overcome some of the limitations of 
metal drug-eluting stents (DES), mainly the late reinterventions which occur at a consis-
tent rate after one year and have not been reduced by use of local drug-elution. Initial 
experience in non-complex lesions established the efficacy in opening the vessel and 
the concept of bioresorption. However, with the use of BRS in more complex lesions, also 
the incidence of BRS failure, including both scaffold restenosis and thrombosis (ScT), has 
increased. Therefore, both understanding of the pathophysiology and of the available 
treatment options of scaffold failure remain important issues in insuring procedural and 
long-term clinical success. 
Over the past years, bioresorbable scaffolds (BRS) have evolved as the new treatment 
strategy for coronary artery disease (CAD) with the Absorb bioresorbable vascular scaf-
fold (BVS, Abbott Vascular, Santa Clara, California, USA) being the device most intensively 
studied. 
A different CE marked scaffold, the DESolve myolimus-eluting bioresorbable coronary 
scaffold system (Elixir Medical Corporation, Sunnyvale, CA, USA) is currently under 
investigation.  [1]. Although the DESolve is also PLLA based the degradation and drug-
elution profile is different and different timings for failure strategies may apply. Recently, 
the Magmaris scaffold (Biotronik AG, Bülach, Switzerland. Previously known as DREAMS 
scaffold), a sirolimus eluting and magnesium based scaffold, received CE mark after its 
safety was tested in the BIOSOLVE-II first-in-man trial. [2] Resorption is faster than in 
PLLA based scaffolds. For both scaffolds, very little is known about the performance in 
real-world patients.
Invasive imaging at two years demonstrated that BVS are largely absorbed and late 
lumen enlargement occurred. In this way, BRS offer transient vessel support to prevent 
acute vessel recoil during angioplasty while eluting an antiproliferative drug to minimize 
neointima hyperplasia during the healing process. Multiple randomized controlled trials 
(ABSORB EXTEND, ABSORB II, ABSORB III, ABSORB China and ABSORB Japan) in non-
complex patients showed results comparable to cobalt-chromium based everolimus 
eluting Xience V metal stent (CoCr-EES; Abbott Vascular, Santa Clara, CA, USA). [3-6] It 
should be underlined that only lesions of moderate complexity were included in these 
RCT’s.  In more real world lesion registries [7-13] BVS failure (including both scaffold 
thrombosis (ScT) and scaffold restenosis (Figure 1) occurs regularly and implantation 
of BVS in more complex patients seems to be associated with a higher rate of adverse 
events. In this chapter we will give a short overview of the pathophysiology and the 
treatment options in case of BRS failure. 
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risk factors for scaffold restenosis
The mechanism for BMS or DES restenosis is multifactorial and consists of stent recoil, 
formation of neointima, organization of thrombus, geographical miss and vessel remod-
eling. The pivotal factor in the process of ISR is neointimal formation, due to migration 
and proliferation of smooth muscle cells and myofibroblasts. In the long-term, metallic 
DES might fracture at hinging points in the coronary artery inducing an inflammatory 
reaction. Occasionally, some patients seem to be `limus` resistant and develop early 
restenosis (Figure 2). [14] Finally, negative remodeling of the vessel contributes to the 
restenosis process. [15]
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Introduction
Since the introduction of drug-eluting stents (DES), the rates of in-
stent restenosis (ISR) and target lesion revascularisation (TLR) dur-
ing the first year have decreased significantly compared to those of 
bare metal stents (BMS). However, after one year, both stent throm-
bosis (ST) and restenosis still occur, most probably caused by in-stent 
neoatherosclerosis due to biocompatibility issues of foreign materials 
(polymers and metallic components of DES). To improve the long-
term outcome, fully bioresorbable scaffolds (BRS) have been devel-
oped which leave no foreign materials and allow the restoration of 
normal coronary physiology, positive remodelling of the atheroscle-
rotic vessel, non-invasive imaging and full pharmacological percu-
taneous and surgical treatment options if symptoms should reoccur.
In recent years, bioresorbable scaffolds (BRS) have evolved 
as the new treatment strategy for coronary artery disease (CAD) 
with the Absorb Vascular Scaffold (BVS; Abbott Vascular, Santa 
Clara, CA, USA)  being the device most intensively studied. The 
Absorb BVS system consists of a poly-L-lactide (PLLA) biore-
sorbable backbone with a poly-DL-lactide (PDLLA) coating that 
releases the antiproliferative drug everolimus. PLLA and PDLLA 
are degraded via hydrolysis of the ester bonds, and the resulting 
lactate and its oligomers are metabolised by the pyruvate and Krebs 
energy cycles. The strut thickness is 156 µm1.
A second CE-marked scaffold, the DESolve™ novolimus-
eluting bioresorbable coronary scaffold system (Elixir Medical 
Corporation, Sunnyvale, CA, USA) is currently under investiga-
tion and very little is known about its performance in real-world 
patients2. Although the DESolve is also PLLA-based, the degrada-
tion, and drug-elution profile is different, and different timings for 
failure strategies may apply.
Using invasive imaging at two years, it was demonstrated that 
Absorb BVS are largely absorbed and late lumen enlargement 
occurred. In this way, BRS offer transient vessel support to prevent 
acute vessel recoil during angioplasty while eluting an antiprolif-
erative drug to minimise neointimal hyperplasia during the healing 
process. Several clinically oriented studies (ABSORB EXTEND, 
ABSORB II) in non-complex patients have shown good results3,4.
However, in other real-world lesion registries5,6 BRS failure still 
occurred including both ST and scaffold restenosis (Figure 1). In 
this review we will try to give a short overview of the pathophysiol-
ogy and the treatment options in case of BRS failure.
Risk factors for scaffold restenosis
The mechanism for BMS or DES restenosis is multifactorial and 
consists of stent recoil, formation of neointima, organisation of 
thrombus, geographical miss and vessel remodelling. The pivotal 
factor in the process of ISR is neointimal formation, due to migra-
tion and proliferation of smooth muscle cells and myofibroblasts. In 
the long term, metallic DES might fracture at hinging points in the 
coronary artery inducing an inflammatory reaction. Occasionally, 
some patients seem to be “limus” resistant and develop early reste-
nosis7 (Figure 2). Finally, negative remodelling of the vessel con-
tributes to the restenosis process8.
Figure 1. Edge restenosis treated with Absorb BVS. A 65-year-old 
male patient presenting with an NSTEMI was treated with 
a 3.5×28 mm Absorb BVS for a trifurcation lesion of the LAD and 
two diagonals (A & B). He returned 142 days later for unstable 
angina due to a subtotal occlusion of the LAD with slow flow distal to 
the scaffold (TIMI 1) (C). OCT imaging revealed edge restenosis as 
the underlying mechanism for BRS failure (D) and restenosis within 
the scaffold with a layered pattern (E), but no luminal thrombus. The 
patient was treated with thrombus aspiration and a 3.5×38 mm DES 
(PROMUS™; Boston Scientific, Marlborough, MA, USA). 
A retrospective review of the post-procedural angiogram at baseline 
showed proximal edge dissection (B) and incomplete lesion coverage 
with geographic miss as the reason for restenosis (F series). Black 
arrows indicate the scaffold markers and white arrows the uncovered 
edge segment. Adapted from Antonis Karanasos et al; Angiographic 
and optical coherence tomography insights into bioresorbable 
scaffold thrombosis. A single-center experience. (Accepted and in 
press Circ Cardiovasc Interv 2015).
The rates of BMS ISR have been described as being as high as 
60%, depending on several risk factors such as lesion complexity, 
patient comorbidities and vessel size9-12. The use of DES has signif-
icantly reduced the rate of ISR, although DES ISR rates at one year 
have been stated as occurring in 3%-20% of patients, depending on 
DES generation and patient, lesion and procedural characteristics13.
Multiple patient, lesion and procedure-related risk factors for 
ISR in BMS and DES have been reported, including diabetes melli-
tus, multivessel disease, stent length, bifurcation lesions, small cali-
bre vessels, chronic total occlusion (CTO), strut thickness, usage of 
multiple stents and stent underexpansion. Hypersensitivity reaction 
to the polymer is another important mechanism. ISR by itself is also 
a predictor for future ISR13-18. In addition, the stent type plays an 
important role which can be related to strut thickness, drug dosage 
and drug release profile. In general, thicker stent struts cause more 
flow disturbances with reduced endothelial shear stress19, which 
enhances the process of neointimal hyperplasia.
figure 1 Edge restenosis treated with Absorb BVS. 
A 65-year-old male patient presenting with an NSTEMI was treated with a 3.5×28 mm Absorb BVS for a 
trifurcation lesion of the LAD and two diagonals (A & B). He returned 142 days later for unstable angina due 
to a subtotal occlusion of the LAD with slow flow distal to the scaffold (TIMI 1) (C). OCT imaging revealed 
edge restenosis as the underlying mechanism for BRS failure (D) and restenosis within the scaffold with 
a layered pattern (E), but no luminal thrombus. The patient was treated with thrombus aspiration and a 
3.5×38 mm DES (PROMUS™; Boston Scientific, Marlborough, MA, USA). A retrospective review of the post-
procedural angiogram at baseline showed proximal edge dissection (B) and incomplete lesion coverage 
with geographic miss as the reason for restenosis (F series). Black arrows indicate the scaffold markers and 
white arrows the uncovered edge segment. Adapted from Antonis Karanasos et al; Angiographic and op-
tical coherence tomography insights into bioresorbable scaffold thrombosis. A single-center experience. 
(Accep ed and in press Circ C rdiovasc Interv 2015).
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The rates of BMS-ISR have been described to be as high as 60%, depending on several 
risk factors such as lesion complexity, patient co-morbidities and vessel size. [16-19] The 
use of DES has significantly reduced the rate of ISR, although DES-ISR rates at one year 
have been stated to occur in 3% - 20% of the patients, depending on DES generation 
and patient, lesion and procedural characteristics. [20]
Multiple patient, lesion and procedure-related risk factors for ISR in BMS and DES have 
been reported, including diabetes mellitus, multi-vessel disease, stent length, bifurca-
tion lesions, small caliber vessels, chronic total occlusion (CTO), strut thickness, usage 
of multiple stents and stent underexpansion. Hypersensitivity reaction to the polymer 
is another important mechanism. ISR by itself is also a predictor for future ISR. [20-25] 
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Figure 2. Absorb BVS and neointimal hyperplasia treated with DES, 
and recurrent failure. A 59-year-old male patient was treated with 
one Absorb BVS (3.5×28 mm) in the proximal LAD for unstable 
angina (A-C). The patient developed an NSTEMI 112 days after the 
index PCI with TIMI 1 flow (D) and was therefore classified as 
a definite ST. OCT showed mild scaffold underexpansion (3 mm 
diameter) with severe neointima development (D’ and D’’’) but also 
areas with late malapposition and potential vasodilatation and 
t rombus resorption (D’’). Treatment con isted of thrombectomy, 
eptifibatide nd a 3.5×32 mm DES (PROMUS; Boston Scientific) 
followed by post-dilatation with 4.0 mm balloon, the lumen increased 
significantly and malapposition was resolved on OCT (E’) with good 
angiographic results (E) . The patient returned almost four months 
later with unstable angina. There was a severe ISR on angiography 
(F) with tot l occlusion (arrow) and collateral flows suggesting 
a resistance to the “limus” drug  used. It wa  decid d o perform 
a semi-urgent CABG, which took place four days later.
It seems likely that most risk factors for ISR with BRS are the 
same as for ISR with BMS or DES; however, at this point in time, 
there is little evidence to confirm this presumption. Recently, a case 
series reported geographical miss and scaffold underexpansion as 
being the most frequent causes of BRS failure20.
Risk factors for scaffold thrombosis
A number of risk factors for ST have been described. Many of 
them are also predictive of stent restenosis. These risk factors can 
be categorised as lesion, patient and procedure-related factors. 
Procedure-related factors are stent malapposition, stent undersiz-
ing, dissection, placement of multiple stents, stent overlap and stent 
length. Lesion-related factors include coronary bifurcations, heav-
ily calcified lesions, long lesion length, small vessel size and CTO. 
Finally, there are patient-related factors such as diabetes mellitus, 
advanced age, renal failure, low ejection fraction, smoking, prior 
CABG, acute coronary syndromes (ACS) at presentation, (early) 
discontinuation of DAPT or resistance to clopidogrel21,22.
Probably, and in line with DES, the rate of BRS ST varies 
depending on lesion, patient and procedure-related characteristics. 
The most remarkable difference between BRS and current DES is 
the increased strut thickness and width (compared to old stainless 
steel BMS and first-generation DES). This will increase the early 
uncovered surface significantly. Also, strut thickness induces con-
vective flow patterns, triggering platelet deposition23. Susceptibility 
to platelet aggregation might be further aggravated in conditions 
such as scaffold underexpansion, treatment of thrombotic lesions, 
e.g., during ACS, and DAPT interruption.
Scaffold underexpansion is an issue with BRS and is an important 
contributor to BRS failure. It is less if lesions are adequately predila-
tated with balloons on a 1:1 ratio to the vessel size24. Discontinuation 
of DAPT and edge dissections have also been described as causes of 
BRS ST25. Currently ongoing and future all-comer, randomised con-
trolled trials will indicate whether BRS have more favourable rates of 
late ST compared to current-generation DES.
Scaffold dislodgement
In severely calcified or tortuous lesions, successful delivery of BRS 
can be difficult: the scaffold could be potentially dislodged26 in the 
same way as metallic stents. However, apart from an early publica-
tion, no further cases of scaffold dislodgement have been reported.
Incidence of scaffold failure in BVS studies and 
registries
Very little is known about the exact incidence of ST and ISR with 
the use of BRS. In most publications the cause of BRS failure, 
whether by ST or ISR, is not clearly reported.
Recently, an interim analysis of the ABSORB II study reported 
a TLR rate at one year of 1% in the Absorb BVS group compared to 
2% in the DES group3. The five-year TLR rate in low-risk patients 
and non-complex lesions of the ABSORB cohort A study was 3.4%27, 
whereas the TLR rate of an everolimus-eluting stent (EES) (XIENCE; 
Abbott Vascular) at five years was 8.6% in the SPIRIT III trial28.
Wohrle et al reported on the one-year outcomes of the ASSURE 
registry: five cases of TLR (2.8%) occurred, all due to ISR. 
Treatment options used were DEB (two patients with long lesions 
in small vessels, treated with overlapping BRS), DES (ISR of 
a saphenous vein graft due to malapposition of the BRS), POBA 
(for incomplete [proximal] BRS expansion) and CABG (total 
occlusion of the target vessel)6.
The GHOST-EU trial, including 1,189 patients, showed a TLR 
rate of 2.5% at six months and target lesion failure (TLF: a composite 
of cardiac death, target vessel myocardial infarction or ischaemia-
driven target lesion revascularisation) rate of 4.4% at six months. In 
a multivariate analysis, TLF was seen more in patients with diabetes 
and in smokers; however, this was not statistically significant5.
Ishibashi et al summarised the rates of Absorb BVS ST reported 
in multiple trials. The incidence of ST varied from 0% up to 3.0% 
in a time period ranging from one to six months29. In another recent 
review article the number of definite ST ranged from 0% at one 
year to 3.2% at six months30.
Most cases of BRS ST occur within the first 30 days after implan-
tation; however, some cases of late ST have also been described. 
figure 2 Absorb BVS and neointimal hyperplasia treated with DES, and recurrent failure. 
A 59-year-old male patient was treated with one Absorb BVS (3.5×28 mm) in the proximal LAD for unstable 
angina (A-C). The patient developed an NSTEMI 112 days after the index PCI with TIMI 1 flow (D) and was 
therefore classified as a definite ST. OCT showed mil  scaffold under xpansion (3 mm diameter) with se-
vere neointima development (D’ and D’’’) but also areas with late malapposition and potential vasodilata-
tion and thrombus resorption (D’’). Treatment consisted of thrombectomy, eptifibatide and a 3.5×32 mm 
DES (PROMUS; Boston Scientific) followe  by post-dilatation with 4.0 mm balloon, the lumen increased 
significantly and malapposition was resolved on OCT (E’) with good angiographic results (E) . The patient 
returned almost four months later with unstable angina. There was a severe ISR on angiography (F) with 
total occlusion (arrow) and collateral flows suggesting a resistance to the “limus” drugs used. It was decided 
to perform a semi-urgent CABG, which took place four days later.
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Also the stent type plays an important role which can be related to strut thickness, drug 
dosage and drug release profile. In general, thicker stent struts cause more flow distur-
bances with reduced endothelial shear stress [26], which does enhance the process of 
neointimal hyperplasia. 
It seems likely that most risk factors for ISR with BRS are the same as for ISR with BMS 
or DES; however, at this moment, there is little evidence to confirm this presumption. 
Recently, a case series reported on geographical miss and scaffold underexpansion as 
being the most frequent causes of BRS failure. [27]
risk factors for scaffold thrombosis
Several risk factors for ST exist. Many of them are also predictive for stent restenosis. 
These risk factors can be categorized as lesion, patient and procedure-related factors. 
Procedure-related factors are stent malapposition, stent undersizing, dissection, place-
ment of multiple stents, stent overlap and stent length. Lesion-related factors include 
coronary bifurcations, heavily calcified lesions, long lesion length, small vessel size and 
CTO. Finally, there are the patient-related factors such as diabetes mellitus, advanced age, 
renal failure, low ejection fraction, smoking, prior CABG, acute coronary syndromes (ACS) 
at presentation, (early) discontinuation of DAPT or resistance to clopidogrel. [28, 29]
Probably, and in line with DES, the rate of ScT varies depending on lesion, patient 
and procedure-related characteristics. The most remarkable difference between BVS 
and current DES is the increased strut thickness and width (comparable to old stain-
less steel BMS and first generation DES). This will increase the early uncovered surface 
significantly. Also, strut thickness induces convective flow patterns, triggering platelet 
deposition. [30] Susceptibility to platelet aggregation might further aggravated be in 
conditions such as scaffold underexpansion, treatment of thrombotic lesions, e.g. dur-
ing ACS, and DAPT interruption. 
Scaffold underexpansion is an important issue in BVS [31] and is an important con-
tributor to BRS failure. It  occurs less if lesions are treated using an optimal implantation 
strategy. Starting with the use of a non-compliant balloon with the same size as RVD 
and with a 1:1 ratio to the vessel, full expansion of the scaffold and with the same size 
as RVD and post-dilatation with a non-compliant balloon up to a maximum of 0.5mm 
larger. [32, 33] Discontinuation of DAPT and edge dissections have also  been described 
as causes of Sct. [34] Currently ongoing and future all-comer, randomized controlled 
trials will indicate whether BRS have more favorable rates of late ScT compared to the 
current generation DES.  
scaffold dislodgement
In severely calcified or tortuous lesions, successful delivery of BRS can be difficult and 
the scaffold could be potentially dislodged [35] in the same way as metallic stents. 
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However after an early publication, no further cases of scaffold dislodgement have been 
reported anymore. 
incidence of scaffold failure in bvs studies and registries
Little is known about the exact incidence of ST and ISR with the use of BRS and in most 
publications the cause of BRS failure, whether by ScT or ISR, is not clearly reported. 
The ABSORB II study reported a TLR rate at one year of 1% in the BRS group compared 
to 2% in the Xience group. [3] Twelve month TLR rate in ABSORB III was 3.0% (vs 2.5% in 
the Xience group). [5] The five year TLR rate in low risk patients and non-complex lesions 
of the ABSORB Cohort A study was 3.4% [36], whereas the TLR rate of an everolimus-
eluting stent (EES, Xience V) at five years was 8.6% in the SPIRIT III trial. [37]
Wohrle et al. reported on the one year outcomes of the ASSURE registry: five cases of 
TLR (2.8%) occurred, all due to ISR. Treatment options used were DEB (two patients with 
long lesions in small vessels, treated with overlapping BRS), DES (ISR of a saphenous vein 
graft due to malapposition of the BRS), POBA (for incomplete (proximal) BRS expansion) 
and CABG (total occlusion of the target vessel). [8]
The GHOST-EU trial, including 1189 patients, showed a TLR rate of 2.5% at six 6 months 
and target lesion failure (TLF: a composite of cardiac death, target-vessel myocardial 
infarction or ischemia-driven target-lesion revascularization) rate of 4.4% at six months. 
In a multivariate analysis, TLF was seen more in patients with diabetes and in smokers, 
however this was not statistically significant. [7] 
Ishibashi et al. summarized the rates of BVS ST reported in multiple trials. The inci-
dence of ST varied from 0 up to 3.0% in a time period ranging from one to six months 
[38]. In another recent review article the number of definite ST ranged from 0% at one 
year to 3.2% at six months. [39] 
Most cases of BRS-ST occur within the first 30 days after implantation; however some 
cases of late ST were also described. The cumulative incidence of ST at six months was 
2.1% in the GHOST-EU trial. In 13% of the cases there was DAPT discontinuation. Other 
possible causes are the low rate of post-dilatation and little usage of invasive imaging 
in B2/C lesions. [7]
Regarding the first 450 patients enrolled in the ABSORB Extend trial, seven cases of 
BRS failure occurred, i.e. three cases (0.67%) of scaffold dislodgement and four cases of 
ST (0.89%). [35]
Of the 101 patients included in the BVS Cohort B trial, only six cases of ISR occurred 
(5%) during a three year follow-up period. The mechanisms for ISR were procedural edge 
injury during the initial procedure, geographical miss, and in one case myocardial bridg-
ing. In three cases the cause of ISR could not be identified. [40]
The BVS Expand single-center registry (excluding STEMI patients) reported a definite 
ScT rate at 18 months of 1.9% and a TLR rate of 4.0%. [9]The mid-term outcomes of the 
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BVS STEMI First registry (including only STEMI patients) showed a high rate of definite 
Sct (4.3%), mainly caused by procedural factors, and TLR (5.7%). [10]
The Amsterdam ABSORB registry, reporting on complex lesion (AHA/ ACC lesion clas-
sification B2/C in 67%),  revealed a one-year TLR rate of 8.9% and 11.4% at two years. 
[13] One-year TLR rate from the Polish National Registry, including both stable and ACS 
patients, was 1.5%. [41]
Summarized, TLR rates can be as high as 8.9% at one year, depending on lesion and pa-
tient complexity. BRS failure can be caused by geographical miss, scaffold dislodgement, 
scaffold malapposition and underexpansion, lesion length and DAPT discontinuation.
how to treat brs failure
Multiple treatment options for treating BRS failure exist: thrombus aspiration, balloon 
angioplasty (POBA), BMS, DES, BRS, drug-eluting balloons (DEB) or medical treatment 
(e.g. with a thrombolytic agent or a glycoprotein IIbIIIa inhibitor (GPI)). Deciding which 
is most suitable depends on the triggering mechanism and not infrequently multiple 
underlying factors are present. Understanding the fundamental pathophysiological 
mechanism underlying the TLF is of key importance to direct subsequent manage-
ment.  Invasive imaging modalities, such as optical coherence tomography (OCT) are 
of paramount importance to achieve treatment success. OCT enables the operator to 
determine between the different mechanisms for BRS-TLF such as scaffold underexpan-
sion, scaffold malapposition or undersizing, geographic miss (edge dissection, edge 
restenosis), neointimal hyperplasia or scaffold strut fracture. 
BRS thrombosis after DAPT interruption, whether acute (<24 hours,) subacute (<1 
month) or late, can be managed with the use of thrombectomy, GPI and/or POBA. In 
patients on clopidogrel that present with an occlusion of the target vessel due to a 
thrombus, platelet function testing and switching to more potent P2Y12 inhibitor has 
to be considered.
Early underexpansion and malapposition can be treated with POBA with non-com-
pliant balloons in a 1:1 balloon – vessel ratio and with sufficient diameter and pressure, 
although the maximum overexpansion limit of 0.5 mm always has to be respected for 
BVS, especially in the situation of undersizing (Figure 5). If the vessel is above 4 mm in 
diameter and there is serious malapposition, large metallic stents are indicated. Prefer-
ably a DES is used, although potentially a BMS could be sufficient for treatment of acute 
or subacute (<30 days) scaffold failure . However, the negative effects of an additional 
dose of antiproliferative drugs when DES are used seem only theoretical and hence not 
of clinical importance. If underexpansion cannot be managed by POBA alone, a BMS or 
DES is indicated to ensure additional radial support (Figure 3). To minimize stent over-
lap, only the insufficiently apposed areas needed be covered with the new stent. After 
thirty days we strongly recommend DES (or even second BVS in larger vessels) as the 
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The cumulative incidence of ST at six months was 2.1% in the 
GHOST-EU trial. In 13% of the cases there was DAPT discontinu-
ation. Other possible causes are the low rate of post-dilatation and 
little usage of invasive imaging in B2/C lesions5.
Regarding the first 450 patients enrolled in the ABSORB 
EXTEND trial, seven cases of Absorb BVS failure occurred, i.e., 
three cases (0.67%) of scaffold dislodgement and four cases of ST 
(0.89%)26.
Of the 101 patients included in the BVS cohort B trial, only six 
cases of ISR occurred (5%) during a three-year follow-up period. 
The mechanisms for ISR were procedural edge injury during the 
initial procedure, geographical miss, and in one case myocardial 
bridging. In three cases the cause of ISR could not be identified31.
In brief, TLR rates can be as high as 3% at one year, depending 
on lesion and patient complexity. BRS failure can be caused by geo-
graphical miss, scaffold dislodgement, scaffold malapposition and 
underexpansion, lesion length and DAPT discontinuation.
How to treat BRS failure
Multiple treatment options for treating BRS failure exist: throm-
bus aspiration, plain old balloon angioplasty (POBA), BMS, DES, 
BRS, drug-eluting balloons (DEB) or medical treatment (e.g., with 
a thrombolytic agent or a glycoprotein IIb/IIIa inhibitor [GPI]). 
Deciding which is most suitable depends on the triggering mecha-
nism, and not infrequently multiple underlying factors are present. 
Understanding the fundamental pathophysiological mechanism 
underlying the TLF is of key importance to direct subsequent 
management. Invasive imaging modalities, such as optical coher-
ence tomography (OCT) are of paramount importance in order to 
achieve treatment success. OCT enables the operator to determine 
between the different mechanisms for BRS TLF such as scaffold 
underexpansion, scaffold malapposition or undersizing, geographic 
miss (edge dissection, edge restenosis), neointimal hyperplasia or 
scaffold strut fracture.
BRS thrombosis after DAPT interruption, whether acute 
(<24 hours), subacute (<1 month) or late, can be managed with the 
use of thrombectomy, GPI and/or POBA. In patients on clopidogrel 
who present with an occlusion of the target vessel due to a throm-
bus, platelet function testing and switching to a more potent P2Y12 
inhibitor has to be considered.
Early underexpansion and malapposition can be treated with 
POBA with non-compliant balloons of sufficient diameter and 
pressure, although the maximum overexpansion limit of 0.5 mm 
always has to be respected for Absorb BVS, especially in the situa-
tion of undersizing (Figure 3). If the vessel is above 4 mm in diam-
eter and there is serious malapposition, large metallic stents are 
indicated. Preferably a DES is used, although potentially a BMS 
could be sufficient for treatment of acute or subacute (<30 days) 
scaffold failure. However, the negative effects of an additional 
dose of antiproliferative drugs when DES are used seem only 
theoretical and hence not of clinical importance. If underexpan-
sion cannot be managed by POBA alone, a BMS or DES is indi-
cated to ensure additional radial support (Figure 4). To minimise 
Figure 3. Absorb BVS failure due to discontinuation of DAPT treated 
with thrombus aspiration and POBA. A 60-year-old male patient 
with a history of smoking, hypertension and heart failure presented 
with stable angina. There was one-vessel disease and a LAD, 
1st diagonal, lesion (Medina 0,0,1) on angiography. A) Two 
3.0×12 mm Absorb BVS were placed in the LAD and 1st diagonal, 
using the T and protrusion technique with good results in the spider 
(B) and RAO (C) projections. After 129 days the patient developed 
a STEMI due to an occluded LAD (D) potentially due to ascal and 
prasugrel discontinuation for CVA. POBA with a 3.0 mm balloon 
was then performed. After three AngioJet (Boston Scientific) runs, 
the angiographic result was acceptable (E) and eptifibatide was 
continued for 24 hours. The treatment of BRS failure was reviewed 
four days later using OCT (F-M). Pullback from the LAD (lower 
row) showed some remaining thrombus (H), and signs of fractures or 
double layer of uncovered struts (I, arrow). Pullback from the 
diagonal branch showed some undersizing distal (J) and some 
double layer and lost struts (K, arrow). Proximal to the bifurcation 
the struts were well apposed and mainly well covered (L and M).
stent overlap, only the insufficiently apposed areas needed be cov-
ered with the new stent. After thirty days we strongly recommend 
DES (or even second BRS in larger vessels) as the remaining dose 
of everolimus on the BRS might not be sufficient to effectively 
reduce neointimal hyperplasia (Figure 4). For undersizing, POBA 
could be sufficient up to six months as the goal is to ensure optimal 
apposition without further vessel dilatation (low pressure) induc-
ing a new healing process.
figure 3 Absorb BVS failure due to discontinuation of DAPT treated with thrombus aspiration and POBA. 
A 60-year-old male patient with a history of smoking, hypertensio  and heart failure presented with stable 
angina. There was one-vessel disease and a LAD, 1 diagonal, lesion (Medina 0,0,1) on angiography. A) Two 
3.0×12 mm Absorb BVS were placed in the LAD and 1st diagonal, using the T and protrusion technique 
with good results in the spider (B) and RAO (C) projections. After 129 days the patient developed a STEMI 
du  to an occluded LAD (D) potentially due to ascal and prasugrel discontinuation for CVA. POBA with a 3.0 
mm balloon was the  performed. After three AngioJet (Boston Scientific) runs, the angiographic result was 
acceptable (E) and eptifibatide was continued for 24 hours. The treatment of BRS failure was reviewed four 
days later using OCT (F-M). Pullback from the LAD (lower row) showed some remaining thrombus (H), and 
signs of fractures or double layer of uncovered struts (I, arrow). Pullback from the diagonal branch showed 
some undersizing distal (J) and some double layer and lost struts (K, arrow). Proximal to the bifurcation the 
struts were well apposed and mainly well covered (L and M).
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remaining dose of everolimus on the BVS might not be sufficient to effectively reduce 
neointimal hyperplasia (Figure 3). For undersizing, POBA could be sufficient up to six 
months as the goal is ensuring optimal apposition without further vessel dilatation (low 
pressure) inducing a new healing process. 
After approximately six months the tie chains between the crystal polylactide lamellae 
become more and more hydrolyzed and the radial strength and subsequent vessel sup-
port gradually decreases (Figure 4). [42] BRS failure after six months due to mechanical 
problems will need placement of an additional stent or scaffold.
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After approximately six months the tie chains between the crys-
tal polylactide lamellae become more and more hydrolysed and the 
radial strength and subsequent vessel support gradually decreases32 
(Figure 5). BRS failure after six months due to mechanical prob-
lems will need placement of an additional stent or scaffold.
In the setting of a geographical miss leading to a clinically rel-
evant acute or subacute edge dissection, a BRS bail-out strategy 
could be used. In case of a geographical miss with apparent edge 
restenosis, placement of an additional BRS is possible, although 
converting to DES with a minimal risk of repeat ISR is more pru-
dent. ISR due to intimal hyperplasia can be treated by a DEB 
(<6 months), but after six months additional vessel support is indi-
cated (with a preference for DES) (Figure 1).
Lastly, in the case of limited scaffold strut fracture, POBA should 
be able to correct the malapposed segments33. For more extensive 
fractures or large diameter vessels, a new stent (BMS or DES) would 
be the treatment of choice. Again, after six months disintegration 
of the scaffold is initiated and additional radial strength is neces-
sary (DES preferred). In case of both fracture and underexpansion, 
lesion dilatation is necessary: we recommend an additional DES 
Figure 4. Scaffold thrombosis due to underexpansion treated with DES. A 69-year-old male patient presented with an NSTEMI. Angiography 
showed one-vessel disease with long narrowing of the proximal and mid LAD and collateral filling (A). Three Absorb BVS (3.0×28 mm, 
3.5×18 mm, 3.5×18 mm) were implanted (D). After placement of the first two scaffolds there was compression and thrombus in the 
1st diagonal. Invasive imaging post procedure revealed organised thrombus behind the struts of the proximal scaffold (B: IVUS) and thrombus 
protrusion at the overlapping scaffolds (C: OCT). After 47 days the patient presented with a non-Q-wave myocardial infarction due to a full 
occlusion in the proximal LAD (E). There was some underexpansion, but a large thrombus on OCT (F). He was treated with thrombectomy, 
eptifibatide and PCI with a 3.5×38 mm DES (XIENCE) covering the proximal BVSs with a good angiographic and OCT result (G & H). The 
control diagnostic angiography made 110 days later (I) displayed good scaffold and stent apposition on OCT with good coverage of the struts 
of the new DES (J) and the untreated original distal Absorb BVS (K).
 
Figure 5. Bioresorption of Absorb BVS. Initially, cleavage of 
polylactides results in minimal molecular weight loss with remaining 
full support until six months. After six months, degradation 
significantly impacted on tie chains between crystal lamellae occurs 
rapidly, reducing radial support when the material starts to become 
brittle. Implantation of additional vessel supportive therapy is 
indicated to successfully treat lumen reduction. Adapted from 
Serruys et al34.
 
figure 4 Scaffold thrombosis due to underexpansion treated with DES. 
A 69-year-old male patient presented with an NSTEMI. Angiography showed one-vessel disease with long 
narrowing of the proximal and mid LAD and collateral filling (A). Three Absorb BVS (3.0×28 mm, 3.5×18 
mm, 3.5×18 mm) were implanted (D). After placement of the first two scaffolds there was compression 
and thrombus in the 1 diagonal. Invasive imaging post procedure revealed organised thrombus behind 
the struts of the proximal scaffold (B: IVUS) and thrombus protrusion at the overlapping scaffolds (C: OCT). 
After 47 days the patient presented with a non-Q-wave yocardial infarction due to a full occlusion in he 
proximal LAD (E). There was some underexpansion, but a large thrombus on OCT (F). He was treated with 
thrombectomy, p ifibatide and PCI with a 3.5×38 mm DES (XIENCE) covering the proximal BVSs with a 
good angiographic and OCT result (G & H). The control diagnostic angiography made 110 days later (I) 
displayed good scaffold and stent apposition on OCT with good coverage of the struts of the new DES (J) 
and th  untreated original distal A sorb BVS (K).
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In the setting of a geographical miss leading to a clinically relevant acute or subacute 
edge dissection, a BRS bailout strategy could be used. In case of a geographical miss 
with apparent edge restenosis, placement of an additional BRS is possible although 
converting to DES with a minimal risk of repeat ISR is more prudent. ISR due to intimal 
hyperplasia can be treated by a DEB (<6 months) but after 6 months, additional vessel 
support is indicated (with a preference for DES) (Figure 1). 
Lastly, in the case of limited scaffold strut fracture, POBA should be able to correct 
the malapposed segments [43].  For more extensive fractures or large diameter vessels, 
a new stent (BMS or DES) would be the treatment of choice. Again, after six months 
disintegration of the scaffold is initiated and additional radial strength is necessary (DES 
preferred). In case of both fracture and underexpansion, lesion dilatation is necessary 
and we recommend an additional DES from thirty days after the initial BRS placement. 
Treatment options for BRS failure are summarized in table 1.
However, we have to mention that most of the clinical experience with BRS failure is 
gained from the experience with the Absorb BVS platform, and that, given the paucity 
of trial numbers, only few data are available for other BRS subtypes such as the DESolve 
novolimus-eluting bioresorbable coronary scaffold system (Elixir) or metal-based (mag-
nesium) resorbable devices. As such, these recommendations for the treatment of BRS 
failure are only applicable to the Absorb BVS.
conclusion
Treatment of scaffold failure should target any suboptimal result. After thrombus aspira-
tion and aggressive medical treatment, intravascular imaging is advised to reveal any 
scaffold abnormalities. A wide range of strategies can be applied to correct suboptimal 
scaffold results. The major difference between BRS and DES in the treatment of target 
lesion failure is the more frequent need for additional vessel support (using a second 
BRS or a DES).
table 1. Treatment options for BRS failure.
Acute
(< 24 h)
Subacute
(< 30 days)
Late
(< 6  months)
Very late
(> 6  months)
DAPT interruption GPI/ thrombectomy/POBA
Underexpansion POBA DES/ BVS
Undersizing/ Malapposition POBA: max 0.5mm > nominal > 4mm: DES/ BMS* DES/ BVS
Geographical miss Dissection: BVS bailout Edge stenosis: DES/ BVS 
Neointimal hyperplasia -- DEB DES/ BVS 
Strut fracture POBA: max 0.5 > nominal > 4mm: DES/ BMS* DES
*In the first period, as drug release is still ongoing, BMS theoretically should be sufficient
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After approximately six months the tie chains between the crys-
tal polylactide lamellae become more and more hydrolysed and the 
radial strength and subsequent vessel support gradually decreases32 
(Figure 5). BRS failure after six months due to mechanical prob-
lems will need placement of an additional stent or scaffold.
In the setting of a geographical miss leading to a clinically rel-
evant acute or subacute edge dissection, a BRS bail-out strategy 
could be used. In case of a geographical miss with apparent edge 
restenosis, placement of an additional BRS is possible, although 
converting to DES with a minimal risk of repeat ISR is more pru-
dent. ISR due to intimal hyperplasia can be treated by a DEB 
(<6 months), but after six months additional vessel support is indi-
cated (with a preference for DES) (Figure 1).
Lastly, in the case of limited scaffold strut fracture, POBA should 
be able to correct the malapposed segments33. For more extensive 
fractures or large diameter vessels, a new stent (BMS or DES) would 
be the treatment of choice. Again, after six months disintegration 
of the scaffold is initiated and additional radial strength is neces-
sary (DES preferred). In case of both fracture and underexpansion, 
lesion dilatation is necessary: we recommend an additional DES 
Figure 4. Scaffold thrombosis due to underexpansion treated with DES. A 69-year-old male patient presented with an NSTEMI. Angiography 
showed one-vessel disease with long narrowing of the proximal and mid LAD and collateral filling (A). Three Absorb BVS (3.0×28 mm, 
3.5×18 mm, 3.5×18 mm) were implanted (D). After placement of the first two scaffolds there was compression and thrombus in the 
1st diagonal. Invasive imaging post procedure revealed organised thrombus behind the struts of the proximal scaffold (B: IVUS) and thrombus 
protrusion at the overlapping scaffolds (C: OCT). After 47 days the patient presented with a non-Q-wave myocardial infarction due to a full 
occlusion in the proximal LAD (E). There was some underexpansion, but a large thrombus on OCT (F). He was treated with thrombectomy, 
eptifibatide and PCI with a 3.5×38 mm DES (XIENCE) covering the proximal BVSs with a good angiographic and OCT result (G & H). The 
control diagnostic angiography made 110 days later (I) displayed good scaffold and stent apposition on OCT with good coverage of the struts 
of the new DES (J) and the untreated original distal Absorb BVS (K).
 
Figure 5. Bioresorption of Absorb BVS. Initially, cleavage of 
polylactides results in minimal molecular weight loss with remaining 
full support until six months. After six months, degradation 
significantly impacted on tie chains between crystal lamellae occurs 
rapidly, reducing radial support when the material starts to become 
brittle. Implantation of additional vessel supportive therapy is 
indicated to successfully treat lumen reduction. Adapted from 
Serruys et al34.
 
figure 5 Bioresorption of Absorb BVS. Initially, cleavage of polylactides results in minimal molecular weight 
loss with remaining full support until six months.
After six months, degradation significantly impacted on tie chains between crystal lamellae occurs rapidly, 
r ducing radial support when the material starts to become brittle. Implantation of additional vessel sup-
portive therapy is indicated to successfully treat lumen reduction. Adapted from Serruys et al (34).
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abstract
objectives
To shed light on the occurrence of very late scaffold thrombosis (VLScT) in patients 
treated with the Absorb bioresorbable vascular scaffold (BVS) and the possible associa-
tion with termination of dual antiplatelet therapy.
background
Multiple studies have proven feasibility and safety of the Absorb BVS. However, more 
recently, concerns were raised regarding the higher incidence of VLScT.
methods
A viewpoint was created by a brief description background literature and three VLScT 
case descriptions.
conclusions
Based on our case series and previous publications, we encourage prolongation of DAPT 
beyond 12 months after implantation of BVS.
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The Absorb bioresorbable scaffold (BVS, Abbott Vascular, Santa Clara, California, USA) is 
a new promising treatment option for coronary artery disease to overcome limitations 
of metal drug eluting stent and is widely investigated.  [1] Lately, concerns were raised 
regarding the occurrence of very late scaffold thrombosis (VLScT) in patients treated 
with BVS. [2] The ABSORB II randomized controlled trial (RCT) reported a disturbing 
number of six VLScT in 335 patients at three years follow-up. None of these patients were 
using dual antiplatelet therapy (DAPT) at time of the event. [3] Two-years results of the 
ABSORB Japan RCT described 4 cases of VLScT; two out of four patients had terminated 
DAPT. [4] These findings stimulated us to investigate the occurrence of this very late 
event and its relation with DAPT termination.
In our daily practice of three regional centers, we also have encountered cases of 
VLScT after discontinuation of DAPT. At 18 months, three of the four VLScT in a cohort 
of 685 patients seemed to be closely related to DAPT discontinuation. These cases oc-
curred within 35 days after DAPT termination, which we believe needs the attention of 
the medical community.
A 60-year old female with risk factors dyslipidemia, hypertension, history of percu-
taneous coronary intervention (PCI), presented with stable angina pectoris and angi-
ography revealed one-vessel disease of the RCA. Treatment consisted of pre-dilatation, 
implantation of 3 overlapping BVS and post-dilatation. Patient was using aspirin and 
clopidogrel for 369 days.  Ten days later, she presented with STEMI with visible thrombus 
on angiography, which was treated with thrombectomy, drug-eluting balloon and 
abciximab.
A 63-year old male without cardiac risk factors was admitted with a STEMI due to an 
occluded mid-LAD. After thrombectomy, he underwent primary PCI with 2 overlapping 
BVS and post-dilatation. Ticagrelor was stopped at day 381 days and 35 days thereaf-
ter, this patient presented with STEMI due VLScT. Intravascular imaging revealed clear 
thrombus and minimal malapposition. Thrombectomy, stenting with everolimus eluting 
stent, and post-dilatation were performed. 
A 50-year old female with positive family history for CAD and a current smoker was 
admitted to the hospital with a STEMI.  After thrombectomy and pre-dilatation, she 
underwent PCI of the RCA with 1 BVS. Post-procedural OCT revealed malapposition 
and therefore, post-dilatation with a 4.0 mm balloon was performed reducing malap-
position but unfortunately not eliminating this. At day 449, twenty days after prasugrel 
was terminated, the patient returned with a Q-wave STEMI due to angiographically and 
OCT proven ScT and malapposition. Treatment consisted of rePCI with thrombectomy, 
balloon angioplasty and Gp IIb/ IIIa inhibitor. 
These cases were reported to draw attention to a problem that is becoming more 
common: VLScT. In our cohort and in the ABSORB II trial, no VLScT occurred in patients 
continued DAPT for a longer period of time. Based on this experience and previous 
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publications [4], we encourage prolongation of DAPT beyond 12 months after implanta-
tion of BVS, likewise as has been demonstrated to be efficient for high-risk DES-treated 
patients with a low bleeding risk [5]. A DAPT score ≥ 2 seems optimal for current DES 
whereas an increased risk of ischemic events for first generation DES would warrant an 
additional point [6] and this could theoretically apply for first generation BVS. Extending 
DAPT even longer, to 30 months as investigated by the DAPT study in DES patients, will 
cover the majority of time period before the resorption process of BVS is completed. 
[7] More data and dedicated studies are needed to confirm this recommendation. We 
believe that, considering inherent difference between BVS and metallic stent, probably 
specific DAPT recommendation is warranted for patients receiving BVS.
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abstract
aims
To investigate the impact of dual antiplatelet therapy (DAPT) termination on late and 
very late scaffold thrombosis (ScT) in patients treated with Absorb bioresorbable vascu-
lar scaffold (BVS).
methods and results
Data of registries of 3 centers were pooled (808 patients). To investigate the effect of 
DAPT termination on ScT after a minimum of 6 months, we selected a subgroup (‘DAPT 
study cohort’ with 685 patients) with known DAPT status > 6 months and excluded the 
use of oral anticoagulants and early ScT. In this cohort,  definite/ probable ScT incidence 
for the period on DAPT was compared to ScT incidence after DAPT termination. ScT 
incidence was 0.83 ScT/ 100 py with 95% confidence interval (CI): 0.34-1.98. After DAPT 
termination, the incidence was higher (1.77/ 100 py; 95% CI: 0.66-4.72), compared to the 
incidence on DAPT (0.26/ 100 py, 95% CI: 0.04-1.86; p=0.12) and increased within the 
month after DAPT termination (6.57/ 100 py, 95% CI 2.12-20.38; p=0.01). No very late ScT 
occurred in patients who continued on DAPT for a minimum of 18 months.
conclusion
Incidence of late and very late definite/ probable ScT was acceptable. Incidence was low 
while on DAPT but potentially higher when DAPT was terminated before 18 months.
Potentially increased incidence of ScT in patients treated with BVS who terminated DAPT before 18 months. 273
14
introDuction
Bioresorbable scaffolds are the new treatment option for coronary interventions with 
the aim to overcome some of the limitations of metal drug-eluting stents (DES), such 
as very late stent thromboses (ST) and reinterventions due to polymer reactions, strut 
fracture, neoatherosclerosis and inflammation. 
The Absorb bioresorbable vascular scaffold (BVS, Abbott Vascular, Santa Clara, Califor-
nia, USA) has been most intensively studied. Multiple meta-analyses, showed compa-
rable one-year outcomes for target lesion failure (TLF) of BVS versus cobalt-chromium 
based everolimus eluting Xience metal stent (CoCr-EES; Abbott Vascular, Santa Clara, 
CA, USA) in selected patients. Numbers of scaffold thrombosis (ScT) and target vessel MI 
tended to be higher in BVS group. [1-3]_ENREF_2 In populations reflecting real-world 
patients [4-8], ScT occurs more frequent. More recently, concerns were expressed about 
the occurrence of very late (> 1 year) scaffold thrombosis (VLScT). [9, 10] In random-
ized controlled trials (RCT’s), VLScT up to 2 years were low on one (1.6%) but higher in 
another (2.0%) at 3 years.  [11, 12] 
Dual antiplatelet therapy (DAPT) reduces the risk of local thrombotic events related 
to stent implantation,  systemic thrombotic events, and cardiovascular mortality. In the 
current ESC and AHA/ ACC guidelines, a minimum DAPT duration of 6 months after DES 
implantation is recommended, with prolonged treatment  in patients with an increased 
risk for thrombotic events and low bleeding risks. For BVS, the optimal DAPT duration is 
not yet clearly defined. [13, 14] The early studies investigating BVS applied a minimum 
DAPT duration of 6 months. In the more recent RCT’s, a minimum duration of 12 months 
was implemented. [11, 15]
To summarize, data on long-term ScT outcomes after BVS implantation in real-world 
patients is lacking and information on optimal DAPT duration missing. To fill the gap, we 
describe the incidence of ScT and investigated the impact of DAPT termination on late 
and very late ScT in regular clinical practice.
methoDs
Population
Patients were pooled from registries of 3 Dutch centers where the Absorb BVS was used 
as part of daily clinical practice. The decision to treat a patient with BVS was made at the 
discretion of the interventional cardiologist. 
The patients of the Erasmus Medical Center were derived from two investigator-initi-
ated, single-center, single-arm registries (BVS Expand and BVS STEMI). In- and exclusion 
criteria have been described elsewhere. [5, 6] Patients included in the two other hospital 
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registries were part of local all-comers registries initiated for the control of quality of 
standard care following introduction of a new CE approved device. 
Between September 2012 and April 2015, 808 patients treated with at least one BVS 
were included in this study (total cohort).  To investigate specifically the association 
between DAPT and late events without interference of oral anticoagulants, the DAPT 
cohort was selected by including patients with a known DAPT status and with duration 
of at least 6 months, without the occurrence of early ScT and without usage of (new) oral 
anticoagulants ((N)OAC). 
ethics
This is an observational study, performed based on international regulations, including 
the declaration of Helsinki. Data were collected in an encrypted database with the ap-
proval of the local ethics committee. The Absorb BVS received the CE mark and the BVS 
can be currently used routinely in Europe in different settings without a specific written 
informed. 
Procedure
PCI was performed according to current clinical practice standards. The radial or femoral 
approach using 6 or 7 French catheters were the principal route of vascular access. All 
patients were treated with unfractionated heparin (at a dose of 70-100 UI/ kg). Accord-
ing to the guidelines, patients with stable angina were preloaded with 300 mg of aspirin 
and 600 mg of clopidogrel. Patients presenting with ACS were preloaded with 300 mg 
of aspirin and 60 mg of prasugrel or 180 mg of ticagrelor. Previous guidelines for DES 
and per hospital policies were used to prescribe DAPT and this was also based on the 
operator’s instructions. 
follow-up
Survival status was obtained from municipal civil registries. Follow-up information 
specific for hospitalization and major cardiovascular events was obtained through ques-
tionnaires that were mailed individual patients at 1, 6, 12 and 18 months after procedure. 
In case of an absent response after reminder mail, patients were called thereafter or 
information was gathered from general practitioners or hospitals.  Information on DAPT 
status and the stopping date of P2Y12 inhibitor were collected. When an exact stop-
ping date was available (through questionnaires, pharmacies, general practitioners or 
hospital letters), the date was used to compute the duration of DAPT. When patients did 
not exactly recall the precise stopping date but instead noted that he or she used DAPT 
for a period of one year, duration of DAPT was recorded as 365 days.  In case of a patient 
writing that he/ she had visited the hospital, aditional medical records and discharge 
letters were consulted to check if any event had occurred.
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Definitions
ScT was classified as ST according to the Academic Research Consortium (ARC). [16] ScT 
were reported reported as either acute (≤24 hours), subacute (1-30 days), late (30-365 
days) and very late (>365 days). DAPT termination was described as the date on which 
one of the two components of DAPT (aspirin or P2Y12 inhibitor) had been terminated.
endpoints
The primary endpoint in the DAPT study cohort was the incidence rate of definite or 
probable ScT beyond 6 months while the patient was either using DAPT or had termi-
nated DAPT. This time period (6 – 18 months) was chosen because we assumed that, 
based on the healing process, the pathophysiology of scaffold thrombosis in the period 
between 6 and 18 months was similar. To investigate the time relation with DAPT more 
in detail, an additional analysis was performed for the first month after  DAPT termina-
tion compared to the incidence rate while on DAPT. 
statistical analysis
Categorical variables are reported as counts and percentages, continuous variables as 
mean ± standard deviation or median (25th-75th percentile).  For each time period, the 
ScT incidence was calculated as the number of events divided by the sum of the follow-
up times for each individual. The variable ‘on DAPT’ was computed as the stopping date 
of DAPT minus the date of the index procedure. In case of a ScT while the patient was 
using DAPT, ‘on DAPT’ was reported as days until the event. ‘Off DAPT’ was calculated as 
18 months post-procedure (or the latest available follow-up date) minus the time period 
until termination of the P2Y12 inhibitor. In case of ScT while DAPT was terminated, days 
off DAPT were computed as follows: date of ScT minus date of DAPT termination. The 
cumulative incidence of study endpoints was estimated according to the Kaplan-Meier 
method. Patients lost to follow-up were considered at risk until the date of last contact, 
at which point they were censored. All statistical tests were patient-based, two-sided 
and the P value of < 0.05 was considered statistically significant.  Statistical analyses 
were performed using SPSS, version 21 (IL, US).
results
Between September 2012 and January 2015, 808 patients were included in the pooled 
database. The DAPT study cohort consisted of 685 patients (figure 1). Survival status in 
this group was known in 100% and median follow-up duration was 730 (interquartile 
range [IQR]: 531.8 – 923.3) days. Median duration of DAPT was 367 (IQR: 365 – 398) days 
and with a range from 180 to 1237 days. Hundred and thirty (19%)  had a DAPT duration 
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ranging between 6 months and 1 year and 81% had a DAPT duration of at least 365 days. 
Eighty-nine patients (12.9%) continued DAPT until the last follow-up.  Figure 3A displays 
the individual duration of DAPT for the patients.
baseline characteristics
Baseline characteristics of both the full cohort and the DAPT study cohort are presented 
in table 1. In the DAPT study cohort, mean age was 57.9 (±10.6) years, 73.9% were male, 
14.3% were diabetic, and 12.4 % had a history of myocardial infarction. Most patients 
(70.3%) presented with ACS. The largest part of the patients used a more potent P2Y12 
inhibitor such as prasugrel or ticagrelor (76.6%). Mean number of lesions/ patients was 
1.19 (±0.45). Moderate or severe lesion calcification, as assessed by angiography, was 
present in 32.9% and bifurcation in 21.3%. AHA/ ACC lesion classification type B2/ C was 
present in 45.7%. 
Procedural details
Procedural details are described in table 2. In the DAPT study cohort, a total of 964 BVS 
were implanted. Pre-dilatation was performed in 88.3% of the patients, post-dilatation 
in 56.7 % and intravascular imaging (OCT or IVUS) in 31.3%. A 2.5 mm BVS was used in 
21.8%. Mean scaffold diameter and mean scaffold length were 3.1 (± 0.4) mm 20.9 (± 
5.8) mm. Device success and procedural success were achieved in 98.3% and 98.0%, 
respectively. 
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Incidence of ScT in Absorb BVS during early DAPT termination
Information on DAPT status and the date of stopping the P2Y12 
inhibitor was collected. When an exact stop date was available 
(through questionnaires, pharmacies, general practitioners or 
hospital letters), that date was used to compute the duration of 
DAPT. When patients did not exactly recall the precise stop date 
but instead noted that he or she used DAPT for a period of one 
year, the duration of DAPT was recorded as 365 days. In the case 
of a patient writing that he/she had visited the hospital, addi-
tional medical records and discharge letters were consulted to 
check if any event had occurred.
DEFINITIONS
ScT was classified as stent thrombosis (ST) according to the 
Academic Research Consortium (ARC)16. Scaffold thromboses 
were reported as either acute (≤24 hours), subacute (1-30 days), 
late (30-365 days), or very late (>365 days). DAPT termination 
was defined as the date on which one of the two components of 
DAPT (aspirin or P2Y12 inhibitor) had been terminated.
ENDPOINTS
The primary endpoint in the DAPT study cohort was the inci-
dence rate of definite or probable ScT beyond six months while 
the patient either was using DAPT or had terminated DAPT. This 
time period (six to 18 months) was chosen because we assumed 
that, based on the healing process, the pathophysiology of scaffold 
thrombosis in the period between six and 18 months was simi-
lar. To investigate the time relation with DAPT in more detail, an 
additional analysis was performed for the first month after DAPT 
termination compared to the incidence rate while on DAPT.
STATISTICAL ANALYSIS
Categorical variables are reported as counts and percentages, continu-
ous variables as mean±standard deviation or median (25th-75th per-
centile). For each time period, the ScT incidence was calculated as 
the number of events divided by the sum of the follow-up times for 
each individual. The variable “on DAPT” was computed as the stop 
date of DAPT minus the date of the index procedure. In case of an 
ScT while the patient was using DAPT, “on DAPT” was reported 
as days until the event. “off DAPT” was calculated as 18 months 
post procedure (or the latest available follow-up date) minus the time 
period until termination of the P2Y12 inhibitor. In the case of ScT 
while DAPT was terminated, days off DAPT were computed as fol-
lows: date of ScT minus date of DAPT termination. The cumulative 
incidence of study endpoints was estimated according to the Kaplan-
Meier method. Patients lost to follow-up were considered at risk 
until the date of last contact, at which point they were censored. All 
statistical tests were patient-based, two-sided and a p-value of <0.05 
was considered statistically significant. Statistical analyses were per-
formed using SPSS, Version 21 (IBM Corp., Armonk, NY, USA).
Results
Between September 2012 and January 2015, 808 patients were 
included in the pooled database. The DAPT study cohort consisted 
of 685 patients (Figure 1). Survival status in this group was known 
in 100% and the median follow-up duration was 730 (interquartile 
range [IQR]: 531.8-923.3) days. The median duration of DAPT 
was 367 (IQR: 365-398) days, with  rang from 180 to 1,237 days. 
One hundred and thirty (19%) patients had a DAPT duration rang-
ing between six months and one year, and 81% had a DAPT dura-
tion of at least 365 days. Eighty-nine patients (12.9%) continued 
DAPT until the last follow-up. Figure 2A displays the individual 
duration of DAPT for the patients.
BASELINE CHARACTERISTICS
Baseline characteristics of both the full cohort and the DAPT 
study cohort are presented in Table 1. In the DAPT study cohort, 
mean age was 57.9 (±10.6) years, 73.9% were male, 14.3% were 
diabetic, and 12.4% had a history of myocardial infarction. Most 
patients (70.3%) presented with ACS. Th  m jority of the patients 
used a potent P2Y12 inhibitor such as prasugrel or ticagrelor 
(76.6%). The mean number of lesions/patient was 1.19 (±0.45). 
Moderate or severe lesion calcification, as assessed by angio-
graphy, was present in 32.9% and bifurcation in 21.3% of patients. 
AHA/ACC lesion classification type B2/C was present in 45.7%.
PROCEDURAL DETAILS
Procedural details are described in Table 2. In the DAPT study 
cohort, a total of 964 BVS were implanted. Predilatation was 
performed in 88.3% of the patients, post-dilatation in 56.7% and 
intravascular imaging (OCT or IVUS) in 31.3%. A 2.5 mm BVS 
was used in 21.8% of patients. Mean scaffold diameter and mean 
scaffold length were 3.1 (±0.4) mm and 20.9 (±5.8) mm, respec-
tively. Device success and procedural success were achieved in 
98.3% and 98.0%, respectively.
CLINICAL OUTCOMES
In the total cohort of 808 patients, 26 definite or probable ScT 
occurred with a cumulative event rate (Kaplan-Meier estimate) of 
3.3% (95% CI: 2.1-4.5) at 18 months (Figure 3). The majority 
(1.7%) were early ScT: the acute ScT rate was 0.2% (95% CI: 
-0.2-0.6) and the subacute ScT rate was 1.5% (95% CI: 0.7-2.3). 
Total cohort (n=808):
– PCI with Absorb BVS since September 2012
– 3 regional centres
DAPT study cohort (n=685):
– Known DAPT status and
– Minimum DAPT duration of 6 months
Excluded from analysis (n=123):
– Unknown DAPT status (n=25)
– DAPT cessation <6 months (n=14)
– (N)OAC usage (n=70)
– Early ScT (n=14)
Figure 1. Study flow chart.
figure 1 Study flow chart
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table 1. Patient and lesion characteristics
Total cohort
N=808, L=949 
DAPT study cohort
N=685, L=813 
Median follow-up in days (IQR) 729 (516 – 899.75) 730 (531.8 – 923.3)
Gender (%)
   Men 73.9 73.9
   Women 26.1 26.1
Mean age in years (±SD) 58.46 (10.91) 57.9 (10.6)
Smoking (%) 50.8 51.5
Hypertension (%) 47.9 45.0
Dyslipidemia (%) 45.9 45.4
Diabetes Mellitus (%) 14.2 14.3
Family history of CAD (%) 48.8 49.5
Prior MI (%) 12.8 12.4
Prior PCI/ CABG (%) 13.7 13.4
Presentation with multivessel disease (%) 30.8 30.3
Indication for PCI (%)
   Stable angina 26.6 26.1
   Unstable angina 10.1 10.0
   NSTEMI 30.7 31.2
STEMI 28.6 29.1
Silent ischemia 3.9 3.6
Periphery artery disease (%) 3.8 3.2
Heart failure (%) 4.0 2.5
Renal insufficiency (%) 3.3 2.5
ASA + P2Y12 inhibitor (%)
clopidogrel 39.8 38.3
prasugrel 38.2 38.3
ticagrelor 22.0 23.4
Median duration of DAPT in days (IQR)
Min and max DAPT duration in days
367 (365 – 398)
180 - 1237
Number of lesions per patient (±SD) 1.17 (0.44) 1.19 (0.45)
Left anterior descending artery (%) 54.4 54.2
Left circumflex artery (%) 20.9 21.4
Right coronary artery (%) 24.7 24.4
Bifurcation (%) 23.0 21.3
Calcification (moderate or severe) (%) 33.7 32.9
CTO (%) 3.1 3.2
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clinical outcomes
In the total cohort of 808 patients, 26 definite or probable ScT occurred with a cumula-
tive event rate, described as Kaplan-Meier estimate, of 3.3% (95% CI: 2.1 – 4.5) at 18 
months (figure 2). The majority (1.7%) were early ScT: acute ScT rate was 0.2%  (95% CI: 
-0.2 – 0.6) and subacute ScT rate was 1.5% (95% CI: 0.7 – 2.3). Late and very late ScT were 
less frequent: 1.0%  (95% CI: 0.2 – 2.0) and 0.6% (95% CI: 0.02 – 1.2) respectively. In the 
DAPT study cohort Kaplan-Meier estimates for late and very late ScT were similar (0.9% 
and 0.7% respectively). 
Figure 3B shows the duration in days while off DAPT and the association with very late 
ScT in the DAPT study cohort. Four cases of very late definite/ probable ScT occurred: 
at 379 days (10 days after DAPT termination), at 416 days (35 days after DAPT termina-
table 1. Patient and lesion characteristics (continued)
Total cohort
N=808, L=949 
DAPT study cohort
N=685, L=813 
ACC/ AHA lesion classification (%)
     A 10.3 10.3
     B1 43.5 44.0
     B2 28.4 27.3
     C 17.8 18.4
ASA: Aspirin; CABG: coronary artery bypass grafting ; CAD: coronary artery disease; CTO: chronic total occlu-
sion; DAPT: dual antiplatelet therapy; IQR: interquartile range; L:lesions; MI: myocardial infarction; NSTEMI: 
non-ST elevation myocardial infarction; P: patients; PCI: percutaneous coronary intervention; STEMI: ST el-
evation myocardial infarction
table 2. Procedural characteristics
Total cohort
P=808, L=949
DAPT study cohort
P=685, L=813
Pre-dilatation (%) 88.4 88.3
Invasive imaging at baseline (%) 30.8 31.3
Total number of scaffolds implanted 1119 964
2.5 mm BVS (%) 22.7 21.8
 3.0 mm BVS (%) 39.2 40.7
3.5 mm BVS (%) 38.1 37.4
Mean scaffold diameter, mm  (±SD) 3.08 (0.38) 3.08 (0.38)
Mean scaffold length, mm  (±SD) 20.90 (5.83) 20.94 (5.83)
Mean total scaffold length per patient, mm  (±SD) 32.48 (20.99) 33.14 (21.60) 
Overlap (%) 29.7 30.6
Post-dilatation (%) 55.4 56.7
Clinical device success (%) 98.0 98.3
Clinical procedure success (%) 97.2 98.0
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tion) at 429 days (20 days after DAPT termination) and 526 (149 after DAPT termination). 
Cases have been described elsewhere. [17] These four patients were using aspirin but 
had terminated P2Y12 inhibitor. Their duration of DAPT was a little over 365 days. How-
ever, this was not based on a specific reason such as an increased ischemic risk. Rate of 
definite/ probable ScT in this particular time frame was 0.7%.
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Late and very late ScT were less frequent: 1.0% (95% CI: 0.2-2.0) 
and 0.6% (95% CI: 0.02-1.2), respectively. In the DAPT study 
cohort, Kaplan-Meier estimates for late and very l te ScT were 
similar (0.9% and 0.7%, respectively).
Figure 2B shows the duration in days while off DAPT and the 
association with very late ScT in the DAPT study cohort. Four 
cases of very late definite/probable ScT occurred: at 379 days 
(10 days after DAPT termination), at 416 days (35 days after 
DAPT termination), at 429 days (20 days after DAPT termination), 
and at 526 days (149 days after DAPT termination). These cases 
have been described elsewhere17. The four patients were using 
aspirin but had terminated P2Y12 inhibitor use. Their duration of 
DAPT was a little over 365 days. However, this was not based 
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B
Figure 2. DAPT duration for all indivudual patients. A) Days on 
DAPT in the DAPT study cohort. B) Days off DAPT in the DAPT 
study cohort. Blue dots indicate the ScT timing in relation to the 
number of days off DAPT.  VLScT: very late scaffold thrombosis.
Table 1. Patient and lesion characteristics.
Total cohort  
N patients=808, 
N lesions=949
DAPT study 
cohort 
N patients=685, 
N lesions=813
Median follow-up in days (IQR) 729 
(516-899.75)
730 
(531.8-923.3)
Gender (%) Male 73.9 73.9
Female 26.1 26.1
Mean age in years (±SD) 58.46 (10.91) 57.9 (10.6)
Smoking (%) 50.8 51.5
Hypertension (%) 47.9 45.0
Dyslipidaemia (%) 45.9 45.4
Diabetes mellitus (%) 14.2 14.3
Family history of CAD (%) 48.8 49.5
Prior MI (%) 12.8 12.4
Prior PCI/CABG (%) 13.7 13.4
Presentation with multivessel 
disease (%)
30.8 30.3
Indication for PCI (%)
Stable angina 26.6 26.1
Unstable angina 10.1 10.0
NSTEMI 30.7 31.2
STEMI 28.6 29.1
Silent ischaemia 3.9 3.6
Peripheral artery disease (%) 3.8 3.2
Heart failure (%) 4.0 2.5
Renal insufficiency (%) 3.3 2.5
ASA+P2Y
12
 inhibitor (%)
clopidogrel 39.8 38.3
prasugrel 38.2 38.3
ticagrelor 22.0 23.4
Median duration of DAPT in 
days (IQR)
367 (365-398)
Min and max DAPT duration in 
days
180-1,237
Number of lesions per patient 
(±SD)
1.17 (0.44) 1.19 (0.45)
Left anterior descending artery 
(%)
54.4 54.2
Left circumflex artery (%) 20.9 21.4
Right coronary artery (%) 24.7 24.4
Bifurcation (%) 23.0 21.3
Calcification (moderate or  
severe) (%)
33.7 32.9
CTO (%) 3.1 3.2
ACC/AHA 
lesion 
classification 
(%)
A 10.3 10.3
B1 43.5 44.0
B2 28.4 27.3
C 17.8 18.4
ACC/AHA: American College of Cardiology/American Heart Association; 
ASA: acetylsalicylic acid; CABG: coronary artery bypass graft; CAD: 
coronary artery disease; CTO: chronic total occlusion; DAPT: dual 
antiplatelet therapy; MI: myocardial infarction; NSTEMI: non-ST-
elevation myocardial infarction; PCI: percutaneous coronary intervention; 
STEMI: ST-elevation myocardial infarction.  
figure 2 DAPT duration for all individual patients
A) Days on DAPT in the DAPT study cohort. B) Days off DAPT in the DAPT study cohort. Blue dots indicate 
the ScT timing in relation to t  number of days ff DAPT. VLScT: very late scaffold thrombosis.
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For reasons of comparability with current literature, incidences per 100 patient-years 
(py) were computed in the DAPT study cohort (figure 4, table 3). For calculating the 
incidence of ScT in the time period 6 - 18 months, 607.52 py were available and 5 events 
occurred (one late ScT and 4 very late ScT) with an incidence of 0.83/ 100 py (95% CI: 
0.34 – 1.98).
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Incidence of ScT in Absorb BVS during early DAPT termination
on a specific reason such as an increased ischaemic risk. The rate 
of definite/probable ScT in this particular time frame was 0.7%.
For reasons of comparability with the current literature, the inci-
dences per 100 patient-years (py) were computed in the DAPT 
study cohort (Figure 4, Table 3). For calculating the incidence of 
ScT in the time period six to 18 months, 607.52 py were available 
and five events occurred (one late ScT and four very late ScT) 
with an incidence of 0.83/100 py (95% CI: 0.34-1.98).
For the period on DAPT, 381.90 py were available and one event 
occurred (at day 208). This resulted in an incidence of 0.26/100 
py (95% CI: 0.04-1.86). For the period after DAPT termination, 
225.62 py and four events were reported with an ScT incidence of 
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3.3% at 
18 months
(26 events)
Def/prob ScT, 0-18 months
No. of patients at risk 808 770 727 547
Time (months)
Figure 3. Cumulative ScT rate in the total cohort from the index 
procedure up to 18 months post procedure. ScT: scaffold thrombosis.
Table 2. Procedural characteristics.
Total cohort  
N patients=808, 
N lesions=949
DAPT study 
cohort  
N patients=685, 
N lesions=813
Predilatation (%) 88.4 88.3
Invasive imaging at baseline (%) 30.8 31.3
Total number of scaffolds 
implanted
1,119 964
2.5 mm BVS (%) 22.7 21.8
3.0 mm BVS (%) 39.2 40.7
3.5 mm BVS (%) 38.1 37.4
Mean scaffold diameter,  
mm (±SD)
3.08 (0.38) 3.08 (0.38)
Mean scaffold length,  
mm (±SD)
20.90 (5.83) 20.94 (5.83)
Mean total scaffold length per 
patient, mm (±SD)
32.48 (20.99) 33.14 (21.60)
Overlap (%) 29.7 30.6
Post-dilatation (%) 55.4 56.7
Clinical device success (%) 98.0 98.3
Clinical procedure success (%) 97.2 98.0
BVS: bioresorbable vascular scaffold.
1.77/100 py (95% CI: 0.66-4.72), numerically 6.8 times higher than 
the incidence on DAPT but not statistically significant (p=0.12).
For the incidence of ScT in the first month after DAPT termi-
nation, 45.64 py were available and three events occurred, which 
subsequently provided an incidence of 6.57/100 py (95% CI: 2.12-
20.38). This was statistically significant when compared to the 
incidence in the on DAPT period (p=0.01). The incidence of ScT 
during the last month of DAPT usage was zero.
Discussion
To the best of our knowledge, this is the first study that reports 
on the impact of DAPT termination on the occurrence of definite/
probable ScT in Absorb BVS in a clearly defined study cohort, 
reflecting real-world patients. The main findings of our study are 
as follows: 1) the incidence of definite or probable late and very 
late ScT in patients who are on DAPT is low; 2) all cases of very 
late ScT at 18 months were not using DAPT at the time of the 
event; 3) the incidence of ScT in patients off DAPT is potentially 
increased within the first 18 months post implantation, with the 
highest incidence within one month after termination of DAPT.
OVERALL INCIDENCE OF LATE AND VERY LATE ScT
Overall, the late and very late scaffold thrombosis rates in this 
multicentre, real-world registry were acceptable and comparable 
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Total
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Figure 4. Incidence densities for the whole DAPT study cohort, in 
patients on and off DAPT and within the first month of termination in 
the DAPT study cohort. DAPT: dual antiplatelet therapy.
Table 3. Incidence of definite/probable ScT per 100 patient-years.
Incidence rates  
per 100 patient-years 
(95% CI) 6-18 months
Total 0.83 (0.34-1.98)
On DAPT period 0.26 (0.04-1.86)
Off DAPT period 1.77 (0.66-4.72)
Within 1 month of DAPT termination 6.57 (2.12-20.38)
DAPT: dual antiplatelet therapy; ScT: scaffold thrombosis
figure 3 Cumulative ScT rate in the total cohort from the index procedure up to 18 months post procedure.
ScT: scaffold thrombosis
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Incid nc  of ScT in Absorb BVS duri g arly DAPT termination
on a specific reason such as an increased ischaemic risk. The rate 
of definite/probable ScT in this particular time frame was 0.7%.
For reasons of comparability with the current literature, the inci-
dences per 100 patient-years (py) were computed in the DAPT 
study cohort (Figure 4, Table 3). For calculating the incidence of 
ScT in the time period six to 18 months, 607.52 py were available 
and five events occurred (one late ScT and four very late ScT) 
with an incidence of 0.83/100 py (95% CI: 0.34-1.98).
For the period on DAPT, 381.90 py were available and one event 
occurred (at day 208). This resulted in an incidence of 0.26/100 
py (95% CI: 0.04-1.86). For the period after DAPT termination, 
225.62 py and four events were reported with an ScT incidence of 
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Figure 3. Cumulative ScT rate in the total cohort from the index 
procedure up to 18 months post procedure. ScT: scaffold thrombosis.
Table 2. Procedural characteristics.
Total cohort  
N patients=808, 
N lesions=949
DAPT study 
cohort  
N patients=685, 
N lesions=813
Predilatation (%) 88.4 88.3
Invasive imaging at baseline (%) 30.8 31.3
Total number of scaffolds 
implanted
1,119 964
2.5 mm BVS (%) 22.7 21.8
3.0 mm BVS (%) 39.2 40.7
3.5 mm BVS (%) 38.1 37.4
Mean scaffold diameter,  
mm (±SD)
3.08 (0.38) 3.08 (0.38)
Mean scaffold length,  
mm (±SD)
20.90 (5.83) 20.94 (5.83)
Mean total scaffold length per 
patient, mm (±SD)
32.48 (20.99) 33.14 (21.60)
Overlap (%) 29.7 30.6
Post-dilatation (%) 55.4 56.7
Clinical device success (%) 98.0 98.3
Clinical procedure success (%) 97.2 98.0
BVS: bioresorbable vascular scaffold.
1.77/100 py (95% CI: 0.66-4.72), numerically 6.8 times higher than 
the incidence on DAPT but not statistically significant (p=0.12).
For the incidence of ScT in the first month after DAPT termi-
nation, 45.64 py were available and three events occurred, which 
subsequently provided an incidence of 6.57/100 py (95% CI: 2.12-
20.38). This was statistically significant when compared to the 
incidence in the on DAPT period (p=0.01). The incidence of ScT 
during the last month of DAPT usage was zero.
Discussion
To the best of our knowledge, this is the first study that reports 
on the impact of DAPT termination on the occurrence of definite/
probable ScT in Absorb BVS in a clearly defined study cohort, 
reflecting real-world patients. The main findings of our study are 
as follows: 1) the incidence of definite or probable late and very 
late ScT in patients who are on DAPT is low; 2) all cases of very 
late ScT at 18 months were not using DAPT at the time of the 
event; 3) the incidence of ScT in patients off DAPT is potentially 
increased within the first 18 months post implantation, with the 
highest incidence within one month after termination of DAPT.
OVERALL INCIDENCE OF LATE AND VERY LATE ScT
Overall, the late and very late scaffold thrombosis rates in this 
multicentre, real-world registry were acceptable and comparable 
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Figure 4. Incidence densities for the whole DAPT study cohort, in 
patients on and off DAPT and within the first month of termination in 
the DAPT study cohort. DAPT: dual antiplatelet therapy.
Table 3. Incidence of definite/probable ScT per 100 patient-years.
Incidence rates  
per 100 patient-years 
(95% CI) 6-18 months
Total 0.83 (0.34-1.98)
On DAPT period 0.26 (0.04-1.86)
Off DAPT period 1.77 (0.66-4.72)
Within 1 month of DAPT termination 6.57 (2.12-20.38)
DAPT: dual antiplatelet therapy; ScT: scaffold thrombosis
figure 4 Incidence densities for the whole DAPT study cohort, in patients on and off DAPT and within the 
first month of termination in the DAPT study cohort.
DAPT: dual antiplatelet therapy.
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For the period on DAPT, 381.90 py were available and 1 event occurred (at day 208). 
This resulted in an incidence of 0.26/ 100 py (95% CI: 0.04 – 1.86). For the period after 
DAPT termination,  225.62 py and  4 events were reported with ScT incidence of  1.77/ 
100 py (95% CI: 0.66 – 4.72), numerically 6.8 times higher than the incidence on DAPT 
but not statistically significant (p=0.12).
For the incidence of ScT in the first month of DAPT termination, 45.64 py were avail-
able and 3 events occurred, which subsequently provided an incidence of 6.57/ 100 py 
(95% CI: 2.12 – 20.38). This was statistically significant when compared to the incidence 
in the on DAPT period (p=0.01). The incidence of ScT during the last month of DAPT 
usage was 0.
Discussion
To our knowledge this is the first study that reports on the impact of DAPT termination 
on the occurrence of definite/ probable ScT in Absorb BVS in a clearly defined study 
cohort, reflecting real-world patients. The main findings of our study are as follows: 1) 
Incidence of definite or probable late and very late ScT in patients that are on DAPT 
is low; 2) All cases of very late ScT at 18 months were not using DAPT at time of the 
event; 3) Incidence of ScT in patients off DAPT is potentially increased within the first 18 
months post-implantation, with the highest incidence within one month after termina-
tion of DAPT.
overall incidence of late and very late sct 
Overall, late and very late scaffold thrombosis rate in this multi-center,  real-world reg-
istry was acceptable and comparable to the rates in selected populations as included in 
approval studies for different countries. [11, 12, 15] In this study and regardless of DAPT 
status, the overall incidence density of late and very late def/ prob ScT were 1.0 and 1.44 
per 100 patient-years respectively. A large all-comer observational cohort study, inves-
tigating ST in metal DES during 4-year follow-up, reported a late ST incidence density of 
table 3. Incidences of definite/ probable ScT per 100 patient-years 
Incidence rates per 100 patient-years (95% CI)
6 – 18 months
Total 0.83 (0.34 - 1.98)
On DAPT period 0.26 (0.04 – 1.86)
Off DAPT period 1.77 (0.66 – 4.72)
Within 1 month of DAPT termination 6.57 (2.12 – 20.38)
DAPT: dual antiplatelet therapy; py: patient-years; ScT: scaffold thrombosis
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0.4 def/ prob ST per 100 patient-years in patients treated with newer-generation EES. For 
SES and PES, incidence densities were higher for both late (SES: 0.7/ 100 patient-years 
and PES: 1.5 per 100 patient-years) and very late ST (SES: 2.8/ 100 patient-years and PES: 
4.0/ 100 patient-years). In this regard, late and very late ScT incidence in BVS patients 
seems comparable to first generation metal DES.[18]
DaPt and late events
At 18 months, there were 4 patients with VLScT, all while not using DAPT during the 
event. Three out of four cases appeared to be associated with DAPT termination. The 
incidence density was 1.79/ 100 patient-years in patients who were not continually on 
DAPT. Importantly, incidence of ScT within one month of DAPT termination was even 
higher. In the Absorb Extend study, 50% of the ScT cases were related to either prema-
ture DAPT termination or resistance to clopidogrel. [19] The ABSORB Japan trial reported 
two years follow-up. Two out of four patients with VLScT were not using DAPT at time of 
the event. In the recently published ABSORB II RCT , three-year results revealed 6 cases 
of VLScT. Of note, all cases of late and very late ScT occurred in patients off  DAPT. More-
over, in patients who did not terminate DAPT up to 3 years, no ScT were described. [12] 
In our series, the relationship between the moment of DAPT termination and occurrence 
of VLScT was notable, with 3 out of 4 cases within 35 days of DAPT termination, a finding 
not so clear in the ABSORB II and ABSORB Japan trials. Thus, as reported in multiple 
studies, DAPT termination seems to play an important role in the occurrence of VLScT.
Possible causes late sct 
Other factors besides DAPT termination, that were associated with ScT were suboptimal 
implantation technique, late discontinuities, uncovered struts, neoatherosclerosis, high 
maximum footprint, small minimal lumen diameter, small vessels, higher % diameter 
stenosis, overlap, ostial lesions and decreased LVEF. [11, 20-25] Late and very late ScT 
while DAPT was terminated, might be explained by the high volume of implanted mate-
rial with special attention the increased strut thickness, which could cause laminar flow 
disturbance and subsequently the triggering of platelet deposition. [26] This might be 
a special problem in small vessels or when full dilatation was not achieved without high 
pressure post-dilatation using non-compliant balloons. In early BVS-registries, there was 
a higher risk of malapposition, often induced by undersizing, which occurs regularly. [5] 
During the first large studies in BVS patients, high pressure post-dilatation with non-
compliant balloons was not mandatory as result of a case where strut fractures were 
observed. Nowadays, a different implantation tactic for BVS is used after an optimal 
implantation strategy, started in January 2014,  was associated with a large reduction in 
ScT incidence. [20, 27] Also, thinner strut BVS are currently being developed, which will 
mitigate the risk of ScT. 
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stuDy limitations
This was a retrospective and registry data – pooled study. As the sample size is limited 
and numbers of this low-frequence event are small, these results should be interpreted 
with caution and considered hypothesis generating. More data and dedicated studies 
are needed to confirm our suggestion to prolong DAPT in BVS treated patients. Lastly, 
quantitative coronary analysis (QCA) was not available in all patients.
conclusion
The incidence of probable/ definite late and very late ScT in BVS patients who are on 
DAPT in our study is low. However, the incidence of early ScT and also the occurrence of 
very late ScT are not negligible. Between 6 and 18 months, incidence of ScT in patients 
who terminated DAPT is potentially increased. 
impact on daily practice
As long as studies with an optimal implantation strategy haven’t revealed data on safe 
DAPT termination before 18 months, it would be reasonable to consider extension of 
DAPT. Prolonging DAPT even up to three years could be a possible solution in patients 
with an increased risk of ischemic events and low bleeding risk (the DAPT score can be 
used for risk assessment [28]), as the resorption process of Absorb BVS is completed in 3 
years and until that time, the polymer is still present and the risk of very late ScT is lurk-
ing. The decision whether or not to continue DAPT beyond a certain time point cannot 
be made by a ‘one size fits all’ principle and should be individual-based.
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abstract
background
Bioresorbable Vascular Scaffolds (BVS) were introduced to overcome some of the limita-
tions of drug-eluting stent (DES) for PCI. Data regarding the clinical outcomes of the BVS 
versus DES beyond 2 years are emerging. 
objective
To study mid-term outcomes.
methods
We searched online databases (PubMed/Medline, Embase, CENTRAL), several websites, 
meeting presentations and scientific session abstracts until August 8th, 2017 for studies 
comparing Absorb BVS with second-generation DES. The primary outcome was target 
lesion failure (TLF). Secondary outcomes were all-cause mortality, myocardial infarction, 
target lesion revascularization (TLR) and definite/probable device thrombosis. Odds 
ratios (ORs) with 95% confidence intervals (CIs) were derived using a random effects 
model.
results
Ten studies, seven randomized controlled trials and three propensity-matched obser-
vational studies, with a total of 7320 patients (BVS n=4007; DES n=3313) and a median 
follow-up duration of 30.5 months, were included. Risk of TLF was increased for BVS-
treated patients (OR 1.34 [95% CI: 1.12-1.60], p=0.001, I2=0%). This was also the case for 
all myocardial infarction (1.58 [95% CI: 1.27-1.96], p<0.001, I2=0%), TLR (1.48 [95% CI: 
1.19-1.85], p<0.001, I2=0%) and definite/probable device thrombosis (of 2.82 (95% CI: 
1.86-3.89], p<0.001 and I2=40.3%). This did not result in a difference in all-cause mortal-
ity (0.78 [95% CI: 0.58-1.04], p=0.09, I2=0%). OR for very late (>1 year) device thrombosis 
was 6.10 [95% CI: 1.40-26.65], p=0.02). 
conclusion
At mid-term follow-up, BVS was associated with an increased risk of TLF, MI, TLR and 
definite/probable device thrombosis, but this did not result in an increased risk of all-
cause mortality. 
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conDenseD abstract
Pooled 1-year results of RCTs in selected patients showed non-inferiority of target le-
sion failure (TLF) for bioresorbable vascular scaffolds (BVS). Meta-analyses that included 
more complex patients revealed an increased risk for TLF and scaffold thrombosis in 
BVS-treated patients. This meta-analysis reports on mid-term outcomes from 10 studies 
comparing Absorb BVS versus second-generation drug-eluting stents. At a weighted 
median FU of 30.5 months, risks of TLF, all myocardial infarction, target lesion revascular-
ization and definite/probable device thrombosis were increased in BVS-treated patients, 
which did not result in higher all-cause mortality.
introDuction
Bioresorbable scaffolds, developed to overcome some of the (late) adverse events of 
metallic drug-eluting stents (DES), are the latest innovation in the treatment of coronary 
artery disease. The Absorb bioresorbable vascular scaffold (BVS, Abbott Vascular, Santa 
Clara, CA, USA) is the most intensively studied. The first-in-man study in 2006 revealed 
promising results and this new device received a CE-mark in 2011 and became com-
mercially available in Europe in September 2012. FDA approval followed in 2016 [1].
The concept of the Absorb BVS consists of treatment of obstructive coronary artery 
disease with temporary support of the vessel wall while avoiding the acute complica-
tions of balloon angioplasty. It was hypothesized that complete resorption would result 
in restoration of vasomotion, a reduction in angina, and the avoidance of caging of the 
vessels or interference with non-invasive imaging. In addition, vessel geometry would 
be less affected after implantation of a BVS. This should result in better outcomes for 
patients, with reduced late event rates. Pooled individual data from the four largest 
randomized controlled trials (RCTs) comparing BVS with second-generation DES did 
support the concept of temporary support of the artery and showed non-inferiority 
of the device during the first year [2]. However, several meta-analyses that included 
data beyond 1 year revealed higher event rates of myocardial infarction, target lesion 
revascularization and scaffold thrombosis [3, 4]. Data on the performance of BVS beyond 
1 year primarily came from small registries, propensity-matched observational studies 
and a few RCTs. These raised concerns about the occurrence of very late (after 1 year) 
scaffold thrombosis [5], whereas RCTs assessed only the mid-term time points. We 
therefore undertook this systematic review and meta-analysis, and report the mid-term 
clinical outcomes of the Absorb BVS compared with second-generation DES.
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Data sources and study selection
Inclusion criteria for our study were RCTs comparing the Absorb BVS with the Xience 
CoCr-EES, a second-generation DES, in patients with coronary artery disease with > 12 
months of follow-up available. As randomized mid- to long-term data are scarce, we 
also allowed propensity-matched observational studies comparing BVS with second-
generation DES. Both full-length manuscripts and meeting presentations (containing 
unpublished data) were included. All studies had to report on the outcomes of interest 
and be written in English. Exclusion criteria were non-human studies, single-arm stud-
ies, imaging-only studies, studies with short follow-up (≤ 12 months), studies in <100 
patients, review articles, case series, trial design articles, comparisons other than Absorb 
BVS versus second-generation DES, studies with duplicate data, and those where the 
scaffold or stent was implanted elsewhere than in the coronary artery. This meta-analysis 
was conducted in accordance with the Preferred Reporting Items for Systematic Reviews 
and Meta-analysis guidelines [6] (S4 Table).
Data extraction and quality assessment
On August 8th , 2017, a medical librarian (WB) conducted a systematic search of the on-
line databases Medline/PubMed, Embase and Cochrane Central Register of Controlled 
Trials (CENTRAL), several websites (e.g. www.clinicaltrials.gov) and scientific session 
abstracts and oral presentations from conferences, with the following keywords and 
corresponding MeSH terms: “drug-eluting stent(s)”, “everolimus-eluting stent”, “biore-
sorbable vascular stent”, “bioresorbable scaffold”. On October 31th, during the 2017 TCT 
congress, ABSORB II, III and TROFI II presented their 3- and 4-year outcomes, which we 
also included in our analysis. The bibliographic records retrieved were imported and 
de-duplicated in Endnote bibliographic software. Two physician reviewers (CF and VB) 
independently screened the records for eligibility at title or abstract level. Records that 
were relevant were downloaded and full text manuscripts or meeting presentations 
were reviewed. Differences between reviewers regarding study selection or data extrac-
tion were resolved by consensus. If one study had multiple publications with different 
follow-up lengths, the most recent follow-up record was used.
Quality and risk of bias in reporting data were assessed according to the Cochrane 
Handbook of Systematic Reviews [7] and by using the Newcastle-Ottawa Quality As-
sessment scale for case-control studies (maximum score = 9, meaning low risk of bias). 
Publication bias for the primary endpoint was assessed using funnel plot.
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outcomes and definitions
The primary outcome for this analysis was target lesion failure (TLF), a composite 
endpoint that consists of cardiac death, target-vessel myocardial infarction and 
ischemia-driven TLR. Secondary outcomes were all-cause mortality, all myocardial in-
farction, ischemia-driven TLR and definite or probable device thrombosis. Deaths were 
considered cardiac unless a non-cardiac cause was identified. TLR was described as any 
repeated revascularization of the target lesion. Device thrombosis was classified accord-
ing to the Academic Research Consortium [8]. To investigate the effect of the intended 
bioresorption of the device, we examined outcomes during the first and second years 
separately. Definitions of clinical outcomes per study are described in S1 Table.
statistical analysis
Odds ratios (ORs) with 95% confidence intervals (CIs) were used as summary statistics 
across all studies and were calculated using a random effects model (Dersimonian and 
Laird). We also provide results of the fixed-effect model. Treatment effect was not assessed 
in studies in which no events were reported. Heterogeneity was assessed using Cochran 
Q and Higgins I2. I2 values of <25%, 25-50% or >50% indicate low, moderate or high het-
erogeneity. Cochran Q P<0.10 and I2>50% were considered to be indicative of significant 
heterogeneity. All analyses were conducted with Revman software (version 5.3).
Primary and secondary outcomes are reported for all included studies in which the 
outcome of interest was provided. A sensitivity analysis was performed, as detailed in 
the online supplement. In this analysis, the treatment effect was investigated in studies 
that included low-risk patients (ABSORB II, ABSORB III, ABSORB Japan, ABSORB China) 
versus studies that included more complex population (TROFI II, AIDA, EVERBIO and the 
observational studies, including higher percentage of STEMI, bifurcation, calcification, 
long lesions etc.). Finally, separate subgroup analyses for RCTs (low risk of bias) and 
propensity-matched studies (low/low-moderate risk of bias) were performed.
The risks of adverse events between 0 – 1 year, 1 – 2 and 2 -3 years were estimated 
using a landmark population that censored any casualty and lost to follow-up preceding 
each specific time point.
trial sequential analysis
Meta-analyses may results in type 1 errors due to systematic errors (several forms of 
bias) or random errors (play of chance) due to sparse data and repeated significance 
testing when a meta-analysis is updated with new trials [9]. This can result in spurious 
significant results [10]. Trial sequential analysis (TSA) was introduced to minimize ran-
dom errors. TSA provides the necessary information for meta-analyses and boundaries 
that determine whether the evidence is reliable and conclusive. We calculated required 
information size allowing for a type 1 error of 0.05, type 2 error of 0.20, the control event 
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proportions and effect size calculated from the included trials, and heterogeneity esti-
mated by the diversity (D2) in the included trials. We constructed TSA boundaries based 
on the O’Brien-Fleming alpha-spending function. Trial Sequence Analysis Software 
(Copenhagen Trial Unit’s TSA Software; Copenhagen, Sweden) was used. 
results
The de-duplicated results yielded 1305 records. Figure 1 shows a flow diagram of the 
selection process. Based on the exclusion criteria, 1278 records were excluded after title/
abstract review. Twenty-seven records remained for full-text analysis, of which 17 were 
eliminated (short follow-up or editorials). Ultimately, we included 7 RCTs (3 full-length 
Mid-term outcomes of BVS Vs DES: A systematic review and meta-analysis
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figure 1 Flowchart 
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manuscripts, 4 meeting presentations) with a total of 5578 patients: 3258 received the 
Absorb BVS and 2320 received a second-generation DES. We also included 3 observa-
tional studies (2 manuscripts and 1 meeting presentation) with 1742 patients: 749 were 
implanted with a BVS and 993 with a DES. Weighted median FU was 30.5 months. Table 
1 summarizes the main characteristics of the included studies.
baseline characteristics
Across all studies in this meta-analysis, the mean age of patients ranged from 56.0 to 
67.3 years; the percentage of men between 70.1% and 81.4%; diabetic patients between 
12.8% and 36.1%; and the percentage of patients that presented with an acute coronary 
syndrome between 9.8% and 100%. In all studies except ABSORB II and EVERBIO, the per 
protocol prescribed duration of dual antiplatelet therapy (DAPT) was at least 12 months. 
The percentage of BVS patients using DAPT at 2 years ranged from 5.5% to 66%. The rate 
of post-dilatation ranged from 15.2% to 82.2% (Table 2).
table 1. major characteristics of included studies
study year centres, 
n
bvs/ Des 
treated 
Patients, n
study type clinical 
presentation
Primary 
endpoint
follow-
up, yrs.
absorb ii 28 2016 46 335/ 166 RCT SAP, established 
ACS
Vasomotion & 
LLL (at 3 yrs.)
1, 2, 3, 4
absorb iii 27 2017 193 1322/ 686 RCT SAP, established 
ACS
TLF (at 1 yr.) 1, 2, 3
absorb 
Japan 36
2016 38 266/ 134 RCT SAP, established 
ACS
TLF (at 1 yr.) 1, 2, 3
absorb 
china  37
2016 24 238/ 237 RCT SAP, established 
ACS
LLL (at 1 yr.) 1, 2, 3
trofi ii 26 2016 8 95/ 96 RCT STEMI HS (at 6 
months)
1, 2, 3
everbio 38 2017 1 78/ 80 RCT SAP, ACS, silent 
ischemia
LLL (at 9 
months)
9 months, 
2 yrs.
aiDa 39 2017 5 924/ 921 RCT SAP, ACS TVF (at 2 yrs.) Median of 
707 days
imori et al. 40 2016 8 214/ 215 Propensity 
matched
ACS MACE 2
bvs-
examination 
41
2016 6 290/ 290 Propensity 
matched
STEMI POCE (at 1 yr.) 1, 2
bvs expand 42 2017 1 244/ 488 Propensity 
matched
SAP, UA, NSTEMI, 
silent ischemia
MACE 2
ACS: acute coronary syndrome; DOCE: device oriented composite endpoint; HS: healing score; LLL: late 
lumen loss; MACE: major adverse cardiac events; RCT: randomized controlled trial; SAP: stable angina pec-
toris; STEMI: ST-elevation myocardial infarction; TLF: target lesion failure; LLL: late lumen loss; TVF: target 
vessel failure; UAP: unstable angina pectoris
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clinical outcomes
All studies but one (BVS Expand) reported on TLF. Overall, TLF occurred in 617 patients 
during the mid-term follow-up, with a significantly higher risk in BVS-treated patients 
(OR 1.34 [95% CI: 1.12-1.60], p=0.001 and I2=0%) (Figure 3A). A subanalysis of RCTs 
showed only a significantly similar increased OR (1.31 [95% CI: 1.08-1.58], p=0.005 and 
I2=0%). The pooled OR across the observational studies was numerically higher, but with 
a larger 95% CI (OR 1.57 [95% CI: 0.92-2.68, p=0.10, I2=0%). In the TSA for the primary 
endpoint, the cumulative Z-curve did cross the TSA monitoring boundary, indicating 
that there were a sufficient number of patients to consider this a valid analysis (Figure 
2A). See S2 and S8 Figures for the sensitivity analyses and S3-S7 Figures for fixed effects 
models of the primary and secondary outcomes. 
Secondary endpoints
All-cause mortality occurred in 207 patients, without a statistically significant difference 
between both patient groups (OR 0.78 [95% CI: 0.56-1.37], p=0.09, I2=0%). Results for the 
pooled RCT and pooled observational study subgroups were similar (Figure 3B).
The risks of myocardial infarction and TLR were significantly increased for BVS com-
pared with DES (Figures 3C and 3D). Finally, patients with BVS had a higher risk for 
definite or probable device thrombosis, with ORs of 2.82 (95% CI: 1.86-3.89], p<0.001 
and I2=40.3%), 3.48 (95% CI: 2.06-5.87, p<0.001 and I2=0%) and 2.82 (95% CI: 1.86-4.26, 
p<0.001 and I2=0%), respectively, for the total cohort, RCTs only and observational data 
only (Figure 3E). 
Landmark analysis
Table 3 summarizes event rates and ORs in the periods up to 1 year, 1-2 years and 2-3 
years (for those studies that reported 1- and 2-year and 3-year results of the outcomes 
of interest: ABSORB II, ABSORB Japan, ABSORB China, ABSORB III). In the first year, the 
risks of myocardial infarction and device thrombosis were significantly increased in BVS 
patients. During the second year, all event rates for both BVS and DES were lower, but 
the increased risk for BVS remained. The OR for late device thrombosis was quadrupled 
in BVS-treated patients. In the third year, events rates remained lower and no significant 
differences between the 2 groups existed anymore. However, the OR for device throm-
bosis in BVS patients continued to be high.
Definite/ probable device thrombosis
For the secondary endpoint definite or probable device thrombosis, we specifically 
investigated early (0-30 days), late (31 days-1 year) and very late (> 1 year) device throm-
bosis (for studies that reported the outcome of interest at these three time points). Event 
rates for early thrombosis were 1.07% for BVS versus 0.51% for DES. This resulted in an 
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increased risk for BVS (OR 1.96 [95% CI: 1.01-3.81], p=0.05). Late device thrombosis event 
rates were 0.53% for BVS versus 0.09% for DES (OR 3.14 [95% CI: 0.83-11.82, p=0.09). 
Rates of very late device thrombosis up to three years were 1.09% for BVS compared to 
0.0% for DES (OR 6.10 [95% CI: 1.40-26.65], p=0.02). 
The sensitivity analysis results can be found in S2 Figure.
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figure 2 Trial Sequential Analysis for (A) Primary Endpoint Target Lesion Failure and Definite/Probable De-
vice Thrombosis (B) 
The red dotted line represents the trial sequential monitoring boundaries and the futility boundaries. The 
solid dark red line illustrates the conventional level of significance (p=0.05). The cumulative Z score (solid 
blue line) crosses both the conventional boundary and the trial sequential monitoring boundary, indicating 
sufficient and conclusive evidence.
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Quality assessment
Quality assessments for both RCTs and observational studies are provided in the S2 and 
S3 Tables. All RCTs had a low risk of bias, while the observational studies had a low/
low-moderate risk of bias (all scored 7 out of 9). To assess a possible publication bias, a 
funnel plot for TLF was derived (S1 Figure).
Discussion
This study included 7320 patients, to report on the mid-term clinical outcomes of the 
Absorb BVS compared with second-generation DES. Compared to other meta-analyses 
versus 0.09% for DES (OR 3.14 [95% CI: 0.83–11.82, p = 0.09). Rates of very late device throm-
bosis up to three years were 1.09% for BVS compared to 0.0% for DES (OR 6.10 [95% CI:
1.40–26.65], p = 0.02).
The sensitivity analysis results can be found in S2 Fig.
Z score (solid blue line) crosses both the conventional boundary and the trial sequential monitoring boundary,
indicating sufficient and conclusive evidence.
https://doi.org/10.1371/journal.pone.0197119.g002
Fig 3. 3A – 3E. Forest plots (random effects models) for primary and secondary endpoint of bioresorbable vascular scaffolds versus drug-eluting stents. (A) Target
lesion failure, (B) All-cause mortality, (C) All myocardial infarction, (D) Target lesion revascularization. RCTs reported ischemia-driven TLR and observational studies
reported all TLR. (E) Definite/ probable device thrombosis. CI: confidence interval; M-H: Mantel-Haenszel; OR: odds ratio.
https://doi.org/10.1371/journal.pone.0197119.g003
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fig 3. 3A ± 3E. Forest plots (random effects models) for primary and secondary endpoint of bioresorbable 
vascul r scaffolds ve sus rug-eluting ste ts. (A) Target lesion failure, (B) All-cause mortality, (C) All myo-
cardial infarction, (D) Target lesion revascularization. RCTs reported ischemia-driven TLR and observational 
studies reported all TLR. (E) Definite/ probable device thrombosis. CI: confidence interval; M-H: Mantel-
Haenszel; OR: odds ratio.
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[11-14], our analysis included the RCTs and complemented only with propensity matched 
registries to include the highest quality data available for more complex patients. Using 
this strategy we were able to perform a sub analysis for RCT and propensity match series 
representing the more complex none RCT patients and a  separate analysis for 2 to 3 
year outcomes. Furthermore, a trial sequential; analysis was performed and also, several 
sensitivity analyses were done such an analysis of  more complex patients versus non-
complex patients.
 The main findings of this meta-analysis are: 1) BVS-treated patients were at higher risk 
for TLF, MI, TLR and device thrombosis compared with second-generation DES, across 
all studies included in this meta-analysis; 2) this did not result in an increased risk of all-
cause mortality; 3) based on studies that have reported clinical outcomes of interest at 1, 
2 and 3 years of follow-up, risks of TLF, MI, TLR and especially the risk of very late device 
thrombosis, continued to be higher for BVS in following years after device implantation. 
In our study, propensity matched registries were included.  There are some advantages 
of registries over clinical trials. Firstly, registries handle less strict in- and exclusion criteria 
and therefore create a more ‘real-world’ patient population [15]. Results originating from 
registries are better generalizable. Secondly, registries often make use of longer-term 
follow-up then duration of follow-up observed in RCTs. Thirdly, the larger amount of 
events makes the identification of rare events, such as ScT, possible. Fourth, as registries 
integrate data less selected patients, receiving care in diverse clinical settings, they are 
able to better investigate specific subgroups that are often underrepresented in clinical 
trials. 
table 3. outcomes of interest at 0 -1 year, 1 -2 years and 2 -3 years
(for included studies that presented outcomes at these time points*)
outcome up to 1 year 1 -2 years 2 – 3 years
bvs Des or
(95% ci)
P bvs Des or
(95% ci)
P bvs Des or
(95% ci)
P
tlf (%) 6.39 5.15 1.24
(0.97 – 1.58)
0.09 4.43 2.55 1.55
(0.98 – 2.46)
0.06 1.20 0.34 2.75
(0.97 - 7.78)
0.06
all-cause mortality 
(%)
1.17 1.49 0.90
(0.33 – 2.43)
0.83 1.10 1.73 0.65
(0.4 – 1.05)
0.08 0.20 1.88 0.14
(0.01 – 1.46)
0.10
myocardial 
infarction (%)
5.15 3.50 1.38
(1.04 – 1.83)
0.03 2.20 1.01 2.17
(1.30 - 3.62)
0.003 1.36 0.94 1.18
(0.59 - 2.37)
0.64
iD-tlr (%) 3.08 2.57 1.26
(0.90 – 1.77)
0.18 2.87 1.59 1.67
(0.97 – 2.87)
0.06 2.11 1.02 1.79
(0.62 – 5.15)
0.28
Def/ prob device 
thrombosis (%)
1.60 0.61 2.45
(1.35 – 4.46)
0.03 0.86 0.10 4.75
(1.63 – 13.82)
0.004 0.53 0.00 3.79
(0.67 – 21.37)
0.13
*ABSORB II, ABSORB III, ABSORB China, ABSORB Japan. Def/ prob: definite/probable; OR: Odds ratio; ID-TLR: 
ischemia driven target lesion revascularization; TLF: target lesion failure
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Initial study designs for BVS, based on the concept of temporary vascular support, 
hypothesized non-inferiority at one year and a reduction in TLF of approximately 50% 
beyond the first year. In this analysis, we demonstrated that event rates were highest 
during the first year after PCI and, for all endpoints except all-cause mortality; the use 
of BVS was associated with significantly higher risks of events. The mid-term results 
in this meta-analysis are in line with previous results [12, 16-21]. Beyond 1 year, event 
rates were lower than during the first year, but outcomes such as device thrombosis, 
myocardial infarction and the primary endpoint – TLF – remained not in favour of BVS. 
Four RCT’s reported their three-year results and one RCT presented four-year results. 
All revealed continued higher event rates for BVS. During the EuroPCR 2017 congress, 
longer term data of several large single-arm registries, that included higher percentages 
of complex patients, was presented and with varying results [22].
Definite/ probable device thrombosis
 In our study, we demonstrated that the risk of definite device thrombosis was almost 
three times higher for BVS. Meta-analyses investigating device thrombosis in BVS com-
pared with DES have reported an increased risk of device thrombosis for BVS [5, 23, 24]. 
Multiple factors have been reported to be associated with scaffold thrombosis, such as 
a suboptimal implantation strategy, overlap, ostial lesions and decreased left ventricular 
ejection fraction [25]. Moreover, the first-generation BVS has a strut thickness consider-
ably larger than the competitor metallic DES and similar to first-generation metallic DES. 
Scaffold thrombosis might be triggered by the smaller minimum lumen diameter and 
minimum lumen area at the end of the procedure, as previously demonstrated [26]. This 
has the most impact on smaller vessels (with a diameter <2.5 mm visual or 2.25 mm by 
quantitative coronary analysis (QCA). 
Early device thrombosis is generally considered to be procedure-related, when the 
characteristics of the device and operators experience are important factors. 
The resorption process of the BVS might influence the mechanisms for very late 
scaffold thrombosis. It has been postulated that the disintegration of uncovered and 
malapposed struts (due to resorption-related scaffold discontinuity) might trigger the 
inflammatory process and thrombus formation, potentially for up to 3 years (18, 26, 27). 
recent setback
Recently, the ABSORB BVS suffered a setback after the 3-year results of the ABSORB II 
trial demonstrated similar vasomotion between BVS and everolimus-eluting DES and a 
greater late lumen loss for BVS. [27, 28]  The FDA came with a safety alert after the 2-year 
results of the largest RCT, the ABSORB III, were presented during the ACC congress in 
March 2017. The AIDA trial even published their 2-year results earlier than expected 
after the safety monitoring board recommended to release the preliminary data due to 
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safety concerns (hazard ratio of 3.87 for device thrombosis at 2 years; 95% CI: 1.78 – 8.42; 
p=<0.001). As a consequence, the current generation BVS has been taken out of the 
market. Just recently, a Task Force of ESC and EAPCI stated that bioresorbable scaffolds 
should not be preferred above the current used metallic DES [29]. These unfavourable 
findings were again confirmed during the 2017 TCT congress in Denver, USA on October 
the 31th. [30-32]
Possible solutions and future outlook
It remains uncertain whether implantation technique could improve outcomes. The 
basic concept of optimal implantation includes proper lesion preparation, adequate siz-
ing (avoiding small vessels <2.5 mm) and high-pressure post-dilatation, also known as 
PSP. In retrospective analyses, this implantation strategy showed a reduction in TLF [25] 
[22, 33-35]. Also, the 30-day ABSORB IV results revealed lower device thrombosis rates, 
when implantation of stents/ scaffolds in small vessels was minimalized. [36] The pro-
spective study ‘IT-DIAPPEARS’ showed that when a predefined implantation technique 
was performed, one-year outcomes were favourable with a def/ prob ScT rate of 0.9%. 
[37] However, our meta-analysis was not able to correctly assess the influence of PSP on 
procedural and clinical outcomes, as the included studies did not apply high rates of 
dedicated implantation strategy.
Furthermore, whether DAPT prolongation could prevent late occurrence of scaffold 
thrombosis was to be investigated. DAPT termination is a risk factor for device throm-
bosis, and a possible relationship between scaffold thrombosis and DAPT termination 
has been described. However, information on the precise duration of DAPT after BVS 
implantation is lacking and, up to this moment, no dedicated studies exist on this impor-
tant issue. A recently published review has suggested several considerations for DAPT 
duration in BVS patients [38]. In metal stents, prolongation of DAPT up to 30 months 
showed to reduce thrombotic events [39]. The new generation device should have thin-
ner struts, better mechanical properties and shorter resorption time to facilitate easy 
implantation strategies and to prevent intraluminal dismantling [40].
limitations
The most important limitation is the use of unpublished data in the form of meeting 
presentations. Secondly, the meta-analysis was performed using study-level data rather 
than patient-level data, so time-to-event curves were not possible. Thirdly, heterogene-
ity existed in baseline characteristics of included patients and also in protocols, study 
designs and definitions across the studies. Furthermore, the patients included in the 
RCTs (which provided most patients) were highly selected (except for AIDA) and, there-
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fore, extrapolation to the real world is difficult. Besides, we were not able to completely 
exclude potential confounders in the observational registries. However these studies 
were based on propensity matching. Fourthly, the large AIDA RCT had a median follow-
up duration of 1.93 years (range 1−3.3 years); thus this trial did not report outcomes at 
exactly 2 years. 
Longer follow-up will be necessary to get a better view of the low-frequency endpoint 
mortality.
To assess possible publication bias, we provided a funnel plot in S1 Figure. However, 
this plot should be interpreted with caution as we included ten studies. There was also a 
lack of important information on DAPT status (duration of DAPT, reasons for interruption 
or early termination, type of P2Y12 inhibitor). Lastly, the current data only apply for the 
Absorb BVS and not for other bioresorbable devices.
conclusions
At mid-term follow-up, patients treated with Absorb BVS showed a higher risk of TLF, 
myocardial infarction, TLR and definite or probable device thrombosis. Beyond 1 year, it 
was mainly the risk of late device thrombosis that was increased. However, this did not 
result in a higher risk of all-cause mortality. Despite these unfavourable mid-term out-
comes, long-term follow-up will be necessary to investigate any potential late benefits 
of BVS over DES as this device was not able to show any clinical benefit up to 3 years. 
Specific registries and post-hoc analyses of larger RCTs identified potential improve-
ments in patient and lesion selection. A device specific implantation strategy is another 
factor that can result in better outcomes. As long as this has not been demonstrated 
in prospective and dedicated studies such as ABSORB III (NCT01751906), ABSORB IV 
(NCT02173379) and Compare Absorb (NCT02486068) operators should not use this 
version in routine practice. 
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table 1b.
bvs-examination imori et al. bvs expand
target lesion failure Cardiac death, target-vessel 
MI, TLR
NA Cardiac death, target-vessel 
MI, ID-TLR
Patient oriented 
endpoint
All-cause death, any MI, any 
revascularization
NA NA
Device thrombosis ARC definitions ARC definitions ARC definitions
myocardial infarction Based on Historical 
Extended Definition of MI 
(modified ARC Definition 
according to Vranckx et 
al. 33)
NR Based on Historical Extended 
Definition of MI (modified 
ARC Definition according 
to Vranckx et al. 33) and per 
protocol definition of MI also 
known as the World Health 
Organization Definition of MI.
ID-TLR: ischemia-driven target lesion revascularization; MI: myocardial infarction; NA: not applicable; ULN: 
upper limit of normal
table 2. assessment of risk of bias for randomized controlled trials
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absorb ii IWRS Yes Yes Yes (independent CEC) Yes No Yes Industry
absorb iii IWRS Yes Yes Yes (independent CEC) Yes No Yes Industry
absorb Japan IWRS Yes Yes Yes (independent CEC) Yes No Yes Industry
absorb china IWRS Yes No Yes (independent CEC) Yes No Yes Industry
aiDa IWRS Yes Yes Yes (independent CEC) Yes No Yes Investigator
trofi ii IWRS Yes No Yes (independent CEC) Yes No Yes Investigator
everbio ii IWRS Yes Yes Yes (independent CEC) Yes No Yes Investigator
CEC: clinical event committee; IWRS: interactive web-based response system
table s3. Quality assessment for observational studies
study selection comparability on basis of design and analysis outcome
imori et al. **** * ***
bvs examination **** * ***
bvs expand **** * ***
Score of nine is maximum score (= lowest risk of bias)
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S1 Figure, Funnel plot for TLF 
   s1 fig. Funnel Plot for the Primary Endpoint
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s2 fig. Sensitivity analysis for TLF and device thrombosis. Non-Complex Studies Versus Complex Studies. 
Random eff ects eff ects model. CI: confi dence interval; M-H: Mantel-Haenszel;
OR: odds ratio.
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s3 fig. Target lesion failure. 
Fixed eff ects model. CI: confi dence interval; M-H: Mantel-Haenszel; OR: odds ratio.
S4 Figure All-cause mortality 
 
 
 
s4 fig. All-cause mortality. 
Fixed eff ects model. CI: confi dence interval; M-H: Mantel-Haenszel;
OR: odds ratio.
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S5 Figure. Myocardial infarction 
 
 
 
 
s5 fig. Myocardial infarction. 
Fixed eff ects model. CI: confi dence interval; M-H: Mantel-Haenszel; OR: odds ratio.
S6 Figure. Target lesion revascularization 
 
 
 
 
s6 fig. Target lesion revascularization. 
Fixed eff ects model. CI: confi dence interval; M-H: Mantel-Haenszel; OR: odds ratio.
314 Chapter 15S7 Figure. Definite or probable device thrombosis 
 
 
 
 
 
s7 fig. Defi nite/Probable device thrombosis. 
Fixed eff ects model. CI: confi dence interval; M-H: Mantel-Haenszel; OR: odds ratio.
S8 Figure. Sensitivity analysis for TLF, RCTs versus propensity matched studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
s8 fig. Sensitivity analysis for TLF. RCTs versus propensity matched studies. Randomeff ects eff ects model. 
Caption: CI: confi dence interval; M-H: Mantel-Haenszel; OR: odds ratio.
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Drug-eluting stents (DES) are widely used as first choice devices in percutaneous 
coronary interventions (PCI). However, certain concerns are associated with the use of 
DES, i.e. neo-atherosclerosis, late stent thrombosis and hypersensitivity reactions to the 
DES polymer. Bioresorbable scaffolds (BRS) such as the Absorb Bioresorbable Vascular 
Scaffold (BVS) are the next development within the field of PCI, introducing the concept 
of supporting the natural healing process following initial intervention without leav-
ing any foreign body materials resulting in late adverse events. The first-generation 
devices have shown encouraging results in multiple studies of selected patients with 
non-complex lesions up to the point of full bioresorption. It supported the introduction 
in regular patient care. During its introduction in daily clinical practice outside the previ-
ous selected patient groups, a careful approach should be followed in which outcome is 
continuously monitored. The aim of this thesis was to investigate the safety and efficacy 
of the Absorb BVS in more complex lesions and higher-risk patients, when treated in a 
diverse clinical practice. 
In Chapter 1, an overview was provided of available studies during that time point 
(2014/ 2015), demonstrating encouraging results in selected patients and with limited 
duration of follow-up. Together with a group of early expert users, we set up a Dutch 
consensus statement for the use of BVS (Chapter 2). We reported that the implantation 
of a BVS in a de novo lesion with a diameter between 2.3 –  2.8 mm and maximum length 
of 28 mm was indicated as ‘Appropriate’. ‘Probably appropriate’ involved acute coronary 
syndrome (ACS) patients, long lesions, calcified lesion with proper lesion preparation 
and provisional bifurcation treatment. Off-label implantation included in-stent resteno-
sis, grafts and vessel with diameter > 4.0 mm. More data needed to be gathered in order 
create real BVS guidelines.   
Part I described the early outcomes of the Absorb BVS using different quantitative 
techniques. Chapter 3 described the acute angiographic outcomes of BVS when used in 
a wider range of coronary lesion types such as bifurcation and calcified lesions, chronic 
total occlusions and long lesions, showing feasible results.
All coronary implant will stretch the natural curvatures in the coronary arteries and 
reduce the possibility to increase curvatures during cardiac contraction. This alteration 
in natural morphology does have a known impact on flow patterns and will change 
shear stress within and at the edges of stents. The longer the lesions and subsequent 
implants, the more severe the impact will be. In Chapter 4 we compared the conform-
ability of BVS and DES in long lesions (implants of at least 28mm). Due to the difference 
of materials, the BRS resulted in a non-significant reduction in curvature post-implant 
while the metallic DES results a significant reduction in curvature of the treated vessel.
Part II reported on the short- and mid-term outcomes of the BVS as investigated in 
the BVS registries from the Erasmus MC, including a patient population that was more 
reflective of ‘real-world’ patients and lesions, such as ACS, bifurcation and calcification.
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The BVS Expand registry was the basis for multiple manuscripts, reporting 
on both angiographic (Chapter 3) and mid-term clinical outcomes (Chapter 5) 
The BVS Expand registry is an investigator initiated, single-arm, single-centre registry 
that included patients who presented with non-ST segment elevation myocardial infarc-
tion (NSTEMI), unstable angina, stable angina or silent ischemia and who had a de novo 
lesion in vessels with diameter between minimum 2.0 and maximum 3.8 mm by online 
quantitative coronary analysis (QCA). Main excluding criteria were: previous coronary 
artery bypass grafting (CABG), presentation with ST elevation myocardial infarction 
(STEMI) and an expected survival of less than one year. Although advanced age was 
not an exclusion criterion, BVS were in general reserved for younger patients, and left 
to operator’s interpretation of biological age. We included 249 patients (intention-to-
treat population) with mean age of 61.3±10.2 years; 73.5% were male and 18.5% were 
diabetic. Pre-dilatation was performed in 89.3%, intravascular imaging in 39% and 
post-dilatation in 53.3%. Device success was 99.2%. Post-procedural reference vessel 
diameter (RVD) was 2.89±0.42 mm, minimum lumen diameter (MLD) was 2.41±0.41 
mm and diameter stenosis (%DS) was 17.6±8.6%. Clinical outcomes at 18 months were 
acceptable with rate of major adverse cardiac events (MACE) of 6.8% and rate of definite 
scaffold thrombosis (ScT) of 1.9% (Chapter 5). The BVS STEMI registry was the Erasmus 
MC’s study to investigate the performance of BVS in STEMI patients only.  Main exclusion 
criteria were: known intolerance to contrast medium, uncertain neurological outcome 
after cardiopulmonary resuscitation, previous PCI with the implantation of a metal stent, 
left main (LM) disease.  
In Chapter 6, using pooled data from both the Expand and STEMI registry, our group 
described outcomes in ACS patients and non-ACS patients, demonstrating similar one 
year clinical outcomes. Acute angiographic outcomes such as post-procedural MLD and 
%DS appeared to be better in the ACS group. But of note, stable patients were older, 
had more risk factors and often presented with more complex lesions (higher rates of 
bifurcation, calcification and chronic total occlusions [CTO]). MACE rate and rate of ScT 
was comparable between groups but the latter represented with a different distribu-
tion in time: early ScT (< 30 days) occurred mainly in ACS patients whereas in the stable 
group, all cases of ScT were clustered between 30 days and 1 year (late ScT).
Our group was the first to describe acute outcomes of the BVS in a small group of STEMI 
patients, showing excellent expansion, low malapposition and small in-stent protruding 
masses. [1] Subsequently, we investigated the 18-months clinical outcomes of almost 
150 patients, propensity matched with a metallic DES group (Chapter 7). Procedural and 
angiographic results were similar between groups. However, clinical events rates were 
higher for the BVS groups. Most events occurred in the first 30 days after implantation 
and mainly in cases without post-dilatation. This might suggest that the optimisation 
of the implantation technique in the acute clinical setting is of paramount importance 
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for optimal short and mid-term outcomes. Performance of the BVS in different lesion 
subtypes such as bifurcation and calcified lesions was investigated in Chapters 8 and 9. 
In Chapter 8, 102 patients (107 lesions) with a bifurcation lesion, originating from both 
BVS Expand and BVS STEMI, were investigated to report performance of BVS in this type 
of lesion. The focus was on side branch impairment. Patients were included with at least 
one de novo bifurcation lesion involving a side branch ≥ 2.0 mm by visual estimation and 
treated with at least one BVS. Most patients were treated by T-provisional strategy show-
ing good acute angiographic outcomes. Device and procedural success were 99.1% 
and 94.3% respectively and side branch impairment during the procedure occurred in 
12.1%. One-year results were good with rate of MACE of 5.5% and definite ScT of 2.2%. 
Chapter 9 studied the effect of calcium on acute procedural and clinical outcomes in 
patients treated with BVS. Patients with a calcified lesion were older, had more often 
hypertension and kidney insufficiency and presented less likely with one-vessel disease. 
Also, the calcified group included more complex lesion types: higher rate of AHA/ ACC 
type B2/C lesions, bifurcation, total occlusions, longer lesions and with smaller RVD than 
in the non-calcified group. Device success rate was 99.1% with no significant differences 
between the groups. The calcified group showed more aggressive lesion preparation 
and post-dilatation than the non-calcified group. However, acute lumen gain was 
significantly less in calcified lesions (1.50 ±0.66 mm vs 1.62 ±0.69 mm, p= 0.040) and 
with lower final MLD (2.28± 0.41 mm vs 2.36±0.43, p=0.046). There were no significant 
differences in all-cause mortality, definite ScT, TLR and MI between the groups. Late ScT 
occurred more frequently in the calcified group compared to non-calcified group (2.1% 
vs 0%, p=0.02). 
These results demonstrated that implantation of a BVS in a more complex patient and 
lesion subset may be feasible and associated with acceptable rate of adverse events. 
These observations were also reported in other studies. 
Chapter 10 described the performance of BVS when investigated by multislice com-
puted tomography (CT) in a BVS Expand sub cohort. Mid-term performance of BVS, 
when assessed by computed tomography coronary angiogram (CTCA) was good and 
CTCA as non-invasive investigation was feasible to evaluate scaffold patency and in-
scaffold stenosis.
Part III described the implications of failed cases for future applications. Chapter 
11 reported pilot imaging observations in ‘real-world’ patients with BVS thrombosis. 
Suboptimal implantation with underexpansion, malapposition, and incomplete lesion 
coverage, often in combination with dual antiplatelet therapy (DAPT) discontinuation 
appeared to be the major substrate both for acute and late events.
In Chapter 12 both pathophysiology and treatment of BRS failure are discussed. Chap-
ter 13 describes three cases of very late ScT and their possible relationship with DAPT 
termination before 18 months. In Chapter 14 we report on the impact of DAPT termina-
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tion before 18 months on ScT. Data of three Dutch centres were pooled to investigate 
the impact of DAPT termination on the occurrence of very late ScT. The incidence of ScT 
was most notable in the first month after DAPT termination.
Chapter 15 was a systematic review and meta-analysis comparing the mid-term 
(weighted follow-up duration of 30.6 months) clinical outcomes of the BVS with second-
generation DES, including seven randomized controlled trials and three observational 
propensity matched studies. The use of BVS was associated with an increased risk of 
adverse events (target lesion failure, myocardial infarction, target lesion revasculariza-
tion and device thrombosis, especially the risk of very late (> 1 year) device thrombosis. 
However, this did not result in an increased risk of all-cause mortality. 
references
 1. Diletti, R., et al., Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients 
presenting with ST-segment elevation myocardial infarction: BVS STEMI first study. Eur Heart J, 
2014. 35(12): p. 777-86.
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Percutaneous coronary intervention (PCI) has become an established technique to 
improve coronary flow when obstructive coronary heart disease results in angina symp-
toms which cannot be managed with medical therapy or when the myocardium is at risk 
of necrosis due to acute occlusion. Since the first angioplasty, the field of interventional 
cardiology has been subject to many developments. The advent of bare metal and drug 
eluting stents (DES) improved results by reducing the risk of major cardiovascular 
events. Adverse event rates in the first year post intervention diminished  below 10% 
with convergence approaching  5%. [1]   However, contemporary DES are not devoid of 
limitations such as the risk of stent fracture, coating-polymer induced vascular inflam-
mation and antiproliferative drug related adverse effects. Even the best DES still has an 
average reintervention rate of 1-2% after the first year. [2] To overcome some limitations 
of DES, bioresorbable stents (called ‘bioresorbable scaffolds’ [BRS]) were developed. The 
concept of a fully bioresorbable scaffold consists of providing only transient support to 
the vessel with the following hypothesized benefits: improvement of vascular healing 
after angioplasty with resorption of scaffold material resulting in improved coronary 
physiology with restoration of coronary flexibility and vasomotion, late lumen enlarge-
ment, absence of very late device thrombosis and finally, reduction in target lesion 
reinterventions in the long-term. The Absorb BVS was the first commercially available 
BRS, with a poly-L-lactide (PLLA) constitution while eluting everolimus to suppress neo-
intima formation.
Previous research
During the first-in-man (FIM) trials and subsequent strict controlled early registries, 
BVS was implanted only in highly selected, low-risk patients with low complex lesions. 
Five-year results of the FIM ‘ABSORB Cohort B’ were encouraging, revealing late lumen 
stability and restoration of vasomotor function, together with low event rates. [3, 4] 
Based on the promising imaging surrogate endpoints of the ABSORB Cohort B, the 
Absorb BVS received CE mark approval for clinical use in 2011. Superiority testing on 
angiographic and clinical outcomes for selected patients was hereafter initiated in mul-
tiple large randomised clinical trials i.e. ABSORB II, ABSORB III, ABSORB China, ABSORB 
Japan.  However, these studies were not designed to investigate the performance of the 
BVS in a more complex patient population and hence, these studies will not provide 
sufficiently data to justify extensive clinical usage beyond the inclusion criteria of the 
aforementioned trials.
Post-approval registries play an important role in filling the data gap between the 
performance of a new device in randomized clinical trials (RCTs) and their use in routine 
practice over time. Furthermore, registries incorporate inherent advantages over clinical 
trials. Firstly, registries comprise less strict in and exclusion criteria and thus create a more 
‘real-world’ like patient population. Accordingly, results originating from registries are 
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better generalizable. Secondly, registries provide a longer-term follow-up in comparison 
to follow-up duration in classic stent RCTs. Thirdly; the larger number of events increases 
the likelihood of identification of rare events, such as scaffold thrombosis (ScT). Fourth, 
as registries integrate data of large numbers of (less selected) patients, receiving care in 
diverse clinical settings, they lead to an enhanced investigation of specific subgroups 
that are often underrepresented in clinical trials. Furthermore, RCTs usually require a 
longer preparation time due to a more extensive ethical review process and a requisite 
appropriate budget where registries frequently provide data earlier in a more general 
population. 
With this in mind, the aim of this thesis is to investigate the clinical safety and efficacy 
of the first-generation Absorb BVS, when used in routine practice including high risk 
patients. Furthermore, we attempt to identify potential factors which could influence 
these outcomes to optimize future patient and lesion selection, procedural strategies 
and post-procedural pharmaceutical treatment. Lastly, additional information will be 
collected regarding the mechanisms of scaffold failure in terms of scaffold thrombosis 
and restenosis to advance this treatment further. 
the main observations from this thesis are:
1. BVS used in a routine clinical setting resulted in modest rates of adverse events in the 
short-term period.
2. Implantation of a BVS in more complex patient and lesion subsets may be feasible 
and associated with acceptable rate of adverse events. 
3. Longer term follow-up and a pooled analysis of complex and non-complex lesions 
and patients identified an increased risk in adverse outcomes for BVS-treated pa-
tients versus current DES.
4. BVS failure was related to procedural techniques, specifically pre- and post-dilatation. 
Termination of dual antiplatelet therapy (DAPT) before 18 months was another fac-
tor which contributed to this failure.
bvs used in the routine clinical setting 
The in 2012 initiated BVS Expand and BVS STEMI registries were designed to investigate 
the performance of BVS in the more complex patient and lesion subsets. The BVS Ex-
pand registry included a mixed patient population, involving patients who presented 
with stable or unstable angina, NSTEMI or silent ischemia. In this registry bifurcation, 
long lesion, chronic total occlusion and calcified lesions were not excluded. We included 
249 patients (intention-to-treat population) with a mean age of 61.3±10.2 years; 73.5% 
were male and 18.5% were diabetic. Clinical outcomes at 18 months were modest with 
MACE rate of 6.8% and rate of definite ScT of 1.9%. These results are similar to the largest 
multi-centre BVS registries such as the GHOST-EU [5], which reported even a slightly 
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high rate of thrombosis: definite/ probable ScT rate of 2.1% already at six months. The 
German GABI-R registry showed a MACE incidence of 4.1% after six months and definite/ 
probable ScT was documented in 1.4% of the patients. [6] More recent registries like IT-
DISAPPEARS, showed better results with a device-oriented composite endpoint (DOCE) 
of 9.9% and a definite/ probable ScT rate of 0.9% at 12 months. [7] In 2018, the RAI 
registry presented a DOCE rate of 3.9% and a definite/ probable ScT rate of 1.3%. [8]
The BVS STEMI registry was initiated shortly after the BVS Expand registry and 
recruited exclusively STEMI patients. In theory, ACS patients and particularly STEMI 
patients would be excellent candidates for implantation with a BVS. They are gener-
ally younger and thus have a distinctly longer life expectancy. The plaque burden in 
their coronary arteries is less extensive and the plaque itself ordinarily consists of soft 
material, facilitating the embedment of the device into the vessel wall. On the other 
hand, due to vasoconstriction and the presence of thrombus during the acute setting 
of STEMI, vessel sizing is challenging with the subsequent risk of undersizing or malap-
position. Also, the thicker struts provoke flow disturbances and locally low shear stress, 
which is an independent predictor of plaque progression. A detailed analysis of the first 
31 patients with immediate OCT control (BVS STEMI-first) demonstrated a large vessel 
lumen with a low percentage of malapposed struts, a small incomplete scaffold apposi-
tion area and a small intraluminal defect area. Within 30 day follow-up of the first 49 
patients, no scaffold thrombosis occurred. [9]
The full BVS STEMI registry included 151 patients and indicated modest clinical 
outcomes at 12 months with MACE rate of 8.1% and rate of definite ScT of 2.8%, increas-
ing to 9.8% and 4.3% at 18 months respectively. Event rates were remarkably higher 
compared to a matched series of DES. When compared to other published literature, for 
instance the BVS Examination, the same increase of definite ScT versus DES thrombosis 
was observed although overall lower in both arms (1.7% vs 0.7%). [10] The ISAR-ABSORB 
MI study, which presented their results during the ESC congress of 2018, with 76.3% of 
STEMI patients, showed promising results: comparable one-year event rates between 
the BVS group and the DES group. Definite/ probable ScT rate was 1.7%, the rate of 
pre-dilatation was 95.3% and finally post-dilatation was performed in 56.6%. [10]
The BVS STEMI registry included STEMI patients only and BVS implantation was 
performed in an earlier developmental phase than the studies described above, when 
the operators had less experience, which was reflected by the rates of pre- and post-
dilatation (54.1% and 39.7% respectively).
Both registries demonstrated that BVS used in routine clinical setting resulted in mod-
est rates of adverse events with a potential higher risk of the rare event of ScT. The topic 
ScT needed further investigation in larger data sets and specific analysis of this event 
and was studied in later sections of this thesis
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implantation of bvs in more complex patient and lesion subsets 
Within the combined registries with over 400 patients treated in a single centre, 72% of 
patients presented with ACS, 29% with bifurcation lesions with side branches >2 mm 
and 35% with calcified lesions which allowed a more in-depth analysis of these for clini-
cal practice important subgroups. 
QCA analysis in the ACS population demonstrated that post-procedural acute lumen 
gain and percentage diameter stenosis were superior to non-ACS patients 1.62±0.65mm 
(versus 1.22±0.49mm, P<0.001) and 15.51±8.47% (versus 18.46±9.54%, P=0.04).  This 
did not result in differences in clinical outcomes at one year (MACE of 5.5% for ACS 
and 5.3% for non-ACS, TLR 3.1% vs 3.2; Def/ Prob ScT 2.4 vs 2.1 %). Noteworthy, ScT 
outcomes of the most challenging STEMI only population, as reported above, was 2.8% 
at 12 months rising to 4.3% at 18 months. In this group, the incidence of ScT seems to 
be most pronounced and warrants further investigation. The high incidence of acute 
and subacute ScT in this subgroup can be understood from the relationship between 
the activated coagulation cascade in ACS, the short pre-treatment time within the 
primary PCI setting and the larger strut thickness and width of the BVS resulting in a 
larger contact area between blood and stent material. A high incidence of late and very 
late ScT in STEMI can be elucidated by the relation between stent / scaffold undersizing 
due to vasoconstriction followed by vasodilatation after successful treatment of the 
STEMI [11], resulting in a higher rate of strut malapposition compared to stable angina 
treatment. [12] [13] Malapposition results in larger areas of both abnormal low and high 
shear stress, resulting in an increased risk of thrombosis and delayed strut coverage with 
endothelium and neointima. [14]
The use of BVS in patients with bifurcation lesions is also appealing. Permanent metallic 
stents will always be malapposed along the ostium of the side branch and introduce flow 
disturbances, assumedly related to the higher post-procedural event rate in bifurcation 
treatment. More complex stent adjustments with multiple balloons, finalized with kiss-
ing balloon post-dilatation, have been advocated to minimize this risk. The potential of 
full restoration of the natural bifurcation anatomy has been recognized. [15] Contrarily, 
the relatively broad and thick struts of the BVS could jeopardize the side branch during 
implantation. When analysing our registries data, we identified 102 patients with 107 
bifurcation lesions, having relevant side branches (≥ 2mm in diameter). The incidence 
of side branch impairment was low (12.1% temporary, 6.5% at end of procedure) with 
only one failure to rewire and dilate the ostium of the side branch. Two dimensional and 
three dimensional QCA did not show differences in MLD and % DS in the side branch 
after treating the main branch with a BVS. In these series, the first-year event rate was 
acceptable. In larger studies including bifurcations, such as the GHOST-EU[5] and the 
AIDA RCT[16], treatment of bifurcation lesions was not a predictor of target lesion failure 
(TLF) or ScT. Our series and the GHOST-EU and AIDA studies, mainly practiced provisional 
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stenting of the main branch with low numbers of two-stent techniques. Based on these 
data, provisional scaffolding with BVS can be considered as a favourable treatment op-
tion for bifurcations when a meticulous lesion preparation is adhered to. [17]
Calcified lesions constitute a large measure of all coronary lesion types and the treat-
ment of these lesions often result in poorer clinical outcomes. Lesion expansion during 
balloon angioplasty and the prevention of acute recoil by stent/ scaffold implantation 
are impaired by dense atherosclerosis. The evaluation of new generation stents in 
this lesion category is important particularly when ascertaining if the radial force, as 
measured in bench testing, is clinically sufficient. In smaller series, including 50 OCT 
measurements post BVS implantation, minimal and mean device area in moderately and 
heavily calcified lesions were comparable to DES. [18] Only the mean eccentricity index 
for BVS treated lesions was lower compared to DES, apparently reflecting the slightly 
lower radial force of BVS compared to contemporary DES. In this thesis, acute lumen 
gain in calcified lesions, as seen on angiography, treated with BVS was investigated in 
a much larger subset of 455 patients with 548 lesions. Two hundred of those lesions 
exhibited at least moderate calcification (angiographically). Despite more aggressive 
lesion preparation and post-dilation compared to non-calcified lesions, acute lumen 
gain was significantly less in calcified lesions (1.50±0.66 vs 1.62±0.69mm, p=0.040) 
with lower final MLD (2.28±0.41 vs 2.36±0.43, p=0.046). No differences in MACE were 
observed between both groups.
The current thesis revealed that the performance of BVS in the above described lesion 
subsets may be feasible resulting in acceptable clinical outcomes. Even though ScT may 
be a more frequent phenomenon in these lesion categories, similar observations have 
been described in DES platforms. Further investigation concerning the variations in this 
relatively infrequent phenomenon requires larger studies, meta-analysis of multiple 
studies and registries or, if available, pooled individual data of prospective RCT’s.  
long term follow-up applying pooled analysis of complex and non-complex 
lesions and patients  
Individual one-year results of RCTs (ABSORB II, ABSORB III, ABSORB Japan and ABSORB 
China), which compared the BVS with its best-in-class counterpart: the second-gen-
eration everolimus-eluting stent demonstrated that the BVS was non-inferior to DES. 
[19-21] Subsequently, the Absorb BVS received FDA approval in July 2016. Remarkably 
and similar to the European registries, the rate of definite or probable device thrombosis 
was higher for BVS, although this was not statistically different. [22]  Moreover, the first 
meta-analysis which combined RCT-derived data at one year , performing a patient-level 
analysis did not show any statistical differences in clinical outcomes at one year.  [23] Ac-
cordingly, the performance of BVS at one year was deemed promising during the early 
phase in which solely simple lesions were treated with the device. 
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To gain further insights in relation to outcomes at one year and beyond in a population 
that reflects real-world daily practice, both RCTs and registries, inclusive of complex and 
non-complex lesions, should be incorporated in a meta-analysis. Single arm registries, 
without a control group, retain a major limitation in practice variability, in particular 
with respect to patient and lesion selection for a specific procedure. Local propensity 
matched series avert these concerns and are considered the best alternative when RCT’s 
are not available. We therefore performed a meta-analysis including RCTs and propen-
sity matched registries with a minimum follow-up of 12 months (median follow-up 30.5 
months) and including outcomes of 7320 patients. This meta-analysis revealed that BVS 
was associated with an increased risk of adverse events when compared to DES not 
only in the first year, but also hereafter. Several other meta-analyses focused on throm-
botic events and demonstrated an increased risk of device thrombosis in BVS-treated 
patients. [24-27] Clearly, the reported increased risk of very late (>1 year) ScT [25, 28, 
29]  was unexpected.  This risk of very late ScT suggests in part an association with the 
resorption process, which could cause scaffold disintegration with the subsequent risk 
of thrombosis. [30, 31]
Procedural techniques and the duration of DaPt
Initially, interventional cardiologists implanted scaffolds in an equivalent manner as 
DES. However, findings in this thesis suggested that the clinical success results after 
BVS implantation were sensitive to both underexpansion (Chapter 5) and post-dilation 
(Chapter 7), indicating that a different implantation approach may be indicated for BVS. 
Similarly, post-hoc analyses from other studies reported that correct scaffold sizing was 
imperative. Implantation in small vessels (< 2.5mm on visual estimation and < 2.25mm 
on QCA) increased the rate of DOCE with 60%. [32] Suboptimal implantation of the 
device was reported to play an important role, both in the short- and long-term, as was 
illustrated in this thesis in a first careful evaluation of early and late ScT cases. Incomplete 
lesion coverage, underexpansion and malapposition were revealed as the main potential 
pathomechanisms for both early and late ScT. This was also observed by a similar study, 
revealing underexpansion and malapposition as the most frequent determinants of ScT. 
[31] The sensitivity to underexpansion, implantation in small vessels and malapposition 
reflexes the difference in stent design, with a larger strut thickness and width causing 
disruption of laminar flow and inducing large areas with local low shear stress[33] 
Based on these observations, a dedicated BVS implantation strategy has been sug-
gested focussing on Pre-dilatation, Sizing and Post-dilatation (PSP) to diminish event 
rates. [34] However, due to the lack of long-term data and a randomized design that 
investigates the exact role of an optimal BVS-specific implantation technique, the 
question remains if optimization of the implantation strategy during index procedure 
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can legitimately overcome limitations of this device and improve outcomes in the long-
term. [35] 
Due to increasing evidence of higher rates of very late ScT with an accumulation 
during the degradation period of the PLLA based device, speculation arose that the 
optimal duration of DAPT in BVS-treated patients could be at variance compared to the 
DAPT duration in the DES population. The observations in this thesis, that the rate of 
ScT immediately after late DAPT termination (minimum of 6 months DAPT) was again 
increased, suggests that the prolongation of DAPT during the resorption period might 
be pivotal for BVS. In extension, given the associated risk of bleeding, whether DAPT 
prolongation is advisable for all patients or for those at higher risk of an event remains 
uncertain. The supposition of more potent P2Y12 inhibitors administration or a pro-
longed duration of DAPT with the objective of lowering ScT risk justifies further research 
with dedicated studies. 
current status of bvs, a first-generation brs
After the two-year results of the largest RCT (ABSORB III) were presented during the ACC 
congress in March 2017, the FDA issued a safety alert recommending the use of BVS only 
in appropriately selected patients, adhering to the updated implantation recommenda-
tions and continuation of DAPT for 12 months.[36] Correspondingly, the AIDA trial the 
two-year results were published earlier than expected after the safety monitoring board 
recommended to release the preliminary data due to safety concerns. [37] The afore-
mentioned unfavourable findings were again confirmed during the 2017 TCT congress 
in Denver, USA and in subsequent publications where the three-year data of ABSORB II 
showed again an increased rate of events in the BVS arm beyond one year. [36]  As a con-
sequence, the current generation BVS has been withdrawn from the market. Recently, a 
Task Force of ESC and EAPCI, justifiably declared that bioresorbable scaffolds should not 
be preferred above the currently used metallic DES [38].
Concluding, despite the theoretically advantages of the Absorb BVS for the treatment 
of CAD, this new device appeared to be limited in its application in daily practice as 
its association with increased risk of adverse events became clear over the foregoing 
years. Data on the implantation of the device in complex lesions (bifurcations, severely 
calcified lesions, aorta-ostial lesions and complex CTO lesions) is limited and in gen-
eral, not in favour of the BVS. Multiple shortcomings exist such as the limitation in 
overexpansion. Additionally, the thicker and boarder struts importantly contribute to 
the increased early ScT rate, especially in small vessels or when underexpansion arises. 
Next generations of BRS need to have a reduction in scaffold struts size, in addition to 
increased radial strength. Moreover, the resorption time is relatively long, approximately 
3 years. The detection of potential beneficial outcome effects would materialise within 3 
to 7 years, considering the results of the COMPARE ABSORB and ABSORB III RCTs. Lastly, 
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in selected patients, the duration of dual antiplatelet therapy could be extended beyond 
one year and maybe conceivably up to three years, which could be a burden to patients.
Currently, alternative BRS should be reserved only for highly selected patients, used in 
trials and registries. Notwithstanding BRS implantation in complex lesion subsets such 
as large vessels (with vessel diameter > 4 mm), small vessels (with vessel diameter < 
2.5 mm on visual estimation) should be avoided. One essential deliberation that should 
requires consideration is that this first-generation device direct comparators enjoy 
years of experience and subsequent multiple device iterations, has led to lowest event 
rates currently available. Characteristically, the bar has been set high.  Furthermore, the 
Absorb BVS was used for the first time by most of the operators during the early studies 
and knowledge concerning an optimal implantation strategy was incomplete in the 
corresponding period. 
It is fair to assume that the era of the first-generation BVS has now been concluded. 
The ensuing generations of bioresorbable scaffolds will most likely be both fascinating 
and intriguing when one considers the sage words of George Bernard Shaw “progress is 
impossible without change, and those who cannot change their minds cannot change 
anything”.
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Bij percutane coronaire interventie (PCI) wordt meestal bij voorkeur medicament-afge-
vende stents (drug-eluting stents [DES]) gebruikt. Er bestaan echter zorgen over het ge-
bruik van DES, dat wil zeggen over neo-atherosclerose, laat-optredende stent-trombose 
en hypersensitieve reacties op de in de DES voorkomende polymeer. Bioresorbeerbare 
bloedvatondersteunende stents (BRS), zoals de Absorb Bioresorbable Vascular Scaffold 
(BVS), zijn een recente innovatie op het gebied van de PCI. Hiermee wordt een concept 
geïntroduceerd waarbij het natuurlijke genezingsproces na een initiële interventie 
wordt ondersteund en waarbij geen lichaamsvreemd materiaal achterblijft dat later 
ongunstige gevolgen kan hebben. Gebruik van de eerste generatie BVS heeft in meer-
dere studies onder geselecteerde patenten met niet-complexe laesies bemoedigende 
resultaten opgeleverd, waarbij volledige bioresorptie werd gezien. Dit was aanleiding 
tot introductie in de reguliere patiëntenzorg. Introductie in de dagelijkse klinische prak-
tijk bij buiten de eerdere geselecteerde patiëntengroepen vallende personen vraagt om 
een zorgvuldige benadering en voortdurende bewaking van de resultaten. Het doel van 
dit proefschrift is te onderzoeken hoe veilig en werkzaam de Absorb BVS is bij complexe 
laesies en patiënten met een hoger risico die worden behandeld in de gevarieerde 
klinische praktijk. 
In hoofdstuk 1 wordt een overzicht gegeven van de op dat moment (2014/ 2015) 
beschikbare onderzoeken. Deze lieten, bij geselecteerde patiënten en in de tijd be-
perkt follow-up, bemoedigende resultaten zien. Samen met een groep vroeg bij het 
onderzoek betrokken gebruikers werd een Nederlandse consensus opgesteld voor het 
gebruik van de BVS (hoofdstuk 2). Vastgesteld kon worden dat de implantatie van een 
BVS in een nieuwe laesie met een diameter tussen 2,3 - 2,8mm en met een maximale 
lengte van 28mm als ‘passend’ kon worden beschouwd. De ingreep is ‘waarschijnlijk 
passend’ voor patenten met een acuut coronair syndroom (ACS), lange laesies, op de 
juiste wijze voorbereide gecalcificeerde laesies en voor bifurcatiebehandelingen door 
middel van eenstenttechniek met provisionele zijtak stenting. Tot de afwijkende toepas-
singen behoren in-stent restenose, stents in grafts en bloedvaten met een diameter > 
4,0mm. Om deugdelijke richtlijnen voor het gebruik van BVS te kunnen opstellen is het 
noodzakelijk om meer informatie te verzamelen. 
In deel I worden vroegere resultaten van de Absorb BVS beschreven met behulp van 
verschillende kwantitatieve technieken.
In hoofdstuk 3 worden de acute angiografische resultaten de BVS beschreven als 
deze wordt gebruikt bij een breder scala aan coronaire laesies zoals bifurcaties en 
gecalcificeerde laesies, chronische totale afsluitingen en lange laesies, waarbij redelijke 
resultaten zijn geboekt.
Coronaire implantaten veranderen altijd iets aan in de natuurlijke kromming van de 
coronaire bloedvaten en ze reduceren de mogelijkheid die deze krommingen hebben 
om uit te zetten tijdens de contractie van het hart. Het is bekend dat deze verandering 
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in de natuurlijke morfologie invloed uitoefent op stromingspatronen en de afschuif-
spanning binnen en aan de uiteinden van de stents wijzigt. Hoe langer de laesies en 
dus de implantaten zijn, hoe groter de invloed hiervan zal zijn. In hoofdstuk 4 wordt 
vergeleken hoe de BVS en DES stents zich aanpasten in het geval van gebruik in lange 
laesies (implantaten van ten minste 28mm lang). In de context van het gebruik van 
verschillende materialen gaf de BRS een niet-significante verandering in de bochten na 
implantatie te zien, terwijl de metalen DES een significante reductie van de bochten van 
het behandelde bloedvat veroorzaakte.
In deel II wordt gerapporteerd over met de BVS behaalde korte- en middellange 
termijnresultaten na onderzoek in het BVS-register van het Erasmus MC, dat betrekking 
heeft op een patiëntenpopulatie die meer overeenkomsten vertoond met ‘echte’ pati-
enten en waarin laesies zoals ACS (Acuut Coronair Syndroom), bifurcaties en calcificaties 
voorkomen.
Het BVS Expand-register was de basis voor meerdere tekstverslagen met betrekking 
tot zowel angiografische (hoofdstuk 3) als klinische resultaten op de middellange ter-
mijn (hoofdstuk 5).
Het BVS Expand-register is een door onderzoekers opgezet enkelgroeps, monocen-
trisch register waarin patiënten zijn opgenomen die zich hebben gepresenteerd met 
een niet-ST verhoogd myocard infarct (NSTEMI), onstabiele angina, stabiele angina of 
stille ischemie en bij wie dankzij online kwantitatieve coronaire analyse (QCA) een de 
novo laesie in een bloedvat met een diameter tussen minimaal 2,0 en maximaal 3,8 
mm werd gevonden. De belangrijkste uitsluitingscriteria waren: eerder uitgevoerde 
coronaire omleidingen (CABG), presentatie met een ST-Elevatie Myocard Infarct (STEMI) 
en een verwachte overlevingskans van minder dan één jaar. Een gevorderde leeftijd 
was geen uitsluitingscriterium, maar de BVS werden over het algemeen voorbehouden 
aan jongere patiënten, waarbij inschatting van de biologische leeftijd aan de betrokken 
behandelaar werd overgelaten. De groep bestond uit 249 patiënten (die voor behande-
ling in aanmerking kwamen) met een gemiddelde leeftijd van 61,3±10,2 jaar; 73,5% 
was man en 18,5% leed aan diabetes. Er was sprake van pre-dilatatie in 89,3%, van 
intravasculaire beeldvorming in 39% en van post-dilatatie in 53,3% van de gevallen. Het 
percentage correcte plaatsingen was 99,2%. De postoperatieve referentievatdiameter 
(RVD) was 2,89±0,42 mm, de minimale lumendiameter (MLD) was 2,41±0,41 mm en de 
stenosediameter (%DS) was 17,6±8,6%. De klinische uitkomsten na 18 maanden waren 
acceptabel en lieten een frequentie van grote vasculaire gebeurtenissen (MACE) van 
6,8% en een voorkomen van gedefinieerde stenttrombose (ScT) van 1,9% zien (hoofd-
stuk 5). Het BVS STEMI-register vormde de neerslag van onderzoek aan het Erasmus MC 
dat uitsluitend de prestaties van de BVS bij patiënten met STEMI betrof. De belangrijkste 
uitsluitingscriteria waren: bekend met intolerantie voor contrastmedia, onzekere neu-
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rologische resultaten na reanimatie, eerder uitgevoerde interventie met een metalen 
stent, LM hoofdstam laesie (LM).  
In hoofdstuk 6 zijn gegevens uit zowel het Expand- als het STEMI-register gebruikt om 
over de eenjaars resultaten te schrijven van ACS-patiënten en van stabiele patiënten. In 
de ACS-groep leek minder sprake te zijn van acute angiografische verschijnselen als po-
stoperatieve MLD en %DS. De stabiele patiënten waren echter ouder, hadden met meer 
risicofactoren te maken en vaak presenteerden zij zich met complexere laesies (vaker 
voorkomende bifurcaties, calcificaties en chronische totale occlusies (CTO)). MACE en 
ScT kwamen in beide groepen in vergelijkbare mate voor, maar ScT presenteerde zich 
op een andere manier in de tijd: vroeg optredende ScT (< 30 dagen) kwam vooral voor 
bij patiënten met ACS terwijl in de stabiele groep alle gevallen van ScT voorkwamen 
tussen de 30 dagen en één jaar (laat optredende ScT). 
Onze groep was de eerste die de acute uitkomsten van de BVS in een kleine populatie 
STEMI patienten beschreef met onder andere een goede stent expansie, en weinig 
malappositie. 1 In hoofdstuk 7 worden de klinische resultaten van STEMI-patiënten over 
18 maanden beschreven, afgezet tegen patiënten die met DES waren behandeld in een 
1:1 verhouding, waarbij gebruik is gemaakt van de gelijkheidsbenaderingsmethode 
(propensity matched methode). De procedurele en angiografische resultaten van de 
twee groepen waren vergelijkbaar. Bij de BVS-groepen kwamen echter vaker klinische 
gebeurtenissen voor. De meeste van deze gebeurtenissen deden zich voor in de eerste 
30 dagen na implantatie en vooral in gevallen waarbij geen postdilatatie had plaatsge-
vonden. Dit kan erop wijzen dat de optimalisatie van de implantatietechniek in de acute 
klinische setting van het allergrootste belang is voor optimale resultaten op korte en 
middellange termijn.
De prestaties van de BVS in verschillende typen laesies, zoals bifurcatie en gecalci-
ficeerde laesies, werden onderzocht in hoofdstuk 8 en hoofdstuk 9. In hoofdstuk 8 wordt 
beschreven hoe 102 patiënten (107 laesies) met een bifurcatie-laesie, geselecteerd uit 
zowel het BVS Expand- als het BVS STEMI-register, zijn onderzocht om de prestaties 
van de BVS bij dit type laesie te kunnen rapporteren. De focus lag op afsluiting van 
zijtakken. Patiënten in deze groep hadden ten minste één de novo bifurcatie-laesie met 
een zijtak van ≥ 2,0mm volgens visuele schattingen en waren behandeld met minstens 
één BVS. De meeste patiënten waren behandeld volgens de ‘T-provisional’- strategie en 
presenteerden zich met goede acute angiografische uitkomsten. De BVS en de proce-
dure waren in respectievelijk 99,1% en 94,3% van de gevallen succesvol; zijtakobstructie 
gedurende de procedure trad op bij 12,1%. De resultaten na een jaar waren goed: MACE 
kwam in 5,5% en ScT in 2,2% van de gevallen voor.
In hoofdstuk 9 worden de acute angiografische en klinische uitkomsten van patiënten 
met een gecalcificeerde laesie (gedetermineerd als een matige of ernstige gecalcifi-
ceerde laesie tijdens visuele beoordeling op angiografie) versus patiënten zonder een 
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gecalcificeerde laesie beschreven. In totaal ging het om 548 laesies. De uitgangspositie 
van patiënten was verschillend in termen van leeftijd, hypertensie, nierinsufficiëntie en 
meervoudige vaatziekten (langer bestaand en vaker aanwezig bij patiënten met gecal-
cificeerde laesies). Patiënten met gecalcificeerde laesies hadden ook vaker complexe 
laesies: zij lieten meer AHA/ ACC type B2/C laesies, bifurcaties, totaalocclusies en langere 
laesies met kleinere bloedvatdiameters (RVD) zien dan de niet-gecalcificeerde groep. 
Onder patiënten met gecalcificeerde laesies werden agressieve laesie voorbehandeling, 
na-dilatatie en de intra-coronaire beeldvorming vaker toegepast. Het percentage cor-
recte plaatsingen was 99,1% (vergelijkbaar tussen beide groepen). De acute toename in 
lumen diameter was echter minder in de groep patienten met een gecalcificeerde laesie 
(1,50 ±0,66 mm versus 1,62 ±0,69 mm, p= 0.04). De uiteindelijke MLD  was ook kleiner: 
2,28± 0,41 mm versus 2,36±0,43, p=0,046. De klinische resultaten van de groepen waren 
vergelijkbaar. De ScT presenteerde zich echter op een andere manier in de tijd: bij pa-
tiënten zonder gecalcificeerde laesies (meer ACS-patiënten) kwamen de waargenomen 
gevallen van ScT voornamelijk vroeg voor, terwijl bij patiënten met gecalcificeerde 
laesies meer late ScT optrad. Dit kan een gevolg zijn van de heterogeniteit tussen de 
groepen, omdat er een hoger aantal ACS-patiënten in de groep patiënten zonder ge-
calcificeerde laesies zat, wat een  enigszins ander mechanisme voor de ontwikkeling van 
ScT met zich meebracht.
Bovenstaande hoofdstukken demonstreerden dat de implantatie van een BVS in een 
meer complexe patienten- en laesiepopulatie bemoedigende resultaten liet zien en 
geassocieerd waren met acceptabel percentage ongunstige gevolgen.
Hoofdstuk 10 gaat over de prestaties van de BVS tijdens onderzoek door middel 
van computertomografie (CT) in een BVS Expand-subgroep. De prestaties van de BVS 
op middellange termijn zijn onderzocht door middel van een computertomografisch 
coronairangiogram (CTCA) en als ‘goed’ beoordeeld. CTCA, een niet-invasieve onder-
zoeksmethode, werd als bruikbaar voor de beoordeling van scaffolddoorgankelijkheid 
en in-scaffoldstenose beoordeeld.
In deel III worden ten behoeve van toekomstig gebruik, de implicaties van mislukte 
toepassingen besproken. Hoofdstuk 11 beschrijft beeldvormingsobservaties van een 
proefproject met ‘echte’ patiënten met BVS-trombose. Suboptimale implantaties met on-
voldoende geëxpandeerde, verkeerd geplaatste implantaten en incomplete afdekking 
van de laesie, vaak in combinatie met stopzetting van de dubbele anti-bloedplaatjes 
therapie (DAPT), bleken de belangrijkste voedingsbodems voor zowel acute als later 
optredende gebeurtenissen te zijn.
In hoofdstuk 12 worden de pathofysiologie en de behandeling van mislukte toepas-
sing van BVS besproken. In hoofdstuk 13 worden drie gevallen beschreven van zeer laat 
(> 1 jaar) optredende ScT en de mogelijke relatie daarvan met het binnen 18 maanden 
stopzetten van de DAPT. Hoofdstuk 14 is een verslag van de effecten op ScT van het bin-
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nen 18 maanden stopzetten van de DAPT. Om de effecten van het stopzetten van DAPT 
op het optreden van zeer laat optredende ScT te onderzoeken werden de gegevens van 
drie Nederlandse centra samengevoegd. De incidentie van ScT was het opvallendst in 
de eerste maand na de beëindiging van de DAPT.
Hoofdstuk 15 is een systematisch review en meta-analyse waarin de (bij een 
gewogen-gemiddelde follow-uplooptijd van 30,6 maanden) klinische resultaten van de 
BVS op de middellange termijn worden afgezet tegen die van tweede generatie DES, 
inclusief zeven gerandomiseerde gecontroleerde studies en drie observationele studies 
volgens de gelijkheidsbenaderingsmethode. Het gebruik van BVS wordt geassocieerd 
met een verhoogd risico op ongunstige gevolgen (falen van de doelwitlaesie [TLF], 
myocardinfarct [MI], herbehandeling van de laesie [TLR] en stenttrombose [DT]), met 
name het risico van zeer laat optredende  stenttrombose. Dit resulteert echter niet in 
een verhoogd risico op mortaliteit in het algemeen.
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